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Abstract 
Globally, there has been a substantial rise in the prevalence of obesity amongst 
older persons (≥65 years) since the 1980s. Conflicting evidence exists on the 
impact of this trend for health outcomes. A 2013 meta-analysis documented no 
statistical difference for mortality between those within the body mass index 
(BMI) defined Obese-1 (30.0-34.9 kg/m2) range and those within the 
conventional BMI Normal (18.5-24.9) range, sparking vigorous debate. The 
reduced or similar mortality risks for those within the BMI Obese-1 range 
relative to those within the BMI Normal range has been termed the “obesity 
paradox”. Clarifying associations of obesity with health outcomes could have 
implications for intervention in later life. I aimed to examine this paradox by 
assessing the length of follow-up, the BMI referent group, the inclusion of 
smokers plus those with conditions associated with weight loss, and alternative 
measures of adiposity.  
 
I analysed >955,000 electronic health records from the UK Clinical Practice 
Research Datalink for patients aged ≥60 years. I showed reduced mortality risks 
for those within the BMI Obese-1 range relative to those within the BMI Normal 
range across each age group. Mortality risks were reversed after restricting the 
analysis to ‘healthier agers’, demonstrating that the paradox is partly explained 
by the inclusion of smokers, adults with conditions associated with weight loss, 
and the chosen BMI referent group. Similarly, I document no support for 
reduced dementia risks for those within the BMI Obese-1 range. Additionally, 
there was an increased risk for incident of coronary heart disease and diabetes 
for those within the BMI Obese-1 range.   
 
BMI does not capture body composition changes with ageing. I found additional 
adiposity measures improved the mortality prediction compared to BMI only 
using the UK Biobank comprising >200,000 older volunteers. Mortality risks 
were increased for those who were centrally obese across the BMI Normal to 
Obese-1 range.    
 
In conclusion, I have shown the heterogeneity of older adults can result in 
disparate risk estimates for the association between BMI and health outcomes. I 
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provide additional evidence that reliance on BMI measures only may miss those 
at increased risk for health outcomes due to central adiposity. My results 
provide no support, in relatively healthy older adults, for the hypothesised 
obesity paradox in later life.   
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1.1. Background 
Since 1975 there has been a substantial increase in the global prevalence of 
obesity; in 2014, 266 million men and 375 million women were estimated to be 
obese compared to 34 million men and 71 million women in 1975 (Di Cesare et 
al., 2016). In 2013, the World Health Organization (WHO) published a global 
action plan to reduce health outcomes attributable to non-communicable 
diseases, including a target to halt the prevalence of obesity by 2025 to the 2010 
level (World Health Organization, 2013).  
 
Concurrent with the trend of rising obesity is an ageing population. Globally in 
2015, 901 million people were aged ≥60 years and 125 million aged ≥80 years 
(United Nations, Department of Economic and Social Affairs, Population Division 
2015). Obesity in older persons is emerging as a key public health issue with 
increasing numbers entering this life stage with values of body mass index (BMI) 
greater than that deemed healthy.  
 
It is well established that younger and middle aged adults within the body mass 
index defined Obese-1 (30.0-34.9 kg/m2) range are at an increased risk for 
cardiovascular disease, cancer, and mortality relative to those within the BMI 
Normal (18.5-24.9) range (Calle et al., 1999; Adams et al., 2006; Renehan et al., 
2007; Whitlock et al., 2009; Wormser et al., 2011). There is conflicting evidence, 
however, on the impact of the obesity trend for health outcomes in later life, 
specifically for mortality and dementia. Older persons within the BMI defined 
Obese-1 range have reportedly reduced or similar mortality risks relative to those 
within the BMI Normal range. This opposing mortality risk for the BMI Obese-1 
range has been termed the ‘obesity paradox’. There are several proposed 
contributors to this paradox in later life including: 
 
• Inadequate control for confounders e.g. smoking 
• Inadequate control for health status - reverse causation 
• The BMI referent group 
• The inability of BMI to capture body compositional changes with ageing 
• The length of follow-up 
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Interpretation of this evidence presents challenges regarding treatment and 
management of obesity in later life. Furthermore, there was no reference to the 
health implications of obesity in older persons in the recent WHO report on 
Ageing and Health (2015) (World Health Organization, 2015). It is therefore 
crucial to clarify whether older adults who are obese are or are not at a greater 
risk of mortality and diseases related to adiposity.  
This introductory chapter provides an overview on the definition and the 
prevalence of obesity, body composition changes with advancing age, the 
techniques available to assess adiposity, and epidemiological studies which have 
reported on the associations between BMI and health outcomes in younger and 
middle aged cohorts. Studies reporting on the associations between BMI and 
mortality in later life will then be summarised and the obesity paradox will be 
discussed. Additionally, studies reporting associations between BMI and 
dementia will be reviewed. The data sources used and the overall objective and 
aims of this thesis will be presented. 
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1.2. Definition and causes  
Obesity has been defined as the “abnormal or excessive fat accumulation that 
may impair health” (World Health Organization, 2000). Simplistically, this fat 
accumulation is due to an energy imbalance, in that energy intake has exceeded 
energy expenditure over an extended time frame (Comptroller and Auditor 
General, 2001; Bales and Buhr, 2008). The 2007 Foresight report emphasised 
that the body’s ability to balance energy is influenced by our rapidly changing 
environment; our physiology (including genetic predisposition), eating 
behaviours, physical activity, and psychosocial impacts were identified as four 
core areas influencing obesity. The vast array of influences underpins that obesity 
is a multifactorial disease (Butland et al., 2007).  
 
1.2.1. Body mass index  
In clinical practice, body mass index (BMI) is the most widely used metric to 
assess obesity, with values ≥30 kg/m2 classifying persons as obese (Willett, Dietz 
and Colditz, 1999; Bales and Buhr, 2008). BMI is used as a surrogate for 
adiposity, with a person’s weight (kilograms) scaled to their height (metres) 
squared (Aronne and Segal, 2002; Snijder et al., 2006). BMI is an inexpensive 
surrogate measure of obesity, requiring only height and weight measurements, 
enabling population comparisons and trends to be documented globally (Duren 
et al., 2008).  
 
Table 1.1 shows the WHO definitions for the BMI categories which have been 
incorporated in the National Institute of Health and Clinical Excellence (NICE) 
guidelines (World Health Organization, 2000; NICE Guidelines, 2014). These 
BMI categories were proposed to identify individuals, presently or in the future, at 
a heightened risk of obesity related conditions (Aronne and Segal, 2002). For the 
adult population, BMI categories are applied uniformly across the age range and 
these were primarily derived from epidemiological studies that used younger and 
middle aged adults (Janssen and Mark, 2007; Mathus-Vliegen, 2012). 
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Table 1.1 | WHO BMI Classification (World Health Organization, 2000) 
Definition BMI range kg/m2 
Underweight  <18.5 
Normal weight 18.5-24.9 
Overweight 25.0-29.9 
Obese ≥30.0 
    Obese-1 30.0-34.9 
    Obese-2 35.0-39.9 
    Obese-3 ≥40.0  
 
 
Applicability of the BMI categories across all ethnic groups and age ranges has, 
however, been questioned (Heiat, Vaccarino and Krumholz, 2001; Rolland et al., 
2014; Winter et al., 2014). NICE has recommended for Black African, Black 
African Caribbean, South Asian, and Chinese populations lower BMI thresholds 
for indicating increased type 2 diabetes risk (increased risk from BMI 23.0 kg/m2 
and high risk from BMI 27.5 kg/m2) (NICE Guidelines, 2013, 2014). The 
applicability of BMI categories for older adults will be discussed further in section 
1.8. 
 
1.3. Prevalence 
Globally in 2014, 266 million men (Credible Interval1 [CrI] 240, 290 million) and 
375 million (CrI 344, 407 million) women were classified as obese using the BMI 
metric. The global trend data for obesity do not suggest a substantial decline for 
any country (Di Cesare et al., 2016). In England, the Health Survey for England 
(HSE) is an annual survey which records the health status and lifestyle factors of 
adults and children inhabiting private households, and has enabled trend data to 
be documented since 1993 (NatCen Social Research, 2016). The HSE data for 
2015 further highlighted the severity of obesity across the older age range. Table 
1.2 shows the prevalence of adults within each BMI category for the age groups 
65 to 74, 75 to 84, ≥85 years by gender. For the youngest age group 29.9% of  
the females and 32.3% of the males were classified as BMI Obese (BMI ≥30 
kg/m2), and for the oldest age group this was 21.6% and 13.3%, respectively 
(Health Survey for England, 2017).  
                                            
1 Credible interval is equivalent to the uncertainty interval 
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Table 1.2 | Prevalence of BMI categories by age group for females and males 
from the Health Survey for England 2015 (Health Survey for England, 2017) 
 
BMI 
category 
(kg/m2) 
Females (%) Males (%) 
Age group (years) Age group (years) 
65 to 74 75 to 84 ≥85 65 to 74 75 to 84 ≥85 
  <18.5 1.0 1.6 0.8 0.2 0.7 1.7 
  18.5-24.9 33.9 29.1 37.8 22.3 22.7 25.1 
  25.0-29.9  35.2 39.2 39.8 44.2 51.5 60.0 
  30.0-39.9 26.4 28.0 20.3 30.3 25.1 13.3 
  ≥40.0   3.5 2.2 1.3 2.0 - - 
 
 
It should be noted that the response rate for providing valid height and weight 
measures for the HSE declined with advancing age. A valid BMI measure was 
available for 83% of the females aged 65 to 74 years surveyed, and 56% of the 
females aged ³85 years surveyed. For males, these figures were 88% and 63% 
respectively.  In the oldest age ranges, refusal of height and weight measures 
were predominantly due to health conditions which may have affected prevalence 
estimates (Moody, 2016). Furthermore, the reduced prevalence of obesity in later 
life may be due to selective survival (Villareal et al., 2005). 
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1.4. Body composition changes with ageing 
Overall, body weight and BMI tend to increase up to the seventh decade of life 
(Elia, 2001; Villareal et al., 2005; Zamboni et al., 2005; Miller and Wolfe, 2008). 
Muscle mass tends to decline from the third or fourth decade of life which is 
paralleled by an increase in fat mass (Villareal et al., 2005) and thereby weight 
may remain unchanged (Zamboni et al., 2014). Several longitudinal studies have 
reported on these body composition changes with advancing age. Gallagher et 
al., (2000) showed there was a decline in the total appendicular skeletal mass 
with no significant change in body weight for 24 males and 54 females aged 62 
to 96 years during a mean follow-up period of 4.7 years (Gallagher et al., 2000). 
This loss of skeletal mass during ageing is commonly referred to as sarcopenia 
(Zamboni et al., 2005). Furthermore, Hughes et al., (2004) reported an increase 
in fat mass but no significant change in body weight for 54 males and an increase 
in body weight and fat mass for 75 females during a maximum follow-up period 
of 12 years; participants were aged 46 to 78 years. For both genders, there was 
a significant decrease in subcutaneous fat mass (Hughes et al., 2004). Similarly, 
Fantin et al., (2007) documented that there was an increase in fat mass in weight 
stable (£ 3% weight loss) adults during a 5.5 year follow-up period; this analysis 
included 62 males (mean age 71.6 years) and 97 females (mean age 71.4 years). 
Appendicular and leg fat free mass were reduced during the follow-up (Fantin et 
al., 2007). There is also an increase in the proportion of fat mass within non-
adipose tissues with ageing. Muscular strength can be reduced from the 
deposition of triglycerides intramuscularly (Ellis, Crowe and Lawrence, 2013). 
 
With ageing, energy expenditure is reduced and there is also a redistribution of 
fat mass. Energy expenditure is reduced in part due to decreasing metabolic rate, 
physical activity, and fat oxidation (Elia, 2001; Villareal et al., 2005; Miller and 
Wolfe, 2008). There is a redistribution of excess fat mass into visceral adipose 
tissues (VAT) which is paralleled by a decline in subcutaneous fat mass (Zamboni 
et al., 2005; Miller and Wolfe, 2008). This fat redistribution is not captured using 
BMI (Zamboni et al., 2005; Snijder et al., 2006; Miller and Wolfe, 2008; Ellis, 
Crowe and Lawrence, 2013).  
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A stable BMI may conceal the increase in fat mass and subsequent decrease in 
fat free mass hence adiposity may be underestimated (Zamboni et al., 2005; 
Bales and Buhr, 2008). Gallagher et al., (1996) showed that the body fat 
percentage of older persons (>65 to 94 years) was greater than that of younger 
persons (20 to <35 years) when comparing the same BMI value (Gallagher et al., 
1996). Additionally, an overestimation of adiposity may occur due to loss in height 
from kyphosis and vertebral compression with ageing (Zamboni et al., 2005; 
Bales and Buhr, 2008). Sorkin, Muller and Andres (1999) reported that BMI 
values may be inflated by height loss with advancing age; for males this was 
estimated to be 0.7 kg/m2 by the eighth decade and 1.4 kg/m2 by the ninth decade 
using data from the Baltimore Longitudinal Study of Aging (BLSA). For females, 
these estimates were 1.6 kg/m2 by the eighth decade and 2.6 kg/m2 by the ninth 
decade (Sorkin, Muller and Andres, 1999). 
Batsis et al (2016) compared the BMI defined Overweight and Obese ranges to 
high body fat percentage derived from dual-energy X-ray absorptiometry (DXA) 
using National Health and Nutrition Examination Surveys (NHANES) 1994-2004 
survey data for adults aged ≥60 years (n = 4,984) (Batsis et al., 2016). In the age 
group 60 to 69 years, 85.7% of the males and 80.7% of the females were correctly 
classified as having a BMI value ≥25 kg/m2; for adults aged ≥80 years these 
figures were 65.8% for the males and 70.8% for the females. Furthermore, for 
those aged 60 to 69 years, 48.1% of the males and 49.0% of the females were 
correctly classified as obese; for adults aged ≥80 years these figures were 23.9% 
for the males and 38.4% for the females (Batsis et al., 2016). 
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1.5. Techniques to assess obesity and other components of 
body composition 
Along with BMI, there is a range of techniques available to assess adiposity and 
other components of body composition. The chosen techniques to assess 
adiposity can be influenced by funding, the sample size, and the size limitations 
of scanners (computerised tomography [CT] and magnetic resonance imaging 
[MRI]) (Snijder et al., 2006; Duren et al., 2008; National Academies of Sciences, 
Engineering, and Medicine, 2016; Teigen et al., 2016).  
1.5.1. Anthropometric measurements  
Anthropometric measures are used to determine the degree of adiposity, body 
mass, and body dimensions (Duren et al., 2008). Waist circumference, waist-to-
hip ratio (WHR), and waist-to-height ratio (WHtR) are used as surrogate 
measures of abdominal/central obesity (National Academies of Sciences, 
Engineering, and Medicine, 2016). Yusuf, et al., (2005) showed that 
independently of BMI, waist circumference and WHR were associated with 
myocardial infarction using a case control study (Yusuf et al., 2005). The WHO 
has published sex-specific thresholds for waist circumference measures and 
WHR, which have been defined for metabolic complications (World Health 
Organization, 2008). Skinfold thickness can be measured using callipers. The 
skin and the underlying subcutaneous fat thickness is recorded and these 
measures are incorporated into a pre-chosen formula to derive body fat 
percentage (Duren et al., 2008; National Academies of Sciences, Engineering, 
and Medicine, 2016). These measurements can easily be used in epidemiological 
studies and clinical settings.  
 
1.5.2. Impedance measures  
Bioelectrical impedance analysis (BIA) involves measuring the resistance to a 
low electrical current which is passed through the body, with fat mass acting as 
an insulator. Using these measures, fat mass and fat free mass estimates can be 
derived from prediction models (Kyle et al., 2004; Duren et al., 2008; National 
Academies of Sciences, Engineering, and Medicine, 2016). BIA is beginning to 
be used on a much larger scale in prospective studies including the UK Biobank 
(UK Biobank, 2007).  
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1.5.3. Body density measures  
Body density measures include hydrodensitometry (underwater weighing) and air 
displacement plethysmography and are based on body density assumptions. 
Comparisons are made between a person’s weight in water and a person’s 
weight on land after controlling for lung volume in hydrodensitometry. Persons 
with a greater proportion of body fat will be more buoyant relative to those with a 
lower proportion. In air displacement plethysmography, the air pressure inside 
the chamber with and without the person being assessed is compared. Body 
density measures are not practical at the population level (Duren et al., 2008). 
 
1.5.4. Imaging techniques 
Imaging techniques include DXA, CT and MRI. Bone mineral density, fat mass, 
and fat free mass can be estimated using DXA which is based on the attenuation 
of two different energy X-rays, exerting a very low dose of radiation (Duren et al., 
2008; National Academies of Sciences, Engineering, and Medicine, 2016). A 
disadvantage is that subcutaneous adipose tissue and visceral adipose tissue 
cannot be differentiated. CT scans and MRI scans are considered the most 
accurate techniques (gold standards) for measuring subcutaneous adipose 
tissue and visceral adipose tissue (Ness-Abramof and Apovian, 2008; García-
Ptacek et al., 2014).  CT and MRI scans are not suitable at the population level 
due to costs, length of assessment, and with CT scans persons are exposed to 
high radiation doses (Duren et al., 2008; National Academies of Sciences, 
Engineering, and Medicine, 2016; Teigen et al., 2016).  
 
Suitability of the use of these approaches for measuring obesity in clinical practice 
and research settings is determined by the strengths and weaknesses associated 
with each measure and this is presented in supplementary material table S1.1.  
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1.6. BMI and health outcomes in younger and middle aged 
cohorts 
It has been well established that there is an increased mortality risk for younger 
and middle aged adults within the BMI Obese range relative to those within the 
BMI Normal range. Increased mortality risks were reported for males aged 40 to 
59 years, without coronary heart disease (CHD), diabetes, or stroke within the 
BMI Obese range (Relative Risk [RR] 1.42 95% Confidence Interval [CI] 1.07, 
1.87) relative to those within the BMI 20.0-21.9 kg/m2 range during a 15 year 
follow-up period using the British Regional Heart Study (Wannamethee et al., 
1998). Similarly, increased mortality risks were documented for females without 
cardiovascular disease or cancer and aged 30 to 55 years across the BMI Obese 
range relative to those within the BMI <21.0 kg/m2 range, over a 24 year follow-
up period using the Nurses’ Health Study. Mortality risks were 1.57 (CI 1.44, 1.71) 
for those within the BMI 30.0-32.9 kg/m2  range, and 2.89 (CI 2.47, 3.38) for those 
with a BMI ³40 kg/m2 (Hu et al., 2004).  
 
There has been speculation that the increasing prevalence of obesity in the 
United States of America (US) could lead to gains in life expectancy stagnating 
(Stewart, Cutler and Rosen, 2009) or even declining (Olshansky et al., 2005). 
Globally for 2015, a BMI of >25 kg/m2 was estimated to cause 3.96 million deaths 
(Uncertainty Interval [UI] 2.73 million, 5.3 million) (Forouzanfar et al., 2016). The 
Prospective Studies Collaboration (2009) reported a 37% (CI 1.31, 1.42) 
increased mortality risk per 5 kg/m2 increment in BMI from BMI 25.0 kg/m2 for 
adults aged 35 to 59 years, inclusive of 57 cohorts with the first five years of 
follow-up excluded and adjustments made for age, sex, smoking status, and 
study site. For never smokers the mortality risk was increased by 43% (CI 1.32, 
1.55) per 5 kg/m2 increment (Whitlock et al., 2009). 
 
BMI defined obesity has been associated with a range of cardiovascular risk 
factors. For males within the BMI Obese-1 range there were increased odds for 
diabetes (Odds Ratio (OR) 11.2 CI 9.3, 13.6), hypertension (OR 2.7 CI 2.4, 3.0), 
and high cholesterol (OR 1.2 CI 1.1, 1.3) relative to those within the BMI range 
18.5-24.9 kg/m2 during a 10 year follow-up period using the Health Professionals 
Follow up Study (HPFS) (n = 46,060; mean age 54.5 years). Similarly, for females 
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within the BMI Obese-1 range, there were increased odds of diabetes (OR 10.0 
CI 8.4, 11.8) and hypertension (OR 2.1 CI 1.9, 2.2), but not high cholesterol using 
the Nurses’ Health study (n = 77,690; mean age 52.9 years) (Field et al., 2001). 
Blood glucose, blood pressure and cholesterol have been found to mediate the 
increased risks with elevated BMI for stroke and coronary heart disease by 76.0% 
(CI 65.0, 91.0%) and 46.0% (CI 42.0, 50.0%), respectively, from a combined 
analysis of 97 cohort studies (Lu et al., 2014).  
 
Obesity has been associated with a range of outcomes including asthma, cancer, 
cardiovascular disease, depression, osteoarthritis and type 2 diabetes. Reported 
associations from meta-analyses inclusive of younger, middle and older aged 
cohorts for these health outcomes are presented in the supplementary material 
text S1.1. Obesity has been reported to be associated with disability and 
admittance to a nursing home facility. Backholer et al., (2012) reported increased 
odds for impairment in Activities of Daily Living (ADL) of 16% (CI 1.11, 1.21) for 
persons within the BMI Obese-1 range relative to those within the BMI Normal 
range, from a meta-analysis of eight cross-sectional studies for adults aged ³19 
years. There were increased odds of impairment in ADL of 76% (CI 1.28, 2.41) 
for those within the BMI Obese-2 range, from a meta-analysis of five cross 
sectional studies (Backholer et al., 2012). Persons within the BMI Obese-1 and 
BMI Obese 2 and 3 combined ranges were shown to be more likely to be admitted 
to a nursing home facility relative to those within the BMI Normal range, Hazard 
Ratio (HR) 1.31 (CI 1.07, 1.61) and HR 1.69 (CI 1.22, 2.34), respectively, during 
a maximum follow-up period  of 20 years for white ethnicity adults aged 45 to 75 
years (n = 5,447) using the NHANES (Zizza et al., 2002). 
 
For older adults, there is conflicting evidence on the impact of the obesity trend 
for health outcomes, especially mortality and dementia. Researchers have not 
only questioned the use of the conventional BMI thresholds, which were derived 
primarily from younger and middle aged adults, but also how to define obesity in 
later life (Heiat, Vaccarino and Krumholz, 2001; Zamboni et al., 2005; Oreopoulos 
et al., 2009; Rolland et al., 2014; Winter et al., 2014). The remainder of this 
chapter will, therefore, focus on the associations between obesity and mortality 
and dementia for adults aged ≥65 years.  
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1.7. BMI and mortality in later life 
 
1.7.1. Meta-analyses reporting on BMI defined obesity and mortality  
Prior to the start of my PhD (1st April 2014) there had been two published meta-
analyses assessing the association between BMI and mortality for adults aged 
≥65 years, in terms of reporting relative risks or hazard ratios. During my PhD 
research, there have been four published meta-analyses (with one being an 
individual participant meta-analysis). Table 1.3 documents the time frame, 
inclusion and exclusion criteria, databases searched, number of studies retained, 
statistical methods and the reported mortality risk estimates for these meta-
analyses.  
 
There is conflicting evidence on the association between mortality risk and BMI 
measured obesity. Whilst Jansen and Mark (2007) reported elevated mortality 
risks for those within the BMI Obese-1 range relative to those within the BMI 
Normal range, Flegal et al. (2013) found a stagnation of risks for the BMI ranges 
Obese-1, Obese-2 and Obese-3 combined, as well as reduced risks for those 
within the BMI Overweight range relative to the BMI Normal range (Janssen and 
Mark, 2007; Flegal et al., 2013). Moreover, Janssen and Mark (2007) found 
reduced mortality risks for those within the BMI Overweight and BMI Obese-1 
ranges for analyses which used measured height and weight, had less than ten 
years of follow-up, and were conducted from 1990 onwards. In contrast, an 
increased mortality risk was reported for those within the BMI Overweight range 
for studies which excluded major disease(s) at baseline (RR 1.04 CI 1.01, 1.07). 
Janssen and Mark (2007) noted that very few analyses used the conventional 
BMI categories for the BMI Overweight and BMI Obese ranges. The main 
limitation of the systematic review by Janssen and Mark (2007) is that only one 
database was interrogated, therefore some analyses may have been missed 
(Janssen and Mark, 2007). A major criticism of the review by Flegal et al., (2013) 
is the use of a broad reference category as it encompasses current smokers, 
those with conditions associated with weight loss, and physically active adults 
(Keith, Fontaine and Allison, 2013; Tobias and Hu, 2013; Willett, Hu and Thun, 
2013). Additionally, the baseline examination period, length of follow-up, or ethnic 
origin of the participants were not considered. Flegal et al., (2013) also excluded 
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a high proportion of large scale cohorts and consortia due to the use of narrower 
BMI categories (Tobias and Hu, 2013).  
 
Four additional meta-analyses were published during my PhD. The meta-
analyses by Winter et al., (2014) partly aligns with the BMI mortality risk estimates 
reported by Flegal. Mortality risks were reduced for those within the BMI 
Overweight range (HR 0.90 CI 0.87, 0.93), and the risks were not significantly 
different for those within the BMI Obese-1 range (HR 0.96 CI 0.90, 1.02) or the 
BMI Obese 2 & 3 ranges (HR 1.18 CI 1.00, 1.39) relative to those within the BMI 
referent group 21.0-24.9 kg/m2. However, when a narrower BMI referent group 
was used, 23.0-23.9 kg/m2, there were increased mortality risks for those with 
BMI values exceeding 33.0 kg/m2. For analyses restricted to never smokers and 
analyses which had not adjusted for factors along the causal pathway (e.g. 
diabetes), risks for mortality were increased at BMI values >32.0 kg/m2 (Winter 
et al., 2014). Moreover, Aune et al., (2016) reported an increased mortality risk 
of 4% (CI 1.01, 1.07) per 5-unit increment in BMI for never smokers. However, in 
the non-linear dose response analysis, there was an increased mortality risk 
below the reference BMI 23 kg/m2 (Aune et al., 2016). Recently, the Global BMI 
Mortality Collaboration (2016) reported that the lowest mortality risk was at BMI 
24.0 kg/m2 for never smoking adults aged 70 to 89 years without prevalent 
chronic disease, and with the first five years of follow-up excluded. For all classes 
of obesity, there were increased mortality risks relative to those within the BMI 
Normal range (Di Angelantonio et al., 2016). Additionally, Wang (2015) reported 
that with advancing age there was a decline in the mortality risks for those within 
the BMI Obese range. However, this analysis was carried out by one reviewer, 
only one database was interrogated, and the inclusion and exclusion criteria of 
the studies were not clearly defined. Studies were required to report on two or 
more age groups, and therefore some additional studies could have been used 
within each age category by relaxing this criterion (Wang, 2015). 
 
In Chapter 3 I report on my meta-analysis for the BMI Overweight and Obese-1 
ranges with mortality, therefore, to avoid repetition/ duplication individual studies 
will be discussed in that chapter.  
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1.7.2. Continuous measures of BMI and mortality  
The effect of advancing age on the association between continuous BMI and 
mortality has been documented by several studies. Adams et al., (2006) showed 
a U-shaped association between BMI and mortality; with advancing age, there 
was a marginal decline in the mortality risks for those within the BMI Obese range 
during a 10 year follow-up for adults aged 50 to 71 years (n = 527,265) using the 
NIH-AARP study (Adams et al., 2006). Peter et al., (2015) reported that with 
advancing age the BMI range associated with the lowest mortality risk shifted to 
higher values for never smokers. For males this was to age 80 years, and the 
BMI mortality curves attenuated during a median follow-up duration of 18.6 years 
using the Vorarlberg Health Monitoring and Prevention Program (n = 129,904) 
(Peter et al., 2015).  
 
Several studies have reported on the BMI range associated with the lowest risk 
for mortality. Flicker et al., (2010) documented that the minimum mortality risk for 
adults aged 70 to 75 years was within the BMI Overweight range, with the nadir 
at 26.6 kg/m2 (CI 25.7, 27.5 kg/m2) for males and at 26.3 kg/m2 (CI 25.5, 26.9 
kg/m2) for females during a 10 year follow-up period using the Health in Men 
Study (HIMS) and the Australian Longitudinal Study of Women’s Health (ALSWH) 
(n = 4,677 men and n = 4,563 women). Mortality risks were increased in the 
conventional BMI Normal range and BMI Obese range (Flicker et al., 2010). van 
Ufelen et al., (2010) also reported on the risks for females aged 70 to 75 years 
using the ALSWH but with a longer follow-up duration of 12 years and larger 
sample size (n = 11,553). The association between BMI and mortality was U-
shaped with the minimum mortality risk in accordance with the previous study, 
this being 25.0-27.0 kg/m2 (van Uffelen et al., 2010). Likewise, mortality risks 
were reported by de Hollander et al., (2012) for adults aged 70 to 75 years (n = 
1,970) using the Survey in Europe on Nutrition and the Elderly: a concerted action 
(SENECA) study. Over a maximum follow-up period of 10 years, the nadir of the 
mortality risk was 27.1 kg/m2 (CI 24.1, 29.3 kg/m2) (de Hollander et al., 2012 b). 
An increased mortality risk was found for those with BMI values >31.4 kg/m2. 
Moreover, Rolland et al., (2014) showed that the association between BMI and 
mortality was J-shaped for females aged ³75 years (n = 3,793) during a median 
follow-up period of 17.7 years using the Epidemiologie de l’Osteoporose study.  
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The minimum mortality risk was at a BMI value 28.6 kg/m2. Mortality risks were 
increased from values ≤24.6 kg/m2 (Rolland et al., 2014). Similarly, Cheng et al., 
(2016) reported that the lowest risk for mortality was within the BMI range 28.0-
30.0 kg/m2 during a mean follow-up duration of 10.9 years for adults aged 66.8 
to 93.9 years (n = 4,565 years), from the Geisinger Rural Aging Study (GRAS) 
(Cheng et al., 2016).  
 
Comparing the literature reporting on the association between BMI and mortality 
can be difficult due to studies using varying follow-up periods, model adjustments 
are not uniform, the BMI referent group is not consistent, the number and 
thresholds for BMI groups are not consistent (some studies will categorise all 
obese adults while some will subdivide into classes), subgroups chosen, sample 
size, and age groups (Baumgartner, Heymsfield and Roche, 1995; Zamboni et 
al., 2005; Teucher, Rohrmann and Kaaks, 2010). Additionally, populations differ 
in the prevalence of chronic conditions, risk factor exposure, and overall mortality 
rates. Challenges with epidemiological studies with older adults are documented 
within Table 1.4.  
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Table 1.4 | Challenges of epidemiological studies with older adults  
Challenges 
Participation 
 
Behavioural factors and health status (e.g. prevalent 
diseases) may differ between those who respond and 
non-responders. Volunteers may be healthier (Karasu, 
2012; Rizzuto and Fratiglioni, 2014). 
Selective survival Adults susceptible to adverse effects of the exposure of 
interest may have already died (Karasu, 2012; Rizzuto 
and Fratiglioni, 2014). 
Cognitive decline  Older adults may have difficulty comprehending 
questionnaires, providing accurate information (e.g. 
height may be recalled from an earlier stage of life), and 
recalling previous exposures and health conditions 
(Karasu, 2012; Rizzuto and Fratiglioni, 2014). 
Exposure  Reverse causality may affect the exposure. Exposures 
may be misclassified due to self-report (e.g. adults may 
be embarrassed to reveal the extent of behavioural 
factors) (Karasu, 2012; Rizzuto and Fratiglioni, 2014). 
Attrition  Older adults are more likely to die during the study period 
or drop out due to declining health. This could lead to an 
underestimation of the association between exposures 
and morbidity (Karasu, 2012; Rizzuto and Fratiglioni, 
2014).  
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1.8. The obesity paradox 
As discussed early an increased mortality risk for those within the BMI Obese 
range relative to those within the BMI Normal range has been established for 
younger and middle aged cohorts. In later life, those within the BMI Obese range 
have reportedly reduced or similar mortality risks relative to those within the BMI 
Normal range. This opposing mortality risk for the BMI Obese range has been 
termed the obesity paradox (Bales and Buhr, 2008; Oreopoulos et al., 2009; 
Dorner and Rieder, 2012; Mathus-Vliegen, 2012; Cetin and Nasr, 2014; García-
Ptacek et al., 2014; Dixon et al., 2015). This has led to further debate regarding 
the optimal BMI range for longevity in later life (Al Snih et al., 2007; Bales and 
Buhr, 2009).   
 
Some researchers have argued that there should be a major revision of the BMI 
thresholds, and claim that the obesity paradox is not a paradox but rather the 
result of an upwards shift for the BMI range associated with the lowest mortality 
risk with advancing age (Dixon et al., 2015). Additionally, Bales and Buhr (2009) 
and Fontana and Hu (2014) have emphasised that these paradoxical BMI 
mortality findings are in discordance with longevity expansion documented in 
non-humans following dietary restriction (Bales and Buhr, 2009; Fontana and Hu, 
2014).  
 
Concerns have been raised on the health implications of the obesity paradox, as 
health care treatment and management of older persons with obesity will be 
determined by the interpretation of the evidence (Al Snih et al., 2007; Heymsfield 
and Cefalu, 2013; Cetin and Nasr, 2014). There is apprehension that this could 
undermine and reduce momentum in public health interventions aimed at 
preventing and treating obesity (Stevens et al., 2015). However, if persons with 
obesity in later life are at a reduced mortality risk, treatment may, therefore, 
provide no benefit, and perhaps cause harm (Cetin and Nasr, 2014). Table 1.5 
details some of the main methodological and biological explanations for the 
‘obesity paradox’. This will be followed by a discussion of epidemiological studies 
which have assessed some of these proposed explanations.  
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Table 1.5 | Methodological and biological explanations for the obesity paradox 
Explanations  
Adjustment for 
intermediate 
mediators 
 
Mortality risk estimates may be biased if adjustment is made 
for intermediates (e.g. diabetes and hypertension) as these 
are within the causal pathway linking obesity to mortality 
(Manson et al., 1995; Willett, Dietz and Colditz, 1999).  
Cohort effect 
 
The BMI and mortality risk estimates may vary for different 
cohorts due to different lifestyle factors, environmental 
factors and characteristics (Seidell and Visscher, 2000; Elia, 
2001; Zamboni et al., 2005; Oreopoulos et al., 2009). 
Competing risk 
factors 
 
The number of competing risk factors accumulates with 
advancing age thereby the effect of BMI on health outcomes 
may be attenuated (Janssen and Mark, 2007; Teucher, 
Rohrmann and Kaaks, 2010). 
Higher BMI 
values exerts a 
protective 
effect 
 
A higher BMI may provide metabolic reserves during acute 
illness (Berraho et al., 2010; Fontana and Hu, 2014; Rizzuto 
and Fratiglioni, 2014). Weight loss may be tolerated to a 
greater extent in persons with higher BMI values (Al Snih et 
al., 2007). Additionally, the risk of fracture may be reduced 
with higher BMI values due to a greater proportion of bone 
mineral density (Heymsfield and Cefalu, 2013; Cheng et al., 
2016). 
Length of 
follow-up 
 
Studies with shorter follow-up durations are less likely to 
report a positive association between BMI and mortality for 
persons within the BMI Obese range (Oreopoulos et al., 
2009; Mathus-Vliegen, 2012; Rizzuto and Fratiglioni, 2014). 
Life expectancy 
 
Life expectancy declines with advancing age. Obesity related 
diseases/conditions take years to develop, and people may, 
therefore, die of non-obesity related causes (Seidell and 
Visscher, 2000; Elia, 2001; Zamboni et al., 2005; Oreopoulos 
et al., 2009; Mathus-Vliegen, 2012). 
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Table 1.5 continued 
Physical activity 
and 
cardiorespiratory 
fitness 
These may confound or modify the relationship between 
BMI and mortality (Teucher, Rohrmann and Kaaks, 2010; 
Yerrakalva, Mullis and Mant, 2015). 
Reverse 
causality 
 
Chronic disease or undiagnosed disease, which are 
associated with an increased mortality risk, can result in 
weight loss thereby lowering a person’s BMI value (Willett, 
Dietz and Colditz, 1999; Kvamme et al., 2012; Tobias and 
Hu, 2013; Fontana and Hu, 2014). Following a diagnosis 
(e.g. diabetes), a person may consciously attempt to lose 
weight. With advancing age, the likelihood of reverse 
causality contributing to the obesity paradox increases 
(Tobias and Hu, 2013; Fontana and Hu, 2014). This can be 
minimised by excluding persons with weight loss associated 
diseases, reported weight loss, and excluding early follow-
up to account for undiagnosed disease (as deaths during 
the initial follow-up period are likely to be due to pre-clinical 
disease) (Willett, Dietz and Colditz, 1999; Adams et al., 
2006; Fontana and Hu, 2014). 
Risk measures  
 
Stevens et al., (1998) and Calle et al., (1999) highlighted 
from analyses of the Cancer Prevention Study I and Study 
II that with advancing age there is a decline in the relative 
risk for the associations between BMI and mortality, 
although the absolute mortality rates are much higher in the 
oldest age group relative to the youngest (Stevens et al., 
1998; Calle et al., 1999). 
Selective 
survival 
 
Persons may have already died at a younger age from 
obesity related diseases or conditions, thereby survivors 
may be “resistant” to the effects of obesity  (Elia, 2001; 
Zamboni et al., 2005; Oreopoulos et al., 2009; Mathus-
Vliegen, 2012; Fontana and Hu, 2014). 
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Table 1.5 continued 
Smoking   
 
Smoking is associated with an elevated mortality risk and 
also with lower weight thereby a decreased BMI (Willett, 
Dietz and Colditz, 1999; Chiolero et al., 2008). BMI mortality 
risk estimates can, therefore, be distorted with the inclusion 
of smokers. There will be variability in the intensity and the 
extent of cigarette smoking (Tobias and Hu, 2013). For older 
adults, the health implications of smoking are likely to be 
accentuated compared to younger adults due to a longer 
exposure to cigarette smoking (Stevens, 2000). Therefore, 
adjusting for smoking status has been considered 
inadequate. Residual bias can be minimised by excluding 
smokers (Willett, Dietz and Colditz, 1999; Tobias and Hu, 
2013; Fontana and Hu, 2014).             
The BMI 
referent group  
 
The conventional BMI Normal range in later life will comprise 
of persons who have always been within this range and 
physically active, smokers, and those who previously were 
in the BMI Overweight or Obese ranges but are at a lower 
BMI due to weight loss associated conditions. The 
combining of these different groups may elevate the 
mortality risk for the conventional BMI Normal range and 
thereby distort mortality risk estimates for higher BMI values 
(Willett, Dietz and Colditz, 1999; Heymsfield and Cefalu, 
2013; Tobias and Hu, 2013; Fontana and Hu, 2014). 
Approaches have included modelling BMI continuously to 
determine the BMI range associated with the lowest 
mortality risk (de Hollander et al., 2012 b; Cheng et al., 
2016). Persons within the BMI Normal range could 
additionally be centrally obese. This is not captured by BMI 
and could lead to distorted mortality risk estimates for higher 
BMI values as persons who are centrally obese have been 
shown to have increased mortality risks. 
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Table 1.5 continued 
The inability of 
BMI to capture 
body 
compositional 
changes with 
ageing 
 
Body compositional changes with advancing age can lead 
to both an underestimation of BMI due to increased fat 
mass, but also an overestimation of BMI due to height loss 
(Zamboni et al., 2005; Bales and Buhr, 2008). Allison et al., 
(1997) highlighted that the use of BMI may conceal the 
contributions of fat mass and fat free mass to mortality, and 
recommended the use of body composition measures in 
future analyses (Allison et al., 1997). Additionally, BMI does 
not measure fat distribution. With ageing fat is redistributed 
to a centralised position, and accounting for this body 
change may be of greater importance in later life (Zamboni 
et al., 2005; Miller and Wolfe, 2008). 
Treatment  
 
Treatment of hypertension, cholesterol, and diabetes, which 
are associated with obesity, may have led to the mortality 
risk estimates for persons with obesity lessening (Zamboni 
et al., 2005; Keith, Fontaine and Allison, 2013; Holme and 
Tonstad, 2015). Persons within the BMI Overweight and 
Obese ranges may be more likely to be monitored, to 
receive medical treatment, and present earlier to health care 
practitioners (Mehta and Chang, 2011; Heymsfield and 
Cefalu, 2013; Holme and Tonstad, 2015). Additionally, 
public health interventions aimed at the general population 
(e.g. Change for Life) and specific patient populations may 
have attenuated the mortality risks (Holme and Tonstad, 
2015). Thus, these lifestyle and medical treatments would 
not have been encompassed in studies with earlier baseline 
periods (e.g. pre 1990s)  (Heymsfield and Cefalu, 2013; 
Holme and Tonstad, 2015).  
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1.8.1. Explanations for the obesity paradox  
 
BMI referent group 
Increased mortality risks have been documented for those within the conventional 
BMI Normal range. As discussed earlier, Rolland et al., (2014) showed there were 
increased mortality risks for females with BMI values ≤24.6 kg/m2 and aged ≥75 
years (Rolland et al., 2014). Likewise, Winter et al., (2014) reported there were 
increased mortality risks for those with BMI values <23.0 kg/m2 relative to those 
within the BMI range 23.0-23.9 kg/m2 for adults aged ≥65 years (Winter et al., 
2014). Additionally, de Hollander et al., (2012) highlighted that using BMI 
categories may conceal BMI associations with mortality. There were no 
significant associations between BMI categories and mortality. However, when 
BMI was assessed continuously there were significant associations with 
mortality, with an increased risk reported for BMI values >31.4 kg/m2 (de 
Hollander et al., 2012 b). 
    
Several studies have reported on the association between continuous measures 
of BMI and mortality to investigate whether the lowest mortality risk lies at the 
boundary of the current BMI thresholds. These continuous associations were 
discussed previously in section 1.7.2. The BMI range associated with the lowest 
mortality risk tended to be within the BMI Overweight range (Flicker et al., 2010; 
van Uffelen et al., 2010; Rolland et al., 2014; Cheng et al., 2016). In contrast, the 
Prospective Studies Collaboration (2009) reported that the lowest mortality risk 
was within the BMI range 22.5-25.0 kg/m2 for all age groups, inclusive of 57 
cohort studies (Whitlock et al., 2009). Associations between continuous 
measures of BMI will be discussed further in Chapter 5.  
 
Body compositional changes  
Sarcopenia  
BMI is a measure of the combination of fat mass and fat free mass. Allison, et al., 
(1997) documented that fat mass and fat free mass have opposing effects on 
mortality, with fat mass increasing the risk, thus potentially limiting the use of BMI 
in the elderly (Allison et al., 1997). As highlighted in section 1.4, with ageing there 
is a decrease in fat free mass and muscle mass which is paralleled by an increase 
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in fat mass and thereby weight and thus BMI may remain unchanged (Villareal et 
al., 2005; Zamboni et al., 2014). The age-associated loss of skeletal muscle mass 
and function is referred to as sarcopenia (Zamboni et al., 2005). Brown, et al., 
(2016) reported that for adults aged ≥60 years (n = 4,425), sarcopenia was 
associated with an increased mortality risk of 29% (95% CI 1.13, 1.47) over a 
median follow-up period of 14.4 years using data from NHANES III. Participants 
were classified with sarcopenia if they had low muscle mass (skeletal mass index 
<10.76 kg/m2 for men and <6.75 kg/m2 for women) combined with low gait speed 
(gait speed ≤0.8m/s) (Brown, et al., 2016). Similarly, Hirani, et al., (2015) reported 
an increased mortality risk for males aged ≥70 years (n = 1,705) who were 
classified as having sarcopenia, with a 69% increased risk in the fully adjusted 
model (95% CI 1.17, 2.44) over a median follow-up period of 7.0 years using data 
from Concord Health and Ageing in Men Project (CHAMP). Sarcopenia was 
defined as both low appendicular lean mass (<19.75 kg) and low gait speed (≤0.8 
m/s) (Hirani, et al., 2015). At present there is, however, no universal agreement 
on the thresholds for defining sarcopenia (Wannamethee and Atkins, 2015). 
Therefore, the inability for BMI to account for the age-related changes with body 
composition could contribute to the paradoxical associations reported in later life.        
 
Central adiposity 
As highlighted in section 1.4, with ageing fat mass is redistributed into visceral 
adipose tissues (VAT) which is paralleled by a decline in subcutaneous fat mass 
which BMI is not able to capture (Zamboni et al., 2005; Snijder et al., 2006; Miller 
and Wolfe, 2008; Ellis, Crowe and Lawrence, 2013). Persons with central obesity, 
even within the BMI Normal range, have been shown to have increased mortality 
risks (de Hollander et al., 2012 a). The use of other measures will be discussed 
in greater detail within the remainder of this chapter, Chapter 7 and Chapter 8.  
Length of the follow-up period 
As highlighted earlier, Janssen and Mark (2007) reported there were reduced 
mortality risks for those within the BMI Obese-1 range (RR 0.78 CI 0.72, 0.84) 
relative to those within the BMI Normal range for studies which had a follow-up 
period <10 years with 13 analyses meta-analysed. In contrast, there were 
increased mortality risks for those within the BMI Obese-1 range (RR 1.22 CI 
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1.17, 1.28) for studies which had a follow-up period of ≥10 years with 11 analyses 
meta-analysed (Janssen and Mark, 2007).  
 
Confounding by smoking  
Corrada et al., (2006) reported that for never and former smokers there was an 
increased mortality risk for persons within the BMI Obese range relative to those 
within the conventional BMI Normal range during a maximum follow-up period of 
23 years (3% of the sample were aged <65 years). For current smokers, there 
was no increased mortality risk for those within the BMI Obese range relative to 
those within the conventional BMI Normal range (Corrada et al., 2006). Similarly, 
Adams et al., (2006) showed that the magnitude of the association between 
obesity and mortality during a 10 year follow-up was stronger for never smokers 
compared to former or current smokers for adults aged 50 to 71 years (n = 
527,265) using the NIH-AARP study. The authors analysed associations between 
BMI and mortality for never smokers without prevalent disease (cancer, 
emphysema, end-stage renal disease, heart disease and stroke) across narrower 
age groups, however, these results were not presented (Adams et al., 2006). 
Dolan et al., (2007) documented that there were reduced mortality risks for 
women within the second, third, and fourth quintile of BMI relative to those within 
the first quintile during 8 years of follow-up for women aged  ³67 years (n = 8,029) 
using the Study of Osteoporotic Fractures. Those within the fifth BMI quintile were 
not significantly different to those within the first quintile for mortality. All the 
quintiles became not significantly different to those within the first quintile for 
mortality when the analysis was restricted to never smokers (Dolan et al., 2007). 
de Hollander et al., (2012) reported that the BMI range associated with the lowest 
mortality risk was shifted to the left when the analyses was restricted to never 
smokers for adults aged 70 to 75 years using the SENECA study (de Hollander 
et al., 2012 b). 
 
Confounding by chronic disease 
van Uffelen et al., (2010) documented that the shape of the mortality risk curve 
and the minimum mortality BMI range were little changed after the exclusion of 
women with a history of cancer. A U-shaped relationship was shown and the 
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minimum mortality risk was found within the range 25.0–27.0 kg/m2 for women 
aged 70 to 75 using the ALSWH (van Uffelen et al., 2010). 
 
Confounding by smoking and pre-existing diseases 
Al Snih et al., (2007) found that excluding current smokers plus those who died 
during the first two years of follow-up did not markedly alter the BMI and mortality 
associations for those aged ³65 years from 5 sites of the Established Populations 
for Epidemiologic Studies of the Elderly (EPESE) with a maximum follow-up 
period of seven years (n = 12,725). Those with a BMI of 25.1 kg/m2 (CI 23.6, 26.6 
kg/m2) had the lowest mortality risk (Al Snih et al., 2007). Flicker et al., (2010) 
also reported that the minimum mortality risk for adults aged 70 to 75 years was 
little changed when the analysis was restricted to a healthier subset (exclusion of 
smokers and those with a history of chronic respiratory illness, diabetes, heart 
disease, hypertension, or stroke) with the minimum mortality risk remaining within 
the BMI Overweight range during a 10 year follow-up period using the HIMS and 
ALSWH studies (Flicker et al., 2010). Conversely, Berrington de Gonzalez et al., 
(2010) found a U-shaped association between BMI and mortality during a median 
follow-up duration of 10 years for adults aged 19 to 84 years using data from 19 
prospective cohorts. Exclusion of current and former smokers, and subsequently 
those with heart disease or cancer, resulted in higher mortality risks associated 
with BMI values of ≥25 kg/m2 and a J-shaped association (Berrington de 
Gonzalez et al., 2010). Furthermore, Cheng et al., (2016) reported reduced 
mortality risks from the fully adjusted model, for those within the BMI Overweight 
range HR 0.80 (CI 0.71, 0.90) and the BMI Obese-1 range HR 0.78 (CI 0.69, 
0.89) relative to those within the conventional BMI Normal range during a mean 
follow-up duration of 10.9 years for adults aged 66.8 to 93.9 years (n = 4,565) 
using the GRAS. Restricting the analyses to never smokers without prevalent 
disease at baseline (Charlson index), or to never smokers with the first two or five 
years of follow-up excluded, shifted the mortality risk estimates to be non-
significant for both the BMI Overweight and BMI Obese ranges relative to those 
within the conventional BMI Normal range (Cheng et al., 2016).    
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Exclusion of early deaths 
Allison et al., (1999) reported that the effect of excluding deaths was significant 
but there was little change in the magnitude of the association between BMI and 
mortality from a meta-analysis of 29 studies. Assessing the mortality risks by 
smoking status did not markedly change the results. There were also no 
significant age associations. The range of years excluded was 1 to 10 years, with 
an overall mean of 3.78 years. The age range was 14 to 100 years, with an overall 
mean age of 52.24 years (Allison et al., 1999). Berraho et al., (2010) documented 
that the BMI mortality risk estimates were not markedly changed after excluding 
deaths during the first three years of follow-up for adults aged ≥65 years (n = 
3,646) during a maximum follow-up period of 13 years using the PAQUID cohort 
study (Berraho et al., 2010). Mortality risks were not significantly different for 
those within the BMI Overweight and BMI Obese-1 range relative to those within 
the BMI range 22.0-24.9 kg/m2. Similarly, Flicker et al., (2010) reported that the 
minimum mortality risk for adults aged 70 to 75 years was little changed when 
the analysis excluded those who died within the first, second, or third year of 
follow-up, remaining within the BMI Overweight range using the ALSWH and 
HIMS studies (Flicker et al., 2010). van Uffelen et al., (2010) also used the 
ALSWH and showed that the shape of the mortality risk curve and the minimum 
mortality BMI range were little changed after the exclusion of the first five years 
of follow-up with a U-shaped relationship and the minimum mortality risk within 
the range 25.0–27.0 kg/m2 for women aged 70 to 75 years (van Uffelen et al., 
2010). 
 
Physical activity and cardiorespiratory fitness 
The “fit but fat” theory was coined after some research findings showed that 
persons within the BMI Obese range combined with good fitness levels had 
survival advantages compared to those who were thin combined with poor fitness 
levels. Yerrakalva, Mullis and Mant (2015) reported from their systematic review 
that 14 out of 15 studies showed that the inverse associations between BMI and 
mortality remained after further adjustment for physical activity or 
cardiorespiratory fitness for adults aged ³60 years. However, only two studies 
out of all the analyses adjusting for physical activity used a validated physical 
activity questionnaire, and thus the poor measure of physical activity could 
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contribute to paradoxical findings. The authors commented that more studies are 
required using cardiorespiratory fitness rather than a poor physical activity 
measure (Yerrakalva, Mullis and Mant, 2015).  
 
Use of other measures to assess obesity and components of body 
composition  
The prognostic value of other adiposity measures such as circumference 
measures (e.g. waist, waist-to-hip and waist-to-height), and body fat measures 
(e.g. body fat percentage and fat mass) has been examined in the literature. 
Furthermore, some studies have estimated the associations between measures 
of fat free mass and health outcomes. These approaches have assessed 
individual and combined measures (either through cross classification or 
adjustment for other measures) with health outcomes in later life. Comparisons 
between these measures have included examining the risk estimates per one 
standard deviation increment, deriving the area under the receiver operator 
curve, and comparing category risk estimates (e.g. quintiles). 
 
There have been two systematic reviews on the use of other measures to assess 
obesity and components of body composition. Chang et al., (2012) reported there 
was no consistency on which of the body fat distribution measures is associated 
with the strongest mortality risk from a systematic review of 17 studies, with most 
inclusive of adults aged ≥65 years (Chang et al., 2012). Carmineke et al., (2013) 
reported that measures of abdominal adiposity provide additional risk information 
independently of BMI and both measures could be utilized in general practice for 
risk stratification from a systematic review of 18 prospective cohort studies (6 
studies were inclusive of adults aged ≥65 years) (Carmienke et al., 2013). Chang 
et al., (2012) and Carmineke et al., (2013) highlighted that comparisons between 
studies can be difficult due to the choice and number of covariates incorporated 
into statistical models, the age range chosen (risks may differ between the 
youngest and oldest old), the methods used to assess body composition (e.g. 
BIA or DXA), categorization of anthropometric measures, and any chosen 
exclusion criteria (Chang et al., 2012; Carmienke et al., 2013).  
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de Hollander et al., (2012) reported on the joint associations of BMI and waist 
circumference measures from a meta-analysis of 29 cohorts (n = 58,000). The 
following groups were used for the waist circumference measures; small (<94 cm 
for males and <80cm for females) and large (≥102 cm for males and ≥88cm for 
females). For adults aged 65 to 74 years, there were elevated mortality risks 
during the five year follow-up period across the BMI categories for those with a 
large waist relative to those with a BMI within the range 20.0-24.9 kg/m2 
combined with a small waist, with adjustments made for age and smoking. Males 
and females within the BMI range 20.0-24.9 kg/m2 combined with a large waist 
had an increased mortality risk (males RR 1.7 CI 1.2, 2.2; females RR 1.7 CI 1.3, 
2.3). Similarly, for those within the BMI Overweight range combined with large 
waist there were increased mortality risks (males RR 1.1 CI 1.0, 1.3; females RR 
1.4 CI 1.1, 1.7). Likewise, for those within the BMI Obese range combined with 
large waist there were increased mortality risks (males RR 1.1 CI 1.0, 1.3; 
females RR 1.6 CI 1.3, 1.9). Analyses restricted to never smokers, exclusion of 
those with major prevalent disease, exclusion of deaths within the first two years, 
or narrower age groups (65 to 69 years and 70 to 74 years) did not significantly 
alter the results for mortality. However, this review had a response rate of 28 out 
of 100 contacted investigators collaborating to the meta-analysis (de Hollander 
et al., 2012 a).  
Additional studies which have reported on mortality risks for other adiposity 
measures and components of body composition will be discussed in Chapters 7 
and 8 to avoid repetition.  
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1.9. Obesity and dementia 
Paradoxical BMI risks have been shown for dementia. In midlife, those within the 
BMI Obese range have been reported to be at an increased risk for dementia 
relative to those within the BMI Normal range (Kivipelto et al., 2005; Whitmer et 
al., 2005). Pedditzi et al., (2016) reported an increased risk for dementia of 41% 
(CI 1.20, 1.66) for those within the BMI Obese range relative to those within the 
BMI Normal range, from a meta-analysis of four studies which had a mean 
participant age <65 years. However, there were reduced risks for dementia of 
17% (CI 0.74, 0.94) for those within the BMI Obese range relative to those within 
the BMI Normal range from a meta-analysis of four studies with a mean 
participant age of ³65 years. There was no significant difference between those 
within the BMI Overweight range (RR 0.88 CI 0.76, 1.02) relative to those within 
the BMI Normal range for dementia from a meta-analysis of five studies. 
Additionally, the authors reported that six studies had used a continuous measure 
for BMI for those within the BMI Obese range with one positive, two inverse, and 
three non-significant associations for dementia. For the overweight range, three 
showed inverse associations and four non-significant associations (Pedditizi, 
Peters and Beckett, 2016; Pedditzi, Peters and Beckett, 2016). In a previous 
meta-analysis by Xu et al., (2015) estimates were also reported for the 
association between high BMI and dementia. However, the included studies 
differed on their definition of a high BMI and the BMI control category was not 
clearly defined (Xu et al., 2015).   
 
Individual studies 
Epidemiological studies which have reported on the associations between BMI 
and dementia for adults aged ³65 years published since 1st January 2000 and 
including over 1,000 adults are summarised in the supplementary material tables 
S1.2 and S1.3. Comparability, again, between these studies is challenging due 
to the different age ranges chosen, the length of follow-up, the BMI categories, 
and model adjustments. None of the studies used a competing risks approach to 
estimate the association between BMI and incident dementia.  
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Dementia risks for the BMI Obese range 
Equivocal risks have been reported for the association between the BMI Obese 
range and incident dementia relative to those within the BMI Normal range. An 
increased risk for incident dementia was reported for those within the BMI Obese 
range (HR 1.76 CI 1.03, 2.88) relative to those with a BMI <30.0 kg/m2 over a 
maximum follow-up period of 5 years for adults aged ≥65 years from the Cache 
Country Study of Memory Health and Aging (Hayden et al., 2006). In contrast, 
Fitzpatrick et al., (2009) documented reduced risks for incident dementia for 
those within the BMI Obese range (HR 0.63 CI 0.44, 0.91) relative to those within 
the BMI range 20.0-25.0 kg/m2 over a mean follow-up period of 5.4 years for 
adults aged 65 to 97 years from the Cardiovascular Health Study (CHS) 
(Fitzpatrick et al., 2009). Power et al., (2010) found the risk for incident dementia 
was not significantly different for those within the BMI Obese range (HR 0.82 CI 
0.67, 1.01) relative to those within the BMI 18.5-24.9 kg/m2 over a maximum 
follow-up period of 13.4 years for males aged 65 to 84 years using the HIMS 
(Power et al., 2011). Tolppanen et al., (2014) also showed the risk for incident 
dementia was not significantly different for those within the BMI >30 kg/m2 range 
(HR 0.55 CI 0.23, 1.34) relative to those within the BMI <25 kg/m2 range during 
the follow-up period for adults aged 65 to 79 years from the Cardiovascular risk 
factors, Aging and Dementia Study (Tolppanen et al., 2014). Moreover, Wotton 
and Goldacre (2014) documented the risks for incident dementia differed 
depending on the age range.  The risks for incident dementia were not 
significantly different for those within the BMI Obese range (RR 0.97 CI 0.93, 
1.01) relative to those who were non-obese according to BMI for adults aged 70 
to 79 years but was associated with a reduced risk for adults aged ≥80 years (RR 
0.78 CI 0.74, 0.82) over a maximum follow-up period of 14 years using a record 
linkage cohort study (Wotton and Goldacre, 2014). The BMI associations with 
dementia will be discussed further in Chapter 6.  
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Explanations 
The proposed explanations for the reversal of BMI risks with dementia show 
similarities to those suggested for the reversal of BMI risks with mortality in later 
life (Luchsinger et al., 2007; Atti et al., 2008; Fitzpatrick et al., 2009; Tolppanen 
et al., 2014). 
These include:  
• Attenuation of health risks with advancing age  
• Broad age range 
• Reverse causation  
• Selective survival 
• The BMI referent group 
• The inability of BMI to capture body compositional changes with ageing 
 
Weight loss has been reported to precede the clinical diagnosis of dementia 
within the previous decade (Knopman et al., 2007). Therefore, the conventional 
BMI Normal range may contain persons whose BMI has been reduced due to 
preclinical stages of dementia and thus risk estimates for higher BMI categories 
may be distorted. 
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1.10. Overall summary 
There is conflicting evidence on the association between the BMI Obese-1 range 
and mortality in later life. Moreover, several analyses have shown that those 
within the BMI Overweight range have the lowest mortality risk. There is equivocal 
evidence on the association between BMI defined obesity and incident dementia. 
These mixed results can lead to confusion on how to treat, manage, and convey 
research evidence to the public. Comparisons between studies are challenging 
due to different age groups, time frames used, model adjustments, BMI 
categories, the BMI referent group and the exclusion criteria. Assessing the 
association between BMI and health outcomes in later life is crucial as this is the 
predominant metric used to assess obesity. As highlighted in Table 1.5 there are 
many proposed contributors to the paradoxical associations in later life. A multiple 
simultaneous approach is required as BMI mortality risk estimates may be biased 
if only one contributor (e.g. smoking) is assessed. A limited number of studies 
have used a multiple simultaneous approach. Thus, there is a need to use large 
datasets to account concurrently for multiple contributors (e.g. smoking, weight 
loss associated disease, and the BMI referent group) to the paradox.   
1.11. Data sources 
In this thesis, I use two English datasets, namely the Clinical Practice Research 
Datalink (CPRD) and the UK Biobank. These complimentary datasets offer a 
unique opportunity to provide updated estimates on the health implications of BMI 
defined obesity using a population-representative dataset (CPRD) and from a 
volunteer cohort study (UK Biobank). The CPRD is a research service which 
maintains a large database of de-identified medical health records collated in 
primary care establishments (CPRD, 2017). For English patients there has been 
external linkage to Hospital Episode Statistics (HES) and the Office for National 
Statistics (ONS) (Williams et al., 2012; Herrett et al., 2015; Stevenson, 2015). 
Due to the large scale of the datasets, stratified analyses accounting for smoking 
and conditions associated with weight loss, both of which can distort risk 
estimates, can be achieved whilst maintaining a sufficient sample size to detect 
statistical associations. The UK Biobank is a prospective cohort study with 
enrolment of volunteers aged 40 to 69 years initiated in 2006-2010. As with the 
CPRD there has been external linkage to HES and ONS (Allen et al., 2012; 
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Sudlow et al., 2015; Trehearne, 2016). This dataset not only allows estimates for 
health outcomes to be reported for BMI but also for other surrogate measures of 
adiposity (e.g. waist circumference, WHR, and WHtR) and components of body 
composition measures (e.g. body fat percentage, and fat mass index) as these 
were concurrently collected at baseline.              
 
1.12. Thesis objectives  
The overall aim of this thesis is, therefore, to clarify whether older persons with 
obesity are or are not at a greater risk for mortality and for dementia. I will then 
assess whether persons within the BMI Overweight range have the lowest 
mortality risk. The associations between BMI and CHD and diabetes will also be 
estimated. There is great urgency to provide updated risk estimates due to the 
increasing prevalence of obesity in England in later life. Methodological flaws in 
the analysis stages of previous studies such as inadequate control for smoking, 
inclusion of persons with conditions associated with weight loss, and the chosen 
BMI referent group may have caused these mixed messages regarding the health 
implications of obesity for mortality and dementia. Assessing the impact of a 
single contributor (e.g. smoking) to the paradox could still result in flawed BMI 
mortality risk estimates and thus a multiple simultaneous approach is required. 
Clinical practice guidelines on managing and treating obesity were not intended 
to be used for already ill persons. Other adiposity measures and components of 
body composition will be assessed as BMI is unable to capture the body 
composition changes with ageing. These will be assessed individually and jointly 
with BMI.  
 
 
The objectives of this thesis are:  
 
1. To conduct a review and meta-analysis of cohort studies which reported 
mortality risk estimates for adults aged ≥65 years for the BMI Overweight 
range and/or BMI Obese-1 range. To determine the influence of specific 
exclusions (smokers, conditions associated with weight loss, and early 
follow-up) and combinations of exclusions with consideration of the BMI 
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referent group for the risk of mortality. This is presented in Chapter 3.  
2. To estimate the associations between the WHO BMI categories and 
mortality using a large cohort of population representative patients (aged 
³60 years) – the CPRD –  within narrower age bands, and additionally to 
estimate the associations in subgroups of ‘healthier agers’ and ‘non-
healthier agers’. This is presented in Chapter 4. 
 
3. To re-define the BMI referent group by estimating the continuous BMI 
association with mortality, and to use this revised referent group to 
estimate the associations for mortality, incident coronary heart disease, 
and type 2 diabetes using the CPRD for adults aged ³60 years. This is 
presented in Chapter 5. 
 
4. To estimate BMI associations with incident dementia using a revised 
referent BMI group assessing the impact of short and longer term follow-
up with a competing risks approach using the CPRD for adults aged 65 to 
74 years. This is presented in Chapter 6. 
 
5. To estimate the associations between the WHO BMI categories and 
mortality using a large volunteer cohort. Secondly, to compare established 
measures of body fat distribution and body composition to BMI for mortality 
prediction for ‘healthier agers’ within the seventh decade of life and to 
describe the concordance (percentage agreement) between categories of 
BMI and these different measures using the UK Biobank. This is presented 
in Chapter 7. 
 
6. To estimate associations between combined measures of BMI and waist-
hip ratio with mortality, and incident coronary heart disease using the UK 
Biobank. This is presented in Chapter 8. 
 
An overview of the methods used in this thesis will be provided in Chapter 2.  
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1.13. Publications  
 
During my PhD I have had two first author paper publications. One forms the 
basis of Chapters 4 and 5.  
 
Bowman, K., Delgado, J., Henley, W. E., Masoli, J. A., Kos, K., Brayne, 
C., Thokala, P., Lafortune, L., Kuchel, G. A., Ble, A., & Melzer, D. (2017) 
Obesity in Older People With and Without Conditions Associated With 
Weight Loss : Follow-up of 955,000 Primary Care Patients. J Gerontol A 
Biol Sci Med Sci.  Editor’s Choice. 72(2): 203–209. 
   
The second manuscript forms the basis of Chapter 8. 
 
Bowman, K., Atkins, J.L., Delgado, J., Kos, K., Kuchel, G.A., Ble, A., 
Ferrucci, L., & Melzer, D. (2017) Central adiposity and the overweight risk 
paradox in aging:  follow-up of 130,473 UK Biobank participants. AJCN.  
06(1):130-135.  
  
 
I have submitted Chapter 6 for publication. I have also collaborated on several 
papers which are presented in the supplementary material text 1.2.   
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1.14. Structure of thesis 
Chapter 1 provides the background to this thesis. An overview on the definition 
and prevalence of obesity is provided. Epidemiological studies reporting on the 
association between BMI and health outcomes in younger and middle aged 
cohorts, and in later life are summarised. Contributors to the ‘Obesity paradox’ 
are discussed. The overall aim and objectives are presented. Chapter 2 
describes the data sources (CPRD and UK Biobank) and the statistical 
techniques used within this thesis. Chapters 3 to 8 presents the analyses from 
the six objectives and are structured in the format of a manuscript: summary, 
introduction, methods, results, discussion and conclusion. Chapter 9 
summarises the research findings from this thesis.   
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Table S1.1 | Advantages () and disadvantages (x) to the approaches to 
assess adiposity and other components of body composition 
Approach ü Advantages û Disadvantages 
Anthropometric measures   
   Body mass index 
 
 
ü Most frequently 
used index 
ü Population and 
trend comparisons 
ü Inexpensive and 
non-invasive  
ü Quick and easy to 
measure  
ü Minimal to zero 
training required 
û Fat mass and fat 
free mass cannot 
be differentiated 
û Surrogate measure 
of adiposity  
û Correlation between 
BMI and fat mass 
modified with 
fitness, ethnicity, 
and age  
û Does not measure 
fat distribution 
    Skinfold thickness ü Inexpensive û Training required 
û Intraobserver/ 
interobserver errors 
û Body contact 
required 
û Different methods 
and formulas 
    Waist circumference 
 
ü Inexpensive 
ü One measure 
ü Quick to measure 
ü Suitable for 
population 
surveillance 
û Subcutaneous 
adipose tissue and 
visceral adipose 
tissue cannot be 
differentiated 
û Training required 
and different 
protocols 
û Intraobserver/ 
interobserver errors  
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Table S1.1 continued 
 ü Advantages û Disadvantages 
   Waist circumference  
   continued 
 û Body contact 
required 
û Proxy for central 
adiposity 
û Does not account 
for body stature 
   Waist-to-hip ratio/ 
   Waist-to-height ratio 
 
ü Inexpensive 
ü Adjustment for 
body shape 
ü Quick to measure 
ü Suitable for 
population 
surveillance 
 
û Subcutaneous 
adipose tissue and 
visceral adipose 
tissue cannot be 
differentiated  
û Training required 
and different 
protocols 
û Intraobserver/ 
interobserver errors 
û Body contact 
required 
Impedance   
    Bioelectrical Impedance 
    Analysis (BIA) 
             
 
ü Easily measured 
ü Non-invasive 
ü Inexpensive 
ü Portable devices 
ü Quick to measure 
û Differences in 
quality and 
accuracy of 
devices 
û Intraobserver/ 
interobserver 
errors 
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Table S1.1 continued 
 ü Advantages û Disadvantages 
    BIA continued  û Readings can be 
affected by skin 
conditions, body 
composition, and 
fluid volume 
û Subcutaneous 
adipose tissue and 
visceral adipose 
tissue cannot be 
differentiated  
û Some machines 
may estimate from 
specific limbs only 
e.g. arms 
Densitometry   
   Air displacement 
  plethysmography 
 
ü Measure of body 
fat  
û Training required 
û Specialised and 
expensive 
equipment 
û Persons required to 
wear close fitting 
bathing suit and cap 
û Not practical at the 
population level 
   Hydrodensitometry 
   (underwater weighing) 
 
ü Measure of body 
fat 
û Not practical at the 
population level 
û Time consuming 
û Training required 
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Table S1.1 continued 
 ü Advantages û Disadvantages 
   Hydrodensitometry  
   continued 
 
 û Requires full body 
water submersion 
and for the person 
to remain still 
û Specialised and 
expensive 
equipment 
û Measurements can 
be affected by the 
humidity and 
temperature 
Imaging   
   Computed tomography  
   (CT) 
 
ü Subcutaneous 
adipose tissue and 
visceral adipose 
tissue measured 
ü Non-adipose 
tissues can be 
measured 
 
û High radiation 
doses  
û Time consuming 
û Not practical at the 
population level 
û Interpretation of 
results can be 
affected by patient 
alignment and the 
slice thicknesses  
û Specialised and 
expensive 
equipment 
   Dual energy X-ray  
   absorptiometry 
 
ü Bone, fat mass and 
fat free mass can 
be estimated 
ü Whole body 
imaging 
û Manufacturer 
assumptions vary 
û Machine algorithms 
vary  
û Training required 
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Table S1.1 continued 
 ü Advantages û Disadvantages 
   Dual energy X-ray  
   absorptiometry 
    continued 
 
 û Subcutaneous 
adipose tissue and 
visceral adipose 
tissue cannot be 
differentiated 
û Specialised and 
expensive 
equipment 
   Magnetic resonance  
   imaging (MRI) 
 
ü Subcutaneous 
adipose tissue and 
visceral adipose 
tissue measured 
ü No radiation 
exposure  
û Specialised and 
expensive 
equipment  
û Not practical at the 
population level 
û Time consuming  
 
This table has been based on a number of papers (Kyle et al., 2004; Snijder et 
al., 2006; Duren et al., 2008; Ness-Abramof and Apovian, 2008; World Health 
Organization, 2008; National Academies of Sciences, Engineering, 2016; Teigen 
et al., 2016).   
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Text S1.1 | Reported associations between BMI and a range of health 
outcomes from meta-analyses 
	
Cardiovascular outcomes  
Wormser et al., (2011) reported an increased risk for CHD of 29% (CI 1.22, 1.37) 
per 4.56 kg/m2 increment for adults (mean age 58 years) with a BMI ³20 kg/m2 
using 51 studies. There was an increased risk for ischaemic stroke of 20% (CI 
1.12, 1.28) per 4.56 kg/m2 increment for adults (mean age 58 years) with a BMI 
³20 kg/m2 using 25 studies. Adjustments were made for age, sex, and smoking 
(Wormser et al., 2011).  
 
Cancer subtypes 
Renehan et al., (2008) documented on the relative risks associated with a 5 kg/m2 
increment for a range of cancer subtypes from 141 articles. For males, there was 
an increased relative risk for the following cancer sites and types: oesophageal 
adenocarcinoma (RR 1.52 CI 1.33, 1.74), thyroid (RR 1.33 CI 1.04, 1.70), colon 
(RR 1.24 CI 1.20, 1.28), renal (RR 1.24 CI 1.15, 1.34), malignant melanoma (RR 
1.11 CI 1.05, 1.18), multiple myeloma (RR 1.11 CI 1.05, 1.18), rectum (RR 1.09 
CI 1.06, 1.12), leukaemia (RR 1.08 CI 1.02, 1.14), and non-Hodgkin lymphoma 
(RR 1.06 CI 1.03, 1.09). For females, there were increased risks for the following: 
endometrium (RR 1.59 CI 1.50, 1.68), gallbladder (RR 1.59 CI 1.02, 2.47), 
oesophageal adenocarcinoma (RR 1.51 CI 1.31, 1.74), renal (RR 1.34 CI 1.25, 
1.43), leukaemia (RR 1.17 CI 1.04, 1.32), thyroid (RR 1.14 CI 1.06, 1.23), 
postmenopausal breast (RR 1.12 CI 1.08, 1.16), pancreas (RR 1.12 CI 1.02, 
1.22), multiple myeloma (RR 1.11 CI 1.07, 1.15) and colon (RR 1.09  CI 1.05, 
1.13) (Renehan et al., 2007).  
 
Type 2 diabetes 
Vazquez et al., (2007) showed an increased risk for type 2 diabetes of 87% (CI 
1.67, 2.10) per 4.3 kg/m2 increment for adults aged between 20 and 80 years 
using 32 studies (Vazquez et al., 2007).  Moreover, Guh et al., (2009) reported 
the risks for incident type 2 diabetes separately for males and females. For males 
aged ³35 years, there was an increased risk for type 2 diabetes for those within 
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the BMI Obese range (RR 6.74 CI 5.55, 8.19) relative to those within the BMI 
Normal range using four studies. For females aged ³30 years, there was an 
increased risk for type 2 diabetes for those within the BMI Obese range (RR 12.41 
CI 9.03, 17.06), using four studies (Guh et al., 2009).    
 
Depression 
Luppino et al., (2010) documented an increased odds of depression of 57% (CI 
1.23, 2.01) for persons within the BMI Obese range relative to those who were 
non-obese using four studies (Luppino et al., 2010). Increased odds of 
depression of 18% (CI 1.01, 1.37) for those within the BMI Obese range relative 
to those who were non-obese were also reported for adults aged ³14 years using 
17 studies (de Wit et al., 2010). Gariepy, Nitka and Schmitz (2010), found the 
odds of anxiety disorders were increased by 40% (CI 1.2, 1.6) for persons within 
the BMI Obese range relative to those who were non-obese for adults aged ³15 
years using 13 studies (Gariepy, Nitka and Schmitz, 2010).  
 
Asthma 
Beuther and Sutherland (2007) reported an increased odds of incident asthma 
after 12 months of follow-up for those within the BMI Obese range (OR 1.92 CI 
1.43,  2.59) relative to those within the BMI Normal range using seven studies 
(Beuther and Sutherland, 2007).  
	
Osteoarthritis and back pain  
Guh et al., (2009) showed an increased risk for osteoarthritis for males and 
females within the BMI Obese range (males: RR 4.20 CI 2.76, 6.41; females RR 
2.19 CI 1.77, 2.71) relative to those within the BMI Normal range using two 
studies (Guh et al., 2009). Jiang et al., (2011) found an increased risk for hip 
osteoarthritis per 5-unit increment in BMI (RR 1.11 CI 1.07, 1.16) using 14 studies 
(Jiang et al., 2011). Blagojevic et al., (2010) reported increased odds of knee 
osteoarthritis for those within the BMI Obese range (OR 2.22 CI 1.91, 2.57) 
relative to those within the BMI Normal range using 12 cohort studies with the 
participants mean age 50 years (Blagojevic et al., 2010). An increased risk for 
knee osteoarthritis per 5-unit increment in BMI (RR 1.35 CI 1.21, 1.51) was also 
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found from a meta-analysis of 21 studies. (Jiang et al., 2012). Shiri et al., (2009) 
reported increased odds of lower back pain for those within the Obese range (OR 
1.33 CI 1.14, 1.54) relative to those within the BMI Normal range, using eight 
cross sectional studies. This was also the case using five cohort studies, (OR 
1.53 CI 1.22, 1.92) (Shiri et al., 2010).   
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2.1. Summary 
This chapter provides an overview of the datasets used in this thesis, namely the 
UK Clinical Practice Research Datalink (CPRD) and the UK Biobank. The 
strengths, challenges, and suitability of these datasets, as well as a description 
of the statistical analyses used and their appropriateness for addressing the 
research objectives set in Chapter 1, will be discussed.  
 
The CPRD and the UK Biobank were chosen as the datasets to analyse for this 
thesis as both are large scale, provide recent, 1st January 2000 onwards, BMI 
measures for older adults and offer high quality UK data. The two datasets are 
complimentary as the CPRD is a population representative dataset and the UK 
Biobank is a volunteer prospective cohort study. Both datasets allow stratified 
analyses (e.g. by smoking status and health status) whilst maintaining a sufficient 
sample size to detect statistical associations.  
 
2.2. Overview of the UK Clinical Practice Research Datalink 
(CPRD) 
The UK Clinical Practice Research Datalink (CPRD) is a research service which 
operates to maintain a large electronic health database of de-identified medical 
records collated in primary care establishments (CPRD, 2017). Initiated in April 
2012 and financially supported by the NHS National Institute for Health Research 
(NIHR) and the Medicines and Healthcare Projects Regulatory Agency (MHRA), 
the CPRD is an expansion of the General Practice Research Database (GPRD); 
this former database incorporated the Value Added Medical Products (VAMP) 
dataset which was founded in 1987 (Herrett et al., 2015; CPRD, 2017). The 
overarching aim of the CPRD is to facilitate researchers with access to de-
identified health and social care datasets for observational research which may 
lead to enhanced public health care (Herrett et al., 2015; Stevenson, 2015). Since 
the commencement of this research service, advances in drug safety have been 
made and research findings have steered health guidelines. One of the major 
advantages with the CPRD is that multiple datasets can be linked e.g. primary 
and secondary care.   
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2.2.1. National Health Service 
In the UK, universal healthcare is provided by the National Health Service (NHS) 
without cost being incurred to patients for appointments or hospital admissions 
and treatment (prescriptions, however, may involve payment). More than 98% of 
the UK population are registered with a general practitioner (GP) for primary care  
with each patient having a specific NHS number (Williams et al., 2012; Herrett et 
al., 2015; Stevenson, 2015). Within the NHS, GPs provide the initial consultation 
forum for health situations perceived as non-emergency i.e. not assumed to need 
hospital care (Wood and Martinez, 2004). Following an appointment at the 
general practice surgery, patients may be referred to specialists at the secondary 
care level (Garcia Rodriguez and Perez Gutthann, 1998). Secondary care data 
can be submitted back to the GP.  
 
2.2.2. Quality and Outcomes Framework (QOF) 
In England, the Quality and Outcomes Framework (QOF) was initiated in 2004 
and is comprised of indicators (achievement measures) offering financial rewards 
to general practitioners. These indicators are centralised around three main 
domains: clinical, public health, and public health-additional services. Examples 
of indicators include documenting patients with cancer (clinical domain), 
documenting patients aged ≥45 years who have had a blood pressure reading 
within the preceding five years (public health domain), and the uptake of cervical 
screening for women aged 25 to 64 years (public health-additional services). 
QOF indicators are annually updated with the removal and addition of indicators 
(Primary Care Domain, NHS Digital,  2016). Melzer et al., (2015) reported on the 
prevalence of 18 common diseases using the CPRD (n = 27,109) for the time 
frame 2003/2004 to 2011/2012 for the two age groups 65 to 84 years and ≥85 
years. For the youngest age group, the prevalence of chronic kidney disease 
(CKD) stages 3-5 was 0.2% (95% CI 0.1, 0.6%) in 2003/2004 and 16.0% (CI 
14.4, 17.9%) in 2011/2012, showing an absolute difference of 15.8% (CI 14.4, 
17.2%). For the oldest age group these figures were 0.0% (CI 0.0, 0.3%) for 
2003/2004 and 36.4% (CI 33.9, 39.1%) for 2011/2012 showing an absolute 
difference of 36.4% (CI 34.8, 38.0%). Between 2005 to 2007 there was a marked 
increase in the prevalence of CKD which may partly be explained by the 
introduction in 2006 of the QOF CKD register (Melzer et al., 2015).  
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2.2.3. CPRD GOLD Dataset 
De-identified primary care medical records are held by the research service within 
the CPRD GOLD dataset for UK patients registered with general practices which 
have opted to be part of this service (Herrett et al., 2015; Stevenson, 2015). This 
constitutes approximately 8.8% of the UK population as of September 2014 
(Stevenson, 2015). Figure 2.1 shows the map of the CPRD practices which were 
considered up to standard on the 2nd July 2013. Patients may opt out of the 
service and to date less than 0.5% have declined to have their medical records 
used for research (Herrett et al., 2015; Stevenson, 2015). The CPRD GOLD 
dataset reliably supplies information relating to health care, demographics, 
lifestyle factors, and referrals for further consultations in secondary care (Herrett 
et al., 2015).  
 
Figure 2.1| Distribution of the CPRD practices which were up to standard on the 
2nd July 2013. Figure from (Herrett et al., 2015) 
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2.2.4. Primary care records 
Patients can receive health care consultations in person or via telephone 
conversations, which are logged electronically on a continuous basis (Herrett et 
al., 2015). Medical records for patients from practices contributing to the CPRD 
GOLD dataset may span from their first consultation through to death, relocation, 
or until the last data collection for the practice. Medical health care data are 
collated monthly from the practices. During or following a medical consultation, 
symptoms, diagnoses, test results, health related behaviours, and prescriptions 
can be logged. Most diagnoses and symptoms are documented using Read 
Codes alongside the relevant date, with multiple codes permitted. Additional 
clinical data can be added numerically in association with the appropriate Read 
Code, e.g. weight can be recorded in kilograms. GP’s can also supplement the 
records with text input, although this is not freely accessible for research 
purposes (Herrett et al., 2015). Table 2.1 presents details on the range of files 
available within the CPRD GOLD Dataset.  
 
Table 2.1 | Data files available within the CPRD GOLD dataset 
Data file Data content and example(s) 
Practice Demographics e.g. region 
Patients Demographics e.g. age, gender, registration 
Staff Staff details e.g. nurse 
Consultation Type e.g. surgery consultation 
Clinical Medical diagnoses e.g. diabetes 
Symptoms e.g. exhaustion  
Additional  
(linked to the clinical file) 
Provides further details on diagnoses and 
symptoms e.g. weight in kilograms 
Therapy Prescriptions e.g. beta blockers 
Referral Referrals to specialists at secondary care level 
e.g. nose, throat and ear specialist 
Test Laboratory results e.g. estimated glomerular 
filtration rate 
Immunisations Vaccinations e.g. tetanus 
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2.2.5. CPRD data quality  
There are internal reviews to improve the quality of the electronic health records 
conducted by CPRD personnel before release to researchers. Data are inspected 
at both the patient level (patient acceptability) and practice level (up to standard 
date). Checks at the patient level include registration status, ensuring 
consultations occur after the patient’s year of birth, patients are aged <115 years, 
and gender is documented (Wood and Martinez, 2004; Williams et al., 2012). At 
the practice level this involves checking the reported mortality is in line with the 
anticipated range and without gaps in data capture (Williams et al., 2012; Herrett 
et al., 2015). Following the introduction of the Quality and Outcomes Framework 
(QOF) in 2004, the recording of many diagnoses, health behaviours, and 
conditions has improved (Herrett et al., 2015).     
 
2.2.6. CPRD data linkage 
Where possible the CPRD facilitates linkages to other datasets. Currently 75% of 
practices involved with the CPRD in England (overall 55% of the UK CPRD 
practices) can be linked to additional datasets, including Hospital Episode 
Statistics (HES), socioeconomic status, registered cancers, and deaths (Office 
for National Statistics [ONS]) (Williams et al., 2012; Herrett et al., 2015; 
Stevenson, 2015). 
 
2.2.7. Validity and completeness of electronic health records  
Although electronic records are advantageous in terms of the scale of data that 
can be analysed, it is important to consider the quality of the medical records.  
Herrett et al., (2010) systematically reviewed the literature on the quality of 
medical records for diagnoses or syndromes and death records. The authors 
included 212 publications which comprised 357 validations of 183 unique 
diagnoses with most using external data sources. The median number of 
confirmed cases was 86.2% (range 33.0 to 100.0%) for validations carried out 
internally (n = 31) and 88.6% (range 24.0 to 100.0%) for those carried out 
externally (n = 143). More specifically, the median proportion of confirmed cases 
was 95.3% (range 74.0 to 100.0%) for the disease group neoplasms and 85.3% 
(range 48.0 to 100.0%) for circulatory diseases. Comparisons of the incidence 
and prevalence of diseases tended to be comparable to external data sources 
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except for rheumatoid arthritis and musculoskeletal diseases (Herrett et al., 
2010).  
 
Similarly, Khan, Harrison and Rose (2010) conducted a systematic review of the 
validity of the GPRD electronic medical records, which included 49 papers with 
40 of these validating diagnoses or lifestyle variables; the positive predictive 
value (PPV) tended to be over 50%. However, papers reporting on acute liver 
injury or acute renal failure reported lower PPVs (<50%). Three papers reported 
on the validity of myocardial infarctions (MI), with the lowest PPV reported as 
81.6% (range 79.3 to 83.7%), and the highest PPV as 92.6% (range 88.3 to 
95.7%). For diabetes, the PPV was reported as 98.6% (range 92.2 to 100.0%) 
(Khan, Harrison and Rose, 2010). Further details on the validity and 
completeness of the variables used in the CPRD analyses for Chapters 4 to 6 
are provided in Table 2.2.  
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Table 2.2 | Validity and completeness of variables from the CPRD used in this 
thesis 
Variable Validity and completeness  
   BMI Bhaskaran et al., (2013) assessed the completeness of BMI records 
using a random sample of one million patients aged ³16 years from 
the CPRD. From the period 1990-1994 to 2005-2011 there was an 
increase in the proportion of registered patients with a BMI record. 
For those aged 65 to 74 years 36.0% had a BMI record (within the 
preceding three years) in the time frame 1990-1994, whereas 67.0% 
had a BMI record for the time frame 2005-2011. Compared to the 
Health Survey for England data (HSE) 2010, the age and sex 
standardised mean BMI was considerably lower. The difference 
between the data sources was smaller when using more recent BMI 
values (within the previous 3 years) (Bhaskaran et al., 2013). 
  Cancer 
 
Boggon et al., (2012) reported on the concordance between cancer 
records within the CPRD and cancer registries. The concordance 
rate was reported to be 83.3% for the two sources using a sample 
of 101,020 patients during the time frame 1st April 1997-31st 
December 2006 (Boggon et al., 2013). Dregan et al., (2012) also 
reported on the agreement between cancer records within the 
CPRD and cancer registries using a sample of 42,556 patients for 
the time frame 1st January 2002-31st December 2006. The 
concordance between the two sources was 91% (Dregan et al., 
2012). 
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Table 2.2 continued  
Dementia Dunn et al., (2005) reported on the survey results from GPs of 95 
dementia cases (probable and possible) and 55 controls, who had 
been asked questions regarding diagnosis of dementia and the 
date of diagnosis. The first date of dementia diagnoses matched 
for 53.0%. The range for the date of diagnosis of the unmatched 
cases was between -7 and 0 weeks (Dunn et al., 2005). Brown et 
al., (2016) compared dementia diagnoses in the CPRD, HES and 
a GP survey using a sample of 102,076 women enrolled in the 
Million Women Study. The concordance between a dementia 
record with HES and CPRD was 85.0% (CI 80.0, 88.0%). Read 
codes relating to the first mention of dementia tended to appear in 
the CPRD 1.6 years (SD 2.6 years) ahead of those in HES (Brown 
et al., 2016). 
Ethnicity Mathur et al., (2014) reported on the completeness of ethnicity data 
within the CPRD and HES; with an additional comparison to the 
2011 UK Census. For patients within CPRD practices during 1990-
2012 (n = 12,099,672) 27.1% had an ethnicity record. For patients 
registered after April 2006 (18.2% of the whole sample) 78.3% had 
an ethnicity record. For HES inpatients (n = 51,965,028) 41.0% had 
a useable ethnicity record in 1997 and 86.0% in 2011. Combining 
CPRD and HES for patients registered after April 2006 resulted in 
97.1% having useable ethnicity records. Concordance between the 
two data sources was 85% when using five broad ethnic groups. 
For 2011 the ethnicity breakdown was comparable between CPRD 
and the census (Mathur et al., 2014).  
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Table 2.2 continued 
Myocardial 
infarction 
Hammad et al., (2008) reported on the PPV of Read/OXMIS 
codes to identify acute MI cases. GPs were asked to confirm the 
MI diagnoses with a response rate of 91.0%. The PPV was 
documented to be 93.0% (CI 90.0, 96.0%) from the 217 
questionnaires The reported dates of MI tended to coincide within 
15 days (90.0% of cases) (Hammad et al., 2008). Furthermore, 
Herrett et al., (2013) reported on the completeness and diagnostic 
validity of MI using CPRD, HES, MINAP and ONS. The authors 
identified patients with acute MI between January 2003 and March 
2009. There was a record in CPRD for 74.5% of patients with a 
non-fatal MI. For HES and MINAP, this was 67.9% and 52.5%, 
respectively. An MI record was documented in CPRD, HES, and 
MINAP for 31.0% of patients with non-fatal MI. A MI record within 
two sources were reported for 63.9% of the patients. The 
incidence of MI recording ranged from 25.0% lower (CPRD) and 
50.0% lower (MINAP)  (Herrett et al., 2013). 
 Smoking Lewis and Brensinger (2004) compared smoking data from the 
GPRD, a survey of GPs, and the 1996 Living in Britain National 
Household Survey. Using the survey responses from the GPs 
(136 surveys), the sensitivity of current smoking was 78.0% (CI 
52.0, 94.0%) and the PPV was 70.0% (CI 46.0, 88.0%). For former 
smoking the results were 53.0% (CI 28.0, 77.0%) and 60.0% (CI 
32.0, 84.0%) respectively. Compared to the survey current 
smoking in the GPRD was 79.0% and former smoking 29.0% of 
these rates (Lewis and Brensinger, 2004). Moreover, Booth, 
Prevost and Gulliford (2013) compared smoking records within 
the CPRD (n = 279,682) to the HSE for the period 2007-2011. The 
difference between the prevalence of current smoking tended to 
be <1.0% between the sources. The prevalence of non-smoking 
was similar between the two data sources. The prevalence for 
former smoking was lower within the CPRD with estimates for 
males of 26.7% and women 22.9% compared to 31.3% and 25.0% 
from the HSE (Booth, Prevost and Gulliford, 2013b). 
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2.2.8. Strengths of the CPRD  
Major strengths of the UK CPRD database include that it is longitudinal and 
incorporates a large number of patients and variables (Herrett et al., 2015; 
Stevenson, 2015). The large scale improves statistical power to detect 
associations between exposures and health-related outcomes and the 
opportunity to research rare conditions (Garcia Rodriguez and Perez Gutthann, 
1998; Wood and Martinez, 2004). Primary care consultations can be incorporated 
with links to socioeconomic data, hospital admissions, cancer registrations, and 
patient deaths. Sole use of one dataset (e.g. primary care) may not capture 
medical events occurring at different levels (e.g. secondary care) and thus 
estimates on chosen health outcomes may be biased (Herrett et al., 2013). CPRD 
patients are reported to typify the general population regarding age, gender, and 
ethnicity (Herrett et al., 2015). Similarly, patients in practices which have been 
externally linked to other datasets (HES, disease registries, and ONS) have been 
reported to be representative of all the patients within the CPRD (Gallagher, Puri 
and Van Staa, 2011). CPRD data undergoes a quality review before release to 
researchers (Herrett et al., 2010, 2015). QOF rules have also had an impact on 
the standard of the electronic health records.  
 
2.2.9. Suitability of the CPRD  
This dataset was chosen for my statistical analyses presented in Chapters 4 to 
6 due to the large size and the linkage to additional datasets including HES, the 
index of multiple deprivation (IMD), and ONS for registered deaths.  Analyses can 
be stratified based on patient characteristics whilst maintaining a large sample 
size. Outcome ascertainment of coronary heart disease (CHD) is improved 
substantially with links to HES. In Chapter 4 I present an analysis where I have 
estimated the BMI associations, using the WHO BMI Classification, with mortality 
across progressively older age groups, and for subgroups of ‘healthier agers’ and 
‘non-healthier agers’ due to a paucity of studies that have provided recent BMI 
estimates. In Chapter 5 I extend on the work presented in Chapter 4, using a re-
defined BMI referent group from the estimated continuous BMI association with 
mortality. This revised referent group was used to estimate the associations for 
mortality, incident CHD, and Type 2 diabetes. The rationale for this analysis was 
that persons within the lower end of the conventional BMI Normal range may be 
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at a heightened risk for mortality and thereby mortality risk estimates for higher 
BMI values may be distorted. Additionally, there has been a lack of studies which 
have presented risk estimates for CHD and type 2 diabetes across narrower age 
groups. In Chapter 6 I present an analysis where I estimated the BMI 
associations with incident dementia using a revised referent BMI group 
estimating short (0 to <10 years) and long (≥10 to 14.9 years) term risks, due to 
inconsistent results in the literature regarding the association for the BMI Obese 
range. 
 
2.2.10. Potential issues with using the CPRD  
One of the key issues with the CPRD is that data are not collected for research 
purposes (Herrett et al., 2015). Whether a medical event is recorded is 
determined by the general practitioner. Medical data may be collected during 
health checks (e.g. NHS health check) or opportunistically. The number of 
variables which are complete and useable varies for CPRD patients, for example 
lifestyle factors could be documented more often for subsets of patients with 
certain health conditions (Welch and Bartlett, 2014; Herrett et al., 2015). Using 
complete cases only may produce biased estimates and can severely reduce the 
sample size. Variables may not be documented for the same baseline date and, 
therefore, the appropriate time frame for incorporating earlier healthcare records 
(or prospective healthcare records) will need to be considered (Sterne et al., 
2009; Herrett et al., 2015). Transference of data collected from secondary care 
may be lacking relevant detail due to being completed at the general practice 
level. 
 
Chronic diseases may only be documented once and this should be taken into 
consideration when deciding appropriate time frames for selecting subsets of 
patients or confounders (Lawson, Sherman and Hollowell, 1998). It could be 
assumed that patients without pre-specified Read Codes for health outcomes 
may be free of that disease or condition of interest (Herrett et al., 2015). This 
could be due to differences in Read Codes selected by health practitioners, the 
documentation of symptoms and diagnoses in free text, and from patients 
avoiding primary care consultations.  
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Moreover, the Read Codes chosen during analyses to identify a specific disease 
may differ leading to discrepancies between studies, for instance in prevalence 
estimates (Khan, Harrison and Rose, 2010). Additionally, clinical presentations 
of diseases may be hard to distinguish due to the Read Codes chosen. For 
instance, Bhattarai et al., (2012) evaluated the Read Codes used to identify 
incident CHD using a random sample of 300,020 patients aged >30 years for the 
time frame 1st January 2004 - 30th June 2010, and documented that 39.6% were 
reported with a diagnostic code of ‘Other CHD’ (Bhattarai et al., 2012). 
Furthermore, Tate et al., (2017) reported that estimates on the incidence of type 
2 diabetes may be dependent on the chosen Read Codes. The incidence of type 
2 diabetes was reported to have increased up to 2004, stagnated to 2009, and 
decreased thereafter when only diagnosis codes were used for 684 practices 
within the CPRD. In contrast, when non-diagnosis codes (e.g. codes suggestive 
of diabetes) were additionally used the incidence of type 2 diabetes increased up 
to 2012 (Tate et al., 2017).  
2.2.11. CPRD approval 
Before researchers can use the CPRD GOLD and linkage datasets, all research 
protocols need to be approved by the MHRA Independent Scientific Advisory 
Committee (ISAC). During my PhD, I was involved in collaborating on the 
research proposal to enable access to use the CPRD for my statistical analysis.  
The overall aim of the protocol was to “improve evidence on predictive value of 
general practice recorded risk factors for cardiovascular disease onset and 
mortality, at various stages of later life”. My contribution to the approval included 
identifying the risk factors (including BMI), confounders, and the outcomes 
(mortality and cardiovascular endpoints) to be analysed. Furthermore, I reviewed 
the literature for the predictive value of risk factors (high cholesterol, high blood 
pressure, smoking, diabetes, and high BMI) with mortality and cardiovascular 
mortality in later life and contributed to writing the background section. I finalised 
the Read Codes to be used for the various risk factors based on a literature 
review and discussions with clinicians within the research group. The CPRD has 
been granted Multiple Research Ethics Committee approval (05/MRE04/87) to 
undertake purely observational studies, with external data linkages including HES 
and ONS mortality data. The work of CPRD is also covered by NIGB-ECC 
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approval ECC 5-05 (a) 2012. My CPRD analyses were approved by the 
Independent Scientific Advisory Committee for MHRA database research (ISAC) 
under protocol number 14_135 (2014). 
 
2.2.12. Variables used for data analysis with the CPRD 
The analyses presented in Chapters 4 to 6 use a sample of registered patients 
who have been linked to HES, the IMD 2007 dataset, and ONS. These data 
linkages are only available for patients residing in England. Outcome 
ascertainment for the chosen health outcomes is substantially improved with the 
linkage to the HES. All analyses used BMI as the exposure variable, hence 
patients were required to have a BMI record. The earliest baseline date was the 
1st January 2000 and patients were required to be aged ³60 years at the time of 
the BMI record. 
 
Read Codes for defining variables and health outcomes were derived from the 
QOF Business Rules (version 18.0), from published literature of Read Codes, 
and from two clinicians who were blinded to each other’s work. Any discrepancies 
were resolved by a third clinician. A similar approach was undertaken for defining 
health outcomes and variables from the HES regarding ICD 10 codes.  For health 
behaviour measures such as BMI, the additional field containing numerical data 
was checked against the Read Codes documented at the same entry time. Read 
Codes which were deemed not to relate to the measurement were thus excluded 
(and the relating measure) during the data preparation stage. Table 2.3 provides 
information on the variables used in the CPRD analyses presented in Chapters 
4 to 6.  Details on the numbers of participants and missing/unrecorded variables 
will be presented in each chapter.  
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Table 2.3 | Variables used from the CPRD GOLD dataset and external linkages 
Variable  Data available from CPRD Gold dataset plus 
external linkages and additional analyses 
details  
Patient characteristics 
       Age • Month and year of birth are provided within 
the demographics file.  
• For the analyses the day of birth is set to the 
middle of the month.	
      Gender • Gender: male, female, or indeterminate are 
provided within the demographics file. 
• Only a small number are classified as 
indeterminate.	
       Ethnicity • CPRD GOLD database and HES contains 
data on ethnicity improving completeness of 
data. 
Anthropometric measures 
       Weight  • Weight is entered numerically in the 
additional clinical file which aligns with the 
clinical file.  
        BMI • BMI is entered automatically following entry 
of a weight measure and is reported in the 
additional file. 
• For the analyses the numerical data were 
used rather than medical codes associated 
with obesity e.g. “on examination, obese”. 
Medical codes would not provide an 
indication of the patient’s BMI value.  
• Booth, Prevost and Gulliford, (2012) reported 
that medical diagnostic codes for obesity 
were not consistently reported. In a sample 
of 67,000 patients with Obesity, defined by 
diagnostic codes or BMI ³30.0 kg/m2, aged 
18 to 100 years during the time frame 1997-
2007, only 29.7% had a diagnostic code 
recorded. BMI values were available for 
99.2% of the patients (Booth, Prevost and 
Gulliford, 2013a).	
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Table 2.3 continued 
Lifestyle and socioeconomic circumstances  
       Smoking • Smoking status was based on GP recorded 
Read Codes within the clinical file. 
• Patients were classified as current smokers, 
ex-smokers, never smokers, and not 
recorded.		
         Alcohol • Alcohol status was based on GP recorded 
Read Codes and units of alcohol per week 
(where available) from the clinical and 
additional file.  
• Patients were classified as heavy drinkers, 
non-drinkers, current drinkers, former 
drinkers, and not recorded. 
• Heavy drinkers were defined as >35 units for 
females and >50 units for males.		
        Physical activity  • Physical activity was recorded in CPRD as 
inactive, gentle activity, moderate activity, 
vigorous activity, or not recorded within the 
clinical file. 
         Relative social 
          deprivation 
• Relative social deprivation was recorded 
using the IMD 2007 dataset.  
Prevalent/ incident disease plus mortality 
-Asthma 
-Atrial Fibrillation 
-Cancer 
-Chronic Kidney Disease 
stages 3-5 
-Chronic Obstructive 
Pulmonary Disease 
-Coronary Heart Disease 
-Dementia 
-Depression 
-Epilepsy 
-Heart Failure 
-Hypertension 
-Hypothyroidism 
-Mental Health 
-Stroke 
-Type 2 Diabetes 
• Based on CPRD Read Codes and ICD codes 
for HES.  
• The cause, location, and date of deaths are 
provided by both ONS and those recorded 
within the CPRD GOLD. ICD codes are used 
for the cause specific deaths.	
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2.2.13. Follow-up periods  
Patients within practices which have opted to be part of the CPRD research 
service can be followed up from the chosen baseline period to the health outcome 
of interest (e.g. CHD), transfer out date (e.g. patient has transferred from the 
practice due to relocation), last collection date of the practice, or date of death. 
For patients who transferred out of practices but have been registered to have 
died, the date of death can be used as this is recorded within the ONS dataset. 
Figure 2.2 depicts the follow-up periods for mortality for patients who died and 
patients who did not die. For patients who transferred out of practices, the 
transfer out date is used when morbidity outcomes (e.g. MI) are the focus, as the 
patient may have had the chosen health outcome after the transfer out date. 
Figure 2.3 depicts follow up-periods for morbidity (e.g. MI).  
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Figure 2.2 | Follow-up periods for mortality 
 
Patients who died 
 
A) Patient remains in the CPRD practice 
 
 
 B) Patient transfers out of the CPRD practice. Date of death can be obtained 
from ONS. 
 
 
Patients who survived  
C) Patient remains in the CPRD practice 
 
 
D) Patient transfers out of the CPRD practice.  
 
 
 
 
 
 
 
 
 
 
 
Baseline date Date	of	death (ONS/CPRD)
Baseline	date Transfer out date
Date of death 
(ONS)
Baseline date Last collection date of the practice
Baseline date Transfer out date
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Figure 2.3 | Follow-up periods for morbidity (e.g. myocardial infarction) 
 
Patient has a MI 
 
A) Patient remains in the CPRD practice and has a MI. 
 
 
Patient dies during the follow-up  
 
 B) Patient dies during the follow-up period 
 
 
Patient does not have a MI during the follow-up period 
C) Patient remains in the CPRD practice 
 
 
Patient transfers out of the practice (no MI recorded prior to this date) 
D) Patient transfers out of the CPRD practice.  
 
Baseline date Date	of	MI (HES/CPRD)
Baseline	date Date of death (ONS)
Baseline date Last collection date of the practice
Baseline date Transfer out date
111	
 
Chapter 2 | Methods  
 
2.2.14. Challenges of using electronic health records  
Electronic health medical records have the advantage that research questions that 
may not have been feasible on a large scale can be addressed. However, there are 
many challenges with using this data source. The quality and completeness of medical 
records may alter with new or updates to health guidelines and financial incentives 
(such as QOF) throughout time, and similarly the Read Codes chosen for symptoms 
and diagnoses (McDonald et al., 2016). It is important to consider which patients, and 
essentially, why patients access primary and secondary care. Patients may access 
over the counter medicines which would not be captured. A patient’s symptoms may 
trigger the collection of lifestyle variables and testing of conditions (e.g. ordering a 
blood test), in contrast to volunteer studies, and therefore affect the generalisability. 
Volunteer studies tend to collect baseline measures on all participants who are 
typically healthier (Bhaskaran et al., 2013; McDonald et al., 2016). New patients 
registering with practices have been shown to increase the reported incidence of acute 
and chronic conditions, due in part to joining practices when symptoms arise (Lewis 
et al., 2005).   
 
2.2.15. Reporting checklists  
In 2015, RECORD was published, a reporting checklist for analyses which use 
routinely collected health data, this being an extension of the STROBE guidelines (von 
Elm et al., 2007; Benchimol et al., 2016). These extensions include: providing 
additional details about the data source (time frame and region) plus other linkages, 
selection criteria for the population, codes used, and implications of using health 
records. This checklist was used for the reporting of the published paper (Bowman et 
al., 2017) which has been adapted in Chapters 4 and 5.          
 
 
 
 
 
 
 
112	
 
Chapter 2 | Methods  
 
2.3. Overview of the UK Biobank  
The UK Biobank is a large prospective volunteer study (Allen et al., 2012).  The UK 
Biobank was constituted by the Medical Research Council, the Wellcome Trust, the 
Department of Health, and the Scottish Government (Trehearne, 2016). The 
overarching aim was to enable investigation of environmental, lifestyle, and genetic 
exposures to a broad range of health outcomes which can occur in middle age and in 
later life (Allen et al., 2012; Sudlow et al., 2015; Trehearne, 2016). Major strengths of 
this dataset are the wealth of variables concurrently collected at baseline with external 
links to HES and cancer registries. 
 
2.3.1. UK Biobank participants 
Adults aged 40 to 69 years who were within a 25-mile radius of one of the 22 
assessment centres (across England, Scotland and Wales) and registered with the 
NHS were eligible to participate (Allen et al., 2012; Manolio et al., 2012). Figure 2.4 
shows the UK Biobank assessment centres. Recruitment took place during 2006 to 
2010 with postal invitations (Sudlow et al., 2015; Trehearne, 2016). Most of the 
volunteers were aged 40 to 69 years (range 37 to 73 years) (UK Biobank, 2017a). The 
recruitment process ensured that participants were from diverse socioeconomic 
backgrounds and ethnic origins with the inclusion of participants from rural villages to 
urban areas (Manolio et al., 2012; Sudlow et al., 2015; Trehearne, 2016). Volunteers 
are able to withdraw from the study at any time, although there have been few cases 
in which this has occurred (Trehearne, 2016).   
 
 
 
 
 
 
 
113	
 
Chapter 2 | Methods  
 
Figure 2.4 | UK Biobank assessment centres (UK Biobank, 2017b) 
 
The overall response rate was 5.5% (Allen et al., 2012), with 502,632 volunteers 
recruited (UK Biobank, 2017a). A recent analysis compared the UK Biobank 
volunteers to the UK Census, HSE, and ONS. The ethnicity data for the UK Biobank 
volunteers was less comparable to the 2011 UK Census (95.0% white ethnicity for the 
UK Biobank compared to 91.0% for the Census). For those aged 65 to 69 years both 
the incidence of cancer and mortality rates were reported to be lower than the general 
population (cancer: 31.0% lower for the males and 42.0% lower for females, mortality: 
56.0% lower for males and 68.0% lower for females). The prevalence of current 
smokers and the prevalence of obesity is lower for the UK Biobank participants 
compared to the HSE, therefore, inferring healthy volunteers  (Fry et al., 2016).  
Volunteers provided their consent at the assessment centre alongside extensive 
information on medical history, lifestyle and environmental exposures through touch 
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screen questionnaires (reducing transcription errors) and personal interviews (Allen et 
al., 2012; Manolio et al., 2012; Sudlow et al., 2015; Trehearne, 2016). Anthropometric 
measurements and biological samples were also collated during the assessment 
centre visit (Allen et al., 2012). The volunteers have been linked to cancer registries, 
hospital admissions, and mortality databases. Volunteers are, therefore, continuously 
followed up for health outcomes using these external dataset linkages.  All of the data 
provided to researchers are de-identified (Sudlow et al., 2015).      
 
2.3.2. Strengths of the UK Biobank 
A major strength of the UK Biobank is that detailed information was collated on a broad 
range of exposures at the assessment centre visit (Collins, 2012). The baseline visits 
were conducted during 2006-2010, enabling researchers to provide updated 
quantification on associations (Allen et al., 2012). Lifestyle factors and physical 
measures were collected at the same time point. The large sample size improves the 
range of exposures, health outcomes, and thus the statistical power to detect 
associations (Trehearne, 2016). For each exposure of interest several health 
conditions can be addressed (Allen et al., 2012). Recall bias and reverse causation 
are minimised from the prospective study design; data on exposures can be 
ascertained before the diagnosis of the health outcome(s) of interest (Collins, 2012). 
The external linkage to cancer registries, hospital admissions, and mortality is another 
advantage to the UK Biobank improving the accuracy of both prevalent and incident 
diseases (Collins, 2012). There is a continual update of hospital admissions, cancer 
registrations, and deaths. The recruitment process ensured there was diversity in 
terms of socioeconomic background, ethnic origin, area of residence, and exposures 
improving the generalisability (Manolio et al., 2012; Sudlow et al., 2015; Trehearne, 
2016). 
 
2.3.3. Suitability of the UK Biobank  
This dataset was chosen for the statistical analyses presented in Chapters 7 and 8. 
One of the key strengths of this dataset is that lifestyle variables were collected at the 
same time point rather than opportunistically or during health checks as is the case for 
the CPRD. A further strength is that a range of anthropometric measures were 
collected at baseline (CPRD has limited data on anthropometric measures other than 
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weight and height). This allows comparisons of different body measures and the 
combining of physical measures. In Chapter 7 I present an analysis where I compared 
established measures of body fat distribution and body composition to BMI for 
mortality prediction for ‘healthier agers’ within the seventh decade of life and described 
the concordance between categories of BMI and these different measures. In Chapter 
8 I present an analysis where I estimated the associations between combined 
measures of BMI and waist-to-hip ratio (WHR) with mortality, and incident CHD.  
 
2.3.4. Potential issues with using the UK Biobank  
In a similar manner to the CPRD, there is also the issue that some participants may 
be missing data. Volunteers could opt to select the “prefer not to answer” or “do not 
know” for the touchscreen questionnaire (UK Biobank, 2013). To date, there is no data 
available on primary care consultations (this is planned to be linked in the future). This 
could lead to an underestimation of diagnoses which may be more commonly recorded 
at the primary care level such as diabetes.  
 
2.3.5. Variables used for data analysis with the UK Biobank 
The analyses presented in Chapters 7 to 8 use a sample of ‘healthier agers’ from the 
UK Biobank. For these chapters I included participants aged 60 to 69 years. ‘Healthier 
agers’ were non-smokers without cancer, dementia, or heart failure. Table 2.4 
provides information on the variables used in the analyses presented in Chapters 7 
and 8. The ICD-10 codes and combining of data from the touchscreen questionnaire 
was shared and agreed by clinicians, research fellows, and myself all from the 
Epidemiology and Public Health Group. The ICD-10 codes for each of the diseases 
were derived from relevant ICD codes in the literature and by two clinicians who were 
blinded to each other’s judgements. Any disagreement in coding was resolved by a 
third clinician.  
 
The touchscreen questions asked to participants were based on previous surveys 
including the HSE, longitudinal studies and expert opinions (UK Biobank, 2007). The 
physical activity questions asked to the volunteers were based on a validated survey 
(Craig et al., 2003).   
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Adiposity measures and other components of body composition 
UK Biobank staff were trained and monitored, adhering to a standard protocol for 
physical measures (UK Biobank, 2007, 2014). Weight, fat mass, fat free mass, and 
body fat percentage were measured using the Tanita BC-418 MA body composition 
analyser for participants who had bio-impedance (BIA) measures taken. Body 
composition measures are quickly determined using in built algorithms. Advantages 
of using this analysis include accurate weight measurement (+/- 0.1 kg), recalibration 
is required infrequently and automatic transferal of readings to IT systems, removing 
transcription errors. These advantages combined with the relatively low cost of 
measurement can make this technique preferable to imaging techniques such as DXA, 
CT, and MRI. The European consensus on defining and diagnosing sarcopenia 
concluded that BIA could be a portable substitute to DXA (Cruz-Jentoft et al., 2010). 
Studies have shown that compared to DXA the estimated fat mass may be lower for 
both genders (Völgyi et al., 2008), lower for females and higher for males (Mally et al., 
2011), and comparable for both genders (Pietrobelli et al., 2004). Discrepancies may 
be due to using different populations compared to the populations on which the 
algorithms were derived. Measures which are manually entered (e.g. height, waist 
circumferences and hip circumferences) which are deemed to be implausible are 
flagged instantaneously.  
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Table 2.4 | Variables used from the UK Biobank and external linkages 
Variable  Data available from the UK Biobank and  
additional analyses details  
Volunteer characteristics 
     Age • Month and year of birth were collected prior to the 
initial visit from local NHS Care Trust registries (UK 
Biobank, 2016). 
• For the analyses the day of birth is set to the 
middle of the month. 
      Gender • Collated from local NHS Care Trust registries: 
female or male (UK Biobank, 2017a).   
      Ethnicity • Participants first completed a question on their 
ethnic group with responses including: White, 
Mixed, Asian or Asian British, Black or Black 
British, and Chinese.  
• Some participants were asked further about their 
ethnic background dependent on response to the 
ethnic group question (UK Biobank, 2013).    
Anthropometric measures 
       Weight  • Collected by nurses and health technicians during 
the assessment centre visit with a Tanita 
BC418MA body composition analyser or with 
standard scales (for participants who did not 
undergo BIA measures)  (UK Biobank, 2007, 
2014). 
      Height • Collected by nurses and health technicians during 
the assessment centre visit using Seca 240cm 
height measure  (UK Biobank, 2007, 2014).  
      BMI • Derived from height and weight measures taken at 
baseline. 
      Waist • Collected by nurses and health technicians during 
the assessment taken with a Seca 200cm tape 
measure at the natural indent (UK Biobank, 2007, 
2014). 
      Hip • Collected by nurses and health technicians  during 
the assessment taken at the widest part with a 
Seca 200cm tape measure (UK Biobank, 2007, 
2014). 
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Table 2.4 continued 
Anthropometric measures continued 
     -Whole body fat mass/  
     -Whole body fat free    
      mass 
     -Body fat percentage 
• Collected by nurses and health technicians during 
the assessment using the Tanita BC418MA body 
composition analyser (UK Biobank, 2007, 2014). 
      Weight loss • Participants were asked to compare their weight at 
baseline to the previous year with responses 
including: no change, gained, and lost (UK 
Biobank, 2013). 
Lifestyle factors and socioeconomic circumstance 
      Smoking • Derived from multiple questions from the touch 
screen questionnaire which participants completed 
during the assessment centre visit. Participants 
were asked whether they currently smoked 
tobacco.  
• Participants who responded that they did not 
currently smoke were subsequently asked how 
often they smoked tobacco in the past (UK 
Biobank, 2013).  
       Alcohol intake • The frequency of alcohol intake was recorded by 
the volunteers on the touch screen questionnaire 
during the initial assessment visit. Responses 
included: never, special occasions, once to three 
times per month, once or twice per week, three or 
four times per week, daily or almost daily (UK 
Biobank, 2013). 
       Physical activity • The volunteers also completed questions on their 
duration and intensity of physical activity in a 
typical week (UK Biobank, 2013).     
      Educational  
      Attainment 
• During the assessment participants were asked 
about their educational qualifications. Participants 
could select multiple choices (UK Biobank, 2013). 
Responses included: NVQ/HND/HNC/ equivalent, 
CSEs/equivalent, O levels/ GCSEs/ equivalent, A 
levels/AS levels/equivalent, other professional 
qualifications (nursing/ teaching), 
College/University degree.  The questions were 
adapted from those used within the HSE (UK 
Biobank, 2007, 2013). 
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Table 2.4 continued 
Prevalent/incident disease and mortality 
     -Cancer 
     -CHD 
     -Dementia 
     -Heart Failure 
     -Type 2 Diabetes 
• Data on prevalent and incident diseases were 
derived from the touchscreen questionnaire, 
personal interviews, ICD-10 codes for hospital 
admissions (HES), and ICD-10 codes from the 
cancer registries.  
• Cancer registrations were provided by the Health 
& Social Care Information Centre (HSCIC) for 
England and Wales and by the Information 
Services Department for Scotland. Cancer 
registrations are available from the 1980s for 
England and Wales and 1950s for Scotland.  
• Hospital admission data was provided by HES 
(HSCIC) for England, Patient Episode Data for 
Wales (Secure Anonymised Information Linkage) 
for Wales, and Scottish Morbidity Records for 
Scotland. Hospital admission data are currently 
available from 1997 for England, 1999 for Wales, 
and 1981 for Scotland (Biobank, 2009). 
• Data on deaths (cause and date) for England and 
Wales was provided by the HSCIC and by the ISD 
for Scotland (Biobank, 2009).  
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2.4. Statistical analysis 
 
2.4.1. Statistical packages 
For the analyses reported in Chapters 3 to 8 I used Stata versions 13 and 14 and R 
versions 3.1.2 and 3.2.0. These statistical packages are particularly suitable due to 
their ability to manage large datasets. Detailed below are the main statistical methods 
I used throughout this thesis. An overview of each methodology is provided within 
each of the subsequent chapters (3 to 8).    
 
2.4.2. Meta-analysis 
In Chapter 3 I conducted a review and meta-analysis of cohort studies which reported 
mortality risk estimates for adults aged ≥65 years for the BMI Overweight range and/or 
BMI Obese-1 range. This involved searching Embase, Medline, and Scopus electronic 
databases up to 13th August 2016 which were limited to English language articles 
published from 1st January 2000. The inclusion criteria were: cohort studies with ≥3y 
of follow-up, participants aged ≥65 years, minimum of 1,000 participants within each 
sub-group, risk estimates reported for the BMI Overweight range and/or BMI Obese-
1 range, and all-cause mortality as the outcome. A meta-analysis involves combining 
several studies to provide a pooled estimate with the assumption that this will be more 
precise and reliable (due to the increased statistical power) than those reported from 
the individual studies (Peacock, 2011; Bowers, 2014). For the analysis presented in 
Chapter 3 this involved pooling the hazard ratios for mortality for the BMI Overweight 
and BMI Obese-1 range. In Chapter 3 I used fixed effects models to combine reported 
mortality risk estimates for individual studies (within studies) e.g. where estimates 
were reported for males and females separately these were pooled used fixed effects, 
as it  was assumed that each study was estimating one single fundamental effect 
(Peacock, 2011). I used the random effects approach when analysing multiple studies 
as it was assumed that there would be variability amongst the participants within each 
study and variability between the analyses. This model, however, tends to produce 
wider confidence intervals than those from fixed effects due to greater variability 
attributed to the individual studies (Peacock, 2011).  I used the I2 statistic to test the 
heterogeneity between the included analyses (Peacock, 2011; Bowers, 2014). Values 
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above 50% are considered large, 25 to 50% modest, and <25% low (Patsopoulos, 
Evangelou and Ioannidis, 2008). Advantages of using a meta-analysis approach 
include summary estimates can be derived as the statistical power is increased, 
publication bias can be assessed, and heterogeneity between the individual studies 
can be assessed. Limitations of meta-analyses include the quality of the studies 
included may vary, the choice of model adjustments may differ between studies, 
publication bias, and the heterogeneity of studies.   
 
2.4.3. Directed Acyclic Graphs 
In Chapter 4 I use a Directed Acyclic Graph (DAG) to model the preconceived 
variables which may affect the chosen exposure and outcome of interest. In this case, 
BMI was the exposure and mortality was the outcome. This DAG was constructed 
using the webpage DAGitty (http://dagitty.net). The graphic contains no cycles, with 
each arrow pointing in one direction to imply that a variable could cause/influence the 
other variable (Vanderweele and Robins, 2007). This allows the identifications of 
confounders and mediators (Vanderweele and Robins, 2007; Shrier and Platt, 2008). 
Conditioning on disease states has been shown to accentuate bias by confounders 
such as smoking (Preston and Stokes, 2014; Banack and Kaufman, 2015). 
 
2.4.4. Logistic regression 
Logistic regression models are based on the logit concept and are suitable when the 
outcome is binary	(Peng, Lee and Ingersoll, 2002). The logarithm of the odds of the 
outcome is modelled as a linear function of explanatory variables.  The odds of the 
outcome for both the exposed and unexposed group can then be derived, before or 
after adjustment for confounding variables. Observations are assumed to be 
independent and the binary outcomes are assumed to follow a binomial distribution. 
These models can be used to test cross sectional associations e.g. between BMI and 
prevalent diabetes, and prospective associations e.g. BMI and incident diabetes. In 
Chapter	4 logistic regression models were used to test the associations of 15 major 
diseases with measured weight loss. A common rule of thumb is that the sample size 
for these models should be such that there are at least 20 or more outcomes in each 
of the binary groups per variable included in the model, and this was checked within 
each of my datasets	(van der Ploeg, Austin and Steyerberg, 2014) . This condition was 
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easily satisfied for both the CPRD and the UK Biobank analyses due to the large 
number of outcomes. A limitation of logistic regression models includes the 
requirement of large sample sizes, although for these analyses this was not relevant. 
 
2.4.5. Survival analysis  
The UK Biobank includes baseline data on exposures and follow up data for mortality 
and incident health outcomes from hospital admissions with dates provided for all. 
Similarly, in the CPRD dates are derived for when the exposure of interest was 
measured and dates are provided for mortality and incident health outcomes from GP 
surgery visits and hospital admissions. This lends both datasets to survival analysis 
due to the time element between the exposure and health outcome of 
interest (Bowers, 2014). These methods compute survival probabilities (Peacock, 
2011). Participants who withdraw early and those who are alive at the end of the study 
period are censored (Peacock, 2011; Bowers, 2014).  In the UK Biobank participants 
are censored only at the end of the follow up as all data are removed for any participant 
who wishes to withdraw from the study. In the CPRD participants may be censored if 
they change to a new GP surgery. Survival models can incorporate censored 
observations (Peacock, 2011). 
 
2.4.6. Cox proportional hazard models 
Cox proportional hazards models are often used to assess associations between a 
binary exposure and the time to an outcome event. Researchers can include and 
adjust for several confounders in these models. The hazard rate is defined as the 
instantaneous risk of the event conditional on having survived to that point in time. The 
hazard ratio is then the ratio of hazard rates in two groups.  A key assumption of these 
models is that the hazard ratio between exposure groups is constant over the time 
period, referred to as the proportional hazards assumption	(Peacock, 2011; Bowers, 
2014). This assumption can be tested using Schoenfeld residuals and I checked this 
assumption for all my analyses. Cox proportional hazards models were used to 
estimate the association between BMI (and other anthropometric measures) with 
mortality using the CPRD and UK Biobank datasets (Chapters 4	to	8).  
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2.4.7. Spline models  
Spline models can be used to explore the shape of the relationship between 
continuous functions such as BMI and mortality with the results being graphically 
displayed using a smooth non-linear curve. The model fits a series of non-linear 
functions (e.g. cubic polynomials) which are constrained to join at a series of pre-
specified points referred to as knots. Spline models were used in Chapter 
5 and Chapter 7. 
 
2.4.8. Competing risks models  
With ageing, there is an increased likelihood that other health outcomes may occur 
before the health outcome of interest. For example, a competing risk in a study where 
the primary outcome of interest is the incidence of second hip fracture would be deaths 
following the first hip fracture (Berry et al., 2010). These competing risks (e.g. death 
following the first hip fracture) can impede the chosen health outcome and models 
should address this issue (Wolbers et al., 2009). As highlighted in Chapter 1 and in 
Chapter 5 several analyses reporting on the association between BMI and either 
CHD, diabetes, or dementia did not incorporate the competing risk of death into the 
models. Within my data analyses I used the Fine and Gray Competing Risk Models 
as it is extensively utilised (Wolbers et al., 2009). This model considers the existence 
of competing risks and reports the cumulative incidence of the health outcome of 
interest, which is reported as the sub-distribution hazard ratio (sHR) (Wolbers et al., 
2009; Berry et al., 2010). I used this model in Chapters 5, 6 and 8. 
 
2.4.9. Multiple imputation 
As stated in the potential issues for using the UK CPRD and the UK Biobank, an 
important challenge in using these datasets is that relevant variables (baseline 
covariates as well as outcomes) may be missing. One approach to manage this is to 
use multiple imputation, assuming that we view subjects without the record of interest 
as a missing-data problem (Welch and Bartlett, 2014). Multiple imputation is based on 
the Bayesian concept and is widely used to manage missing variables (Sterne et al., 
2009; Peacock, 2011; Welch and Bartlett, 2014). This method imputes data for missing 
fields utilising values from related covariates (Peacock, 2011).  Multiple datasets are, 
therefore, imputed due to the uncertainty surrounding the missing values (Sterne et 
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al., 2009; Peacock, 2011; Welch and Bartlett, 2014). The appropriate statistical 
techniques for analysing the complete data can then be carried out on each of these 
data sets (Sterne et al., 2009; Peacock, 2011). The assumption is made when using 
multiple imputation that values are missing at random: this means that given the 
observed data, the data are missing independently of the unobserved data.  Where 
this assumption cannot be made, the data are said to be missing not at random and 
more complex methods are needed that account for the missing data mechanism. 
Multiple imputation was used in Chapter 5 to impute smoking and alcohol records. 
This was not used for the UK Biobank analyses as missing patient variables were not 
considered to be missing at random. There were a limited number of participants 
missing variables on smoking, alcohol intake, or educational attainment.  
 
2.4.10. Model selection 
Model selection involves assessing several candidate models (Wagenmakers and 
Farrell, 2004). One method which is widely used is the Akaike information criterion 
(AIC) (Jones, 2011; Fabozzi et al., 2014). The lowest value for this criterion is 
considered the “best” model approximating the data when comparisons are made 
using the same data source (Jones, 2011; Fabozzi et al., 2014). I used this method to 
compare established measures of body fat distribution and body composition to BMI 
for mortality prediction for ‘healthier agers’ within the seventh decade of life, which is 
presented in Chapter 8.          
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3.1. Summary  
Background: Equivocal risks for mortality have been reported for older adults 
(≥65 years) within the body mass index (BMI) defined Overweight (25.0-29.9 
kg/m2) and BMI Obese-1 (30.0-34.9 kg/m2) ranges relative to those within the 
conventional BMI Normal range (18.5-24.9 kg/m2). Inclusion of smokers, adults 
with conditions associated with weight loss, and the choice of BMI referent group 
may distort mortality risk estimates.  
 
Objective: To conduct a review and meta-analysis of cohort studies which 
reported mortality risk estimates for adults aged ≥65 years for the BMI Overweight 
range and/or BMI Obese-1 range. To determine the influence of specific 
exclusions (smokers, conditions associated with weight loss, and early follow-up) 
and combinations of exclusions with consideration of the BMI referent group for 
the risk of mortality.  
Methods: Embase, Medline and Scopus electronic databases were searched up 
to 13th August 2016 and were limited to English language articles published from 
1st January 2000. The inclusion criteria were: cohort studies with ≥3 years of 
follow-up, participants aged ≥65 years, minimum of 1,000 participants within each 
sub-group, risk estimates reported for the BMI defined Overweight range and/or 
BMI Obese-1 range, and all-cause mortality as the outcome. The baseline period, 
study characteristics (age, gender, sample size), exclusion criteria, the method 
of obtaining height and weight, the follow-up period, the number of deaths, model 
adjustments, the BMI groups, and the reported mortality risk estimates were 
extracted from each study. Random effects models were used to pool effect 
sizes.  
 
Results: Forty studies were included in this review, with all studies reporting 
mortality risk estimates for the BMI Overweight range and 19 studies for the BMI 
Obese-1 range. Summary mortality risks were calculated relative to those with 
BMI values within the Normal range. Summary hazard ratios (HRs) for mortality 
for the unrestricted (i.e. no exclusion) analyses were 0.88 (95% Confidence 
Interval [CI] 0.84, 0.91) for those within the BMI Overweight range and 0.95 (CI 
0.85, 1.05) for those within the BMI Obese-1 range. Summary mortality risk 
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estimates for specific exclusions were either associated with a reduced risk or 
were not significantly different for both BMI ranges. There was a reversal of the 
mortality risk, with an increased mortality risk for analyses which had 
simultaneously excluded smokers, conditions associated with weight loss, early 
deaths and had used a referent group falling in the BMI range ≥20 to <25.0 kg/m2. 
Summary mortality HRs were 1.08 (CI 1.03, 1.13) for the BMI Overweight range 
and 1.31 (CI 1.17, 1.47) for the BMI Obese-1 range. 
 
Conclusions: This meta-analysis showed that the risks for mortality for the BMI 
defined Overweight range and BMI Obese-1 range were markedly altered with 
combined exclusions. For healthier non-smokers (exclusion of conditions 
associated with weight loss) aged ≥65 years the BMI Overweight range and BMI 
Obese-1 range were associated with an elevated risk for mortality relative to 
those within the BMI Normal range.        
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3.2. Introduction  
As highlighted in Chapter 1, body mass index (BMI) is widely used in clinical 
practice and research settings as a surrogate for adiposity. The World Health 
Organization (WHO) have set BMI ranges to classify adults as BMI Normal (18.5-
24.9 kg/m2), BMI Overweight (25.0-29.9 kg/m2), and BMI Obese (³30 kg/m2, with 
sub-divisions for classes of obesity) (World Health Organization, 2000). These 
BMI ranges, however, were derived predominately from studies including 
younger and middle aged adults (Janssen and Mark, 2007; Mathus-Vliegen, 
2012). Between 1980 and 2013 the global prevalence of adults classified as 
Overweight or Obese has increased across the age range, and overall it has been 
estimated that the global prevalence has increased by 27.5% during this time 
frame (Ng et al., 2014). Due to the ageing population and the substantial increase 
in the numbers of adults classified as BMI Overweight or BMI Obese, it is 
therefore of public health importance to establish the prognostic utility of the 
current BMI thresholds in later life, and whether estimates differ for subgroups of 
older adults.  
 
Previous reports have shown that  younger and middle aged adults within the 
BMI Obese range are at an increased risk for mortality compared to those within 
the BMI Normal range (Calle et al., 1999; Adams et al., 2006; Whitlock et al., 
2009). However, for older adults (aged ³65 years) several analyses have shown 
that the BMI Obese-1 (30.0-34.9 kg/m2) range is associated with reduced (Al Snih 
et al., 2007) or a similar mortality risk to those within the BMI Normal range (Flegal 
et al., 2005; Lang et al., 2008). This finding has been termed the ‘obesity 
paradox’. Similarly, it has been shown that persons within the BMI Overweight 
range have a reduced (Al Snih et al., 2007; Flicker et al., 2010) or a similar (i.e. 
not significantly different) risk for mortality (Ajani et al., 2004; Flegal et al., 2005; 
Lang et al., 2008) to those within the BMI Normal range.  
 
Several meta-analyses have summarised the association between BMI and 
mortality for older adults (Chapter 1). Janssen and Mark (2007) reported that the 
mortality risk for those within the BMI Overweight range was not significantly 
different to those within the BMI Normal range, for persons within the BMI Obese-
1 range there was a 10% increased risk (95% CI 1.06, 1.13) (Janssen and Mark, 
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2007). However, Flegal et al., (2013) reported that persons within the BMI 
Overweight range had reduced mortality risks relative to those within the  BMI 
Normal range, whilst persons classified as BMI Obese-1 were not significantly 
different (Flegal et al., 2013). Moreover, Winter et al., (2014) showed increased 
mortality risks for those with BMI values <23 kg/m2 and >33kg/m2 relative to those 
within the BMI range 23.0-23.9 kg/m2 (Winter et al., 2014). 
 
As outlined in Chapter 1 there are several possible contributors to the emergence 
of the obesity paradox in later life including the inclusion of smokers, inclusion of 
persons with conditions associated with weight loss, and the choice of the 
referent BMI group. Although Janssen and Mark (2007) and Winter et al., (2014) 
reported estimates for subgroups, i.e. exclusion of current smokers, no estimates 
were provided for combined subgroups (Janssen and Mark, 2007; Winter et al., 
2014). Excluding one subgroup only (e.g. smokers) may still distort the mortality 
risk estimates as other subgroups (e.g. those with conditions associated with 
weight loss) remain within the analysis cohort.    
 
In this chapter I summarise cohort studies that have reported on the association 
between BMI and mortality for adults aged ³65 years. Only studies with mortality 
risk estimates for the BMI Overweight range and/or BMI Obese-1 range and with 
the referent group consisting of BMI values within the BMI Normal range were 
included. In this chapter I focus on the effect of both the individual (e.g. specific) 
and combined exclusions of subgroups (smokers, early deaths, conditions 
associated with weight loss) on the obesity paradox with consideration of the BMI 
referent group using a meta-analysis approach.   
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3.3. Methods 
3.3.1. Data sources  
This review includes articles that reported risk estimates for adults aged ≥65 
years for the BMI Overweight and/or BMI Obese-1 ranges with all-cause 
mortality. Publications were identified by searching Embase, Medline, and 
Scopus electronic databases up to 13th August 2016. Search terms included 
“body mass index” or “obesity” or “overweight”; “mortality” or “deaths”; “aged, 65 
and over” or “elderly” or “aged, 80 and over” or “aged” or “geriatrics”; or 
“prospective” or “cohort”; “hazard ratio(s)” or “relative risk(s)” or “rate ratio(s)”. 
These were subsequently limited to English language articles published since 1st 
January 2000 as mortality risks may be altered with changing treatment patterns 
for other cardiovascular risk factors (e.g. high blood pressure). Publications were 
also identified from previous systematic reviews and meta-analyses.  
 
3.3.2. Study selection 
Inclusion criteria consisted of cohort studies with a minimum of 3 years of follow-
up, subjects aged ≥65 years, minimum of 1,000 subjects within each subgroup, 
risk estimates reported for the BMI Overweight and/or BMI Obese-1 range, all-
cause mortality as the outcome, and with the referent group consisting of BMI 
values within the BMI Normal range. Studies were excluded which comprised of 
nursing home residents only, populations with specific medical 
conditions/diagnoses (e.g. frailty), and wholly non-Caucasian populations. 
Publications which presented mortality risk estimates in figure form were also 
excluded. Publications which used the same cohort were included if mortality risk 
estimates were reported for different subgroups. Articles which were excluded 
are presented in the supplementary material Table S3.1. 
 
3.3.3. Data extraction 
The following were extracted from each publication: surname of the first author, 
year of publication, study name, baseline year(s), number of subjects, age range, 
gender, exclusion criteria, follow-up period, number of deaths, model 
adjustments, BMI groups, method of obtaining height and weight, and reported 
mortality risk estimates. Mortality risk estimates were extracted from the most 
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complex model unless it included adjustments for intermediate variables along 
the causal pathway (e.g. cholesterol, diabetes, or hypertension), in which an 
alternative model was used. However, if the alternative model was adjusted for 
age only then the most complex model was used.  
 
3.3.4. Statistical analysis  
A fixed-effects model was used to determine overall mortality risk estimates for 
individual studies which reported estimates separately by gender or age group 
(supplementary material tables S3.2 and S3.3). A random-effects model was 
used to combine the estimates from the individual studies. The I2 statistic was 
used to assess the degree of heterogeneity. Summary mortality risk estimates 
were derived for the BMI Overweight range and the Obese-1 range relative to 
those within the BMI Normal range. Estimates were summarised for the following:  
 
• analyses with no restrictions (unrestricted) 
• analyses excluding smokers only 
• analyses excluding early deaths only 
• analyses excluding conditions associated with weight loss only 
• analyses excluding smokers and early deaths 
•  analyses excluding smokers and conditions associated with weight loss 
•  analyses excluding early deaths and conditions associated with weight 
loss 
• analyses excluding smokers, early deaths, and conditions associated 
with weight loss.  
 
	
Estimates were also summarised for studies using either the whole of the 
conventional BMI Normal range (18.5 to 24.9 kg/m2) or where the referent group 
fell within the BMI range ≥20 to <25.0 kg/m2. For this analysis, I used R version 
3.2.0 with the packages (“metafor” version 1.9-9).   
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3.4. Results 
3.4.1. Characteristics of the studies 
A total of 40 articles were included in this review (see supplementary material 
figure S3.1). Study characteristics and the reported mortality risk estimates for 
unrestricted analyses (no restrictions) and restricted analyses (e.g. exclusion of 
smokers) are presented in Table 3.1 and Table 3.2 respectively. Most studies 
were conducted in the United States of America or Europe, had ³10 years of 
follow-up, and had baseline periods before 1st January 2000. Four studies had a 
baseline period in the 21st century only. Reported sample sizes ranged from 
1,000 to 28,466 participants. Eighteen studies used the conventional BMI Normal 
range and fourteen studies used a BMI group of ≥20.0 kg/m2 (≥20.0 to <25.0 
kg/m2) for the referent. Nineteen studies had a lower age boundary of 65 years. 
Most studies included broad age ranges of >10 years.   
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Notes for Table 3.2 
1 except missing variables 
2 except non-melanoma skin cancer 
3 AARP, AHS-1, AHS, BCDDP, CTS, CLUE, COSM, HFPS, IWHS, MCCS, NHS, 
NYUWHS, PHS, PLCO, SMC, USRT, VITAL, WHS, WLHS 
4 number reported by Winter et al., (2014) (Winter et al., 2014) 
5 based on Charlson Index 
6 number reported by Aune et al., (2016) (Aune et al., 2016) 
7 number of deaths for males and females aged ≥65 years 
For terms which have been abbreviated see List of abbreviations Table. For 
studies which have been abbreviated see List of Studies abbreviations Table. 
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3.4.2. BMI Overweight range and mortality  
Forty studies reported mortality risk estimates for the BMI Overweight range. 
Figure 3.1 shows the summary mortality hazard ratios (HR) for the BMI 
Overweight range relative to studies which used referent groups falling anywhere 
within the BMI Normal range for unrestricted (no exclusion) analyses, specific 
exclusions (e.g. never smokers only) and combined exclusions. For the BMI 
defined Overweight range there were reduced mortality risks for analyses which 
were considered unrestricted (summary HR 0.88 95% CI 0.84, 0.91) and for 
analyses which excluded never smokers only (summary HR 0.92 95% CI 0.84, 
0.99). There were increased mortality risks for the BMI Overweight range for 
analyses which simultaneously excluded never smokers, early deaths, and 
conditions associated with weight loss (HR 1.08 CI 1.03, 1.13, with low 
heterogeneity I2 0.0%) relative to those within the BMI Normal range. The 
mortality risks for the BMI Overweight range were not significantly different to 
those within the BMI Normal range for the remaining analyses.   
 
 
Figure 3.1 | Summary mortality risk estimates for the BMI Overweight range 
relative to studies which used a referent group falling anywhere within the BMI 
Normal range for unrestricted analyses, specific exclusions and combined 
exclusions 
 
Note: Unrestricted refers to analyses which did not exclude smokers, conditions 
associated with weight loss or early deaths. Excl conditions refers to analyses 
which excluded conditions associated with weight loss. Excl deaths refers to 
analyses which excluded early deaths during the follow up. NS refers to analyses 
which were restricted to never/non-smokers. The number in brackets refers to 
the number of analyses included.      
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Summary mortality risk estimates for studies which used the whole of the 
conventional BMI Normal range as the referent group (18.5-24.9 kg/m2) are 
presented in Figure 3.2. For analyses which used the whole of the conventional 
BMI Normal range there were reduced mortality risks for the BMI Overweight 
range for unrestricted analyses (summary HR 0.84 95% CI 0.81, 0.88, with low 
heterogeneity 10.3%). The mortality risks for the BMI Overweight range were not 
significantly different to the conventional BMI Normal range for analyses which 
excluded never smokers only or excluded both never smokers and early deaths, 
with lower heterogeneity reported compared to the unrestricted analyses. The 
remaining analyses had higher heterogeneity, with the summary mortality risk not 
being significantly different to the referent range.   
 
Figure 3.2 | Summary mortality risk estimates for the BMI Overweight range for 
studies which used the whole of the conventional BMI Normal range (18.5-24.9 
kg/m2) as the referent group for unrestricted analyses, specific exclusions and 
combined exclusions 
 
Note: Unrestricted refers to analyses which did not exclude smokers, conditions 
associated with weight loss or early deaths. Excl conditions refers to analyses 
which excluded conditions associated with weight loss. Excl deaths refers to 
analyses which excluded early deaths during the follow up. NS refers to analyses 
which were restricted to never/non-smokers. The number in brackets refers to 
the number of analyses included. The number in brackets refers to the number 
of analyses included.      
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Summary mortality risk estimates for studies which had used a referent group 
falling in the BMI range ≥20 to <25.0 kg/m2 are presented in Figure 3.3. The 
summary mortality risks for the BMI Overweight range were not significantly 
different for analyses which were unrestricted, excluded deaths only, or excluded 
both never smokers and conditions associated with weight loss. Increased 
mortality risks were reported for analyses which simultaneously excluded 
smokers, deaths, and conditions associated with weight loss with low 
heterogeneity.  
 
Figure 3.3 | Summary mortality risk estimates for the BMI Overweight range 
relative to those which used a referent group falling within the BMI range ≥20.0 
to 24.9 kg/m2 for unrestricted analyses, specific exclusions and combined 
exclusions 
 
Note: Unrestricted refers to analyses which did not exclude smokers, conditions 
associated with weight loss or early deaths. Excl conditions refers to analyses 
which excluded conditions associated with weight loss. Excl deaths refers to 
analyses which excluded early deaths during the follow up. NS refers to analyses 
which were restricted to never/non-smokers. The number in brackets refers to 
the number of analyses included.      
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3.4.3. BMI Obese-1 range and mortality  
Nineteen studies reported mortality risk estimates for the BMI Obese-1 range. 
Figure 3.4 shows the summary mortality hazard ratios (HR) for the BMI Obese-
1 range relative to studies which used referent groups falling anywhere within the 
BMI Normal range for unrestricted (no exclusion) analyses, specific exclusions 
(e.g. never smokers only) and combined exclusions. The summary mortality risks 
for the BMI Obese-1 range were not significantly different to those within the BMI 
Normal range for analyses which were unrestricted, had singular exclusions (e.g. 
never smokers), excluded both smokers and early deaths, and those which 
excluded both smokers and conditions associated with weight loss, all with larger 
heterogeneity. There were increased mortality risks for analyses which 
simultaneously excluded smokers, conditions associated with weight loss and 
early deaths (HR 1.31 95% CI 1.17, 1.47), with lower heterogeneity compared to 
the other analyses. 
 
Figure 3.4 | Summary mortality risk estimates for the BMI Obese-1 range relative 
to studies which had used a referent group falling anywhere within the BMI 
Normal range for unrestricted analyses, specific exclusions and combined 
exclusions 
 
Note: Unrestricted refers to analyses which did not exclude smokers, conditions 
associated with weight loss or excluding early deaths. Excl conditions refers to 
analyses which excluded conditions associated with weight loss. Excl deaths 
refers to analyses which excluded early deaths during the follow up. NS refers to 
analyses which were restricted to never/non-smokers. The number in brackets 
refers to the number of analyses included.      
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Summary mortality risk estimates for studies which used the whole of the 
conventional BMI Normal range as the referent group (18.5-24.9 kg/m2) are 
presented in Figure 3.5. There were reduced mortality risks for those within the 
BMI Obese-1 range compared to those within the conventional BMI Normal range 
for unrestricted analyses (HR 0.90 CI 0.82, 0.99). There were increased mortality 
risks for analyses which excluded never smokers and conditions associated with 
weight loss with low heterogeneity. The remaining analyses, with large 
heterogeneity, showed that the mortality risks were not significantly different.   
 
Figure 3.5 | Summary mortality risk estimates for the BMI Obese-1 range for 
studies which used the whole of the conventional BMI Normal range (18.5-24.9 
kg/m2) as the referent group for unrestricted analyses, specific exclusions and 
combined exclusions 
 
Note: Unrestricted refers to analyses which did not exclude smokers, conditions 
associated with weight loss or excluding early deaths. Excl conditions refers to 
analyses which excluded conditions associated with weight loss. Excl deaths 
refers to analyses which excluded early deaths during the follow up. NS refers to 
analyses which were restricted to never/non-smokers. The number in brackets 
refers to the number of analyses included.      
 
Summary mortality risk estimates for studies which had used a referent group 
falling within the BMI range ≥20.0 to 24.9 kg/m2 are presented in Figure 3.6. The 
summary mortality risks for the BMI Obese-1 range were not significantly different 
for unrestricted analyses and analyses which excluded early deaths only, both 
with large heterogeneity. There were increased mortality risks for analyses which 
excluded both smokers and conditions associated with weight loss and analyses 
which simultaneously excluded smokers, early deaths, and conditions associated 
with weight loss.  
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Figure 3.6 | Summary mortality risk estimates for the BMI Obese-1 range relative 
to those which used a referent group falling within the BMI range ≥20.0 to 24.9 
kg/m2 for unrestricted analyses, specific exclusions and combined exclusions 
 
Note: Unrestricted refers to analyses which did not exclude smokers, conditions 
associated with weight loss or excluding early deaths. Excl conditions refers to analyses 
which excluded conditions associated with weight loss. Excl deaths refers to analyses 
which excluded early deaths during the follow up. NS refers to analyses which were 
restricted to never/non-smokers. The number in brackets refers to the number of 
analyses included.      
 
 
3.4.4. Sensitivity analyses 
Several studies (Ellekjaer, Holmen and Vatten, 2001; Yates, Djousse and Kurth, 
2013; Holme and Tonstad, 2015; Cheng et al., 2016) adjusted for intermediates 
along the causal pathway (e.g. cholesterol, diabetes, or hypertension) between 
BMI and mortality. These were excluded from the unrestricted and subgroup 
analyses where possible (supplementary material table S3.4). The direction of 
the mortality association tended to be the same following the exclusion of these 
analyses. The mortality risk estimate, however, for the BMI Overweight range 
(HR 0.91 CI 0.82, 1.01) relative to those with a BMI within the Normal range 
became non-significant for the never smokers analysis overall after the exclusion 
of the analysis by Cheng et al., (2016).   
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3.5. Discussion 
The findings of this review and meta-analysis show that the mortality risks for the 
BMI Overweight range and BMI Obese-1 range are markedly altered with 
combined exclusions compared to specific exclusions or unrestricted analyses. 
There were reduced mortality risks for the BMI Overweight range for the 
unrestricted analyses relative to those within the BMI Normal range. Mortality 
risks were not significantly different in analyses which either singularly or jointly 
excluded deaths or conditions associated with weight loss. Risks were either 
reduced or not significantly different for analyses excluding smokers only or in 
combination with deaths or conditions associated with weight loss. However, for 
healthier non-smokers (e.g. exclusion of smokers, conditions associated with 
weight loss, and early deaths), there were increased mortality risks for those 
within the BMI Overweight range, with low heterogeneity.  
For the BMI Obese-1 range, the summary mortality risk was reduced for analyses 
considered unrestricted and which had used the whole of the conventional BMI 
Normal range as the referent group, with large heterogeneity. The summary 
mortality risks for singular exclusions, and combinations of two exclusions were 
not significantly different to those within the BMI Normal range. The lowest 
heterogeneity was reported for analyses which used the whole of the 
conventional BMI Normal range as the referent group and had simultaneously 
excluded smokers and conditions associated with weight loss, conferring an 
increased mortality risk. There was also an increased mortality risk, with a similar 
point estimate, for analyses which simultaneously excluded smokers, early 
deaths, and conditions associated with weight loss.  
From a public health perspective smokers, persons with conditions associated 
with weight loss and those who are relatively healthy may be managed differently 
in terms of weight control. Persons with conditions associated with weight loss 
(e.g. cancer, dementia, and heart failure) may be monitored for further weight 
loss and signs of malnutrition. Smokers considering smoking cessation may be 
advised on potential weight gain following complete cessation. Whilst for persons 
who are relatively healthy (e.g. with no apparent weight loss and not currently 
smoking), the focus may be more towards preventing weight gain and obesity. 
Interestingly, the summary mortality risks were elevated for the BMI Overweight 
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and BMI Obese-1 ranges for analyses which used all three exclusions and a BMI 
referent range with a lower bound of 20 kg/m2 (Berrrington de Gonzalez et al., 
2010 used the range 22.5-24.9 kg/m2 and Park et al., 2012 used the range 23.0-
24.9 kg/m2).  
3.5.1. Comparison to previous literature 
Previous meta-analyses have reported that the mortality risk for adults aged ≥65 
years within the BMI Overweight range is reduced (Flegal et al., 2013; Winter et 
al., 2014)  or not significantly different (Janssen and Mark, 2007) to those within 
the BMI Normal range. It has been documented that the mortality risk for adults 
within the BMI Obese-1 range is either not significantly different (Flegal et al., 
2013) or is associated with a modest increased risk when compared to those 
within the BMI Normal range  (Janssen and Mark, 2007). Winter et al., (2014) 
found increased mortality risks for those with BMI values >33.0kg/m2 compared 
to those within the BMI range 23.0-23.9 kg/m2 (Winter et al., 2014). The meta-
analysis I presented in this chapter showed reduced mortality risks for the BMI 
Overweight range and non-significant mortality risks for the BMI Obese-1 range 
relative to those within the BMI Normal range for analyses without restrictions. 
However, the results following all three combined exclusions contest the notion 
that those within the BMI Overweight and BMI Obese-1 ranges have improved 
survival compared to those within the BMI Normal range.        
 
Several of the previous meta-analyses reported mortality risk estimates for the 
BMI Overweight and BMI Obese-1 ranges for adults aged ≥65 years using 
subgroups (e.g. never smokers). Neither of the previous reviews, however, 
explicitly reported mortality risk estimates for specific exclusions only (e.g. non-
smokers only) or combined exclusions (Janssen, and Mark, 2007 & Winter, 
2014). Recently, Aune et al., (2016) reported an increased mortality risk of 4% 
(CI 1.01, 1.07) per 5-unit increment in BMI for never smokers aged ≥65 years. 
Conversely, in the non-linear dose response analysis there was no significant 
association with mortality for BMI values within the range 24.0 to <45.0 kg/m2. In 
the overall analysis (i.e. in all ages) the nadir of the BMI mortality curve was 
reported to be reduced following exclusions of smokers and those with conditions 
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associated with weight loss. Combined exclusions for the age group ≥65 years 
were not reported in the meta-analysis by Aune et al., (2016) (Aune et al., 2016). 
 
The Global BMI Mortality Collaboration (2016) individual participant meta-
analysis, which was not available at the start of my PhD, reported that the BMI-
Obese 1 range was associated with an increased mortality risk (HR 1.19 CI 1.14, 
1.23) for never smoking adults aged 70 to 89 years without pre-existing disease, 
excluding the first five years of follow-up (Di Angelantonio et al., 2016).  There 
was no significant mortality risk for the BMI Overweight range (HR 1.00 CI 0.98, 
1.02). Findings from the meta-analysis presented in this chapter are partly in line 
with those from the Global BMI Mortality Collaboration (2016). However, the 
mortality association magnitudes for the BMI Overweight and BMI Obese-1 
ranges reported in the Global BMI Mortality Collaboration (2016) and the analysis 
presented in this chapter differ. This may be due to the chosen age range (70 to 
89 years in the Global collaboration versus ≥65 years in this chapter). 
Additionally, it was noted that individual records on chronic conditions were not 
always complete and thereby residual confounding may have persisted (Di 
Angelantonio et al., 2016). Questions remain on the BMI associations with 
mortality using recent measures for narrower age groups.  
 
3.5.2. Analyses included in this review   
Comparisons between BMI and mortality analyses can be difficult due to the 
chosen age groups, model adjustments, baseline period, length of follow-up, and 
number of years of follow-up excluded. For instance, some studies have used 
relatively narrow age ranges of within ten years (Adams et al., 2006; Ford, Spallek 
and Dobson, 2008; de Hollander et al., 2012 b) whereas others have used 
broader age ranges of ≥30 years (Ma et al., 2013; Koster et al., 2015). Reported 
mortality risk estimates may be diluted by the inclusion of both the young-old and 
the oldest-old. The model adjustments for the analyses included in this review 
were not consistent, and none of these were chosen based on using a directed 
acyclic graph approach.  Most studies had baseline periods within the 1980s and 
1990s. Since the 1980s the number of adults with a BMI within the Overweight or 
Obese range has risen substantially. Additionally, the diagnosis and treatment of 
many of the cardiovascular risk factors associated with obesity has been 
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enhanced and therefore mortality risk estimates may be altered (see Chapter 1). 
Most studies had a long follow-up period (≥10 years). Studies which had shorter 
follow-up periods showed reduced mortality risks for the BMI Overweight range 
and reduced or non-significant mortality risks for the BMI Obese-1 range relative 
to the BMI Normal range. This further highlights that shorter follow-up periods are 
more likely to report reduced/non-significant mortality risks. Deaths during the 
first few years are likely to reflect undiagnosed disease and thus reverse 
causation (see Chapter 1). Additionally, it can take years for obesity-related 
conditions to develop. The chosen number of years to exclude during the follow-
up for early deaths differed amongst the studies with the shortest amount of time 
excluded being one month (Graf et al., 2015) and the longest being five years 
(Dey et al., 2001; Ma et al., 2013; Cheng et al., 2016). Opinions on the need to 
exclude early mortality have been divided. Empirical data is, therefore, required 
to assess how many years of follow-up are needed to be excluded to provide 
stable BMI mortality estimates.  
The exclusion criteria, BMI groups, and BMI referent group have also not been 
consistent between studies. There was no uniformity in the number and choice 
of conditions to exclude. Previous analyses which excluded persons with 
conditions associated with weight loss did not empirically test these associations; 
I will demonstrate this in Chapter 4. Only two studies excluded persons with 
reported weight loss, one excluding those with a loss of ≥10 pounds within the 
preceding year (Patel, Hildebrand and Gapstur, 2014) and the other a loss of ≥10 
pounds within the preceding five years (Baik et al., 2000). The BMI groups 
representing the BMI Overweight range were not consistent between the studies, 
with some studies subdividing this range. Although most studies showed similar 
mortality risks for these subdivisions, there were some instances in which non-
significant and increased mortality risks were reported for the lower and higher 
ends of the BMI Overweight range respectively (Berrington de Gonzalez et al., 
2010; Park et al., 2012; Patel, Hildebrand and Gapstur, 2014). 
The BMI referent group was not uniform with 18 studies using the standard 
Normal BMI range and 14 studies using a referent group commencing at a BMI 
of ≥20 kg/m2. The two studies which used all three exclusions had a BMI 
reference range ≥22.0 kg/m2 (Berrington de Gonzalez et al., 2010; Park et al., 
161	
 
Chapter 3 | Meta-analysis  
2012). As discussed in Chapter 1, another explanation for paradoxical BMI 
associations (reduced or non-significant mortality risks) is that persons within the 
lower end of the conventional BMI Normal range may be at an increased mortality 
risk, thereby distorting mortality risk estimates for the higher BMI ranges. The 
choice of the BMI referent group will be analysed and discussed further in 
Chapter 5.      
Findings from the meta-analysis presented in this chapter highlight that there is 
a lack of analyses for BMI mortality estimates across the age-range for older 
adults. None of the analyses included in this review concurrently provided 
mortality risk estimates for narrower age groups which could be used in this 
review (some studies did not provide confidence intervals or had less <1000 
subjects in additional age groups). There has been a limited number of studies 
(n = 4) which have provided recent BMI mortality estimates e.g. using a baseline 
period from the 21st Century (Hirani et al., 2014; Holme and Tonstad, 2015; 
Koster et al., 2015; Cheng et al., 2016). As highlighted in Chapter 1 the global 
prevalence of persons classified as obese has risen substantially and there is a 
need to update the reported associations between higher BMI values and health 
outcomes. Similarly, there has been an increase in the treatment of many of the 
metabolic risk factors associated with obesity (hypertension and cholesterol) and, 
therefore, the estimates for mortality may differ. Analyses of the BMI associations 
using NHANES I, II, and III has shown a secular decline in mortality from obesity 
(Flegal et al., 2005).   
3.5.3. Strengths and limitations 
In this chapter I summarised cohort studies that have reported on the association 
between the BMI Overweight range and BMI Obese-1 range with all-cause 
mortality for adults aged ³65 years. This is the first meta-analysis that has 
presented mortality risk estimates for both specific exclusions and combined 
exclusions as well as assessing the contribution of the length of the follow-up 
period and the choice of the BMI referent group.  
 
There are several limitations with my analysis. One limitation of this review was 
that the outcome addressed was all-cause mortality. Therefore, risk estimates for 
the BMI Overweight and BMI Obese-1 ranges with specific causes of death or 
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morbidity may differ to those presented in this chapter for all-cause mortality. 
Furthermore, this review focused on adults aged ≥65 years and mortality risk 
estimates may have been diluted due to the inclusion of younger and older adults. 
The findings may not be generalisable to populations which were not included in 
this analysis. Most of the current studies were conducted in the United States of 
America or Europe (Finland, France, Iceland, Norway, Sweden, Switzerland, the 
United Kingdom and the SENECA study). A further limitation of this review was 
that I did not assess the quality of the included studies, for instance by using the 
Newcastle-Ottawa scale, which may have affected the summary mortality risks.  
Aune, et al., (2016) highlighted in their meta-analysis that study quality could alter 
the shape of the BMI mortality curve and the BMI range associated with the 
lowest mortality risk. For all age-groups, the BMI range associated with lowest 
mortality risk was higher when summarising studies considered as medium 
quality compared to studies considered to be high quality (Aune et al., 2016).  
Additionally, the quality of the data used for summarising the mortality risks could 
have been enhanced by using individual patients’/participants’ data rather than 
the study data. Conducting a meta-analysis of individual participant data has 
several advantages including the harmonisation of the inclusion/exclusion 
criteria, the choice of the statistical model, and covariates (Riley, Lambert and 
Abo-Zaid, 2010). As highlighted in this chapter, the inclusion/exclusion criteria 
and the model adjustments were not uniform. A final way to enhance this analysis 
would be to include multiple reviewers searching, extracting, and checking the 
data.  
 
3.5.4. Future Work 
My review and meta-analysis highlighted that there is a lack of analyses which 
have concurrently reported on the association between the BMI Overweight and 
BMI Obese-1 ranges and mortality across progressively older age groups. A 
limited number of studies (n = 2) have reported mortality estimates combining all 
three exclusions (Berrington de Gonzalez et al., 2010; Park et al., 2012) and 
using baseline periods within the 21st century. In Chapter 4, I present an analysis 
using the Clinical Practice Research Datalink (CPRD) to estimate the association 
between the WHO BMI categories and mortality for narrower age groups using a 
baseline period of ≥1st January 2000. Mortality risk estimates for the BMI 
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categories are reported for the unrestricted sample (no exclusions) and for 
simultaneous exclusions (smokers, conditions associated with weight loss, and 
early follow-up) for each age group. Furthermore, I systematically identify 
conditions associated with weight loss and assess the number of years of early 
follow-up to exclude to minimise reverse causality and thereby achieve stable 
mortality risk estimates.   
 
3.6. Conclusions 
This meta-analysis showed that the risks for mortality for the BMI Overweight 
range and BMI Obese-1 range were markedly altered with combined exclusions. 
For healthier non-smokers (exclusion of conditions associated with weight loss) 
the BMI Overweight range and BMI Obese-1 range were associated with an 
elevated risk for mortality relative to those within the BMI Normal range. 
Outstanding questions remain, however, on the BMI associations with mortality 
using recent measures from the 21st century across progressively older age 
groups.   
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Figure S3.1 | Flow diagram of the study selection 
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Table S3.1 | Studies or sub-samples excluded from analysis 
Author, Year Study or sample Reason 
(Afzal et al., 2016) 
 
Study: Copenhagen City 
Heart Study & 
Copenhagen General 
Population Study  
Age issues 
(Ajani et al., 2004) 
 
Study: Physicians’ Health 
Study  
Figure format 
(Auyeung et al., 2010) 
 
Study: Health check 
carried out in the School 
of Public Health of The 
Chinese University of 
Hong Kong  
Population 
(Beleigoli et al., 2013) 
 
Study: Bambuí (Brazil) 
Cohort Study of Aging  
BMI Overweight and 
obese combined 
(Breeze et al., 2006) 
 
Study: Whitehall cohort of 
male civil servants  
BMI overweight and 
obese combined 
(Buys et al., 2014) 
 
Study: University of 
Alabama at Birmingham 
Study of Aging  
Sample size 
(Corrada et al., 2006) Sample:  
70-74 years and 75-79 
years 
Mortality risk estimates 
not reported  
(Dey et al., 2001a)   Samples: 
Women excluding 
Cancer ≤ 70 y & BMI > 
40. Restricted to never 
smokers or quit smoking 
before 40 y. 
Plus exclusion of first 5 
years 
Referent group outside 
BMI normal range 
(Dobson et al., 2012) Studies: HIMS & ALSWH 
1996-1999;1999 
Odds ratios reported 
(Dutta et al., 2011) 
 
Study: Iowa Established 
Populations for 
Epidemiologic Study of 
the Elderly  
Odds ratios reported 
(Flegal et al., 2005) 
 
Studies: NHANES I-III 
1971-1975; 1976-1980; 
1988-1994 
Overlapping and no 
sample size numbers 
(Flicker et al., 2010) Studies: HIMS & ALSWH 
1996 
Overlapping population 
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Table S3.1 continued   
Author, Year Study or sample Reason 
(Grabowski and Ellis, 
2001) 
Study: Longitudinal Study 
of Aging (LSOA)  
 
Figure format 
(Greenberg, 2001) 
 
Study: National Health 
and Examination Survey 
(NHANES 1) 
Epidemiologic Follow-up 
Study 
Figure format 
(Gulsvik et al., 2009) 
 
Study: Bergen Clinical 
Blood Pressure Study  
Sample size 
(Klenk et al., 2009) Study: Vorarlberg Health 
Monitoring & Promotion 
Program (VHM&PP) 
 
Figure format 
(Koster et al., 2015) Sample 
Males aged 66-96 years 
Mortality risk estimates 
not reported 
(Kuk and Ardern, 2009) 
 
Study: NHANES III Sample size 
(Kvamme et al., 2012) Study: Tromsø Study & 
North-Trøndelag 
Health Study; 
1994-1995; 
1996-1997 
 
Referent range outside 
of BMI Normal 
(Lahmann et al., 2002) Study: Malmo Diet and 
Cancer Study 
Age 
(Lang et al., 2008) Study: ELSA Mortality risk estimates 
in figure format 
(Lu et al., 2015) Study: RCAV study Reference was those 
aged <40 y & BMI <20  
(Masters, Powers and 
Link, 2013) 
Study: 19 waves of NHIS 
(US) 
No sample size 
numbers and 
overlapping population 
(Mazza et al., 2006) Study: CASTEL Reference group 
outside of BMI Normal 
range 
(Orpana et al., 2009) 
 
Study: National 
Population Health 
Survey, a longitudinal 
panel study conducted by 
Statistics Canada  
Age issues  
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Table S3.1 continued 
 
  
Author, Year 
 
Study or sample Reason 
(Pischon et al., 2008) Study: EPIC Sample size / mortality 
numbers not reported 
for oldest age group 
(Reis et al., 2009) Study: NHANES Overlapping population 
(Rillamas-Sun et al., 
2014) 
Study: WHI OS & CT 
programs 
 
Odds ratios and 
overlapping population 
(Rogers, Hummer and 
Krueger, 2003) 
Study: NHIS No confidence interval 
(Rolland et al., 2014) 
 
Study: EPIDOS study  Continuous measure 
(Schneider et al., 2010) Study: DETECT and 
SHIP  
Figure format 
(Schonberg et al., 2011) 
 
Study: National Health 
Interview Survey (NHIS, 
2001–2004)  
BMI Overweight and 
obese combined 
(Sergi et al., 2005) 
 
Study: The Italian 
Longitudinal Study on 
Aging  
BMI referent outside of 
the Normal range 
(Singh et al., 2011) 
 
Study: Adventist Health 
Study and Adventist 
Mortality Study in 
California. 
BMI overweight and 
obese combined 
(Stessman et al., 2009) Study: West Jerusalem 
residents  
Sample size 
(Suemoto et al., 2015) 
 
Study: SABE Study  
 
Age issues  
(Thomson et al., 2016) Study: WHI Figure format and 
overlapping population 
(Van Uffelen et al., 
2010) 
 
Study: ALSWH  
 
Continuous measure 
(Walter et al., 2009) 
 
Study: Rotterdam Study 
cohort,  
Age issues  
(Zunzunegui et al., 
2012) 
 
Study: The Aging in 
Leganés cohort  
 
Sample size 
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Table S3.2 | Combining of reported risk estimates using fixed effect models for 
unrestricted analyses (no exclusion of smokers, conditions associated with 
weight loss or early follow up) 
Author, 
Year 
Gender or 
age group 
BMI group Reported 
Estimate HR 
(95% CI) 
Combined 
HR (95% CI) 
Adams, 
2006 
(Adams et 
al., 2006) 
Males 25.0-26.4 0.91 (0.87, 0.96) 
 
 
Males 
 
26.5-27.9 0.95 (0.90, 1.00) 
 
 
Males 28.0-29.9 0.96 (0.91, 1.01) 
 
 
Males 25.0-29.9 - 0.94 (0.91, 0.97) 
 
Females 25.0-26.4 1.01 (0.92, 1.10) 
 
 
Females  26.5-27.9 1.04 (0.95, 1.14) 
 
 
Females 28.0-29.9 1.06 (0.97, 1.16)  
Females 25.0-29.9 - 1.04 (0.98, 1.09) 
 
Males & 
Females 
25.0-29.9 - 0.97 (0.94, 0.99) 
 
Males 30.0-34.9 1.05 (0.99, 1.10) 
 
 
Females 30.0-34.9 1.14 (1.05, 1.23) 
 
 
Males & 
Females 
30.0-34.9 - 1.08 (1.03, 1.13) 
 
Holme, 2015 
(Holme and 
Tonstad, 
2015) 
Males 25.0-27.4 0.91 (0.78, 1.00) 
 
 
Males 27.5-29.9 0.86 (0.76, 0.98)  
Males 25.0-29.9 - 0.89 (0.81, 0.97) 
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Table S3.3 | Combining of reported risk estimates using fixed effect models for 
restricted analyses 
Author, Year Gender or 
age group 
BMI group Reported 
Estimate HR 
(95% CI) 
Combined 
HR (95% CI) 
Baik, 2000 
(Baik et al., 
2000) 
Males 25.0-26.9 
 
0.75 (0.53, 1.08) 
 
 
Males 27.0-29.9 
 
0.83 (0.56, 1.23) 
 
 
Males 25.0-29.9 - 0.79 (0.60, 1.02) 
 
Berrington de 
Gonzalez, 
2010 
(Berrington 
de Gonzalez 
et al., 2010)  
Males & 
Females 
25.0-27.4 1.04 (0.96, 1.13)  
 
 
Males & 
Females 
27.5-29.9 1.15 (1.04, 1.26) 
 
 
Males & 
Females 
25.0-29.9 - 1.08 (1.02, 1.15) 
 
Dey, 2001 
(Dey et al., 
2001) 
Males 26.5-28.5 1.01(0.81, 1.26) 
 
 
Females 26.6-29.2 1.16 (0.88, 1.52) 
 
 
Males & 
Females 
Overweight 
range 
- 1.07 (0.9, 1.27) 
 
Ellekjaer, 
2001 
(Ellekjaer, 
Holmen and 
Vatten, 2001) 
Males 25.11-27.35 0.80 (0.69, 0.93) 
 
 
Females 25.98-29.00 0.62 (0.52, 0.75)  
Males & 
Females 
Overweight 
range 
- 0.72 (0.64, 0.81) 
 
Males 25.0-29.9 0.77 (0.57, 1.03) 
 
 
Females 25.0-29.9 1.09 (0.89, 1.33) 
 
 
Males & 
Females 
25.0-29.9  0.98 (0.83, 1.15) 
 
Males 30.0-34.9 1.15 (0.70, 1.89) 
 
 
Females 30.0-34.9 1.44 (1.08, 1.92)  
Males & 
Females 
30.0-34.9  1.36 (1.06, 1.75) 
 
Graf, 2015 
(Graf et al., 
2015) 
Males 25.0-29.9 0.76 (0.66, 0.88) 
 
 
Females 25.0-29.9 0.89 (0.74, 1.07) 
 
 
Males & 
Females 
25.0-29.9 - 0.81 (0.72, 0.90) 
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Table S3.3 continued 
 
Author, 
Year 
Gender or 
age group 
BMI group Reported 
Estimate HR 
(95% CI) 
Combined 
HR (95% CI) 
Graf, 2015 
(Graf et 
al., 2015) 
Males 30.0-34.9 0.53 (0.40, 
0.70) 
 
 
Females 30.0-34.9 1.02 (0.80, 
1.30) 
 
Males & 
Females 
30.0-34.9 - 0.77 (0.64, 
0.92) 
 
Moore, 
2008 
(Moore et 
al., 2008) 
Females 25.0-27.4 1.17 (1.02, 
1.34) 
 
 
Females 27.5-29.9 1.01 (0.84, 
1.21) 
 
 
Females 25.0-29.9 NA 1.11 (1.00, 
1.24) 
 
Park, 2012 
(Park et 
al., 2012) 
Males 25.0-27.4 1.03 (0.89, 
1.18) 
 
 
Males 27.5-29.9 1.23 (1.04, 
1.46) 
 
 
Males 25.0-29.9 - 1.11 (0.99, 
1.23) 
 
Females 25.0-27.4 1.03 (0.92, 
1.17) 
 
 
Females 27.5-29.9 1.11 (0.97, 
1.27) 
 
 
Females 25.0-29.9 - 1.06 (0.97, 
1.16) 
 
Males & 
Females 
25.0-29.9 - 1.08 (1.01, 
1.16) 
 
Males 30.0-34.9 1.46 (1.21, 
1.75) 
 
 
Females 30.0-34.9 1.36 (1.19, 
1.55) 
 
Males & 
Females 
30.0-34.9 - 1.39 (1.25, 
1.55) 
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Table S3.3 continued 
 
Author, Year Gender or 
age group 
BMI group Reported 
Estimate HR 
(95% CI) 
Combined 
HR (95% CI) 
Patel, 2014 
(Patel, 
Hildebrand 
and Gapstur, 
2014) 
Males 25.0-27.4 1.00 (0.94, 1.05) 
 
 
Males 27.5-29.9 1.08 (1.01, 1.16) 
 
 
Males 25.0-29.9 - 1.03 (0.99, 1.08) 
 
Females 25.0-27.4 1.02 (0.99, 1.06) 
 
 
Females 27.5-29.9 1.07 (1.02, 1.12) 
 
 
Females 25.0-29.9 - 1.04 (1.01, 1.07) 
 
Males & 
Females 
25.0-29.9 - 1.04 (1.01, 1.06) 
 
Males 30.0-34.9 1.06 (0.95, 1.17) 
 
 
Females 30.0-34.9 1.13 (1.08, 1.19) 
 
 
Males & 
Females 
30.0-34.9 - 1.12 (1.07, 1.17) 
 
Price, 2006 
(Price et al., 
2006) 
Males >25.0-26.7 0.77 (0.67, 0.88) 
 
 
Males >26.7-29.0 0.73 (0.63, 0.85) 
 
 
Males 25.0-29.0 - 0.75 (0.68, 0.83) 
 
Females 26.8-29.7 0.76 (0.67, 0.87)  
Males & 
Females  
Overweight 
range 
- 0.75 (0.70, 0.82) 
 
Reuser, 2008 
(Reuser, 
Bonneux and 
Willekens, 
2008) 
Males 25.0-29.9 0.86 (0.70, 1.06) 
 
 
Females 25.0-29.9 0.80 (0.66, 0.98) 
 
 
Males & 
Females 
25.0-29.9  0.83 (0.72, 0.96) 
 
Males 30.0-34.9 0.85 (0.60, 1.21) 
 
 
Females 30.0-34.9 0.95 (0.72, 1.26)  
Males & 
Females  
30.0-34.9  0.91 (0.73, 1.13) 
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Table S3.3 continued 
 
Author, 
Year 
Gender 
or age 
group 
BMI group Reported 
Estimate HR 
(95% CI) 
Combined 
HR (95% CI) 
Wee, 2011 
(Wee, 2011) 
Males 25.0-27.4 0.84 (0.78, 
0.92) 
 
 
Males 27.5-29.9 0.81 (0.73, 
0.90) 
 
 
Males 25.0-29.9 - 0.83 (0.78, 
0.88) 
 
Females 25.0-27.4 0.90 (0.81, 
0.99) 
 
 
Females 27.5-29.9 0.82 (0.74, 
0.92) 
 
 
Females 25.0-29.9 - 0.86 (0.80, 
0.93) 
 
Males & 
Females 
25.0-29.9 - 0.84 (0.80, 
0.88) 
 
Males 30.0-34.9 0.89 (0.81, 
0.99) 
 
 
Females 30.0-34.9 0.98 (0.88, 
1.08) 
 
Males & 
Females 
30.0-34.9 - 0.93 (0.87, 
1.00) 
 
Xiao, 2014 
(Xiao et al., 
2014) 
Males 25.0-29.9 1.06 (0.98, 
1.16) 
 
 
Females 25.0-29.9 1.03 (0.93, 
1.15) 
 
Males & 
Females 
25.0-29.9 - 1.05 (0.98, 
1.12) 
 
Males 30.0-34.9 1.31 (1.17, 
1.46) 
 
 
Females 30.0-34.9 1.26 (1.10, 
1.43) 
 
Males & 
Females 
30.0-34.9 - 1.29 (1.18, 
1.40) 
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Table S3.4 | Exclusions of studies which had adjusted for intermediates along 
the causal pathway 
Analyses  Author(s) of 
study/studies 
excluded  
Summary estimates  I2 
Overweight and 
exclusion of 
conditions 
associated with 
weight loss 
Cheng, 2016 
(Cheng et al., 
2016) 
Ellekjaer, 2001 
(Ellekjaer, 
Holmen and 
Vatten, 2001) 
Yates, 2008 
(Yates, Djousse 
and Kurth, 2013) 
 
1 study in analysis 
after excluding 
Cheng, Ellekjaer, and 
Yates. 
 
Overweight and 
exclusion of 
smokers only 
Cheng, 2016 
(Cheng et al., 
2016) 
0.91 (0.82, 1.01) 42.5 
Overweight 
exclusion 
smokers and 
deaths all follow 
up & ≥ 10y follow 
up 
Cheng, 2016 
(Cheng et al., 
2016) 
1 study left in the 
analysis 
 
Overweight and 
exclusion of 
smokers only & ≥ 
10y follow up 
Cheng, 2016 
(Cheng et al., 
2016) 
0.97 (0.92, 1.01) 0.0 
Overweight and 
exclusion of 
smokers only & 
standard BMI 
Normal as the 
reference 
Cheng, 2016 
(Cheng et al., 
2016) 
0.91 (0.82, 1.01) 42.5 
Overweight and 
exclusion of 
smokers only and 
deaths & 
standard BMI 
Normal as the 
reference 
Cheng, 2016 
(Cheng et al., 
2016) 
1 study left in the 
analysis 
 
Overweight and 
exclusion of 
smokers only & 
standard BMI 
Normal as the 
reference& ≥ 10y 
follow up 
Cheng, 2016 
(Cheng et al., 
2016) 
0.91 (0.82, 1.01) 42.5 
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Table S3.4 continued 
Analyses  Author(s) of 
study/studies 
excluded  
Summary estimates  I2 
Overweight and 
exclusion of 
smokers only and 
deaths & 
standard BMI 
Normal as the 
reference & ≥ 10y 
follow up 
Cheng, 2016 
(Cheng et al., 
2016) 
1 study left in the 
analysis 
 
Obese-1 and 
exclusion of 
smokers only 
Cheng, 2016 
(Cheng et al., 
2016) 
1 study left in the 
analysis 
 
Obese-1 
exclusion 
smokers and 
deaths 
Cheng, 2016 
(Cheng et al., 
2016) 
1 study left in the 
analysis 
 
Obese-1 and 
exclusion of 
smokers only & ≥ 
10y follow up 
Cheng, 2016 
(Cheng et al., 
2016) 
1 study left in the 
analysis 
 
Obese-1 
exclusion 
smokers and 
deaths & ≥ 10y 
follow up 
Cheng, 2016 
(Cheng et al., 
2016) 
1 study left in the 
analysis 
 
Obese-1 and 
exclusion of 
smokers only & 
BMI Normal as 
the reference 
Cheng, 2016 
(Cheng et al., 
2016) 
1 study left in the 
analysis 
 
Obese-1 
exclusion 
smokers and 
deaths & BMI 
Normal as the 
reference 
Cheng, 2016 
(Cheng et al., 
2016) 
1 study left in the 
analysis 
 
Obese-1 and 
exclusion of 
smokers only & 
BMI Normal as 
the reference & ≥ 
10y follow up 
Cheng, 2016 
(Cheng et al., 
2016) 
1 study left in the 
analysis 
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Table S3.4 continued 
Analyses  Author(s) of 
study/studies 
excluded  
Summary estimates  I2 
Obese-1 
exclusion 
smokers and 
deaths & BMI 
Normal as the 
reference & ≥ 10y 
follow up 
Cheng, 2016 
(Cheng et al., 
2016) 
1 study left in the 
analysis 
 
Unrestricted 
Overweight  
Holme, 2015 
(Holme and 
Tonstad, 2015) 
0.88 (CI 0.84, 0.91) 63.8 
Unrestricted 
Overweight & ≥ 
10y follow up 
Holme, 2015 
(Holme and 
Tonstad, 2015) 
0.91 (CI 0.86, 0.95) 57.7 
Unrestricted 
Overweight & 
with BMI referent 
≥20 
Holme, 2015 
(Holme and 
Tonstad, 2015) 
0.91 (CI 0.85, 0.98) 62.4 
Unrestricted 
Overweight & 
with BMI referent 
≥20 & ≥ 10y 
follow up 
Holme, 2015 
(Holme and 
Tonstad, 2015) 
0.97 (0.95, 0.99) 0.0 
Unrestricted 
Obese-1  
Holme, 2015 
(Holme and 
Tonstad, 2015) 
0.92 (CI 0.82,1.02) 82.4 
Unrestricted 
Obese-1 & ≥ 10y 
follow up 
Holme, 2015 
(Holme and 
Tonstad, 2015) 
0.98 (CI 0.87, 1.11) 73.7 
Unrestricted 
Obese-1 & with 
BMI referent ≥20 
Holme, 2015 
(Holme and 
Tonstad, 2015) 
0.92 (0.67, 1.27) 94.3 
Unrestricted 
Obese-1 & with 
BMI referent ≥20 
& ≥ 10y follow up 
Holme, 2015 
(Holme and 
Tonstad, 2015) 
1 study in analysis 
after excluding Holme, 
2015 
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4.1. Overview of the chapter  
This chapter is based mainly on my first author published paper: 
 
Bowman, K., Delgado, J., Henley, W.E., Masoli, J.A., Kos, K., Brayne, C., 
Thokala, P., Lafortune, L., Kuchel, G.A., Ble, A., & Melzer, D. (2017) 
Obesity in Older People With and Without Conditions Associated With 
Weight Loss : Follow-up of 955,000 Primary Care Patients. J Gerontol A 
Biol Sci Med Sci.  Editor’s Choice. 72(2): 203–209. 
 
My contribution to this published work included conducting the literature review, 
designing and conducting the analyses, and writing the manuscript. Therefore, 
much of the methods, results and discussion are direct translations from this 
paper. Some sentences have been modified to make the sentences clearer and 
additional headings have been used.     
 
I have, however, redrafted the abstract, introductory section, and concluding 
remarks to emphasise the links throughout this thesis. Additionally, I have 
restructured parts of the original manuscript with some of the supplementary 
material now added to this chapter to make clearer the progression of the 
analysis. I have also changed some of the formatting of the supplementary 
material e.g. tables in the original manuscript have been changed to forest plots 
and are now within the main text. I have also added an additional analysis to this 
chapter where the mortality model was additionally adjusted for physical activity. 
Furthermore, additional sections have been added to the discussion to show the 
links throughout this thesis.     
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4.2. Summary  
Background: Older people within the body mass index (BMI) defined Obese-
1(30.0-34.9 kg/m2) range reportedly have lower or similar mortality risks to those 
within the conventional BMI Normal range (18.5-24.9 kg/m2), termed the obesity 
paradox, casting doubt on responses to the obesity epidemic. However, these 
estimates may be distorted by pooling relatively healthy subjects, smokers, and 
those with conditions associated with weight loss. 
 
Objective: To estimate BMI associations with mortality across progressively 
older age groups in a sufficiently large primary care population to allow stratified 
analyses.  
 
Design: This analysis used the Clinical Practice Research Datalink (CPRD) 
which contains primary care, hospital, and death certificate electronic health 
records for registered populations aged ≥60 years in England from 1st January 
2000. The analysis included 955,031 patients, with complete data (smoking, 
alcohol, and socioeconomic status records) available for 822,811 patients. The 
‘healthier agers’ subgroup were non-smokers without conditions associated with 
weight loss and who survived the first 3.9 years of the follow-up period. Cox 
proportional hazards models were adjusted for age, gender, alcohol use, 
smoking, calendar year, and socioeconomic status.  
 
Results: In the 65 to 69 years age group (n = 312,352), 13.1% of the subjects 
died during a maximum follow-up period of 14.9 years. In this age group, those 
within the BMI Obese-1 range had reduced mortality risks relative to those within 
the conventional BMI Normal range, with Hazard Ratio (HR) 0.91 (95% 
Confidence Interval [CI] 0.88, 0.93). However, there was a reversal of the 
mortality risks for those within the BMI Obese-1 range for ‘healthier agers’, with 
an increased mortality risk (HR 1.17 CI 1.11, 1.23). The reversal of the mortality 
risks with the BMI Obese-1 range was observed up to age 74 years and shifted 
to non-significance for those aged 75 to 84 years. 
 
Conclusions: The obesity paradox in later life appears to be the erroneous result 
of combining mortality risks for relatively healthy and already ill older groups. As 
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obesity is associated with excess mortality in otherwise healthy non-smoking 
older people, up to and including those aged 74 years, assertions based on the 
claimed paradox against current obesity control efforts are misplaced.  
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4.3. Introduction 
The worldwide epidemic of obesity clearly requires a concerted, science based 
response to prevent adverse outcomes. As outlined in Chapter 1, younger and 
middle aged adults within the BMI Obese range are at an increased risk of cancer, 
cardiovascular disease and premature mortality (Calle et al., 1999; Adams et al., 
2006; Renehan et al., 2007; Whitlock et al., 2009; Wormser et al., 2011). In later 
life (aged ≥65 years) persons within the BMI Obese-1 range have been reported 
to have reduced or similar mortality risk to those within the conventional BMI 
Normal range. This opposing mortality risk for the BMI Obese-1 range has been 
termed the obesity paradox. Flegal et al., (2013) reported that there was a similar 
mortality risk for adults aged ≥65 years within the BMI Obese-1 (BMI 30.0-34.9 
kg/m2) range relative to those within the conventional BMI Normal (BMI 18.5-24.9 
kg/m2) range. There was a reduced mortality risk for those within the BMI 
Overweight range (BMI 25.0-29.9 kg/m2) (Flegal et al., 2013). Dixon and 
colleagues have argued that this “obesity risk paradox” in older adults is counter 
to “decades of advice to avoid even modest weight gain”, and that current weight 
control policies may be doing harm in older groups (Dixon et al., 2015). Several 
previous analyses have documented that the BMI associated with the lowest 
mortality risk lies within the BMI Overweight range, therefore conferring a 
protective effect  (Flicker et al., 2010; van Uffelen et al., 2010; de Hollander et al., 
2012 b; Cheng et al., 2016). There is, therefore, some urgency to clarify whether 
people with a BMI in the Overweight or Obese-1 range are or are not at greater 
risk of death. 
 
As discussed in Chapter 1 BMI is the most widely used adiposity measure in both 
clinical practice and epidemiological studies. Chang et al., (2014) documented 
that for males and females aged ≥65 years there was a strong correlation 
between BMI and body fat percentage measured by dual energy X-ray 
absorptiometry, r=0.81 and r=0.71, respectively  (Chang et al., 2014). The validity 
and prognostic value of the conventional BMI categories published by the World 
Health Organization (World Health Organization, 2000) for older adults and ethnic 
groups has been questioned (Heiat, Vaccarino and Krumholz, 2001; Zamboni et 
al., 2005; Ntuk et al., 2014; Rolland et al., 2014; Winter et al., 2014). 
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As highlighted in Chapter 1 and Chapter 3 various explanations (Janssen and 
Mark, 2007; Kalantar-Zadeh et al., 2007; Chiolero et al., 2008) have been offered 
for the obesity paradox in later life including: biological mechanisms, length of 
follow-up, reverse causality and smoking. Smoking is associated with lower 
weight and markedly raised health risks and can therefore distort regression 
estimates, even when an adjustment is made in models (Chiolero et al., 2008). 
At older ages, several diseases cause both weight loss and increased mortality, 
introducing reverse causation confounding into models (Kalantar-Zadeh et al., 
2007).  
In Chapter 3, I showed there were reduced and non-significant mortality risks for 
the BMI Overweight and BMI Obese-1 ranges in unrestricted analyses (i.e. no 
exclusion of smokers, early mortality, or weight loss) relative to those within the 
BMI Normal range. These associations (reduced or non-significant mortality 
risks) remained in analyses which had only considered one specific exclusion 
(e.g. smokers). Elevated mortality risks were shown for analyses which excluded 
smokers, early mortality and conditions associated with weight loss, highlighting 
the importance of simultaneous exclusions.   
However, limitations with the meta-analysis I presented in Chapter 3 included a 
lack of studies which had used all three simultaneous exclusions and which 
reported BMI mortality risks within narrow age bands across the older age range. 
Inclusion of the youngest old and the oldest old may dilute risk estimates. 
Furthermore, there was no consistency regarding the number of years to exclude 
during the follow-up for early deaths, or the number and choice of conditions to 
exclude.   
To clarify obesity risks in later life, well powered recent estimates are needed 
which account for confounders. Data from the Clinical Practice Research Datalink 
was analysed as it is representative of the older population. This analysis 
included English patients registered with primary care and linked to hospital 
episode statistics (HES). I aimed to estimate the association between the WHO 
BMI categories and mortality using a large cohort of population representative 
patients (aged ³60 years) within narrower age bands, and additionally to estimate 
the associations in subgroups of ‘healthier agers’ and ‘non-healthier agers’. In 
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this chapter I sought to address the contributions of the inclusion of smokers, 
those with conditions associated with weight loss, and the length of follow-up to 
the obesity paradox.  
4.4. Methods 
4.4.1. Study Population 
Anonymised electronic health records from the CPRD were assessed (Herrett et 
al., 2015). This analysis included patients with primary care health records linked 
to Hospital Episode Statistics data and to the Office for National Statistics (ONS) 
death data. This was available for English patients only. Registration with GPs is 
nearly complete in the UK and includes patients in institutional settings. The 
CPRD database includes all patients who are registered with CPRD participating 
general practices with very few patients withdrawing their data during the study 
period. CPRD diagnostic and outcome coding has generally high validity, (Herrett 
et al., 2010) which has been improved further through linkage to hospital and 
death certificate data.  
4.4.2. Patients 
All patients with BMI records since the 1st January 2000 and registered with a 
CPRD practice at the time of measurement were included (BMI records were 
available for 62% of registered patients, n = 955,031), with GP record inclusion 
to November 17th 2014. Extreme values of BMI were excluded (<14.0 and > 56.5 
kg/m2) (n = 6,431). The earliest age at which a BMI was recorded was calculated 
within the age groups 60 to 64, 65 to 69, 70 to 74, 75 to 84, and 85 years and 
older. The first BMI record was included for each patient within each age group 
as the study ‘index’ BMI for analysis. There were no patient duplications within 
presented models. For instance, a person could be included in the 60 to 64 age 
group model and the 70 to 74 age group model if they met all the inclusion criteria. 
Excluding people from subsequent age group models could result in a 
disproportionate number of patients who joined practices later or avoided contact 
with practices in the older age groups. BMI was categorised by the conventional 
WHO thresholds but the BMI Obese-2 and BMI Obese-3 ranges were combined 
in those aged ≥85 years as there were <200 patients.   
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In patients with more than one BMI measure, weight stability was derived (data 
available for 53.1% patients aged 60 to 64; 58.0% aged 65 to 69; 61.0% aged 70 
to 74; 57.4% aged 75 to 84; and 62.7% ≥85 years). Patients were classified as 
substantial weight losers (lost ≥5 kg), weight gainers (gained ≥5 kg), or weight 
stable (loss or gain <5 kg), using the weight difference between the study index 
weight and the mean of all weight records recorded over the preceding 4 years. 
Smaller fluctuations in weight could reflect measurement errors, acute events, or 
minor changes due to dieting. The sample was predominantly ‘white’ ethnicity, 
e.g. in those aged 65 to 69 years 81.8% had ethnicity data of whom 95.0% were 
‘white’ and 2.3% South Asian.  
4.4.3. Lifestyle and socioeconomic variables  
Hypothesised causal influences on the BMI association with mortality were 
formalised in a Directed Acyclic Graph (supplementary material Figure S4.1), 
which guided covariate selection to avoid inappropriate adjustment for 
intermediates on the causal pathway. Smoking status was based on GP recorded 
Read terms in the previous 10 years. Patients were classified as current smokers, 
ex-smokers, never smokers, and not recorded. Alcohol status was based on GP 
recorded Read terms and units of alcohol per week (where available) in the 
previous 10 years (heavy drinkers were defined as >35 units for females and >50 
units for males). Patients were classified as heavy drinkers, non-drinkers, current 
drinkers, former drinkers, and not recorded. Relative socioeconomic status was 
measured by the Index of Multiple Deprivation 2007 (Mclennan et al., 2010), 
calculated on each patient’s residential postal code and incorporating seven 
deprivation domains (income, employment, education, health, crime, barriers to 
housing and services, and living environment) and categorised by quintiles (1 
least deprived). Calendar year was included in the models to account for 
changing trends in BMI recording and medical care during baseline selection. 
Physical activity was recorded in CPRD as inactive, gentle activity, moderate 
activity, vigorous activity, or not recorded (most recent data preceding index BMI 
but up to 10 years before).   
4.4.4. Conditions  
The following health conditions were coded: asthma, atrial fibrillation, cancer, 
coronary heart disease, chronic kidney disease stages 3 to 5, chronic obstructive 
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pulmonary disease, dementia, depression, epilepsy, heart failure, hypertension, 
hypothyroidism, mental health, stroke and type 2 diabetes.  A multi-morbidity or 
frailty measure was also included which was based on the patient having >6 of 
36 Rockwood frailty index conditions (Song, Mitnitski and Rockwood, 2010). The 
ResearchOne Electronic Frailty Index coding rules were used inclusive of pre-
specified symptoms, signs, diseases, disabilities and abnormal laboratory values. 
4.4.5. Outcomes 
Mortality records were from the Office for National Statistics death certificate data 
up to the 17th November 2014. 
 
 
4.4.6. Statistical analysis 
Cox proportional hazards models were used to estimate the associations 
between the WHO BMI categories and mortality.  The proportional hazards 
assumption was tested for each model using Schoenfeld residuals. Multivariate 
models were adjusted for age, gender, alcohol use, smoking, calendar year, and 
socioeconomic status. A series of sensitivity analyses were conducted including 
adjusting for physical activity (where available), excluding those with a previous 
diagnosis of cardiovascular disease namely angina, myocardial infarction, or 
stroke, and excluding those with a previous diagnosis of cardiovascular disease 
or type 2 diabetes. Analyses were carried out using Stata statistical software 
(version 13.1) and R statistical software (version 3.1.2.).  
 
4.5. Results 
4.5.1. Patients with/without BMI measures  
Persons with measures of BMI were more likely to suffer from chronic kidney 
disease, diabetes, or hypertension, and less likely to be diagnosed with heart 
failure or dementia compared to those without a BMI measure (Table 4.1). 
Furthermore, those with measures of BMI had better survival compared to those 
without BMI measures, (HR 0.46 95% CI 0.45, 0.46) with adjustment for age, sex 
and socioeconomic status.  
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Table 4.1 | Cross sectional analysis of conditions associated with having a BMI 
record compared to no BMI record for CPRD patients aged ≥60 years using age 
and sex adjusted logistic regression  
Condition Odds Ratio (95% CI) 
Heart Failure 0.64 (0.63, 0.65) 
Dementia 0.68 (0.67, 0.69) 
Epilepsy 0.80 (0.78, 0.81) 
Stroke 0.87 (0.86, 0.88) 
Mental Health 0.88 (0.87, 0.90) 
Atrial Fibrillation 1.08 (1.07, 1.09) 
COPD 1.18 (1.16, 1.19) 
CHD 1.19 (1.17, 1.20) 
Depression 1.21 (1.20, 1.22) 
Recent cancer 1.34 (1.33, 1.36) 
Hypothyroidism 1.34 (1.33, 1.36) 
Asthma 1.42 (1.40, 1.43) 
Hypertension 2.04 (2.02, 2.05) 
Type 2 Diabetes 2.39 (2.36, 2.42) 
CKD Stages 3 to 5 3.56 (3.51, 3.61) 
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4.5.2. Empirical identification of conditions  
As highlighted in Chapter 3, the previous analyses included in the meta-analysis 
which excluded persons with weight loss associated disease did not empirically 
test these associations. Excluding chronic conditions that may be associated with 
weight loss could reduce the generalisability of the results as the prevalence of 
these conditions increases with advancing age. To identify groups most 
susceptible to prior weight loss, associations with 15 major diagnoses 
ascertained before the index BMI measures were tested (Table 4.2). In age and 
gender adjusted regression models against weight loss, cancer (excluding non-
melanoma skin cancer) within the preceding five years, dementia, heart failure, 
and multi-morbidity all yielded Odds Ratios (OR) of ≥1.5 for weight loss, with other 
conditions having ORs <1.5. These conditions were, therefore, excluded as part 
of the ‘healthier agers’ subgroup.   
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Table 4.2 | Cross sectional analysis of conditions associated with measured 
weight loss  
Condition Odds Ratio (95% CI) 
Dementia 2.00 (1.82, 2.21) 
Cancer (within 5 years) 1.61 (1.53, 1.69) 
Heart Failure 1.53 (1.44, 1.63) 
Mental Health 1.40 (1.29, 1.52) 
Atrial Fibrillation 1.39 (1.32, 1.47) 
COPD 1.36 (1.30, 1.43) 
Epilepsy 1.19 (1.08, 1.32) 
Depression 1.16 (1.12, 1.20) 
Hypothyroidism 1.15 (1.10, 1.21) 
Stroke 1.12 (1.06, 1.18) 
Diabetes 1.08 (1.05, 1.12) 
CKD Stages 3 to 5 1.08 (1.01, 1.15) 
Asthma 1.06 (1.02, 1.10) 
Hypertension 1.02 (0.99, 1.05) 
CHD 0.89 (0.86, 0.92) 
 
Note: Logistic regression was used for the outcome weight loss adjusted for age and 
gender for patients aged 65 to 100 years with a first BMI measure since 1st January 2000 
who were currently registered and classified as weight losers (≥ 5kg) or stable weight (0 
to +/- 4.9 kg). This was calculated as the difference between the study index weight and 
the mean weights recorded over the preceding 4 years. The logistic regression was run 
after excluding patients with multi-morbidity.   
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4.5.3. Baseline characteristics of patients with BMI measures 
There were 955,031 patients in the analyses (822,811 with complete data, i.e. no 
missing values for smoking, alcohol use, or socioeconomic status), with 
1,540,553 patient follow-ups with some patients contributing in >1 age-specific 
analysis. The maximum follow-up duration was 14.9 years (mean 5.97 years, SD 
4.02 years). The mean BMI was 28.2 kg/m2 for those aged 60 to 64 years and 
24.8 kg/m2 for those aged ≥85 years at baseline (Table 4.3 and supplementary 
material Table S4.1). Covariate distributions also showed age group trends with, 
for example, current smoking declining from 34.2% in those aged 60 to 64 years 
to 19.7% in those aged ≥85 years at baseline. Substantial measured weight loss 
was present in 5.2% and 11.5% of the youngest and oldest groups, respectively.  
 
4.5.4. Mortality  
Overall 13.2% (n = 48,442) of those aged 65 to 69 years died during follow-up, 
with rates rising to 56.9% (n = 67,814) in those aged ≥85 years at baseline 
(supplementary material Table S4.2). While group mean BMI declined modestly 
with advancing age, it declined markedly for 13 years before death (Figure 4.1): 
for example in those aged 65 to 69 years at baseline, 34% were classified as BMI 
Obese-1 13 years before death but only 24% in the year of death, while the 
proportion of those within the BMI Normal range increased from 23% to 39% over 
the same period.  
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Figure 4.1 | Percentage of those aged 65 to 69 years at baseline by conventional 
BMI category and number of years to death 
 
 
4.5.5. The paradoxical model for mortality hazards 
To replicate approaches similar with those producing paradoxical risk estimates 
(i.e. no exclusions), Cox proportional hazards models for all-cause mortality were 
computed, adjusting for age, gender, alcohol intake, smoking status, calendar 
year, and an area-based measure of relative socioeconomic position for all 
subjects with complete data. All follow-up data from baseline to 14.9 years was 
included. Figures 4.2-4.6 present the mortality risks for each age group by the 
conventional BMI categories for the overall sample (complete cases) in black 
(supplementary material Table S4.3). For those aged 65 to 69 years at baseline 
(n = 312,352 with 40,815 deaths), those within the BMI Obese-1 range had 
reduced mortality risks relative to those within the conventional BMI Normal range 
(BMI Obese-1 HR 0.91 95% CI 0.88, 0.93), and estimates were even more 
paradoxical for the BMI Overweight range (HR 0.79 CI 0.77, 0.81). There were 
increased mortality risks for those within the BMI Obese-2 range (HR 1.07 CI 
1.02, 1.11) and for those within the BMI Obese-3 range (HR 1.54 CI 1.46, 1.63). 
A similar pattern of paradoxical mortality hazards was present across the other 
age groups studied for both the BMI Overweight and BMI Obese-1 ranges 
compared to the conventional BMI Normal range. Incidentally, the highest 
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mortality risks were for the BMI Underweight range (age group 65 to 69 years, 
HR 2.54 CI 2.40, 2.69). 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 | Hazard ratios (95% CI) for all-cause mortality by conventional BMI 
categories for those aged 60 to 64 years at baseline for the overall sample 
(black), ‘healthier agers’ (green) and ‘non-healthier agers’ (red) from the 
CPRD. Cox proportional hazards were adjusted for age, gender, alcohol 
status, smoking status, calendar year, and socioeconomic status 
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Figure 4.3 | Hazard ratios (95% CI) for all-cause mortality by conventional BMI 
categories for those aged 65 to 69 years at baseline for the overall sample 
(black), ‘healthier agers’ (green) and ‘non-healthier agers’ (red) from the CPRD. 
Cox proportional hazards were adjusted for age, gender, alcohol status, smoking 
status, calendar year, and socioeconomic status 
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Figure 4.4 | Hazard ratios (95% CI) for all-cause mortality by conventional BMI 
categories for those aged 70 to 74 years at baseline for the overall sample 
(black), ‘healthier agers’ (green) and ‘non-healthier agers’ (red) from the CPRD. 
Cox proportional hazards were adjusted for age, gender, alcohol status, smoking 
status, calendar year, and socioeconomic status 
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Figure 4.5 | Hazard ratios (95% CI) for all-cause mortality by conventional BMI 
categories for those aged 75 to 84 years at baseline for the overall sample 
(black), ‘healthier agers’ (green) and ‘non-healthier agers’ (red) from the CPRD. 
Cox proportional hazards were adjusted for age, gender, alcohol status, smoking 
status, calendar year, and socioeconomic status 
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Figure 4.6 | Hazard ratios (95% CI) for all-cause mortality by conventional BMI 
categories for those aged ≥85 years at baseline for the overall sample (black), 
‘healthier agers’ (green) and ‘non-healthier agers’ (red) from the CPRD. Cox 
proportional hazards were adjusted for age, gender, alcohol status, smoking 
status, calendar year, and socioeconomic status 
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4.5.6. Accounting for confounding and follow-up period 
To account for confounders, current smokers plus patients with multi-morbidity, 
recent cancer at baseline (within the previous five years, excluding non-
melanoma skin cancer), dementia, or heart failure (i.e. the factors most strongly 
associated with prior weight loss – see methods and Table 4.2) were excluded 
to yield a ‘healthier agers’ group. To clarify the length of follow-up to exclude, 
mortality risks were plotted for two-year time periods to avoid the biasing effects 
of serious disease present at baseline (Figure 4.7 and supplementary material 
Table S4.4). For the age group 65 to 74 years at baseline, those within the BMI 
Obese-1 range had a survival advantage during the first two years of follow-up 
and this reversed after two years. Mortality risks for the other BMI categories 
showed similar patterns, all reaching apparent stability after four years (except 
for the BMI Underweight range which stabilized after six years). For the ‘healthier 
agers’ subgroup, persons that died within the first 3.9 years of follow-up were 
excluded to enable estimation of stable longer term mortality hazards.  
 
4.5.7. ‘Healthier agers’ 
Figures 4.2-4.6 present the mortality risks for each ‘healthier agers’ age-group 
by the conventional BMI categories for the complete cases, shown in green 
(supplementary material Table S4.5). Using the conventional BMI categories 
there were increased mortality risks for those within the BMI Obese-1 range up 
to age 74 years: in the 65 to 69 age group this was HR 1.17 (CI 1.11, 1.23) relative 
to those within the conventional BMI Normal range. In the conventional BMI 
Overweight range for those aged 65 to 69 years at baseline, the apparent 
protective effect also reversed to yield a non-significant difference relative to 
those within the conventional BMI Normal range (HR 0.96 CI 0.92, 1.01). The 
mortality risks for the ‘healthier agers’ within the BMI Obese-2 and BMI Obese-3  
(green) were accentuated compared to the overall sample (black) for each of the 
age groups up to age 84 years.    
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Figure 4.7 | Hazard ratios for mortality by conventional BMI category and length 
of follow-up in those aged 65 to 74 years at baseline, compared to those within 
the conventional BMI Normal range from the CPRD 
 
4.5.8. ‘Non-healthier agers’  
Figures 4.2-4.6 present the mortality risks for each ‘non-healthier agers’ age-
group by the conventional BMI categories for the complete cases, shown in red 
(supplementary material Table S4.6). Mortality risks were estimated for those 
excluded from the ‘healthier agers’ subgroup, i.e. smokers plus patients with 
multi-morbidity, heart failure, dementia, or recent cancer. For the 65 to 69 years 
‘non-healthier agers’ group (n = 127,204 with 24,169 deaths), those within the 
BMI Overweight, BMI Obese-1, and BMI Obese-2 ranges had reduced mortality 
risks relative to those within the conventional BMI Normal range (BMI Overweight 
HR 0.72 CI 0.70, 0.74; BMI Obese-1 HR 0.76 CI 0.73, 0.79; BMI Obese-2 HR 
0.84 CI 0.80, 0.89). The mortality risks were raised in the BMI Obese-3 range HR 
1.14 (CI 1.06, 1.22). A similar pattern of lower mortality risks for the BMI 
Overweight, BMI Obese-1 and BMI Obese-2 ranges was observed across the 
other age-groups.     
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Sensitivity analyses        
Mortality risks remained increased for the ‘healthier agers’ within the BMI Obese-
1, BMI Obese-2, and BMI Obese-3 ranges relative to those within the 
conventional BMI Normal range up to age 74 years after additional adjustment 
for physical activity level (data available for 55.3% patients aged 60 to 64; 55.6% 
aged 65 to 69; 56.1% aged 70 to 74; 55.8% aged 75 to 84; and 55.9% ≥85 years) 
(Table 4.4). The mortality risk for the BMI Obese-1 range for those aged 75 to 84 
years and for those aged ≥85 years was not significantly different from those 
within the conventional BMI Normal range.  
 
Several studies have reported paradoxical BMI associations for both 
cardiovascular disease and type 2 diabetes (Niedziela, et al., 2014; Costanzo, et 
al., 2015). In additional analyses patients with a previous diagnosis of 
cardiovascular disease namely angina, myocardial infarction, or stroke were 
excluded (Table 4.5). In further analyses those with cardiovascular disease 
and/or type 2 diabetes were excluded (Table 4.6). Mortality risks showed a similar 
pattern to the main analysis for the ‘healthier agers’ after further excluding those 
with cardiovascular disease. After excluding those with cardiovascular disease or 
type 2 diabetes, some of the mortality risks reduced. For those aged 65 to 74 
years, the BMI Overweight range was associated with a reduced mortality risk 
relative to those within the BMI Normal range. For those aged 70 to 74 years, the 
BMI Obese-1 range was not significantly different to those within the BMI Normal 
range. For those aged 75 to 84 years, the BMI Obese-1 range was associated 
with a reduced mortality risk relative to those within the BMI Normal range.  
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4.6. Discussion 
Several analyses have reported that older persons within the BMI Overweight 
and BMI Obese-1 ranges have better or similar survival to those within the 
conventionally defined BMI Normal range, apparently undermining the scientific 
rationale for some responses to the global obesity epidemic. In models ignoring 
suggested confounding (i.e. smokers or conditions associated with weight loss) 
similar paradoxical estimates for BMI and mortality were obtained. Severely 
paradoxical estimates for those with conditions strongly associated with weight 
loss were also obtained. However, in models focused on non-smoking relatively 
healthy older people (i.e. free of cancer, dementia, heart failure, and multi-
morbidity) - the results showed a reversal of the mortality risk with no sign of 
protective effects for those within the BMI Obese-1 range and aged 60 to 84 
years. There was an elevated mortality risk for those within the BMI Obese-1 
range for mortality compared to those within the conventional BMI Normal range 
up to age 74 years.  
 
For ‘healthier agers’, the mortality risk for the BMI Overweight group was not 
significantly different compared to those within the conventional BMI Normal 
range for the two youngest age groups (60 to 64 years; 65 to 69 years). Reduced 
mortality risks were found for those aged ≥70 years even after the exclusion of 
smokers and those with diseases associated with major weight loss. Several 
previous analyses have reported that the BMI associated with minimum mortality 
risk lies within the BMI Overweight range (Flicker et al., 2010; van Uffelen et al., 
2010; de Hollander et al., 2012 b; Cheng et al., 2016).  This could be due to the 
BMI referent group (see section 4.6.4), higher BMI exerting a protective effect 
during periods of stress and persons within the BMI Overweight range being 
treated and monitored more closely for vascular risk factors, thus lessening the 
effect on mortality (Chapter 1). Furthermore, as highlighted in Chapter 1, BMI 
does not measure the body compositional changes with ageing i.e. the loss of 
muscle mass and function (sarcopenia), the increase in fat mass, and the 
redistribution of fat mass. Sarcopenia has been shown to be associated with 
increased mortality risks, which will not be captured by BMI (Hirani, et al., 2015; 
Brown, et al., 2016). Additionally, central adiposity has been shown to be 
associated with an increased mortality risk, again not measured by BMI (de 
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Hollander, et al., 2012 a).  These body compositional changes will be 
accentuated in the older age-groups, and thereby the BMI Overweight range 
could appear to be protective. The use of alternative measures of adiposity and 
body composition singularly and jointly will be assessed in Chapters 7 and 8.          
 
Interestingly, after excluding persons with a previous diagnosis of angina, 
myocardial infarction, stroke or type 2 diabetes from the ‘healthier agers’ age-
groups, the mortality risks for the BMI Obese-1 relative to those within the 
conventional BMI Normal range became non-significant for those aged 70 to 74 
years, and significantly reduced for those aged 75 to 84 years. There was a 
reduced mortality risk for the BMI Overweight range for the age-group 65 to 69 
years. However, these findings need to be interpreted cautiously, as these 
exclusionary criteria is more likely to affect the higher BMI values, possibly 
inducing a selection bias. Persons within the BMI Overweight and BMI Obese 
ranges without diabetes, coronary heart disease or stroke, may thereby be 
treated and monitored more frequently for primary prevention of diseases, 
attenuating mortality risks.     
 
4.6.1. Comparison to previous literature 
The results presented in this chapter are difficult to compare with previous work, 
as most reports were based on smaller samples of older volunteers, with varying 
groups of BMI and varying follow-ups. Also, most reports relate to patients who 
were less exposed to modern cardiovascular and diabetes interventions. Ling Lu 
et al (2015) recently reported an analysis of 3.3 million patients admitted to 
Veterans Administration hospitals, and for those aged 60 to 69 years old found 
markedly lower hazard ratios for mortality for those with the BMI Obese-1  range 
compared to those within the BMI Normal range (Lu et al., 2015).  Using pooled 
data from 19 studies, Berrington de Gonzalez et al (2010) reported similarly 
raised hazards for mortality in their Obese-1 older group. Their analysis was 
restricted to never smokers plus participants without cancer, heart disease or 
aged ≥85 years and had relatively small numbers of deaths to analyse in the older 
groups (2,754 and 546 deaths in the BMI Obese-1 range for those aged 60 to 69 
and 70 to 84 years respectively) (Berrington de Gonzalez et al., 2010).  
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4.6.2. Chapter analysis 
Analysing electronic health records offers many advantages (e.g. large sample 
size, near complete population inclusion plus diagnosed disease and outcome 
ascertainment) but can introduce biases where recording of risk factors is 
incomplete or triggered by clinical events. This problem is somewhat reduced 
here as GPs were offered financial incentives to record cardiovascular risk 
measures in the time frame included in the analyses. The proportion of the 
potential sample with no BMI measure (38% of patients) compares well with non-
response levels in most randomized trials and volunteer cohorts.  
 
There is no data on whether the observed weight loss in this analysis was 
intentional or unintentional. A 1996 study in British primary care found that 18% 
of a sample aged 56 to 75 years experienced any perceived weight loss in the 
previous 4 years, with 4% stating this was for personal reasons only, unrelated 
to health concerns or physician advice (Wannamethee, Shaper and Lennon, 
2005). The exclusion of the diseases empirically most closely associated with 
measured weight loss is systematic but incomplete. In the weight change 
subgroup for adults aged 65 to 69 years, 25.1% of the patients with >5 kg weight 
loss would remain in the analysis after excluding patients with recent cancer, 
dementia, heart failure, and multi-morbidity. This residual confounding may 
explain the paradoxical estimates in the oldest old and in the first years of follow-
up, and may have resulted in some underestimation of the mortality risks for the 
BMI Overweight range.   
 
The results I present in this chapter and Chapter 3, suggest that the claimed 
obesity risk paradox in later life is largely the erroneous result of failing to estimate 
risks separately for relatively healthy and already severely ill older groups.  
 
In addition, obesity is associated with substantial excess disability (Angleman, 
Harris and Melzer, 2006; Gregg and Guralnik, 2007). Stenholm and colleagues 
reported that obese (BMI ≥30.0 kg/m2) men and women aged 70 to 79 years from 
the Health, Aging and Body Composition Study had an increased risk of mobility 
limitation during a 6.5-year follow-up period (Stenholm et al., 2010). Obese men 
and women aged ≥65 years from the English Longitudinal Study of Ageing were 
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reported to have an increased risk of self-reported difficulties with activities of 
daily living and with a measure of functional impairment during a five-year follow-
up period (Lang et al., 2008). The widespread publicity given to the claimed 
obesity risk paradox in the elderly is, therefore, inappropriate. Clinical advocacy 
of weight control for general health risk reduction was never claimed to be 
relevant to those already suffering from severe conditions associated with weight 
loss.  
 
4.6.3. Strengths and limitations 
I estimated mortality risks for the conventional WHO BMI categories across 
progressively older age groups and for subgroups of ‘healthier agers’ and ‘non-
healthier agers’. Using the CPRD allowed BMI mortality risk estimates to be 
derived for a near complete older population and permitted stratified analyses. I 
empirically tested the association of 15 major diagnoses with weight loss thus 
guiding which conditions to exclude. BMI mortality risk estimates were derived for 
two-year time segments which steered the length of follow-up to exclude as there 
is no consensus on the appropriate time lag. A major strength of this work is that 
even following sequential exclusions, the sample sizes for the age groups are 
much greater than those previously analysed (Chapter 3).            
 
There are several limitations to this analysis reported in this chapter. One 
limitation of this analysis was that the outcome chosen was all-cause mortality. 
Therefore, risk estimates for the WHO BMI categories with specific causes of 
death or morbidity may differ to those presented in this chapter for all-cause 
mortality. As highlighted earlier the patients were predominately ‘white’ ethnicity 
and therefore the findings may not be generally applicable to other ethnic groups.  
 
A further limitation of this analysis is the use of the Clinical Practice Research 
Datalink. As noted in the methods section (4.4), BMI records were available for 
62% of the registered patients, and thus missing for 38%. As discussed in 
Chapter 2, the decision to take a height and weight measurement and to record 
these measures is dependent on the primary care practitioner, and could be 
captured during registration, opportunistically or during health checks. Height and 
weight may be recorded more often for patients with certain health conditions or 
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those with high cardiovascular risk, thus conferring a selection bias. Mortality 
risks may be inflated for higher BMI ranges if these patients are already at a 
heightened vascular risk. The UK Biobank could be used to address the 
limitations of using the CPRD, as most of the participants (99.4%) had height and 
weight recorded. This will be addressed in Chapter 7.  
 
4.6.4. Future work 
Additional work is needed to assess the choice of the BMI referent group; as 
noted in Chapter 1 persons within the lower end of the conventional BMI Normal 
range may be at an increased risk for mortality which could distort mortality risk 
estimates for higher BMI values. In Chapter 5 I use the CPRD database to re-
define the BMI referent group by estimating the continuous BMI association with 
mortality. This revised groupwas used to estimate the BMI associations for 
mortality, incident Coronary Heart Disease, and Type 2 diabetes for progressively 
older groups of adults.  
  
4.7. Conclusions 
The obesity paradox in later life appears to be the erroneous result of combining 
mortality risks for relatively healthy, smokers, and already ill older groups. As 
obesity is associated with excess mortality in otherwise healthy non-smoking 
older people, up to and including those aged 74 years, assertions based on the 
claimed paradox against current obesity control efforts are misplaced.  
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5.1. Overview of chapter 
 
This chapter, like Chapter 4, is partly based on my first author published paper: 
 
Bowman, K., Delgado, J., Henley, W.E., Masoli, J.A., Kos, K., Brayne, C., 
Thokala, P., Lafortune, L., Kuchel, G.A., Ble, A., & Melzer, D. (2017) 
Obesity in Older People With and Without Conditions Associated With 
Weight Loss : Follow-up of 955,000 Primary Care Patients. J Gerontol A 
Biol Sci Med Sci.  Editor’s Choice. 72(2): 203–209. 
 
Much of the results and discussion are direct translations from this published 
article. Some sentences have been modified to make the sentences clearer and 
additional headings have been used. The methods section is more concise as 
reference has been made to the preceding chapter on how the variables were 
coded and categorised.  
 
The abstract, introductory section and concluding remarks have been revised to 
emphasise the links throughout this thesis. Additionally, I have added some of 
the supplementary material into the main text. Furthermore, additional sections 
have been added to the discussion to show the links throughout this thesis.   
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5.2. Summary  
Background: The obesity paradox refers to instances where mortality risks have 
been reported to be reduced or non-significant for older adults (aged ≥65 years) 
within the body mass index (BMI) defined Obese-1 range (30.0-34.9 kg/m2) 
relative to those within the conventional BMI Normal range (18.5-24.9 kg/m2). 
This is partly due to the pooling of relatively healthy adults, smokers, and already 
ill older groups. These estimates may still be distorted due to the choice of the 
BMI referent group.  
 
Objective: To estimate the continuous BMI association with mortality, to use 
these associations to re-define the BMI referent range and to use this revised 
referent group to estimate the associations for mortality, incident coronary heart 
disease (CHD), and Type 2 diabetes.  
 
Design: This analysis used primary care, hospital and death certificate electronic 
health records for registered populations aged ≥60 years in England from 1 
January 2000 from the Clinical Practice Research Datalink (CPRD) to define a 
subset of patients as ‘healthier agers’. ‘Healthier agers’ were non-smokers 
without conditions associated with weight loss and who survived the first 3.9 
years of the follow-up period. Spline point models, Cox proportional hazards, and 
competing risks models were used with adjustment for age, gender, alcohol use, 
smoking history (never or former), calendar year, and socioeconomic status.  
 
Results: For the ‘healthier agers’, the BMI mortality curve for those aged 65 to 
69 years at baseline was U-shaped, with raised mortality risks at lower BMIs, a 
nadir between 23.0 and 26.9 kg/m2 and steeply rising mortality risks for higher 
BMI values. In older age groups, mortality nadirs were at modestly higher BMIs 
(all <30.0 kg/m2) and risk slopes at higher BMIs were less marked, becoming 
nonsignificant for those aged ≥85 years at baseline. Incidence of diabetes was 
raised for those within the BMI Obese-1 range at all ages and for CHD up to and 
including those aged 84 years, relative to those within the BMI 23.0-26.9 kg/m2 
range.  
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Conclusions: Obesity is associated with shorter survival plus higher incidence 
of coronary heart disease and type 2 diabetes in older populations for ‘healthier 
agers’, at least up to and including those aged 84 years. These results cast doubt 
on calls to revise obesity control policies based on the claimed risk paradox at 
older ages. 
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5.3. Introduction 
In Chapter 3 I showed that mortality risks were reduced for those within the BMI 
Obese-1 (30.0-34.9 kg/m2), and BMI Overweight (25.0-29.9 kg/m2) ranges 
relative to those within the conventional BMI Normal range (18.5-24.9 kg/m2) in 
unrestricted analyses (e.g. no exclusion of smokers, conditions associated with 
weight loss or early deaths) for adults aged ≥65 years. Analyses which had 
simultaneously excluded smokers, early deaths, and those with conditions 
associated with weight loss showed increased mortality risks for those within the 
BMI Obese-1 and the BMI Overweight ranges relative to those within the BMI 
Normal range. The obesity paradox, which refers to the reduced/non-significant 
mortality risks for those within the BMI Obese-1 range, is in part due to the 
inclusion of smokers and those with conditions associated with weight loss.  
Furthermore, In Chapter 4 I presented an analysis which used the Clinical 
Practice Research Datalink (CPRD) to estimate associations between the WHO 
BMI categories and mortality which further demonstrated that the pooling of 
relatively healthy adults, those who are already ill and smokers can distort 
mortality risk estimates. 
 
For the analyses in Chapter 4 I used the conventional BMI Normal range as the 
referent group. As discussed in Chapter 1 the conventional BMI Normal range 
will consist of those who have consistently been within the BMI Normal range and 
active, current smokers, and those whose BMI has decreased due to conditions 
associated with weight loss. Thus, due to the heterogeneous group within the 
conventional BMI Normal range, mortality risk estimates could be distorted for 
higher BMI values. As noted in Chapter 3, increased mortality risks were found 
for those within the BMI Overweight and BMI Obese-1 ranges for analyses that 
had used simultaneous exclusions plus a narrower BMI reference group with a 
lower limit of 22.0 kg/m2.  
 
The meta-analysis conducted by Winter et al., (2014) showed increased mortality 
risks for those with BMI values <23.0 kg/m2 relative to those within the BMI range 
23.0-23.9 kg/m2 for adults aged ³65 years (Winter et al., 2014). Furthermore, 
Aune et al., (2016) showed increased mortality risks for those with BMI values 
<21.0 kg/m2 for non-smokers aged ³65 years (Aune et al., 2016). These analyses 
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indicate that adults within the lower end of the conventional BMI Normal range 
may have an elevated mortality risk. Furthermore, de Hollander et al., (2012) 
showed the importance of reporting both the associations between categories of 
BMI, and continuous measures of BMI, with mortality; whilst there was no 
association between BMI categories and mortality, an association with 
continuous measures of BMI with mortality was found for adults aged 70 to 75 
years from the SENECA study with a maximum follow-up duration of 10 years. 
The BMI value associated with the lowest mortality risk was 27.1 kg/m2 and there 
were increased mortality risks for BMI values <20.0 kg/m2 (de Hollander et al., 
2012 b).   
 
The association of BMI with mortality is important to assess, however, it is also 
important to consider other health outcomes. Coronary heart disease (CHD) was 
the second leading cause of deaths for adults residing in England and Wales in 
2015, and it was the principal cause of death for males aged 65 to 74 years 
(Office of National Statistics, 2016). Furthermore, in 2015 type 2 diabetes 
affected 4.5 million people in the UK (Diabetes UK, 2016). There has been a 
paucity of studies which have reported recent estimates for incident coronary 
heart disease and diabetes using narrower age groups and utilising competing 
risk models (supplementary material Table S5.1-2 and Table S5.3-4, 
respectively).  
 
In this chapter I aimed to re-define the BMI referent group by estimating the 
continuous BMI association with mortality. This new BMI referent group was used 
to estimate the BMI associations for mortality, incident CHD, and Type 2 diabetes 
using a large cohort of ‘healthier agers’ (aged ³60 years). As highlighted by de 
Hollander et al., (2012) associations between BMI and mortality may be 
concealed using categorisation (de Hollander et al., 2012 b). In this chapter, I 
aimed to address the contributions of the BMI referent group to the obesity 
paradox as well as estimating the associations between BMI with incident CHD 
and diabetes using competing risk models that account for mortality.  
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5.4. Methods 
5.4.1.  Study Population 
Using a similar methodology to Chapter 4, de-identified electronic health records 
from CPRD which were linked to the Hospital Episode Statistics (HES) data 
(linkage available for England only) and the government’s Office for National 
Statistics (ONS) were used.  As emphasized in Chapters 2 and 4, registration 
with GPs is nearly complete in the UK. The CPRD diagnostic and outcome coding 
has generally high validity (Herrett et al., 2010). 
 
5.4.2.  Patients 
All patients with BMI records since the 1st January 2000 and registered with a 
CPRD practice at the time of measurement were included. Extreme values of BMI 
were excluded (<14.0 and > 56.5 kg/m2) (n = 6,431).  
 
5.4.3.  ‘Healthier agers’ 
The ‘healthier agers’ subgroup included non-smokers without conditions 
associated with weight loss and who survived the first 3.9 years of the follow-up 
period. The conditions excluded were cancer (except non-melanoma skin cancer) 
within the previous five years, dementia, heart failure, and a measure of multi-
morbidity. These conditions had been empirically identified as being associated 
with weight loss in Chapter 4. The length of follow-up to exclude for early deaths 
had also been assessed in Chapter 4.    
 
5.4.4.  Exposures 
The earliest age at which a BMI was recorded was calculated within age groups 
60 to 64, 65 to 69, 70 to 74, 75 to 84, and 85 years and older. The first BMI record 
was included for each patient within each age-group as the study ‘index’. The 
WHO BMI categories were used which have been reported previously in 
Chapters 1 and 4. The BMI Obese-2 and BMI Obese-3 ranges were combined 
in those aged ≥85 years as there were <200 patients. Additionally, in this analysis 
the BMI referent category was redefined and the revised BMI groups will be 
documented in the results section.  
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5.4.5.  Lifestyle and socioeconomic variables  
In Chapter 4, I reported on the hypothesised causal influences on the BMI 
association with mortality which was depicted in the Directed Acyclic Graph 
presented in supplementary material Figure S4.1. Covariates used were age, 
gender, alcohol use, smoking history (never or former), calendar year, and 
socioeconomic status. The definition and categorising of these covariates were 
detailed in Chapters 2 and 4.  
5.4.6.  Outcomes 
Outcomes included incident Coronary Heart Disease (angina or myocardial 
infarction diagnoses) from ICD 10 coded hospital records, incident type 2 
diabetes (from GP records or hospital) and mortality (from Office for National 
Statistics death certificate data).  
 
5.4.7.  Statistical analysis 
Spline models with 4 knots were used to estimate non-linear associations 
between BMI and mortality. Cox proportional hazards models were used to 
estimate the associations between the revised BMI groups and mortality. 
Although it has been established that there is a linear relationship between BMI 
and CHD and diabetes, the revised BMI referent group was additionally used to 
maintain both consistency and enable comparisons of the associations between 
BMI and different health outcomes. Competing risks models (accounting for 
mortality) for CHD and diabetes events were used. The proportional hazards 
assumption was tested for each model using Schoenfeld residuals. Multivariate 
models were adjusted for age, gender, alcohol use, smoking history, calendar 
year, and socioeconomic status. The effective age of the BMI exposure group 
(Brenner, Gefeller and Greenland, 1993), defined as the number of additional 
years of ageing in the control group that would result in equivalent mortality risks 
to those experienced by the exposed group, was derived using the rate 
advancement periods approach. Interactions between gender and BMI 
categories were assessed. Sensitivity analyses were carried out which further 
adjusted for physical activity levels (where available), restricting the sample to 
those with a ‘white’ ethnicity record, restricting the analyses to those with 
measured weight change, and using multiple imputation for missing records. The 
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missing values for smoking and alcohol intake were imputed multiple times using 
the chained (mlogit) multinomial logistic regression approach. In further sensitivity 
analyses, the revised referent group was split into BMI high Normal (23.0 to <25.0 
kg/m2) and BMI low Overweight (25.0 to <27.0 kg/m2). Analyses were carried out 
using Stata statistical software (version 13.1) and R statistical software (version 
3.1.2.) with packages “pspline” (version 2.37-7) and “survival” (version 1.0-16). 
5.5. Results 
5.5.1.  Baseline characteristics 
The baseline characteristics of the ‘healthier agers’ with complete records for 
smoking, alcohol use, and socioeconomic status are presented in Table 5.1 
(supplementary material table S5.3 for the ‘healthier agers’ with incomplete 
records). The mean BMI was 28.2 kg/m2 for those aged 60 to 64 years and 24.9 
kg/m2 for those aged ≥85 years at baseline. Substantial measured weight loss 
was present in 4.1% and 6.2% of the youngest and oldest groups, respectively.  
 
5.5.2.  BMI continuous associations with mortality  
Spline point regression was used to estimate the mortality risks for continuous 
BMI. Models were adjusted for age, gender, smoking history, alcohol use, 
calendar year, and socioeconomic status. Figures 5.1 to 5.5 present the BMI 
associations for each age group. For all ages, the lower end of the conventional 
BMI Normal range (18.5-22.9 kg/m2) was associated with sharply rising mortality 
risks with reducing BMI. For those aged 60 to 64 years (Figure 5.1) or 65 to 69 
years (Figure 5.2) at baseline the lowest mortality risks were between BMI 23.0 
to 26.9 kg/m2 (although higher in older groups). Mortality risks rise moderately 
between 27.0 to 29.9 kg/m2 and steeply at higher BMIs in the obese range for the 
two youngest age groups. For the age groups 70 to 74 years (Figure 5.3) and 75 
to 84 years (Figure 5.4) there were increased mortality risks across the BMI 
obese range.   
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Figure 5.1 | Spline point estimates for BMI and mortality for ‘healthier agers’ aged 
60 to 64 years at baseline using the CPRD 
 
Note: ‘Healthier agers’ were defined as non-smokers, without recent cancer 
(within the five previous years except non-melanoma skin cancer), dementia, 
heart failure, or multi-morbidity and survived the first 3.9 years of follow-up. 
Models were adjusted for gender, alcohol use, smoking history, calendar year, 
and socioeconomic status. The line in red is the hazard ratio and the broken lines 
in yellow are the 95% confidence intervals.  
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Figure 5.2 | Spline point estimates for BMI and mortality for ‘healthier agers’ aged 
65 to 69 years at baseline using the CPRD 
 
Note: ‘Healthier agers’ were defined as non-smokers, without recent cancer 
(within the five previous years except non-melanoma skin cancer), dementia, 
heart failure, or multi-morbidity and survived the first 3.9 years of follow-up. 
Models were adjusted for gender, alcohol use, smoking history, calendar year, 
and socioeconomic status. The line in red is the hazard ratio and the broken lines 
in yellow are the 95% confidence intervals. 
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Figure 5.3 | Spline point estimates for BMI and mortality for ‘healthier agers’ aged 
70 to 74 years at baseline using the CPRD 
 
 
Note: ‘Healthier agers’ were defined as non-smokers, without recent cancer 
(within the five previous years except non-melanoma skin cancer), dementia, 
heart failure, or multi-morbidity and survived the first 3.9 years of follow-up. 
Models were adjusted for gender, alcohol use, smoking history, calendar year, 
and socioeconomic status. The line in red is the hazard ratio and the broken lines 
in yellow are the 95% confidence intervals. 
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Figure 5.4 | Spline point estimates for BMI and mortality for ‘healthier agers’ aged 
75 to 84 years at baseline using the CPRD 
 
Note: ‘Healthier agers’ were defined as non-smokers, without recent cancer 
(within the five previous years except non-melanoma skin cancer), dementia, 
heart failure, or multi-morbidity and survived the first 3.9 years of follow-up. 
Models were adjusted for gender, alcohol use, smoking history, calendar year, 
and socioeconomic status. The line in red is the hazard ratio and the broken lines 
in yellow are the 95% confidence intervals. 
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Figure 5.5 | Spline point estimates for BMI and mortality for ‘healthier agers’ aged 
≥85 years at baseline using the CPRD 
 
Note: ‘Healthier agers’ were defined as non-smokers, without recent cancer 
(within the five previous years except non-melanoma skin cancer), dementia, 
heart failure, or multi-morbidity and survived the first 3.9 years of follow-up. 
Models were adjusted for gender, alcohol use, smoking history, calendar year, 
and socioeconomic status. The line in red is the hazard ratio and the broken lines 
in yellow are the 95% confidence intervals. 
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5.5.3.  BMI categorical associations with mortality  
For the two youngest age groups, the BMI range 23.0-26.9 kg/m2 corresponded 
to the lowest mortality risk. This BMI range was used as the revised BMI referent 
group for the categorical associations. This was used for all age groups to enable 
comparisons between the magnitudes of the mortality risks for all the BMI groups. 
Following this revision, the other BMI (kg/m2) groups were <18.5, 18.5-22.9, 27.0-
29.9, 30.0-34.9, 35.0-39.9, and ≥40.0. For the distribution of outcomes see 
supplementary material Table S5.6 and S5.7. Table 5.2 shows the BMI and 
mortality associations. In the 65 to 69 years age group those within the BMI 30.0-
34.9 kg/m2 (Obese-1) range had substantially raised mortality risks (HR 1.25 CI 
1.19, 1.32) relative to those within the BMI 23.0-26.9 kg/m2 range. Mortality risks 
for those within the BMI 30.0-34.9 kg/m2 (Obese-1) range were raised in all age 
groups except those aged ≥85 years, for whom mortality risks were non-
significant. Mortality risks for those within the BMI 35.0-39.9 kg/m2 (Obese-2) and 
BMI ≥40.0 kg/m2 (Obese-3) ranges were higher than those for the BMI Obese-1 
range up to age 84 years; in the 65 to 69 years age group mortality hazards were 
1.50 (CI 1.39, 1.62) and 2.35 (CI 2.13, 2.59) respectively. For those aged ≥85 
years the mortality risks were non-significant for those with the BMI ≥35.0 kg/m2 
(Obese-2 and Obese-3) range relative to those within the BMI 23.0-26.9 kg/m2 
range. In the 65 to 69 years age group those within the BMI 27.0-29.9 kg/m2 
range had modestly raised mortality risks (HR 1.06 CI 1.01, 1.12). For those 
within the BMI 27.0-29.9 kg/m2 range, mortality risks were non-significant in the 
70 to 84 age range and paradoxical for those aged ≥85 years (HR 0.92 CI 0.87, 
0.98). Mortality hazards were also raised for those within the BMI <18.5 kg/m2 
range relative to those within the BMI 23.0-26.9 kg/m2 range in all age groups. 
For all age groups there was an increased mortality risk for those within the BMI 
18.5-22.9 kg/m2 range relative to those within the BMI 23.0-26.9 kg/m2 range.  
 
 
 
 
 
 
 
243	
 
Chapter 5 | CPRD re-defining the BMI referent group  
 
 
Ta
bl
e 
5.
2 
| H
az
ar
d 
ra
tio
s 
fo
r m
or
ta
lit
y 
by
 B
M
I c
at
eg
or
y 
fo
r ‘
he
al
th
ie
r a
ge
rs
’ b
y 
ag
e 
gr
ou
p 
us
in
g 
th
e 
C
PR
D
 
  A
ge
 g
ro
up
 (y
ea
rs
) 
≥8
5 
a  
58
1/
79
1 
1.
53
 (1
.4
0,
 1
.6
7)
 
33
03
/5
26
6 
1.
15
 (1
.1
0,
 1
.2
0)
 
41
43
/7
14
1 
1.
00
 
16
59
/3
06
6 
0.
92
 (0
.8
7,
 0
.9
8)
 
91
5/
17
58
 
0.
98
 (0
.9
1,
 1
.0
5)
 
18
8/
31
9 
1.
00
 (0
.8
7,
 1
.1
6)
 
 
a 
C
el
l c
on
te
nt
s:
 e
ve
nt
s/
nu
m
be
r, 
H
R
 (9
5%
 C
I) 
N
ot
e:
 ‘H
ea
lth
ie
r a
ge
rs
’ w
er
e 
no
n-
sm
ok
er
s 
w
ith
ou
t r
ec
en
t c
an
ce
r (
w
ith
in
 th
e 
pr
ev
io
us
 fi
ve
 y
ea
rs
 e
xc
lu
di
ng
 n
on
-m
el
an
om
a 
sk
in
 
ca
nc
er
), 
de
m
en
tia
, 
he
ar
t 
fa
ilu
re
, 
or
 m
ul
ti-
m
or
bi
di
ty
 a
nd
 s
ur
vi
ve
d 
th
e 
fir
st
 3
.9
 y
ea
rs
. 
C
ox
 p
ro
po
rti
on
al
 h
az
ar
ds
 m
od
el
s 
w
er
e 
ad
ju
st
ed
 fo
r 
ag
e,
 g
en
de
r, 
al
co
ho
l u
se
, s
m
ok
in
g,
 c
al
en
da
r 
ye
ar
, a
nd
 s
oc
io
ec
on
om
ic
 s
ta
tu
s.
 F
or
 th
e 
ag
e 
≥8
5 
ye
ar
s 
ag
e 
gr
ou
p 
th
e 
BM
I O
be
se
-2
 a
nd
 B
M
I O
be
se
-3
 w
er
e 
co
m
bi
ne
d.
 
  
75
 to
 8
4 
a  
94
0/
17
28
 
1.
80
 (1
.6
8,
 1
.9
2)
 
72
75
/1
75
74
 
1.
20
 (1
.1
6,
 1
.2
3)
 
12
89
8/
36
24
7 
1.
00
 
69
63
/2
07
81
 
0.
99
 (0
.9
6,
 1
.0
2)
 
48
42
/1
43
79
 
1.
08
 (1
.0
4,
 1
.1
1)
 
11
76
/3
37
9 
1.
28
 (1
.2
0,
 1
.3
6)
 
34
3/
86
9 
1.
75
 (1
.5
7,
 1
.9
5)
 
70
 to
 7
4 
a  
28
4/
95
8 
2.
09
 (1
.8
6,
 2
.3
6)
 
23
63
/1
24
02
 
1.
19
 (1
.1
30
, 1
.2
5)
 
58
68
/3
42
73
 
1.
00
 
39
35
/2
26
55
 
1.
02
 (0
.9
8,
 1
.0
6)
 
33
51
/1
81
18
 
1.
16
 (1
.1
1,
 1
.2
1)
 
11
03
5/
50
31
 
1.
46
 (1
.3
7,
 1
.5
7)
 
38
1/
15
64
 
1.
98
 (1
.7
9,
 2
.2
0)
 
65
 to
 6
9 
a  
12
4/
74
4 
2.
32
 (1
.9
4,
 2
.7
8 
 
12
74
/1
29
50
 
1.
16
 (1
.0
9,
 1
.2
3)
 
36
27
/3
76
80
 
1.
00
 
27
50
/2
64
52
 
1.
06
 (1
.0
1,
 1
.1
2)
 
26
02
/2
24
75
 
1.
25
 (1
.1
9 
to
 1
.3
2)
 
 
84
4/
66
85
 
1.
50
 (1
.3
9,
 1
.6
2)
 
46
3/
25
74
 
2.
35
 (2
.1
3,
 2
.5
9)
 
60
 to
 6
4 
a  
69
/7
67
 
2.
35
 (1
.8
5,
 2
.9
9)
 
73
9/
14
77
7 
1.
18
 (1
.0
8,
 1
.2
8)
 
20
64
/4
16
31
 
1.
00
 
16
86
/2
93
99
 
1.
14
 (1
.0
7,
1.
21
) 
17
14
/2
61
77
 
1.
32
 (1
.2
4,
 1
.4
1)
 
69
1/
86
01
 
1.
79
 (1
.6
4,
 1
.9
6)
 
40
0/
36
08
 
2.
65
 (2
.3
8,
 2
.9
6)
 
  
BM
I 
 <
18
.5
 
BM
I 
   
18
.5
-2
2.
9 
  BM
I 
   
23
.0
-2
6.
9 
 BM
I 
   
 2
7.
0-
29
.9
 
BM
I 
   
 3
0.
0-
34
.9
 
BM
I 
   
 3
5.
0-
39
.9
 
BM
I 
≥4
0.
0 
244	
 
Chapter 5 | CPRD re-defining the BMI referent group  
5.5.4.  Absolute rates 
For those aged 65 to 69 years at baseline with mean values for confounders, the 
estimated death rate between 4 to 14.9 years for those within the BMI 30.0-34.9 
kg/m2 (Obese-1) range was 27.9% (32.6% for BMI 35.0-39.9 kg/m2 and 45.2% 
for BMI ≥40.0 kg/m2), compared to 23.1% for those within the BMI 23.0-26.9 
kg/m2 range (Table 5.3). The estimated death rate during the first 3.9 years of 
follow-up for those aged 65 to 69 years was 3.0% for those within the BMI 30.0-
34.9 kg/m2 (Obese-1) range (3.6% for BMI 35.0-39.9 kg/m2 and 4.7% for BMI 
≥40.0 kg/m2), compared to 2.7% for those within the BMI 23.0-26.9 kg/m2 range.   
 
Table 5.3 | Death Rates for the ‘healthier agers’ by BMI category for those aged 
65 to 69 years at baseline using the CPRD 
BMI category 0 to 3.9 years a ≥4 years a 
   BMI <18.5 11.1 49.5 
   BMI   18.5-22.9   3.8 27.0 
   BMI   23.0-26.9            2.7 23.1 
   BMI   27.0-29.9     2.6 24.3 
   BMI   30.0-34.9          3.0 27.9 
   BMI   35.0-39.9          3.6 32.6 
   BMI ≥40.0 4.7 45.2 
a Cell contents death % 
Note: ‘Healthier agers’ were defined as non-smokers, without recent cancer 
(within the five previous years except non-melanoma skin cancer), dementia, 
heart failure, or multi-morbidity. Cox proportional hazards models were adjusted 
for age, gender, alcohol status, smoking status, calendar year, and Index 
Multiple of Deprivation.   
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5.5.5.  Rate advancement period 
Applying the rate advancement period approach to ‘healthier agers’ aged 65 to 
69 years at baseline who are within the BMI 30.0-34.9 kg/m2 (Obese-1), 35.0-
39.9 kg/m2 (Obese-2) and ≥40.0 kg/m2 (Obese-3) ranges show longer term 
mortality rates, which is equivalent to being 1.96, 3.51 and 7.38 years older than 
their chronological age, respectively, compared to those within the BMI 23.0-26.9 
kg/m2 range (Figure 5.6). Age acceleration in the BMI 27.0-29.9 range was 0.52 
years for those aged 65 to 69 years compared to those within the BMI 23.0-26.9 
kg/m2. Age accelerations were apparent for all age groups, except for those aged 
≥85 years for the BMI 30.0-344.9 kg/m2 (Obese-1) range, with an attenuation of 
the acceleration with advancing age. Age accelerations were observed for all age 
groups for the BMI <18.5 kg/m2, BMI 18.5-22.9 kg/m2, BMI 35.0-39.9 kg/m2, and 
BMI ≥40.0 kg/m2 ranges.   
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5.5.6.  Type 2 diabetes 
For the distribution of outcomes see supplementary material Table S5.6 and 
S5.7. For ‘healthier agers’ the risk for incident diabetes was raised for the 
following ranges relative to those within the BMI 23.0-26.9 kg/m2 for all age 
groups: BMI 27.0-29.9 kg/m2, BMI 30.0-34.9 kg/m2 (Obese-1), BMI 35.0-39.9 
kg/m2 (Obese-2), and BMI ≥40.0 kg/m2 (Obese-3) (Table 5.4). The risks for 
diabetes for those within the BMI 27.0-29.9 kg/m2 range was Sub-Hazard Ratio 
(SHR) 1.79 (CI 1.67, 1.93) and for those within the BMI 30.0-34.9 kg/m2 (Obese-
1) range it was SHR 2.68 (CI 2.49, 2.88) relative to those within the BMI 23.0-
26.9 kg/m2 range for those aged 65 to 69 years at baseline. Risks were reduced 
for those with BMI values <23.0kg/m2 for those aged <85 years.  
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5.5.7.  Coronary Heart Disease 
For the distribution of outcomes see supplementary material Table S5.6 and 
S5.7. For CHD, competing hazards were raised for those within the BMI 27.0-
29.9 kg/m2 range in all age groups. Those within the BMI 30.0-34.9 kg/m2 
(Obese-1) range have raised risks for CHD to age 84 years and a non-significant 
CHD risk estimate in the ≥85 years age group relative to those within the BMI 
23.0-26.9 kg/m2 range (Table 5.5). The risks for CHD for those within the BMI 
27.0-29.9 kg/m2 was SHR 1.14 (CI 1.07, 1.22) and for those within the BMI 30.0-
34.9 kg/m2 (Obese-1) range it was SHR 1.26 (CI 1.17, 1.35) relative to those 
within the BMI 23.0-26.9 kg/m2 range for those aged 65 to 69 years at baseline. 
The magnitudes for the risks of CHD for the higher BMI groups were less than 
those reported for incident diabetes.  
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5.5.8.  Sensitivity analyses  
Interactions between the BMI categories and gender were assessed for the 
‘healthier agers’ which were not significant except in the 70 to 74 age-group 
(p=0.0447) where absolute differences in estimates were small, and there was 
overlap between the confidence intervals. Adjusting for physical activity level 
(Table 5.6) where available had little effect on mortality estimates. Restricting 
estimates to those with a ‘white’ ethnicity health record (Table 5.7) had little 
impact on estimates. Restricting mortality estimates to those with measured 
weight change (Table 5.8) were again little changed. In the ≥85 years age group, 
mortality risks were not significantly different for the BMI 27.0-29.9 kg/m2 or BMI 
30.0-34.9 kg/m2 (Obese-1) ranges relative to those within the BMI range 23.0-
26.9 kg/m2. A similar model excluding measured weight losses of ≥2.5 kg also 
yielded similar estimates (Table 5.9). To check the robustness of estimates 
including unrecorded categories for smoking and alcohol use, mortality hazards 
with multiple imputation were estimated: results were little changed (Table 5.10). 
For the main analysis in this chapter the referent range was revised to include 
the BMI values 23.0 to <27.0 kg/m2 as this range seemed to be associated with 
the lowest mortality risk in the two youngest groups. However, inclusion of the 
higher end of BMI Normal range (23.0 to <25.0 kg/m2) and the lower end of the 
BMI Overweight range (25.0 to <27.0 kg/m2) as one referent range challenges 
the interpretation of the mortality risks for those with a BMI in the Overweight 
range. In the modelling of the BMI continuous associations with mortality the risk 
appears similar for the higher end of the BMI Normal range and lower end of the 
BMI Overweight range for those aged <84 years, and appears a reduced risk for 
the higher BMI values for those aged ≥85 years. The analyses were, therefore, 
repeated using the higher BMI Normal range as the referent group (see 
supplementary material tables S5.8 to S5.17).  
 
Mortality 
For those aged <85 years the risks for mortality were not significantly different for 
those within the BMI range 25.0 to <27.0 kg/m2 relative to those within the BMI 
range 23.0 to <25.0 kg/m2, in all the analyses except the multiple imputation 
analysis for those aged 70 to 74 years with a reduced risk. Reduced risks were 
found for those aged ≥85 years in the main analysis, in the restriction to a ‘white’ 
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ethnicity record, exclusion of ≥2.5kg weight loss and multiple imputation, with the 
rest of the analyses being non-significant. Mortality risks were similar for all the 
BMI ranges to those reported when using the referent range 23.0 to <27.0 kg/m2. 
Except, there were shifts to non-significance in the BMI range 27.0 to <30.0 kg/m2 
(60 to 64 age-group: exclusion ≥2.5kg weight loss; 65 to 69 years: restriction to 
a ‘white ethnicity record, exclusion ≥5.0kg weight loss, and multiple imputation) 
and reduced risks (age group 70 to 74 years after restricting to a ‘white’ ethnicity 
record; ≥85 years multiple imputation) The BMI Obese-1 mortality risks for those 
aged 75 to 84 years also became not significantly different to those within the 
range 23.0 to <25.0 kg/m2 after the exclusions of ≥5.0kg weight loss. For those 
aged ≥85 years, mortality risks for the BMI range 18.5 to 22.9 kg/m2 became not 
significantly different to those within the referent range 23.0 to <25.0 kg/m2 after 
the exclusion of ≥5.0kg weight loss and ≥2.5kg weight loss. Reduced risks were 
also reported for the BMI Obese-1 range for multiple imputation for those aged 
≥85 years.       
 
Coronary heart disease 
For the coronary heart disease analyses, the risks were little changed. There was 
no significant difference between the BMI range 25.0 to <27.0 kg/m2 compared 
to those within the BMI range 23.0 to <25.0 kg/m2, except for those aged 65 to 
69 where there was a 12% increased risk (95% CI 1.02, 1.23). 
 
Diabetes 
For the diabetes analyses, the point estimates for the higher BMI values were 
greater. For the two youngest age-groups, the point estimates and confidence 
intervals were above those reported. There were increased risks for those within 
the BMI range 25.0 to <27.0 kg/m2 compared to the referent range 23.0 to <25.0 
kg/m2, for those aged <85 years.   
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5.6. Discussion  
The aim of this chapter was to re-define the BMI referent range and to use this 
revised group to estimate the BMI associations with mortality, CHD, and diabetes. 
The results show that for ‘healthier agers’ (non-smokers, free of conditions 
associated with weight loss, and excluding early deaths) those within the BMI 
30.0-34.9 kg/m2 (Obese-1) range have elevated risks for all-cause mortality, 
coronary heart disease, and diabetes, compared to the risk nadir (23.0-26.9 
kg/m2) up to and including those aged 84 years. For ‘healthier agers’ these results 
do not support calls to revise policies to reflect the claimed obesity risk paradox 
in the general older population. At age 65 years, ‘healthier agers’ have long life 
expectancies (women 21.0 years, men 18.5 years for England) (Office for 
National Statistics, 2014) during which gains from optimised weight control could 
be enjoyed. My analysis showed that the evidence on being overweight at older 
ages is mixed, but BMI >27.0 kg/m2 was associated with modestly increased 
mortality risks for the younger age groups (60 to 64 years; 65 to 69 years) relative 
to those within the BMI 23.0-26.9 kg/m2 range. On the whole, the mortality risks 
for those within the lower end of the BMI Overweight range (BMI 25.0 to <27.0 
kg/m2) tended to be similar to those within the higher end of BMI Normal 23.0 to 
<25.0 kg/m2 for those aged <85 years. Persons, within the BMI range 25.0 to 
<27.0 kg/m2 did, however, have an increased risk of incident diabetes relative to 
those within the BMI range 23.0 to <25.0 kg/m2.       
Interestingly, even after excluding smokers and those with conditions associated 
with major weight loss (cancer, dementia, heart failure, and multi-morbidity) those 
within the lower end of the BMI Normal range (18.5 to <23.0 kg/m2) had increased 
mortality risks compared to those with a BMI range of 23.0 to <25.0 or 23.0 to 
<27.0 kg/m2. This is in-line with several previous analyses. Berrington de 
Gonzalez et al., (2010) reported that for never smokers, with at least one year of 
follow-up and without cancer or heart disease at baseline there was an increased 
mortality risk for those within the BMI range 18.5-19.9 kg/m2 (aged 60 to 69 years 
HR 1.15 CI 1.04, 1.27; aged 70 to 84 years HR 1.32 CI 1.15, 1.51) relative to 
those with a BMI within the range 22.5-24.9 kg/m2  with a median follow-up 
duration of 10 years using data from 19 pooled prospective cohort studies 
(Berrington de Gonzalez et al., 2010). Similarly, increased mortality risks were 
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reported for those with BMI values <22.5 kg/m2 relative to those with a BMI within 
the range 22.5 to <25.0 for never smoking adults 70 to 89 years, without prevalent 
chronic disease, and the first five years of follow up excluded (Di Angelantonio et 
al., 2016). Conversely, Park et al., (2012) showed that the mortality risks for those 
within the BMI range 18.5-22.9 kg/m2 were not significantly different to those 
within the BMI range 23.0-24.9 kg/m2 during a 12.5 year follow-up duration for 
adults aged 65 to 74 years after excluding smokers, those with cancer or heart 
disease, plus the first three years of follow up (Park et al., 2012).   
In the analysis presented in this chapter, the exclusion of conditions associated 
with weight loss did not capture all the patients with measured substantial weight 
loss thereby residual confounding may have remained in the models, which could 
partly explain the increased mortality risks for those within the lower end of the 
conventional BMI Normal range. Additionally, several diseases have a long pre-
clinical weight loss stage, such as dementia (Chapter 6), which may not have 
been captured by excluding the first 3.9 years. Unmeasured confounders such 
as nutrition could have contributed to the risks. Furthermore, as highlighted 
previously BMI does not measure body compositional changes with ageing. 
Persons within the lower end of the BMI Normal range may conceivably be 
defined as having sarcopenia or be centrally obese. The causes of deaths also 
may differ for those within the BMI Normal range to those with higher BMI values 
e.g. higher risk from respiratory or other causes (i.e. not cancer or cardiovascular) 
(Pischon, et al., 2010).  
My analysis showed that there were increased mortality risks for those with BMI 
values <23.0 kg/m2. Inclusion of persons within the lower end of the BMI Normal 
range (<23.0 kg/m2) as part of the referent group can distort mortality risk 
estimates for the higher BMI values. In comparison to the results presented in 
Chapter 4, where the whole of the conventional BMI Normal range was used as 
the referent group, the point estimates for the BMI Obese ranges were much 
higher when the BMI referent range commenced at 23.0 kg/m2. Additionally, 
persons with the BMI Normal range may not be ‘ideal’ for other adiposity 
measures such as central adiposity or for body composition. This again may 
distort mortality risks. This will be examined further in Chapter 8.   
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5.6.1.  Comparison to previous literature 
The results from this chapter are difficult to compare with previous work due to 
the use of different age groups, exclusions, and the choice of the BMI referent 
group. The nadir of the mortality risk estimates is not easy to compare with prior 
analyses as none of the previous analyses reported estimates after sequential 
exclusion of smokers, those with conditions associated with weight loss, or 
deaths during the early stages of follow-up.  
 
The results of this chapter for the BMI Overweight and BMI Obese-1 ranges are 
partly in accord with other analyses which excluded smokers, conditions 
associated with weight loss, and early deaths. Berrington de Gonzalez et al 
(2010) reported increased mortality risks for the upper end of the BMI Overweight 
(27.5-29.9 kg/m2) and BMI Obese-1 ranges for two age groups, 60 to 69 years 
and 70 to 84 years, relative to those within the BMI 22.5-24.9 kg/m2 range 
(Berrington de Gonzalez et al., 2010). Park et al., (2012) reported increased 
mortality risks for the BMI Obese-1 range relative to those within the BMI 23.0-
24.9 kg/m2 range for adults aged 65 to 74 years. There were increased mortality 
risks for males within the upper end of the BMI Overweight range (27.5-29.9 
kg/m2), and a non-significant mortality risk for females relative to those within the 
BMI referent group (Park et al., 2012).         
The results presented within this chapter for incident type 2 diabetes and 
coronary heart disease are also difficult to compare to previous analyses. Overall, 
the results from this chapter showed an increased risk for type 2 diabetes for the 
BMI Overweight and BMI Obese ranges which parallels those reported in the 
supplementary material table S5.2. The attenuation of the risks for incident type 
2 diabetes with advancing age are similar to those that were reported by Biggs 
et al., (2010) (Biggs et al., 2010).  However, limited studies used a competing risk 
approach and there were no studies providing diabetes risk estimates across 
narrower age groups using a baseline period within the 21st century.  Likewise, 
very few studies as shown in supplementary material table S5.4 used the 
competing risk technique for CHD and there were no studies reporting estimates 
for progressively older age groups using a baseline period within the 21st century.  
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5.6.2.  Strengths and limitations 
In this chapter I re-defined the BMI referent group by estimating the continuous 
BMI association with mortality. A major criticism of the meta-analysis by Flegal et 
al., (2013) was the use of the conventional BMI Normal range (Flegal et al., 2013). 
The results presented in this chapter provide further evidence that participants 
within the lower BMI Normal range may be at an elevated mortality risk which can 
distort mortality risk estimates for higher BMI categories. As noted in Chapter 4 
a major strength of the sequential exclusions leading to the ‘healthier agers’ 
subgroup was that the sample sizes for the age groups are much greater than 
previous analyses (Chapter 3). In this chapter I report recent estimates for 
incident CHD and incident diabetes across progressively older age groups using 
a competing risks approach adding to the limited evidence in this research area. 
Another advantage to this analysis is that outcome ascertainment is improved 
using both health records from general practitioner visits and hospital admissions.  
 
There are several limitations for this analysis. In this analysis, I estimated the 
association with BMI and all-cause mortality, CHD, and type 2 diabetes, it is also 
important to establish associations with other health outcomes which are of 
relevance in later life. The risk estimates reported in this chapter may differ when 
other health outcomes are considered.  As highlighted in Chapter 4 the patients 
were predominately ‘white’ ethnicity and, therefore, the findings may not be 
generally applicable to other ethnic groups. These results also are derived from 
a group of ‘healthier agers’. This group of patients would be the main target for 
obesity prevention. As highlighted in this chapter, the nadir of the mortality risk 
curves was slightly higher at older ages. A decision was made to use the mortality 
risk nadir from the two youngest age groups. This allowed direct comparisons 
between the differing age groups. An extension of this work would be to increase 
the BMI values within the BMI referent group for these older age groups.  
 
In Chapter 6 I use the CPRD database to estimate the association between BMI 
categories with incident dementia for those aged 65 to 74 years. Risks for 
dementia have also been reported to be paradoxical in later life with higher BMI 
categories. Increased risks for incident dementia for the BMI Obese range have 
been reported for younger and middle aged cohorts relative to those within the 
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BMI Normal range. Reduced, non-signifcant, and increased risks for dementia 
have been reported for older adults relative to those within the BMI Normal range 
(Chapter 6).  
 
Future work is required to establish whether other measures of adiposity or body 
composition may improve mortality prediction compared to BMI. As highlighted 
in Chapter 1, the value of BMI as a surrogate adiposity measure for older age 
groups has been questioned due to the alteration of body composition and fat 
distribution across the life cycle. In Chapter 7 I use the UK Biobank to compare 
established measures of body fat distribution (waist circumference, waist-to-hip 
ratio, and waist-to-height ratio) and body composition (percentage body fat, fat 
mass, fat free mass, and skeletal mass index) to BMI in their ability to predict 
mortality for ‘healthier agers’ within the seventh decade of life. 
 
5.7. Conclusions  
The use of the conventional BMI Normal range (18.5 to <25.0 kg/m2) appears too 
broad for defining those with Normal BMI in later life. Persons with BMI values 
below <23.0 kg/m2 have increased mortality risks, and the inclusion of this group 
in the BMI referent group can distort mortality risks for higher BMI values. In this 
large population-based older cohort studying longer-term outcomes, the results 
show that obesity is associated with shorter survival in older people who do not 
have the studied confounding factors, at least to and including those aged 84 
years. These results cast doubt on calls to revise obesity control policies to reflect 
the claimed obesity risk paradox in the general older population. The implications 
of these findings will be discussed in greater detail in Chapter 9.  
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Table S5.9 | Death Rates for ‘healthier agers’ by BMI category for those aged 
65 to 69 years at baseline using the CPRD 
 
BMI Category 0 to 3.9 years a ≥4 years a 
<18.5 11.1 49.5 
18.5 to <23.0. 3.8 27.0 
23.0 to <25.0 2.9 23.4 
25.0 to <27.0 2.6 23.0 
27.0 to <30.0 2.6 24.3 
30.0 to <35.0 3.0 27.9 
35.0 to <40.0 3.6 32.6 
≥40.0 4.7 45.2 
a Cell contents death % 
Note: ‘Healthier agers’ were defined as non-smokers, without recent cancer 
(within the five previous years except non-melanoma skin cancer), dementia, 
heart failure, or multi-morbidity. Cox proportional hazards models were adjusted 
for age, gender, alcohol status, smoking status, calendar year, and Index 
Multiple of Deprivation.   
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6.1. Summary 
Background: The risk for dementia for those within the body mass index (BMI) 
defined Obese range (BMI ≥30.0 kg/m2) in later life is unclear, with reduced, non-
significant, and increased risks reported relative to those within the BMI Normal 
range (BMI 18.5-24.9 kg/m2). Weight loss has been reported to precede the 
clinical diagnosis of dementia within the previous decade. Dementia risks may be 
distorted due to the chosen BMI referent group and the years of follow-up 
excluded to minimise reverse causality.   
 
Objective: To estimate pre-diagnosis weight loss in those diagnosed with 
dementia. Secondly to estimate the associations between BMI and dementia for 
the short (0 to <10 years) and long (10 to <14.9years) term.   
 
Design: This analysis included 257,523 ‘healthier agers’ (from 1st January 2000) 
aged 65 to 74 years using primary care, hospital and death certificate electronic 
health records from the Clinical Practice Research Datalink (CPRD). ‘Healthier 
agers’ are defined as non-smokers without dementia or additional conditions 
associated with weight loss. Competing risks models were used with adjustment 
for age, gender, alcohol use, smoking history, calendar year and socioeconomic 
status. 
 
Results: During a maximum follow-up period of 14.9 years there were 9,774 
incident cases of dementia and 29,466 deaths. Weight loss of ≥2.5 kg was 
documented in 54% of those with repeat measures, and with a dementia 
diagnosis. In the short-term (0 to <10 years), there were reduced risks for incident 
dementia for those within the BMI Overweight (sub Hazard Ratio [SHR] 0.80    
95% Confidence Interval [CI] 0.75, 0.85) and BMI Obese range (SHR 0.69 CI 
0.65, 0.74) relative to those within the BMI 22.5 to <25.0 kg/m2 range. However, 
there was a reversal of the risks in the long term (10 to 14.9 years) with an 
increased risk for those for the BMI Obese range (SHR 1.17 CI 1.03, 1.32), and 
the risks for those within the BMI Overweight range were not significantly 
different.     
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Conclusions: This analysis showed that the risks for incident dementia for those 
within the BMI Obese range relative to those within the BMI 22.5 to <25.0 kg/m2 
range were markedly altered after excluding incident dementia and deaths 
occurring within the first decade. Persons with obesity are at increased dementia 
risk in the longer term. Paradoxical risks (i.e. reduced risks) for dementia for those 
within the BMI Obese range in later life could reflect weight loss in the decade 
before diagnosis.  
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6.2. Introduction 
Dementia is a key public health issue. Globally, the prevalence of dementia was 
estimated to be 46.8 million in 2015, and is anticipated to reach 131.5 million by 
2050 due in part to the increasing proportion of older adults and improved 
recognition of the syndrome (Prince, 2015). In England, in 2015 Alzheimer’s 
disease was ranked the seventh leading cause of disability adjusted life years, 
with this ranking increasing with advancing age (Kassebaum et al., 2016). 
Dementia has a significant impact on the individual’s independence and quality 
of life, and is becoming an increasing financial burden for health and social care 
providers (World Health Organization, 2012, 2015; Prince, 2015). The role of 
modifiable risk factors is of great interest as there is currently no cure for 
dementia.  
A reversal of the risks for incident dementia for those within the BMI Obese range 
relative to those within the BMI Normal range has been reported, with increased 
risks for dementia in midlife (Kivipelto et al., 2005; Whitmer et al., 2005) and 
reduced risks for dementia in later life. Pedditzi et al., (2016) reported an 
increased risk for dementia of 41% (CI 1.20, 1.66) for those within the BMI Obese 
range relative to those within the BMI Normal range from analyses which included 
adults aged <65 years from their meta-analysis. In contrast, analyses with a mean 
participant age of ³65 years showed a reduced risk for dementia of 17% (CI 0.74, 
0.94) for those within the BMI Obese range relative to those within the BMI 
Normal range. The risk for incident dementia was not significantly different for 
those within the BMI Overweight range (RR 0.88 CI 0.78, 1.02). Overall there 
have been a limited number of studies, with four reporting estimates for the BMI 
Obese range and five for the BMI Overweight range, for incident dementia in later 
life (Pedditizi, Peters and Beckett, 2016; Pedditzi, Peters and Beckett, 2016).  
 
The proposed explanations for the reversal of BMI risks with dementia show 
similarities to those suggested for the reversal of BMI risks with mortality in later 
life. These include selective survival, the use of BMI as a surrogate for adiposity 
in older persons, attenuation of health risks with advancing age, and reverse 
causation (Luchsinger et al., 2007; Atti et al., 2008; Fitzpatrick et al., 2009; 
Tolppanen et al., 2014). Weight loss has been reported to precede the clinical 
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diagnosis of dementia within the previous decade (Knopman et al., 2007). It 
follows that the conventional BMI Normal range may contain persons whose BMI 
has been reduced due to preclinical stages of dementia and thus risk estimates 
for higher BMI categories may be distorted. In Chapter 5, I presented an analysis 
which estimated the association between continuous BMI and mortality risk in 
later life. Persons within the BMI 18.5-22.9 kg/m2 range had increased mortality 
risks compared to those within the BMI range 23.0-26.9 kg/m2. Thereby using the 
conventional BMI Normal range may have distorted the mortality risk estimates 
for those with higher BMI values.  
In the supplementary material tables S1.2 and S1.3 I summarised the association 
between BMI and incident dementia/associated dementia subtypes for adults 
aged ≥65 years showing that the findings were equivocal. Discrepancies may be 
due to the age structure of the analyses, sample sizes, and length of the follow-
up (Fitzpatrick et al., 2009; Gustafson et al., 2009). There was a lack of studies 
reporting estimates for BMI groups and incident dementia in later life, especially 
for the BMI Overweight and Obese ranges. Many of the studies pooled broad age 
ranges which may have diluted the dementia risk estimates. A limited number of 
studies used a competing risk approach to assess the relationship between BMI 
and incident dementia, which may have led to an underestimation of the reported 
risks (Chapter 2).  
 
One study reported estimates for BMI and incident dementia using different time 
frames i.e. estimating the risk for dementia after excluding differing years of 
follow-up.  Atti et al., (2008) reported that the risk of incident dementia was not 
substantially different following the exclusion of the first six years relative to the 
whole nine-year period for adults aged ≥75 years from the Kungsholem Project. 
However, this analysis was not able to separate those within the BMI Overweight 
or Obese ranges due to the limited sample size (Atti et al., 2008).  
Many of the studies reported within supplementary material Table S1.2 had a 
baseline period within the 1990s. This necessitates assessing the association 
between recent measures of BMI and dementia due to improved diagnosis, the 
prevalence of persons classified as BMI Overweight or Obese, and the proportion 
of older adults. Here I aimed to estimate pre-diagnosis weight loss in those 
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diagnosed with dementia. Secondly, I aimed to estimate the associations 
between BMI and incident dementia for ‘healthier agers’ aged 65 to 74 years 
using competing risks models, to estimate short-term (0 to <10 years from 
baseline BMI measure), and longer-term (10 to <14.9 years). The age range 65 
to 74 years was chosen to ensure that this would be late onset dementia and with 
enough incident cases of dementia. Additionally, there have been no studies 
which have focused specifically on this age range; using a broader age range 
may dilute risk estimates due to the combining of the youngest old and oldest old.  
 
6.3. Methods 
6.3.1. Study Population 
In this chapter I use a similar methodology to Chapter 4 and Chapter 5, using 
de-identified electronic health records from the CPRD. This includes patients with 
GP records linked to Hospital Episode Statistics data for admissions (linkage 
available for England only) and the government’s Office for National Statistics 
(ONS) death certificate data. As emphasised in Chapters 2 and 4, registration 
with GPs is nearly complete in the UK  and CPRD diagnostic and outcome coding 
has generally high validity (Herrett et al., 2010). 
 
6.3.2.  ‘Healthier agers’ 
The ‘healthier agers’ were defined as non-smokers without dementia plus 
conditions associated with weight loss. The conditions excluded were cancer 
(excluding non-melanoma skin cancer) within the previous five years, heart 
failure, and a measure of multi-morbidity. These conditions had been empirically 
identified as being associated with weight loss which was presented in Chapter 
4. All patients with BMI records since the 1st January 2000 and registered with a 
CPRD practice at the time of measurement were included with extreme values of 
BMI excluded (<14.0 and > 56.5 kg/m2). 
 
6.3.3. Exposure 
The earliest age at which a BMI was recorded was calculated within the age 
group 65 to 74 years. The first BMI record was included as the study ‘index’ BMI 
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for analysis. BMI (kg/m2) was categorised following the Global BMI Mortality 
Collaboration groupings (Di Angelantonio, et al., 2016) as BMI <18.5, 18.5 to 
<20.0, 20.0 to <22.5, 25.0 to <30.0, and ≥30.0 kg/m2. 
 
6.3.4. Lifestyle and socioeconomic variables  
Models were adjusted for age, gender, alcohol use, smoking history (never or 
former), calendar year and socioeconomic status. These variables have been 
previously defined in Chapters 2 and 4 and are in line with model adjustments 
from previous analyses (supplementary material tables S1.2 and S1.3).  
 
6.3.5. Outcomes 
Outcomes included incident dementia (from GP records or Hospital Episode 
Statistics) and mortality (from Office for National Statistics death certificate data) 
up to the 17th November 2014.  
 
6.3.6. Statistical analysis 
Competing risks models (accounting for mortality) were used to estimate the 
associations between the redefined BMI groups and incident dementia. 
Multivariate models were adjusted for age, gender, alcohol use, smoking history, 
calendar year, and socioeconomic status. In a sensitivity analysis participants 
previously diagnosed with angina, myocardial infarction, or type 2 diabetes were 
excluded. Analyses were carried out using Stata statistical software (version 
13.1) and R statistical software (version 3.1.2.)  
 
6.4. Results  
6.4.1. Baseline characteristics 
The characteristics of the 257,523 ‘healthier agers’ aged 65 to 74 years at 
baseline with complete records for smoking history, alcohol status, and 
socioeconomic status are presented in Table 6.1. The mean BMI was 27.7 kg/m2 
(SD 4.9 kg/m2), and 53.4% of the sample were female. 
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Figure 6.1 shows the BMI proportions for all those diagnosed with dementia (n = 
9,774) by the number of years to incident disease. This showed lower obesity 
prevalence in those diagnosed sooner after baseline with 15.5% of those 
diagnosed with dementia in the first year of follow-up being BMI Obese, 
compared to 23.4% for those diagnosed in the 9th year of follow-up. Underweight 
(BMI <18.5 kg/m2) and leaner BMI Normal weights (18.5 to <20.0 kg/m2) showed 
converse changes. Subject weight change was then analysed in those who were 
diagnosed with dementia by subtracting the median recorded weight in the three 
years immediately before dementia diagnosis from the median weight eight to ten 
years before diagnosis. Records allowed weight change calculations for 4,760 
(48.7%) with dementia, and of these 67.7% lost weight, with 54.0% loosing 
≥2.5kg during the decade before diagnosis. 
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Table 6.1 | Characteristics of the ‘healthier agers’ aged 65 to 74 years at baseline 
from the CPRD 
n 257,523 
Follow-up years, mean (SD) 6.2 (4.1) 
Age years, mean (SD) 68.3 (2.9) 
Gender  
    Females, n (%) 137,583 (53.4) 
BMI (kg/m2), mean (SD) 27.7 (4.9) 
BMI (kg/m2), n (%)  
   BMI <18.5 2,367 (0.9) 
   BMI   18.5 to <20.0 4.553 (1.8) 
   BMI    20.0 to <22.5 22,225 (8.6) 
   BMI    22.5 to <25.0 48,577 (18.9) 
   BMI    25.0 to <30.0 109,195 (42.4) 
   BMI ≥30.0  70,606 (27.4) 
Alcohol Status, n (%)  
   Non-drinker 38,696 (15.0) 
   Current drinker 179,839 (69.8) 
   Ex drinker 34,264 (13.3) 
   Heavy drinker 4,724 (1.8) 
Smoking Status, n (%)  
   Never 161,063 (62.5) 
   Ex-smoker 96,460 (37.5) 
Index of multiple deprivation quintiles (1 least 
deprived; 5th most deprived), n (%) 
 
   1 66,513 (25.8) 
   2 68,028 (26.4) 
   3 54,263 (21.1) 
   4 44,326 (17.2) 
   5 24,393 (9.5) 
Note: ‘Healthier agers’ were non-smokers without recent cancer (within the 
previous five years except non-melanoma skin cancer), dementia, heart failure, 
or multi-morbidity. 
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Figure 6.1 | Proportion of study sample with incident dementia by BMI categories 
 
 
Note: ‘Healthier agers’ were non-smokers without recent cancer (within the 
previous five years except non-melanoma skin cancer), dementia, heart failure, 
or multi-morbidity. 
 
 
 
6.4.2. BMI categorical associations with dementia 
There were 9,774 incident cases of dementia and 29,466 deaths during a 
maximum follow-up period of 14.9 years. The BMI range 22.5 to <25.0 kg/m2 was 
used as the referent group. Estimates for dementia were derived for the short (0 
to <10 years from baseline measure) and long (10 to <14.9 years) term.  
 
From analysis baseline to <10 years of follow-up (Figure 6.2), there was a 
reduced risk for incident dementia for those within the BMI Obese range (SHR 
0.69 95% CI 0.65, 0.74) and BMI Overweight range (SHR 0.80 CI 0.75, 0.85) 
relative to those within the BMI 22.5 to <25.0 kg/m2 range. However, for the 
longer-term follow-ups (between 10 and 14.9 years from baseline), there was an 
increased risk of incident dementia for the BMI Obese range (SHR, 1.17; 95% 
CI, 1.03, 1.32 ). The dementia risk for BMI Overweight range was not significantly 
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different to that of the referent range. In models pooling shorter and longer follow-
ups (supplementary material table S6.1), the shorter term protective associations 
predominated, although with smaller overall sub-Hazard Ratios than for the 0 to 
<10 year period only. Low BMIs were consistently associated with increased risks 
of dementia in both the short and long-term.   
 
Sensitivity analysis 
In a sensitivity analysis (supplementary material table S6.2), patients with a 
previous diagnosis of angina, myocardial infarction, or type 2 diabetes were 
excluded. This reduced the sample size to 49,341 and attenuated the 10 to 14.9 
year results only slightly for the BMI Obese range (SHR, 1.16; 95% CI, 1.01,1.33).   
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Note: ‘Healthier agers’ were non-smokers without recent cancer (within the 
previous five years except non-melanoma skin cancer), dementia, heart failure, 
or multi-morbidity. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 | sub-Hazard ratios for incident dementia by BMI groups for the short (0 to <10 
years) and long (≥10 to 14.9 years) term using competing risks models for ‘healthier agers’ 
aged 65 to 74 years (n = 257,523) from the CPRD 
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6.5. Discussion 
In this chapter I aimed to estimate pre-diagnosis weight loss in those diagnosed 
with dementia and secondly to estimate the associations between BMI and 
dementia for the short (0 to <10 years) and long (10 to <14.9 years) term. 
Previous work has indicated that weight loss occurs up to ten years before the 
clinical diagnosis for dementia. I, therefore, hypothesised that excluding this 
follow-up period would markedly alter the risk for incident dementia. I showed that 
there was substantial weight loss during the 10 years before dementia diagnosis. 
There appeared to be a reduced risk for incident dementia for those within the 
BMI Obese range and BMI Overweight range from 0 to 14.9 years. However, 
when outcomes from 10 to 14.9 years after baseline were tested, the risk estimate 
reversed with those within the BMI Obese range having an increased risk for 
dementia. The risks for those within the BMI Overweight range were not 
significantly different to those of the referent range. Previous analyses have 
shown that there is an increased risk for incident dementia for the BMI Obese 
range in younger and middle aged cohorts; dementia risks for older adults, 
however, have not been clear. The ability to evaluate the risks for incident 
dementia for the BMI groups using the short (0 to <10 years) and long term (10 
to 14.9 years) is a unique feature of the analysis I have presented in this chapter. 
Overall, these results contest the notion that persons within the BMI Obese range 
have a reduced risk of dementia in the longer term. Reports of reduced risks for 
dementia for those within the BMI Obese range in later life may be due to the 
long preclinical phase of dementia, during which time weight loss is common.     
 
6.5.1. Comparison to the literature 
The reduced dementia risks for those within the BMI Obese range for the whole 
follow-up period are partly in line with the previous analysis by Fitzpatrick et al., 
(2009). Reduced risks (HR 0.63 CI 0.44, 0.91) for incident dementia were 
reported for those within the BMI Obese range relative to those within the BMI 
range 20.0-24.9 kg/m2 for adults aged 65 to 97 years (n = 2,798) using the 
Cardiovascular Health Study with a mean follow-up period of 5.4 years 
(Fitzpatrick et al., 2009).  However, the results presented in this chapter for the 
whole follow-up period contrast with several previous analyses. Hayden et al., 
(2006) documented increased risks for incident dementia for those within the BMI 
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Obese range (HR 1.76 CI 1.03, 2.88) relative to those outside of the BMI Obese 
range for adults aged ³65 years using The Cache County Study of Memory 
Health and Aging with a five year follow-up period (Hayden et al., 2006). 
Conversely, Power et al., (2011) found that the risk for dementia was not 
significantly different for those within the BMI Obese range relative to those within 
the BMI range <25.0 kg/m2 for males aged 65 to 84 years from the Health In Men 
Study with a 13.4 year follow-up period (Power et al., 2011). Similarly, Tolppanen 
et al., (2014) reported that the risk for dementia was not significantly different for 
those within the BMI Obese range relative to those within the BMI range <25.0 
kg/m2 for adults aged 65 to 79 years from the Cardiovascular risk, factors, Aging 
and Dementia study with a maximum of 10 years of follow-up (Tolppanen et al., 
2014). It is, however, difficult to compare the results presented in this chapter to 
prior analyses due to the different age compositions of the samples, model 
adjustments, statistical models, different BMI referent groups, and the length of 
follow-up.   
 
The dementia risk estimates derived for the short and long term cannot be 
compared directly to previous analyses due to a lack of published literature which 
has reported risk estimates for the age range presented in this chapter. However, 
Atti et al., (2008) used a slightly older cohort (aged ³75 years) with the BMI 
Overweight and BMI Obese ranges combined. For the whole follow-up period (0 
to 9 years) those within the BMI Overweight/Obese range had a reduced risk for 
dementia (HR 0.75 CI 0.59, 0.96) relative to those within the BMI range 20.0-24.9 
kg/m2. After excluding the first six years the dementia risks were not significantly 
different (HR 0.66 CI 0.40, 1.07), although with wide confidence intervals due to 
the limited sample size (Atti et al., 2008).    
 
6.5.2. Strengths and limitations 
My analysis has added to the limited body of literature that has assessed the 
impact of obesity on dementia risk estimates for the short and long term using a 
competing risk approach. Using the BMI range 22.5 to <25.0 as the referent group 
highlighted the increased risks for dementia for those within the lower end of the 
BMI Normal range (BMI 18.5 to <22.5 kg/m2). The conventional BMI Normal 
range is, therefore, biased with the inclusion of persons within the lower end of 
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this range. The heightened risk for dementia for those within the conventional 
BMI Normal range may have led to distortion of dementia risk estimates for higher 
BMI values for previous analyses. The sample size is much greater than those 
previously analysed (supplementary material table S1.2).   
 
There are several limitations to my analysis. As noted previously (Chapters 4 
and 5) the patients analysed in this chapter were predominately British ‘white’ 
ethnicity and, therefore, the findings may not be generally applicable to other 
ethnic groups. These results, like Chapter 5, are derived from a group of 
‘healthier agers’. This group of patients would be the main target for obesity 
prevention (Chapter 3). Risks were estimated for total dementia and, therefore, 
risks for the different subtypes (Alzheimer’s and Vascular Dementia) may differ 
to those presented in this chapter for total dementia. I was unable to adjust for 
other risk factors such as head injuries, hearing loss and there was no data 
available on dietary patterns,  early life factors, education or genetics (Kalaria et 
al., 2008; Flicker, 2010; Lin et al., 2011; Reitz and Mayeux, 2014). 
 
6.6. Conclusions 
This analysis showed that the risks for incident dementia for those within the BMI 
Obese range relative to those within the BMI 22.5 to <25.0 kg/m2 range were 
markedly altered after excluding incident dementia and deaths occurring within 
the first decade. For non-smoking ‘healthier agers’ aged 65 to 74 yeas obesity is 
associated with an increased incidence of dementia in the longer-term. 
Paradoxical risks for dementia for those within the BMI Obese range in later life 
could be due to the long preclinical phase of dementia.  
 
307	
 
Chapter 6 | Supplementary material 
 
Supplementary material for Chapter 6 
 
List of Tables for supplementary material for Chapter 6 
Table S6.1 | sub-Hazard Ratios for incident dementia for 0 to 14.9 years for 
‘healthier ages’ aged 65 to 74 years at baseline from the Clinical Research 
Practice Datalink ...................................................................................... 308	
Table S6.2 | sub-Hazard Ratios for incident dementia for 10 to 14.9 years for 
‘healthier ages’ aged 65 to 74 years at baseline from the Clinical Research 
Practice Datalink with further exclusion of those with a diagnosis of type 2 
diabetes, angina, or myocardial infarction ................................................ 309	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
308	
 
Chapter 6 | Supplementary material 
 
Table S6.1 | sub-Hazard Ratios for incident dementia for 0 to 14.9 years for 
‘healthier ages’ aged 65 to 74 years at baseline from the Clinical Research 
Practice Datalink 
BMI category Sub-Hazard 
Ratio (95% 
Confidence 
Interval)  
   BMI <18.5  1.63 (1.40, 1.91) 
   BMI   18.5 to <20.0 1.58 (1.40, 1.79) 
   BMI    20.0 to <22.5 1.31 (1.22, 1.41) 
   BMI    22.5 to <25.0 1.00 
   BMI    25.0 to <30.0 0.84 (0.80, 0.89) 
   BMI ≥ 30.0 0.78 (0.73, 0.83) 
Note: ‘Healthier agers’ were non-smokers without recent cancer (within the 
previous five years except non-melanoma skin cancer), dementia, heart failure, 
or multi-morbidity.  
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Table S6.2 | sub-Hazard Ratios for incident dementia for 10 to 14.9 years for 
‘healthier ages’ aged 65 to 74 years at baseline from the Clinical Research 
Practice Datalink with further exclusion of those with a diagnosis of type 2 
diabetes, angina, or myocardial infarction 
BMI category Sub-Hazard 
Ratio (95% 
Confidence 
Interval)  
   BMI <18.5  2.10 (1.45, 3.05) 
   BMI   18.5 to <20.0 1.27 (0.91, 1.78) 
   BMI    20.0 to <22.5 1.46 (1.23, 1.73) 
   BMI    22.5 to <25.0 1.00 
   BMI    25.0 to <30.0 1.00 (0.88 ,1.13) 
   BMI ≥ 30.0 1.16 (1.01, 1.33) 
Note: ‘Healthier agers’ were non-smokers without recent cancer (within the 
previous five years except non-melanoma skin cancer), dementia, heart failure, 
or multi-morbidity.  
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7.1. Summary 
Background: Inclusion of smokers and persons with conditions associated with 
weight loss partly explain the reduced mortality risks reported for the body mass 
index (BMI) defined Obese range in later life relative to those within the BMI 
Normal range. BMI, however, does not measure the increase in fat mass or 
redistribution of fat with ageing; this may additionally contribute to the obesity 
paradox. Measures of body fat distribution and body composition have been 
proposed as alternative measures of adiposity although the ability of these 
measures to predict mortality in later life is uncertain.  
 
Objectives: To assess BMI associations with mortality using the World Health 
Organization classification. Secondly, to compare established measures of body 
fat distribution and body composition to BMI for mortality prediction for ‘healthier 
agers’ within the seventh decade of life and to describe the concordance between 
categories of BMI and these different measures.  
 
Design: This analysis included 136,933 ‘healthier agers’ aged 60 to 69 years 
enrolled in the UK Biobank (baseline 2006-2010). ‘Healthier agers’ were non-
smokers without conditions associated with weight loss (cancer, dementia or 
heart failure) or reported weight loss and who survived the first two years of 
follow-up. BMI, body fat distribution (waist circumference [WC], waist-to-hip ratio 
[WHR] and waist-to-height ratio [WHtR]), and body composition measures (body 
fat percentage [BF%], fat mass index [FMI], fat free mass index [FFMI] and 
skeletal mass index [SMI]) were derived from baseline measures. Population and 
sex-specific tertiles were derived for each measure and Cox proportional hazard 
models were used to estimate the mortality risks. Adjustments were made for 
age, sex, alcohol intake, smoking history and education. The Akaike information 
criterion (AIC) was used to assess the best model fit for mortality.  
 
Results: A total of 3,180 participants died during the follow-up period (≤8.3 years 
of follow-up). There were increased risks for mortality for the Obese classes 
relative to those within the conventional BMI Normal range (Obese-1 range, 
Hazard Ratio 1.24 [HR] 95% Confidence Interval [CI] 1.14, 1.47). The risks for 
mortality were not significantly different for those within the BMI Overweight range 
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relative to those within the BMI Normal range. The mortality model fit was 
substantially improved (lowest AIC values) compared to the BMI model when 
tertiles of the WC, WHR and WHtR were used. There were increased mortality 
risks for those within the higher tertiles of WC (HR 1.40 CI 1.28, 1.52), WHR (HR 
1.43 CI 1.31, 1.56) and WHtR (HR 1.37 CI 1.25, 1.49) relative to those within the 
lowest tertile of each measure. The model fit for models containing body fat 
percentage or FMI were comparable to the BMI model. Models containing FFMI 
and SMI did not show any improvement on mortality prediction compared to BMI, 
achieving the highest AIC values. The concordance between tertiles of BMI and 
tertiles of FMI was high. The lowest concordance was found between tertiles of 
BMI and WHR tertiles. 
   
Conclusions: Measures of fat distribution (WC, WHR, or WHtR) for ‘healthier 
agers’ within the seventh decade of life improved mortality prediction compared 
to models containing BMI. Persons with higher adiposity (measured overall or 
centrally) are at a substantially increased risk for mortality. The lowest 
concordance was found between BMI tertiles and WHR tertiles.  
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7.2. Introduction 
Many clinical practice guidelines endorse BMI to classify persons as overweight 
or obese (Jensen et al., 2013; NICE Guidelines, 2014). It is well established that 
younger and middle aged adults with a high BMI are at an increased risk for 
premature mortality compared to those within the BMI Normal range (Calle et al., 
1999; Adams et al., 2006; Whitlock et al., 2009). However, mortality risks for the 
obese range has been shown to attenuate with advancing age (Calle et al., 1999; 
Stevens et al., 1999) and reduced risks have even been reported (Al Snih et al., 
2007). Inclusion of smokers and those with weight loss associated disease partly 
explains these findings as shown in Chapters 3, 4 and 5. BMI is unable to 
distinguish between fat and fat free mass and does not measure body fat 
distribution. As highlighted in Chapter 1, changes in body composition occur 
across the life cycle and the use of BMI for prediction of health outcomes in later 
life has, therefore, been questioned. Fat mass tends to accumulate and is 
redistributed centrally with advancing age (Zamboni et al., 2005; Miller and Wolfe, 
2008). 
 
Body fat distribution measures (abdominal adiposity) including waist 
circumference (WC), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR) 
have been proposed as alternative measures for assessing health outcomes in 
later life. Mortality risks associated with each body fat distribution measure have 
been equivocal. Increased mortality risks during a median follow-up period of 
eight years have been documented for females aged 60 to 79 years from the 
British Women’s Heart and Health Study for each standard deviation increment 
in WC, WHR, and WHtR (Taylor et al., 2010). Conversely, no significant mortality 
associations were reported for WC, WHR, and WHtR from a 22 year follow-up 
period for adults aged ³65 years enrolled in the Rotterdam Study (Dhana et al., 
2016). Similarly, no significant associations between WC or WHR categories and 
mortality have been reported for males aged ≥65 years from the Health 
Professional Follow up Study or for males aged 60 to 79 years from the British 
Regional Heart Study (Baik et al., 2000; Wannamethee et al., 2007). In contrast, 
higher levels of WC and WHR were shown to be associated with a reduced 
mortality risk relative to those within the lowest quintiles for males aged 65 to 102 
years enrolled in NHANES III over a 12 year follow-up period. There was a 
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reduced mortality risk for females within the highest WC quintile relative to those 
within the lowest quintile. No significant associations were reported for WHR and 
overall there were no significant trends for WC or WHR for the females (Reis et 
al., 2009).  
 
Likewise, body composition measures including body fat percentage (BF%), fat 
mass (FM), fat free mass (FFM), and skeletal mass (SM) have been considered 
to identify those at higher risk for adverse health outcomes. Mortality associations 
were U shaped for women aged ³67 years enrolled in the Study of Osteoporotic 
Fractures during an eight year follow-up period for lean mass (LM), FM, and BF%. 
The lowest mortality risk was for those within the third quintile of each measure. 
Body composition measures (FM, LM, BF%) were not considered superior to the 
anthropometric measures (BMI or WC) (Dolan et al., 2007). Reduced mortality 
risks for women aged 60 to 69 years enrolled in the Women’s Health Initiative 
during 13.6 years of follow-up for those within the third and fourth quintile of BF% 
and the third quintile of lean BF% have also been documented (Bea et al., 2015). 
In contrast, no associations were reported between tertile measures of BF% or 
LM with mortality for adults aged ³60 years (excluding current smokers and those 
with heart failure, cancer, kidney disease, or respiratory disease) enrolled in 
NHANES III; the tertiles used in this analysis were not sex specific (Batsis, Singh 
and Lopez-Jimenez, 2014). 
Mortality risks associated with measures of body fat distribution are unclear. 
There is a paucity of studies which have provided mortality estimates for 
measures of body composition, with some researchers suggesting that these 
may not be superior to BMI. Additionally, there has been a limited number of 
studies which have reported on mortality risks for body fat distribution measures 
and body composition measures concurrently. The UK Biobank is one of the 
largest studies to date with bio-impedance measures and abdominal adiposity 
measures. This dataset offers a unique opportunity to compare established 
measures of body fat distribution and body composition with mortality for 
‘healthier agers’ within the seventh decade of life. ‘Healthier agers’ are defined 
as non-smokers without diseases associated with weight loss (cancer, dementia 
or heart failure) or reported weight loss and survived the first two years.     
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7.3. Methods 
7.3.1. Participants 
A more detailed description of the UK Biobank was presented in Chapter 2.  Over 
500,000 volunteers across England, Wales, and Scotland were enrolled within 
the UK Biobank between 2006-2010, with most participants aged 40 to 69 years. 
The overall response rate for the UK Biobank was 5.5% (Allen et al., 2012). 
Participants aged 60 to 69 years were included in this analysis. This age group 
was chosen because paradoxical reports for the associations between BMI and 
mortality have predominately been reported for this age range and older age 
groups. Although a small number of participants were aged >69 years, these 
participants were excluded as the UK Biobank set out initially to recruit adults 
aged 40 to 69 years (UK Biobank, 2007).    
 
Participants were excluded who: (a) were missing BMI records (n = 1,299), (b) 
had a BMI in the underweight range (<18.5 kg/m2) due to the substantial 
increased mortality risk relative to the BMI Normal category (HR 2.74 CI 2.22, 
3.39 using complete cases n = 208,307 adjusted for age, sex, smoking, alcohol 
intake, and education), (c) were missing waist circumference (n =44), hip 
circumference (n = 19), whole body fat mass (n = 3,868), whole body fat free 
mass (n = 4), and impedance of whole body (n = 16), (d) were missing responses 
to smoking status, alcohol intake or educational attainment (n = 5,335), (e) were 
current smokers and/or with a previous diagnosis of cancer, dementia, or heart 
failure (n = 40,679) due to these conditions being associated with weight loss 
(see Chapter 4) and altered body fat distribution; these diagnoses were derived 
from cancer registries, hospital admissions and responses to the questionnaires 
at baseline from the participants, (f) were known to have died but missing a death 
date (n =1), (g) died within the first two years of follow up (n = 727) to minimize 
the effects of reverse causation whereby underlying diseases are associated with 
a lower BMI and increased risk of death and (h) reported at baseline that they 
had lost weight compared to the previous year or didn’t know or preferred not to 
answer (n = 25,252); weight loss has been reported to be associated with 
increased mortality risks and the degree of weight change or the intentionality of 
the weight change were not asked at baseline. The resulting group was termed 
‘healthier agers’ (n =136,933).  
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7.3.2. Exposures 
During the baseline visit, height, weight, hip circumference and waist 
circumference measures were obtained using the widest part of the hip and the 
natural indent of the waist (UK Biobank, 2014). Body mass index (BMI), waist-to-
hip ratio (WHR), and waist-to-height ratio (WHtR) were derived from the baseline 
measures. Body fat percentage, whole body fat mass, whole body fat free mass, 
and impedance of the whole body were recorded using Tanita BC418MA body 
composition analyses at baseline (see Chapter 2). Fat mass index (FMI) was 
derived from the whole-body fat mass/ height2 and the fat free mass index (FFMI) 
was derived from the whole body fat free mass / height2. Skeletal mass was 
derived using the following equation published by Janssen et al., (2000):  
 
Skeletal mass (kg) = [(Ht2/R x 0.401) + (gender x 3.825) + (age x -0.071)] 
+ 5.102 (Janssen et al., 2000) 
  
Skeletal mass index (SMI) was then derived from the skeletal mass/ height2. BMI 
was categorised by the conventional WHO thresholds. Population and sex-
specific tertiles were then derived for all exposures.  
 
7.3.3. Lifestyle and education variables 
Participants reported their alcohol intake frequency at their baseline visit with the 
following possible responses: never, one to three times per month, one to two 
times per week, three to four times per week, and daily/almost daily. Participants 
were categorised as never or former smokers. Highest educational attainment 
was defined as: none, CSEs (Certificate of Secondary Education), GCSE’s/O-
levels (General Certificate of Secondary Education/Ordinary Level taken at age 
15 to 16 years), A-levels/NVQ/HND/HNC (Advance level/ National Vocational 
Qualification/Higher National Diploma/Higher National Certificate, further 
education after age 16), professional qualification, and college or university 
degree. Participants were categorised according to their level of physical activity 
as low, moderate or vigorous. This was derived from participant responses to 
frequency and duration of walking, moderate activity, and vigorous activity using 
the validated International Physical Activity Questionnaire. Total metabolic 
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equivalent (MET) minutes of exercise per week were then derived (Craig et al., 
2003).    
 
7.3.4. Outcomes 
Death data was collected by the Health and Social Care information Centre 
(HSCIC) for English and Welsh participants, and by the Information Services 
Department (ISD) for Scottish participants. Death data was available up to the 
15th August 2015.  
 
7.3.5. Statistical analysis 
Pearson correlation coefficients were derived for BMI, body fat distribution 
measures, and body composition measures. Cox proportional hazards models 
were used for the categorical mortality analyses for each exposure. Population 
and sex specific tertiles were derived for each exposure. Spline models with 4 
knots were used to estimate non-linear associations between each continuous 
exposure and mortality. The follow-up time for the mortality risks was computed 
from the baseline visit date until date of death or until 15th August 2015 (for 
survivors). Schoenfeld residuals were used to test the proportional hazard 
models. Multivariate models were adjusted for age, gender, alcohol intake 
frequency, smoking history, and educational attainment. The Akaike Information 
Criterion (AIC) was obtained for each model, with lower AIC values generally 
indicating improved mortality model fits. Interactions between BMI, the body fat 
distribution measures, and body composition measures, with age (60 to 64 years 
and 65 to 69 years), gender, smoking history, and physical activity were 
evaluated. Analyses were carried out using Stata statistical software (version 
14.1) and R (version 3.1.2).  
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7.4. Results 
7.4.1. Baseline characteristics 
Table 7.1 shows the baseline characteristics of the 136,933 ‘healthier agers’ 
included in this analysis. Persons with a BMI <18.5 kg/m2 were excluded from 
this analysis due to the high mortality risk for this group. The mean age of the 
male participants was 64.1 years (SD 2.8 years) and the mean age of the female 
participants was 63.9 years (SD 2.8 years). The proportion of never smokers 
relative to previous smokers was higher for the female participants (62.1%) 
compared to the male participants (47.4%). The mean BMI was in the Overweight 
range for both males (BMI 27.9 kg/m2 SD 4.0 kg/m2) and females (BMI 27.3 kg/m2 
SD 4.8 kg/m2). The population and sex-specific tertiles for BMI, WC, WHR, WHtR, 
BF%, FMI, FFMI, and SMI are presented in Tables 7.2 and 7.3.   
 
7.4.2. Associations with mortality 
During the follow-up (≤8.3 years) 3,180 participants died. Using the World Health 
Organization categories, there was an increased risk for mortality for those within 
the BMI Obese range (Obese-1 HR 1.25 95% CI 1.14, 1.47, Obese-2 HR 1.42 CI 
1.24, 1.64, Obese-3 HR 2.17 95% CI 1.78, 2.63) relative to those within the 
conventional BMI Normal range (Table 7.4). Those within the BMI Overweight 
range were not significantly different to those within the BMI Normal range for 
mortality.    
 
Figure 7.1 shows the association between the tertiles of BMI and mortality with 
adjustments for age, sex, smoking history, alcohol intake, and education 
attainment, and the AIC model fit. The BMI tertile ranges can be found in Table 
7.2. Supplementary material Table S7.1 shows the number of deaths per BMI 
tertile.  There were increased mortality risks (HR 1.28 95% CI 1.17, 1.39) for 
those within the higher BMI tertiles relative to those within the lower tertile.  The 
AIC for the BMI model was 72937.  
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Table 7.1 | Baseline characteristics of the ‘healthier agers’ aged 60 to 69 years 
(n = 136,933) from the UK Biobank 
Variable Males  
(64,607) 
Females 
(72,326) 
Age years, mean (SD) 64.1 (2.8) 63.9 (2.8) 
BMI mean (SD) 27.9 (4.0)  27.3 (4.8) 
Waist circumference mean (SD) 97.8 (10.9)  85.8 (11.9) 
Waist-to-hip ratio (WHR) mean (SD) 0.94 (0.06) 0.83 (0.07) 
Waist-to-height ratio (WHtR) mean (SD)  0.56 (0.06)  0.53 (0.08) 
Body fat percentage mean (SD) 26.2 (5.5) 37.7 (6.2) 
Fat mass index (FMI) mean (SD)  7.5 (2.6)  10.6 (3.5) 
Fat free mass index (FFMI) mean (SD) 20.4 (1.8) 16.8 (1.6) 
Skeletal mass index (SMI) mean (SD) 9.0 (0.9) 6.5 (0.9) 
Alcohol intake frequency, n (%)   
    Never 3,566 (5.5) 7,229 (10.0) 
    Special occasions only 4,382 (6.8) 11,074 (15.3) 
    One to three times a month 4,744 (7.3) 8,546 (11.8) 
    Once or twice a week 15,284 (23.7) 17,606 (24.3) 
    Three of four times a week 17,239 (26.7) 14,490 (20.0) 
    Daily or almost daily 19,392 (30.0) 13,381 (18.5) 
Smoking status, n (%)   
    Never 30,598 (47.4) 44,892 (62.1) 
    Previous 34,009 (52.6) 27,434 (37.9) 
Education, n (%)   
    None 16,000 (24.8) 19,507 (27.0) 
    CSEs 884 (1.4) 1,610 (2.2) 
    GCSEs/O-levels 6,604 (10.2) 12,987 (18.0) 
    A-levels/NVQ/HND/HNC 11,691 (18.1) 8,683 (12.0) 
    Professional Qualification 9,737 (15.1) 12,129 (16.8) 
    College of University degree 19,691 (30.5) 17,410 (24.1) 
Diagnosed disease at baseline, n (%)   
    Coronary Heart Disease 7,541 (11.7) 3,432 (4.8) 
    Type 2 Diabetes 5,322 (8.2) 2,957 (4.1) 
Follow-up years, mean (SD) 6.4 (0.9) 6.5 (0.9) 
Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, or heart failure and survived the first 1.9 years. 
Persons with a BMI <18.5 kg/m2 were excluded.  WHR: waist-to-hip, WHtR: 
waist-to-height, FMI: fat mass index, FFMI: fat free mass index, SMI: skeletal 
mass index.  
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Table 7.4 | Hazard ratios for mortality by BMI category ‘healthier agers’ aged 60 
to 69 years (n = 136,933) from the UK Biobank 
BMI Category HR (95% CI) 
Normal weight 
18.5 to <25.0 
1.00 
Overweight 
25.0 to <30.0 
1.08 (0.99, 1.17) 
Obese-1 
30.0 to <35.0 
1.25 (1.14, 1.37) 
Obese-2  
35.0 to <40.0 
1.42 (1.24, 1.64) 
Obese-3 
≥40.0  
2.17 (1.78, 2.63) 
Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, or heart failure and survived the first 1.9 years. 
Persons with a BMI <18.5 kg/m2 were excluded.   
 
Figure 7.1 | Association of BMI tertiles with mortality and the AIC model fit for 
‘healthier agers’ aged 60 to 69 years (n =136,933) from the UK Biobank 
 
 
Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years. 
Cox proportional hazards models were adjusted for age, sex, alcohol intake, 
smoking history, and education. BMI tertiles were population and sex specific. 
For males, the BMI tertiles were lower 18.56-25.91, intermediate >25.91-28.97, 
and higher >28.97kg/m2. For females, the BMI tertiles were lower 18.50-24.81, 
intermediate >24.81-28.56, and higher >28.56 kg/m2. Persons with a BMI <18.5 
kg/m2 were excluded. 
Measure	(AIC) HR [95% CI] 
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The body fat distribution measures were divided into population and sex specific 
tertiles. An overview of the WC, WHR, and WHtR tertiles can be found in Table 
7.2. Supplementary material Table S7.1 shows the number of deaths per WC, 
WHR and WHtR tertile. Figure 7.2 displays the association between tertiles of 
WC, WHR, and WHtR and mortality, and the AIC model fit. There was an 
increased mortality risk for those within the higher tertile of WC (HR 1.40 CI 1.28, 
1.52), WHR (HR 1.43 CI 1.31, 1.56), and WHtR (HR 1.37 CI 1.25, 1.49) relative 
to those within the lower tertiles of each measure. All three models showed a 
substantial improvement in the mortality model fit relative to the BMI model. The 
lowest AIC value was achieved for the WHR model; however, all the body fat 
distribution measures were comparable (AIC values within 10).  
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Figure 7.2 | Association of WC, WHR, and WHtR tertiles with mortality and the 
AIC model fit for ‘healthier agers’ aged 60 to 69 years (n = 136,933) from the UK 
Biobank 
 
 
Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years. 
Cox proportional hazards models were adjusted for age, sex, alcohol intake, 
smoking history, and education. Waist circumference, WHR, and WHtR tertiles 
were population and sex specific. For males, the tertiles for waist circumference 
were lower 60.0-93.0, intermediate >93.0-101.0, and higher >101.1 cm. For 
females, the tertiles for waist circumference were lower 52.0- 80.0, intermediate 
>80.0-90.0, and higher >90.1cm. For males, the tertiles for WHR were lower 0.59-
0.92, intermediate >0.92- 0.97, and higher >0.97. For females, the tertiles for 
WHR were lower 0.50-0.79, intermediate >0.79-0.85, and higher >0.85. For 
males, the tertiles for WHtR were lower 0.34-0.53, intermediate >0.53-0.58, and 
higher >0.58. For females, the tertiles for WHtR were lower 0.35-0.49, 
intermediate >0.49-0.56, and higher >0.56. WHR: waist-to-hip ratio, WHtR: waist-
to-height ratio. Persons with a BMI <18.5 kg/m2 were excluded.   
Measure	(AIC) HR [95% CI] 
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The body composition measures (BF%, FMI, FFMI, and SMI) were divided into 
population and sex specific tertiles with the corresponding ranges presented in Table 
7.3. Supplementary Table S7.1 shows the number of deaths per BF%, FMI, FFMI and 
SMI tertiles. Figure 7.3 displays the association between tertiles of BF%, FMI, FFMI, 
and SMI with mortality and the AIC model fit. There was an increased mortality risk for 
those within the higher tertile of body fat percentage (HR 1.30 CI 1.19, 1.42), FMI (HR 
1.29 CI 1.18, 1.41), and FFMI (HR 1.15, CI 1.06, 1.25) relative to those within the 
lower tertiles of each measure. There were no significant mortality associations for the 
tertiles of SMI. The mortality model fit using models containing body fat percentage or 
FFMI were comparable to the BMI model (AIC values within 10 units). The mortality 
model fit using FFMI and SMI showed no improvement compared to the model 
containing BMI.  
 
A further analysis was conducted for the SMI tertiles after adjusting for the WHO BMI 
categories. This was due to a positive association between BMI and SMI (Table 7.5). 
This, analysis revealed there was a reduced mortality risk for those within the 
intermediate and higher SMI tertiles compared to those within the lower SMI tertile. 
The AIC was 72907, which was comparable to the model fits for WC, WHR, and WHtR.          
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Figure 7.3 | Association of BF%, FMI, FFMI, and SMI tertiles with mortality and the 
AIC model fit for ‘healthier agers’ aged 60 to 69 years (n =136,933) from the UK 
Biobank 
 
 
 
 
Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years. Cox 
proportional hazards models were adjusted for age, sex, alcohol intake, smoking 
history, and education. BF %, FMI, FFMI and SMI tertiles were population and sex 
specific. For males, the BF % tertiles were lower 6.9-24.0, intermediate >24.0-28.6, 
and higher >28.6%. For females, the BF % tertiles were lower 10.7-35.1, intermediate 
>35.1-40.5, and higher >40.5%. For males, the FMI tertiles were lower 1.46-6.26, 
intermediate >6.26-8.20, and higher >8.20. For females, the FMI tertiles were lower 
2.03-8.74, intermediate >8.74-11.52, and higher >11.52. For males, the FFMI tertiles 
were lower 13.58-19.52, intermediate >19.52-21.00, and higher >21.00. For females, 
the FFMI tertiles were lower 11.39-15.98, intermediate >15.98-17.25, and higher 
>17.25. For males, the SMI tertiles were lower 5.53-8.65, intermediate >8.65- 9.33, 
and higher >9.33. For females, the SMI tertiles were lower 4.18-6.10, intermediate 
>6.10-6.67, and higher >6.67. BF %: body fat percentage, FMI: fat mass index, FFMI: 
fat free mass index, SMI: skeletal mass index. Persons with a BMI <18.5 kg/m2 were 
excluded.   
     
 
                       
Measure	(AIC)	 HR [95% CI]	
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Table 7.5 | Hazard ratios for mortality by SMI tertiles with adjustment for BMI for 
‘healthier agers’ aged 60 to 69 years (n = 136,933) from the UK Biobank 
SMI tertiles adjusted for 
BMI category  
HR (95% CI) 
Lower SMI tertile 1.00 
Intermediate SMI tertile 0.87 (0.79, 0.95) 
Higher SMI tertile 0.89 (0.80, 0.98) 
 
Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years. Cox 
proportional hazards models were adjusted for age, sex, alcohol intake, smoking 
history, and education. SMI tertiles were population and sex specific. For males, the 
SMI tertiles were lower 5.53-8.65, intermediate >8.65- 9.33, and higher >9.33. For 
females, the SMI tertiles were lower 4.18-6.10, intermediate >6.10-6.67, and higher 
>6.67. SMI: skeletal mass index. Persons with a BMI <18.5 kg/m2 were excluded. BMI 
was categorised according to the World Health Organization.                              
 
 
7.4.3. Interactions  
There were no significant interactions between gender, age (60 to 64 years and 65 to 
69 years), or physical activity (data available for n = 125,873) and BMI, the body fat 
distribution measures, or body composition measures. There was a significant 
interaction between SMI tertiles and smoking history. Table 7.6 shows the hazard 
ratios for mortality stratified by smoking history. The mortality risk for those within the 
higher SMI tertile was increased for never smokers, and not significantly different for 
former smokers, relative to those within the lower tertile for never smokers and former 
smokers, respectively. The mortality risk for those within the intermediate SMI tertile 
was not significantly different for never smokers, whereas there was a reduced risk for 
former smokers relative to those within the lower tertile for never smokers and former 
smokers, respectively.   
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Table 7.6 | Hazard ratios (95% CI) for mortality by SMI tertiles for ‘healthier agers’ 
aged 60 to 69 years (n =136,933) stratified by smoking history using the UK Biobank 
SMI tertiles  Never smokers a Former smokers a 
Lower SMI tertile 458/25999 
1.00 
621/19648 
1.00 
Intermediate SMI tertile 454/25144 
1.07 (0.94 to 1.22) 
510/20503 
0.82 (0.73 to 0.92) 
Higher SMI tertile 484/24347 
1.19 (1.05 to 1.36) 
653/21292 
0.99 (0.89 to 1.11) 
a Cell contents: events/number, HR (95% CI) 
Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years. Cox 
proportional hazards models were adjusted for age, sex, alcohol intake, smoking 
history, and education. SMI tertiles were population and sex specific. For males, the 
SMI tertiles were lower 5.53-8.65, intermediate >8.65- 9.33, and higher >9.33. For 
females, the SMI tertiles were lower 4.18-6.10, intermediate >6.10-6.67, and higher 
>6.67. SMI: skeletal mass index. Persons with a BMI <18.5 kg/m2 were excluded.                             
 
7.4.4. Adjustment for physical activity  
Mortality risk estimates were little changed with further adjustment for physical activity 
where available (Table 7.5 and 7.6).  
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7.4.5. Continuous measures  
The associations between the continuous measures of BMI, WC, WHR, WHtR, BF%, 
FMI, FFMI, SMI and mortality were estimated.  Figures 7.4 and 7.5 show these 
associations for males and females separately. For males, there were positive 
associations with mortality for BMI, WC, WHR, WHtR, and FMI. For males ≥25th 
percentile of BF%, there was also a positive association. A similar pattern presented 
for the females with an attenuation of the mortality risks and gradients for these 
measures. There was no association between FFMI and SMI, apart from extreme 
upper values showing an increased mortality risk for the males. There was also no 
association between FFMI and SMI and mortality was for the females.  
 
7.4.6. Correlations between measures   
Correlations between BMI, measures of body fat distribution and body composition 
are presented in Table 7.9 (see supplementary material figures S7.1 and S7.2 for the 
correlations between BMI and the other measures). There were strong correlations 
between BMI and WC, WHtR, FMI, FFMI, and body fat percentage (for males this 
ranged from 0.79 to 0.93; females this ranged from 0.84 to 0.97). Modest correlations 
were found between BMI and WHR (males 0.59; females 0.44), and SMI (males 0.62; 
females 0.49). SMI exhibited modest to weak correlations with all variables except 
FFMI in males (0.89).    
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Figure 7.4 | Spline point estimates for male ‘healthier agers’ aged 60 to 69 years (n = 
64,607) from the UK Biobank for BMI (A), WC (B), WHR (C), WHtR (D), BF% (E), FMI 
(F), FFMI (G), and SMI (H) 
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Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years. 
Models were adjusted for age, sex, alcohol intake, smoking history, and education 
WC: waist circumference, WHR: waist-to-hip ratio; WHtR: waist-to-height ratio; BF%: 
body fat percentage; FMI: fat mass index; FFMI: fat free mass index; SMI: skeletal 
mass index. Persons with a BMI <18.5 kg/m2 were excluded. 
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Figure 7.5 | Spline point estimates for female ‘healthier agers’ aged 60 to 69 years (n 
= 72,326) from the UK Biobank for BMI (A), WC (B), WHR (C), WHtR (D), BF% (E), 
FMI (F), FFMI (G), and SMI (H) 
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Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years. 
Models were adjusted for age, sex, alcohol intake, smoking history, and education 
WC: waist circumference, WHR: waist-to-hip ratio; WHtR: waist-to-height ratio; BF%: 
body fat percentage; FMI: fat mass index; FFMI: fat free mass index; SMI: skeletal 
mass index. Persons with a BMI <18.5 kg/m2 were excluded. 
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7.4.7. Concordance agreement between tertile measures 
Figure 7.6 (A to G) shows the concordance between tertiles of BMI with tertiles of WC, 
WHR, WHtR, BF%, FMI, FFMI, and SMI (see Tables 7.2 and 7.3 for the tertile ranges). 
Concordance refers to persons being within the same tertile measure for each 
comparison, for example in both BMI lower tertile and WHtR lower tertile. Overall, the 
highest concordance was found between BMI tertiles and the FMI tertiles. Specifically, 
for the lower BMI tertile the lowest concordance was found for the SMI lower tertile 
(58.8%). For the intermediate and higher BMI tertiles the lowest concordance was 
found for the WHR intermediate and higher tertiles, respectively (40.0% for the 
intermediate tertile and 57.9% for the higher tertile). For most measures, there was 
high concordance for those within the lower and higher tertiles of BMI and the 
corresponding lower/higher tertiles of the other measures, respectively. The 
concordance of the other measures varied within the intermediate BMI tertile, except 
for FMI which showed high concordance. 
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Figure 7.6 | Concordance between BMI tertiles and WC (A), WHR (B), WHtR (C), 
BF% (D), FMI (E), FFMI (F) and SMI (G) tertiles for ‘healthier agers’ aged 60 to 69 
years (n = 136,933) from the UK Biobank 
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Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure & survived the first 1.9 years. 
Population & sex specific tertiles were derived for each measure. For males, the BMI 
tertiles were lower 18.56-25.91, intermediate >25.91-28.97 & higher >28.97. For 
females, the BMI tertiles were lower 18.50-24.81, intermediate >24.81-28.56 & higher 
>28.56 kg/m2. For males, the tertiles for waist circumference were lower 60.0-93.0, 
intermediate >93.0-101.0 & higher >101.1 cm. For females, the tertiles for waist 
circumference were lower 52.0-80.0, intermediate >80.0-90.0 & higher >90.1cm. For 
males, the tertiles for WHR were lower 0.59-0.92, intermediate >0.92-0.97 & higher 
>0.97. For females, the tertiles for WHR were lower 0.50-0.79, intermediate >0.79-
0.85 & higher >0.85. For males, the tertiles for WHtR were lower 0.34-0.53, 
intermediate >0.53-0.58 & higher >0.58. For females, the tertiles for WHtR were lower 
0.35-0.49, intermediate >0.49-0.56 & higher >0.56. For males, the BF % tertiles were 
lower 6.9-24.0, intermediate >24.0-28.6 & higher >28.6%. For females, the BF % 
tertiles were lower 10.7-35.1, intermediate >35.1-40.5 & higher >40.5%. For males, 
the FMI tertiles were lower 1.46-6.26, intermediate >6.26-8.20 & higher >8.20. For 
females, the FMI tertiles were lower 2.03-8.74, intermediate >8.74-11.52 & higher 
>11.52. For males, the FFMI tertiles were lower 13.58-19.52, intermediate >19.52-
21.00 & higher >21.00. For females, the FFMI tertiles were lower 11.39-15.98, 
intermediate >15.98-17.25 & higher >17.25. For males, the SMI tertiles were lower 
5.53-8.65, intermediate >8.65-9.33 & higher >9.33. For females, the SMI tertiles were 
lower 4.18-6.10, intermediate >6.10-6.67 & higher >6.67. WHR: waist-to-hip ratio, 
WHtR: waist-to-height ratio, BF %: body fat percentage, FMI: fat mass index, FFMI: 
fat free mass index, SMI: skeletal mass index. Persons with a BMI <18.5 kg/m2 were 
excluded. 
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7.5. Discussion 
I aimed to compare established measures of body fat distribution and body 
composition to BMI for mortality prediction for ‘healthier agers’ within the seventh 
decade of life and to describe the concordance between categories of BMI and these 
alternative measures. The findings I presented in this chapter showed that the 
mortality model fit was substantially improved when tertile measures of body fat 
distribution (WC, WHR, WHtR) were used compared to a model using BMI tertiles. 
The lowest AIC value was achieved for the model containing WHR tertiles. Overall, 
the results showed that ‘healthier agers’, after excluding underweight participants, 
within the higher tertile of adiposity whether measured overall or centrally were at 
increased risks of mortality relative to those within the lower tertiles. No significant 
associations were found for tertiles of SMI. However, after accounting for BMI, there 
were reduced mortality risks for those within the intermediate and higher tertiles of SMI 
compared to the lower tertile. Modest correlations were found between BMI and WHR, 
and SMI. The concordance (i.e. a person being in both the BMI lower tertile and WHtR 
lower tertile) was high between BMI tertiles and FMI tertiles. The lowest concordance 
was found between BMI tertiles and WHR tertiles for those within the intermediate or 
higher tertiles. The lowest concordance for the lower BMI tertile out of all the measures 
was with the SMI tertiles. The intermediate tertile of BMI, which corresponded to 
values within the BMI Overweight range, showed that the proportions of the different 
measures were variable.  
 
7.5.1. Comparison to Chapter 4 
In Chapter 4 I showed for ‘healthier agers’ aged 60 to 64 years and 65 to 69 years 
there were increased mortality risks for those within the BMI Obese ranges relative to 
those within the conventional BMI Normal range using electronic health records. In 
this chapter, I also confirmed for ‘healthier agers’ aged 60 to 69 years from a large 
volunteer cohort that there were increased mortality risks for those within the BMI 
Obese ranges compared to those within the conventional BMI Normal range for those 
aged 60 to 69 years. The point estimates derived from the 60 to 64 year olds from the 
electronic health records were larger for the BMI Obese-2 and Obese-3 ranges, 
however, the confidence intervals overlap between the two datasets. In Chapter 4 I 
showed that the mortality risks were not statistically different for those within the BMI 
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Overweight range compared to those within the BMI Normal range. In this chapter I 
also document that those within the BMI Overweight range are not significantly 
different to those within the BMI Normal range.   
 
7.5.2. Comparison to Chapter 5 
In Chapter 5 I showed that there were elevated mortality risks for those within the 
lower end of the conventional BMI Normal range for all age groups. The analysis 
presented in this chapter did not find a substantial excess mortality for those within the 
lower end of the conventional BMI Normal range, as shown in the continuous BMI 
association with mortality. This may be due to the use of a volunteer cohort study and 
the different age composition.   
 
7.5.3. Comparison to previous literature 
The results presented in this chapter for the tertiles of WC and WHR tertiles contrast 
with a previous analysis which also divided the body fat distribution measures into 
tertiles. Batsis, et al., (2014) reported the mortality risks for those within the higher 
tertiles of WC or WHR  were not significantly different to those within the lower tertiles 
for adults aged ³60 years (excluding current smokers and those with heart failure, 
cancer, kidney disease, or respiratory disease) enrolled in NHANES III during a mean 
follow-up period of 11.8 years (Batsis, Singh and Lopez-Jimenez, 2014). This could 
be due to the different cut points for the body fat distribution measures, exclusions, 
model adjustments, and the different age composition. The NHANES III study used a 
much broader age range. Inclusion of the youngest and oldest old may have distorted 
the mortality risks for the NHANES III study (Chapter 1). Similarly, the results 
presented in this chapter for body fat percentage are also in discordance to those 
presented by Batsis, et al., (2014) where non-significant mortality risks were 
presented.    
 
Previous analyses have shown non-significant mortality risks  (Baik et al., 2000; 
Wannamethee et al., 2007), or reduced mortality risks (Reis et al., 2009) for measures 
of central adiposity. Reduced mortality risks for women within the middle distribution 
of body fat percentage has also been documented (Dolan et al., 2007; Bea et al., 
2015) which was not observed in this chapter. However, there are challenges 
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comparing my results with prior analyses due to differing categories of body fat 
distribution and body composition measures, age composition, and exclusions. 
7.5.4. Strengths and limitations 
In this chapter I compared established measures of body fat distribution (WC, WHR, 
and WHtR) and body composition (BF %, FMI, FFMI, and SMI) to BMI in their ability 
to predict mortality for ‘healthier agers’ within the seventh decade of life. This is one of 
the largest studies which has concurrently estimated the association for mortality for 
surrogate measures of adiposity, and body composition measures derived from bio-
impedance. This work, therefore, adds further evidence to this limited research area 
on the mortality risks associated with measures of body fat distribution and body 
composition measures. The concordance between tertile measures was also 
presented, highlighting the variability of the proportions of different measures within 
the intermediate tertile of BMI, which corresponded to values within the BMI 
Overweight range.     
 
There are several limitations with this analysis. One limitation of this analysis was that 
the outcome addressed was all-cause mortality. Risk estimates may differ for other 
health outcomes for the range of measures assessed in this chapter. This chapter 
focused on ‘healthier agers’ aged 60 to 69 years, therefore, the results may not be 
generally applicable to those younger or older than this age range. The participants 
included were predominately white British ethnicity and the results therefore may not 
be generalisable to wholly non-Caucasian populations. This analysis used sex-specific 
tertiles to enable comparisons between BMI, body fat distribution measures, and body 
composition measures rather than pre-defined thresholds.  
 
Further work is needed to clarify the associations between measures of body fat 
distribution and body composition with other health outcomes. In this chapter I focused 
on comparing individual measures with mortality. Mortality risks may be improved by 
combining measures. In Chapter 8 I use the UK Biobank to estimate associations 
between combined measures of BMI and waist-to-hip ratio (WHR) with mortality and 
incident coronary heart disease (CHD) for ‘healthier agers’ aged 60 to 69 years. This 
combination was chosen as BMI is one of the most widely used measures in clinical 
practice. Models with WHR tertiles achieved the lowest AIC values.    
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7.5.5. Conclusions 
For ‘healthier agers’ within the seventh decade of life measures of fat distribution (WC, 
WHR, and WHtR) improved mortality prediction compared to models containing BMI. 
Persons with higher adiposity (measured overall or centrally) are at a substantially 
increased risk for mortality. The lowest concordance was found between tertiles of 
BMI and WHR tertiles 
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Table S7.1 Number of deaths per tertile of BMI, fat distribution measures, and 
body composition measures for ‘healthier agers’ aged 60 to 69 years from the UK 
Biobank 
Measure Tertile 1 Tertile 2 Tertile 3 
BMI 889/45660 1008/45638 1273/45655 
Waist 
circumference 
938/49620 937/43389 1305/43924 
Waist-to-hip ratio 841/45852 1018/45650 1321/45431 
Waist-to-height 
ratio 
853/45764 976/45568 1351/45601 
Body fat 
percentage 
887/45838 986/45835 1307/45260 
Fat Mass Index 890/45660 980/45644 1310/45629 
Fat Free Mass 
Index 
992/45678 1003/45656 1185/45599 
Skeletal Mass 
Index 
1979/45647 964/45647 1127/45639 
Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years. 
Persons with a BMI <18.5 kg/m2 were excluded. 
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Figure S7.1 | Distribution of waist, waist-to-hip, waist-to-height, body fat 
percentage, fat mass index, fat free mass index, and skeletal mass index against 
BMI for male ‘healthier agers’ from the UK Biobank 
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Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-melanoma 
skin cancer), dementia, heart failure and survived the first 1.9 years. Models were 
adjusted for age, sex, alcohol intake, smoking history, and education WHR: waist-to-hip 
ratio; WHtR: waist-to-height ratio; BF%: body fat percentage; FMI: fat mass index; FFMI: 
fat free mass index; SMI: skeletal mass index. Persons with a BMI <18.5 kg/m2 were 
excluded. 
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Figure S7.2 | Distribution of waist, waist-to-hip, waist-to-height, body fat 
percentage, fat mass index, fat free mass index, and skeletal mass index against 
BMI for female ‘healthier agers’ from the UK Biobank 
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Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years. 
Models were adjusted for age, sex, alcohol intake, smoking history, and 
education WHR: waist-to-hip ratio; WHtR: waist-to-height ratio; BF%: body fat 
percentage; FMI: fat mass index; FFMI: fat free mass index; SMI: skeletal mass 
index. Persons with a BMI <18.5 kg/m2 were excluded. 
 
 
 
 
 
 
 
 
356	
 
Chapter 7 | Supplementary material 
 
 
357	
 
Chapter 8 | UK Biobank combined measures 
Chapter 8 – Joint associations of BMI and central adiposity 
measures for mortality and coronary heart disease: follow-
up of 130,473 UK Biobank participants  
 
Table of Contents 
Chapter 8 – Joint associations of BMI and central adiposity measures for 
mortality and coronary heart disease: follow-up of 130,473 UK Biobank 
participants .................................................................................................... 357 
8.1. Overview of the chapter ..................................................................... 359 
8.2. Summary ............................................................................................. 360 
8.3. Introduction ......................................................................................... 362 
8.4. Methods ............................................................................................... 365 
8.4.1. Participants .................................................................................. 365 
8.4.2. Exposures .................................................................................... 366 
8.4.3. Lifestyle factors, educational attainment, and ethnicity .......... 367 
8.4.4. Outcomes ..................................................................................... 367 
8.4.5. Statistical analysis ...................................................................... 367 
8.5. Results ................................................................................................. 368 
8.5.1. Baseline characteristics ............................................................. 368 
8.5.2. Mortality ........................................................................................ 370 
8.5.3. Combined associations of BMI categories and WHR tertiles with 
mortality ...................................................................................................... 371 
8.5.4. Interactions .................................................................................. 373 
8.5.5. Coronary heart disease .............................................................. 373 
8.5.6. Sensitivity analyses .................................................................... 373 
8.6. Discussion........................................................................................... 379 
8.6.1. Comparison to previous literature ............................................. 379 
8.6.2. Strengths and limitations ........................................................... 380 
8.6.3. Future work .................................................................................. 381 
8.7. Conclusions ........................................................................................ 382 
 
 
 
 
 
 
358	
 
Chapter 8 | UK Biobank combined measures 
List of Tables  
Table 8.1 | Baseline characteristics of the ‘healthier agers’ aged 60 to 69 years 
(n = 130,473) from the UK Biobank .......................................................... 369	
Table 8.2 | Joint association of the BMI categories and WHR tertiles with mortality 
using age as the time scale for ‘healthier agers’ aged 60 to 69 years (n = 
130,473) from the UK Biobank ................................................................. 374	
Table 8.3 | Joint association of the BMI categories with binary WHR cut points 
and higher threshold WHR cut points with mortality for ‘healthier agers’ aged 
60 to 69 years (n = 130,473) from the UK Biobank .................................. 376	
Table 8.4 | Joint associations of the BMI categories and WHR tertiles with 
mortality for ‘healthier agers’ identifying as ‘white’ British aged 60 to 69 years 
(n = 120,151) from the UK Biobank .......................................................... 377	
Table 8.5 | Joint associations of the BMI categories and WHR tertiles with 
mortality for ‘healthier agers’ aged 60 to 69 years who responded that their 
weight was the same as one year previously i.e. weight stable (n = 93,764) 
using the UK Biobank ............................................................................... 378	
 
List of Figures 
Figure 8.1 | Hazard and sub-Hazard ratios for mortality (A) and coronary heart 
disease (B) for combined BMI categories and waist-to-hip tertiles for 
‘healthier agers’ aged 60 to 69 years from the UK Biobank (n = 130,473)
 ................................................................................................................. 372	
 
 
 
 
 
 
 
 
 
 
 
359	
 
Chapter 8 | UK Biobank combined measures 
8.1. Overview of the chapter 
 
This chapter is based predominately on a published manuscript. 
 
Bowman, K., Atkins, J.L., Delgado, J., Kos, K., Kuchel, G.A., Ble, A., 
Ferrucci, L., & Melzer, D. (2017) Central adiposity and the overweight 
risk paradox in aging:  follow-up of 130,473 UK Biobank participants. 
AJCN.  06(1):130-135.  
 
My contribution to this manuscript included conducting the literature review, 
designing and conducting the analyses, and writing the manuscript. Therefore, 
much of this chapter is a direct translation from this paper. Some sentences have 
been modified to make them clearer. The terms used for describing the BMI 
categories and groups have also been altered to be consistent throughout this 
thesis. Additional sections have been added to the introduction and discussion to 
emphasise the links throughout this thesis. 
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8.2. Summary  
Background: In later life (aged ≥65 years), persons within the body mass index 
(BMI) defined Overweight range (25.0-29.9 kg/m2) have been reported to have 
reduced or similar mortality risks to those within the conventional BMI Normal 
range (18.5-24.9 kg/m2). However, this paradox for mortality is partly explained 
by the inclusion of smokers and those with conditions associated with weight loss. 
The paradox may also arise from BMI failing to measure fat redistribution to a 
centralized position in later life. Combining BMI with abdominal adiposity 
measures may more accurately identify those at higher risks for adverse health 
outcomes. 
 
Objective: To estimate associations between combined measures of BMI and 
waist-to-hip ratio (WHR) with mortality and incident coronary heart disease 
(CHD).  
 
Design: This analysis included 130,473 ‘healthier agers’ aged 60 to 69 years 
enrolled in the UK Biobank (baseline 2006-2010) with a BMI in the range 18.5-
34.9 kg/m2. ‘Healthier agers’ were non-smokers without conditions associated 
with weight loss or reported weight loss and who survived the first two years of 
follow-up. Population and sex specific WHR tertiles were derived from baseline 
measures. For men, these were ‘lower’ <0.91 and ‘higher’ ≥0.96, and for women 
these were ‘lower’ <0.79 and ‘higher’ ≥0.85. Cox proportional hazards and 
competing risks models were adjusted for age, sex, alcohol intake, smoking 
history and education.     
  
Results: Ignoring WHR, those within the BMI Overweight range had similar 
mortality risks relative to those within the BMI Normal range (Hazard ratio [HR] 
1.09 95% Confidence Interval [CI] 0.99, 1.19, p=0.066). However, those within 
the BMI Normal range plus higher WHR tertile had an increased mortality risk 
(HR 1.33 CI 1.08, 1.65) relative to the referent group, consisting of those within 
the BMI Normal range plus lower WHR tertile. Those within the BMI Overweight 
range plus higher WHR tertile had increased mortality risks (HR 1.41 CI 1.25, 
1.61) relative to the referent group, with increased risks for incident CHD (Sub 
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HR [SHR] 1.64 CI 1.39, 1.93). There was no interaction for mortality between 
physical activity and the combined BMI and WHR groups.  
 
Conclusions: For healthier agers (i.e. non-smokers, without conditions 
associated with weight loss) being within the BMI Normal or BMI Overweight 
range but also having central adiposity is associated with substantial excess 
mortality. The claimed BMI Overweight risk paradox may in part result from failing 
to account for central adiposity, rather than reflecting a protective physiological 
effect of higher body fat content in later life.   
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8.3. Introduction 
The prevalence of body mass index (BMI) defined Overweight (25.0-29.9 kg/m2) 
and Obesity (≥30.0 kg/m2) in adults has increased dramatically since 1980, with 
an estimated 2.1 billion adults affected globally in 2013 (Ng et al., 2014). Younger 
and middle aged adults within the BMI Overweight or BMI Obese-1 (30.0-34.9 
kg/m2) ranges have substantially increased mortality risks, relative to those within 
the conventional BMI Normal range (18.5-24.9 kg/m2) (Whitlock et al., 2009; 
Berrington de Gonzalez et al., 2010). However, paradoxical associations for 
those within the BMI Overweight and BMI Obese-1 ranges have been reported 
in adults ≥65 years; several meta-analyses and cohort studies showed that the 
BMI Overweight range was associated with reduced (Flegal et al., 2013; Winter 
et al., 2014) or similar mortality risks (Janssen and Mark, 2007; Pischon et al., 
2008; Bea et al., 2015) to those within the BMI Normal range. Some researchers 
have claimed that this paradox may reflect a protective physiological effect of 
slightly higher BMI (Dixon et al., 2015) and challenged the idea that conventional 
BMI thresholds should be used in older persons (Janssen and Mark, 2007; Flicker 
et al., 2010; Dixon et al., 2015; Peter et al., 2015) arguing that this paradox 
justifies a major revision of the current scientific consensus on the health dangers 
of being Overweight. Others have claimed that public health researchers ‘would 
rather not talk about’ studies that show that being Overweight does not always 
shorten life  (Hughes, 2013).  
 
In Chapters 4 and 5 I presented analyses of 955,000 population representative 
primary care patients and showed that paradoxical BMI Overweight and BMI 
Obese-1 mortality risks for adults aged 60 to 84 years were partly explained by 
the inclusion of smokers and patients with conditions associated with weight loss. 
The inclusion of this population can result in confounding, in which certain 
disease processes that carry higher risk of death also cause weight loss. This 
weight loss can occur even before diagnoses are made and can thereby distort 
risk estimates. In ‘healthier agers’ (non-smokers without conditions associated 
with weight loss), BMI Obese-1 was associated with excess mortality and 
coronary heart disease (CHD), i.e. the BMI Obesity risk paradox reversed.  
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A further possible bias in the paradoxical associations for those within the BMI 
Overweight (and BMI Obese-1) range(s) may be that BMI does not distinguish 
between fat and fat free mass (Snijder et al., 2006; Janssen and Mark, 2007) or 
the distribution of fat mass. This limitation of BMI may be accentuated in older 
age groups; after 60 years, fat-free mass decreases and fat mass is redistributed 
(Kuk et al., 2009; St-Onge and Gallagher, 2010) to a more central position. 
Therefore, in older adults, those within the BMI Normal range might include 
people with higher fat mass and lower fat free mass. Elevations in waist 
circumference (WC), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR) 
have been reported to be associated with incident CHD (Taylor et al., 2010; Kizer 
et al., 2011; Wormser et al., 2011). However, findings of increased mortality risks 
with elevated WC or WHR have been inconsistent among older adults, with no 
associations (Baik et al., 2000; Dolan et al., 2007; Batsis, Singh and Lopez-
Jimenez, 2014) or inverse associations found in men only (Reis et al., 2009). 
 
In Chapter 7 I presented an analysis using the UK Biobank to compare 
established measures of body fat distribution (WC, WHR, and WHtR) and body 
composition (body fat percentage [BF%], fat mass index [FMI], fat free mass 
index [FFMI], and skeletal mass index [SMI]) to BMI for mortality prediction for 
‘healthier agers’ within the seventh decade of life. ‘Healthier agers’ were non-
smokers without conditions (cancer, dementia or heart failure) associated with 
weight loss or reported weight loss and who survived the first two years of follow-
up. The analysis showed that measures of body fat distribution improved mortality 
prediction compared to models containing BMI. The lowest AIC value (preferred 
model) was achieved for the model containing WHR tertiles. Overall my analysis 
provided further evidence that ‘healthier agers’ with higher adiposity (measured 
overall or centrally) are at a substantially increased risk for mortality.   
 
In Chapter 7 I also highlighted the variability in the proportions of the alternative 
measures of body fat distribution and body composition for those within the 
intermediate tertile of BMI which corresponded to BMI values within the 
Overweight range. The lowest concordance (i.e. a person being in both the BMI 
lower tertile and WHtR lower tertile) was found between BMI tertiles and WHR 
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tertiles for those within the intermediate or higher tertiles for both measures. The 
lowest concordance for the lower BMI tertile was found with SMI tertiles.    
 
Several previous analyses have estimated the risks for mortality or coronary heart 
disease by either mutually adjusting for general adiposity (e.g. BMI) and 
measures of fat distribution (WC and WHR) or cross classified participants. 
Increased mortality risks have been reported for higher waist circumference 
values (Janssen, Katzmarzyk and Ross, 2005; Pischon et al., 2008) and WHR 
values (Pischon et al., 2008) after adjustment for BMI. Increased risks for incident 
coronary heart disease with higher waist circumference values or WHR values 
have been reported for females aged ≥65 years after adjustment for BMI (Canoy 
et al., 2007). However, no significant associations for coronary heart disease 
have been reported for males aged ≥65 years for body fat distribution measures 
after adjustment for BMI (Rexrode, Buring and Manson, 2001; Canoy et al., 
2007). Studies assessing the combined associations of BMI plus body fat 
distribution measures with mortality have not been consistent. One study showed 
no associations between combined BMI and WHR categories for adults aged 65 
to 102 years (Reis et al., 2009). In contrast a meta-analysis by de Hollander et 
al., (2012) showed that after combining BMI and waist circumference categories, 
there were increased mortality risks for those within the higher waist 
circumference categories across the BMI groups for adults aged ≥65 years (de 
Hollander et al., 2012 a).  
 
Overall there has been a paucity of recent studies which have used combined 
BMI and central adiposity measures for assessing mortality and coronary heart 
disease risks. The limited studies in this area have been inconsistent. Here I 
aimed to estimate the associations between combined BMI and central adiposity 
measures with mortality and incident CHD in a large older cohort. The central 
adiposity measure chosen for the main analyses was WHR as it is a well-
recognised measure of central adiposity (Snijder et al., 2006) and has a relatively 
weak correlation with BMI (compared to waist circumference alone) (Pischon et 
al., 2008; Taylor et al., 2010). Furthermore, in Chapter 7 I showed the preferred 
model for mortality for ‘healthier agers’ was one which contained tertile measures 
of WHR. The UK Biobank offers an ideal opportunity to estimate these 
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associations in a large sample of ‘healthier agers’ (non-smokers, without 
conditions associated with weight loss) in their seventh decade, in whom 
distribution of fat stores to a more central distribution is measured. 
 
8.4. Methods  
8.4.1. Participants 
Between 2006 and 2010 the UK Biobank recruited over 500,000 volunteers 
across England, Wales and Scotland; the great majority of respondents were 
aged 40 to 69 years (range 37 to 73 years). At baseline the participants provided 
self-reports for demographic, socioeconomic, and lifestyle factors. Participants 
also had a range of physical measures taken at the baseline visit including 
anthropometrics and blood samples (UK Biobank, 2007; Sudlow et al., 2015). 
The overall response rate was 5.5% and participants provided informed consent 
to have their records linked to cancer registrations, hospital admissions, and 
death registries.  
 
For this analysis participants aged 60 to 69 years at recruitment were included 
as highlighted in the previous chapter (7) the UK Biobank aimed to recruit 
participants aged 40 to 69 years, with 2,247 participants aged >69 years by the 
time of their assessment visit (UK Biobank, 2007). Only those aged 60 to 69 were 
selected as the obesity paradox has been reported predominantly for this and 
older groups. Most women participants were postmenopausal. Additionally, fat 
mass re-distribution to a more central deposition is generally well established in 
this age-group.  
 
Participants who were missing BMI (n = 1,299), waist circumference (n = 44) or 
hip circumference measures (n =20) were excluded. Participants with a BMI value 
<18.5 kg/m2 or BMI ≥ 35 kg/m2 (n = 14,926) were excluded as the paradox has 
predominately been reported for those with BMI values within the Overweight 
(25.0-29.9 kg/m2) and Obese-1 (30.0-34.9 kg/m2) ranges.   
 
Participants with missing responses to questions on alcohol intake, educational 
attainment, or smoking status were excluded (n = 5,019). To account for subjects 
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with conditions associated with weight loss or altered body distribution, current 
smokers, and patients who had a previous diagnosis of cancer, heart failure, or 
dementia (n = 38,991) were excluded. The associations of 15 major diagnoses 
with measured weight loss in a large sample (n = 955,000) of primary care 
patients were empirically tested in Chapter 4: cancer, heart failure, and dementia 
conferred the highest odds ratios (≥1.5) for measured weight loss. The resulting 
group consists of ‘healthier agers’ for whom population level obesity prevention 
may be relevant. Diagnoses at or before baseline were derived from participants’ 
self reports, cancer registries, and hospital admissions (in-patients). Participants 
who died but had no associated death date (n = 1) were excluded. The first two 
years of follow-up (n = 677) were excluded to reduce the effects of reverse 
causation whereby underlying diseases are associated with a lower BMI and an 
increased risk of death. Participants who reported at baseline having lost weight 
compared to 1 year previously, didn’t know, or preferred not to answer (n = 
23,662) were excluded; previous weight loss has been shown to be associated 
with adverse outcomes. The question on weight loss at baseline did not ask about 
the degree of weight change or whether this weight change was intentional or 
unintentional. This exclusion therefore covered more substantial weight losses 
as well as minor losses. The remaining sample for analysis therefore included 
130,473 participants (62,418 men and 68,055 women).  
 
8.4.2. Exposures 
Height, weight, waist and hip circumferences were measured at the baseline 
examination. The natural indent (umbilicus was used if the natural indent could 
not be observed) was measured for the waist circumference. The hip 
circumference was recorded at the widest part of the hips (UK Biobank, 2014). 
Body mass index and waist-to-hip ratio were derived from the baseline measures. 
The World Health Organization (WHO) BMI Classification was used, i.e. Normal 
weight (18.5-24.9 kg/m2), Overweight (25.0-29.9 kg/m2) and Obese-1 (30.0-34.9 
kg/m2) (World Health Organization, 2000). WHR was categorised by population 
and sex-specific tertiles; ‘lower’ (men <0.91, women <0.79), ‘intermediate’ (men 
0.91 to <0.96, women 0.79 to <0.85) and ‘higher’ (men ≥0.96, women ≥0.85). The 
proposed WHO binary WHR cut points for abdominal Obesity of >0.85 for 
females and >0.90 for males were also used (World Health Organization, 2008). 
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8.4.3. Lifestyle factors, educational attainment, and ethnicity 
Lifestyle factors included alcohol intake, smoking history (never or previous), and 
physical activity. Education was based on the highest educational attainment. 
These factors had previously been defined and details on the categories are 
documented in Chapters 2 and 7. Ethnicity was categorized as White, Mixed, 
Asian, Black, Chinese, and other. The Mixed category combined the responses 
of the UK Biobank ethnicity questions of ‘mixed’, ‘White and Black Caribbean’, 
‘White and Black African’, ‘White and Asian’ and ‘Any other mixed background’.  
 
8.4.4. Outcomes 
Death certificate data was available up to August 15th 2015. For the English and 
Welsh participants this was collected by the Health and Social Care Information 
Centre (HSCIC) and for Scottish participants this was collected by the Information 
Services Department (ISD). Incident coronary heart disease (ICD-10 codes I20-
I25) was available up to February 27th 2015 from Hospital Episode Statistics 
(HES, England), Scottish Morbidity Record (SMR, Scotland), and the Patient 
Episode Database for Wales (PEDW, Wales).  
 
8.4.5. Statistical analysis  
Pearson Correlation analysis was used to evaluate the correlations between the 
anthropometric measures. For categorical mortality analyses (BMI categories, 
WHR tertiles, and the joint associations of BMI and WHR) Cox proportional 
hazards models were used. The follow-up time for the mortality risks was 
computed from the assessment date until the date of death, or until August 15th 
2015 (for survivors). Schoenfeld residuals were used to test the proportional 
hazards assumption. Competing risks models (accounting for mortality) were 
used to estimate the association between the anthropometric measures and 
incident coronary heart disease. The follow up time for incident CHD risks was 
computed from the assessment date until the date of incident CHD, date of death, 
or until February 27th 2015. Multivariate models were adjusted for age, gender, 
alcohol intake, never or previous smoker, and educational attainment. These 
variables were chosen as they are in line with previous reports and similar to 
those chosen for the analyses in Chapter 4 and Chapter 5. The Akaike 
Information Criteria (AIC) was obtained for each model, with lower AIC values 
368	
 
Chapter 8 | UK Biobank combined measures 
generally indicating improved model fits. Physical activity, age (60 to 64 years 
and 65 to 69 years), smoking history and gender interactions with the combined 
associations of BMI plus WHR tertiles were assessed. Analyses were carried out 
using Stata statistical software (version 13.1) and R version 3.2.0 with the 
packages (“metafor” version 1.9-9). 
 
8.5. Results  
8.5.1. Baseline characteristics 
Table 8.1 presents the baseline characteristics of the study population (n = 
130,473).  The mean BMI was 26.9 kg/m2 (SD 3.4 kg/m2), 48.9 % were classified 
as being within the BMI Overweight range, and 19.5% as being within the BMI 
Obese-1 range. The mean WHR was 0.82 (SD 0.07) for women and 0.94 (SD 
0.06) for men. The correlation between BMI and WHR was r=0.58 in men, and r= 
0.44 in women. Sex specific tertiles of WHR were defined and derived from the 
overall study population as follows: ‘lower’ (men <0.91, women <0.79), 
intermediate (men 0.91 to <0.96, women 0.79 to <0.85) and ‘higher’ (men ≥0.96, 
women ≥0.85) WHR. For participants in the BMI Normal range 57.7% had a lower 
WHR and 12.8% had a higher WHR, in the BMI Overweight range, 27.1% had a 
lower WHR and 35.2% had a higher WHR, and within the BMI Obese-1 range 
9.6% had a lower WHR and 62.0% had a higher WHR (supplementary material 
Table S8.1). 
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Table 8.1 | Baseline characteristics of the ‘healthier agers’ aged 60 to 69 years 
(n = 130,473) from the UK Biobank  
Variables n = 130,473 
Age years, mean (SD) 64.1 (2.8) 
Gender  
      Females, n (%)  68,055 (52.2) 
BMI, mean (SD) 26.9 (3.4) 
BMI (kg/m2), n (%)  
       18.5-24.9 41,369 (31.7) 
       25.0-29.9 63,731 (48.9) 
       30.0-34.9    25,373 (19.5) 
WHR, mean (SD)  
        Females, mean (SD) 0.82 (0.07) 
        Males, mean (SD) 0.94 (0.06) 
Alcohol intake frequency, n (%)  
        Never            9,845 (7.6) 
        Special occasions only 13,973 (10.7) 
        One to three times a month 12,393 (9.5) 
        Once or twice a week 31,348 (24.0) 
        Three or four times a week 30,818 (23.6) 
        Daily or almost daily 32,096 (24.6) 
Smoking status, n (%)  
        Never 72,419 (55.5) 
        Previous 58,054 (44.5) 
Education, n (%)  
        None 33,157 (25.4) 
        CSEs  2,353 (1.8) 
        GCSEs/O-levels 18,627 (14.3) 
        A-levels/NVQ/HND/HNC 19,318 (14.8) 
        Professional Qualification 20,862 (16.0) 
        College or University degree 36,156 (27.7) 
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Table 8.1 continued 
Variables n = 130,473 
Diagnosed disease at baseline, n (%)  
     Coronary Heart Disease 10,115 (7.8) 
     Type 2 Diabetes 6,781 (5.2) 
Follow-up years, mean (SD) 6.5 (0.9) 
Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years 
 
8.5.2. Mortality  
Over a maximum follow-up period of 8.3 years 2,974 adults died (mean follow-up 
period 6.5 years SD 0.9 years). In survival models adjusted for age, sex, never 
or former smoker, alcohol intake, and level of education, those within the BMI 
Overweight range were not at a significantly increased risk for mortality (HR 1.09 
95% CI 0.99, 1.19 p=0.066) relative to those within the conventional BMI Normal 
range. Those within the BMI Obese-1 range had a substantially increased 
mortality risk HR 1.27 (CI 1.14, 1.41) relative to those within the conventional BMI 
Normal range. Compared to those within the lowest tertile of WHR, those within 
the intermediate tertile had a 12% increased risk for mortality (CI 1.01, 1.23), and 
those within the highest tertile had a 36% increased risk for mortality (CI 1.24, 
1.49). These associations with WHR tertiles were attenuated after adjustment for 
BMI category (intermediate WHR tertile HR 1.10 CI 1.00, 1.21, higher WHR tertile 
HR 1.32 CI 1.19, 1.46).  
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8.5.3. Combined associations of BMI categories and WHR tertiles with 
mortality 
The mortality model fit was improved when both BMI and WHR were included 
compared to a model with BMI only. Figure 1A shows the joint association of BMI 
category and WHR tertiles for mortality (supplementary material Table S8.2). 
Those within the BMI Normal range plus higher WHR tertile had an increased 
mortality risk (HR 1.33 CI 1.08, 1.65) compared to the referent group consisting 
of those within the BMI Normal range plus lower WHR tertile. Also, compared to 
adults within the BMI Normal range plus lower WHR, there was an increased 
mortality risk of 22% for the overall (not accounting for WHR) BMI Overweight 
range (CI 1.09, 1.36), and 42% for the overall BMI Obese-1 range (CI 1.25, 1.61). 
Those within the BMI Overweight range plus higher WHR tertile had a 41% 
increased mortality risk (CI 1.25, 1.61) and those within the BMI Obese-1 range 
plus higher WHR tertile had a 51% increased mortality risk (CI 1.32, 1.73) relative 
to those within the BMI Normal range plus lower WHR tertile. 
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8.5.4. Interactions 
There was no significant interaction between the joint associations of BMI and 
WHR tertiles with age group (60 to 64 years and 65 to 69 years), gender, physical 
activity, or smoking history (never or former) for mortality.   
 
8.5.5. Coronary heart disease 
At baseline, there were 10,115 prevalent cases of coronary heart disease (CHD) 
and these were excluded from the competing risks analysis for incident CHD with 
120,358 participants analysed (incident CHD cases n = 1,878). Figure 1B shows 
the joint association of the BMI categories and WHR tertiles for CHD 
(supplementary material Table S8.2). There was an increased risk for incident 
CHD for those within the BMI Overweight range plus higher WHR (SHR 1.64 CI 
1.39, 1.93) relative to those within the BMI Normal plus lower WHR. Additionally, 
there was an increased risk for those within the lower WHR and intermediate 
WHR for those within the BMI Overweight range. Within the BMI Obese-1 range, 
there were increased risks for incident CHD for all the WHR tertiles.  
 
8.5.6. Sensitivity analyses  
The main analysis was also run (for the joint association of BMI and WHR tertiles) 
with age as the underlying time scale, but the results were not substantially 
changed (Table 8.2).  
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Table 8.2 | Joint association of the BMI categories and WHR tertiles with mortality 
using age as the time scale for ‘healthier agers’ aged 60 to 69 years (n = 130,473) 
from the UK Biobank 
BMI range and WHR tertile 1 Mortality 
HR (95% CI) 
Normal and lower WHR Ref 
 
Normal and intermediate WHR 1.26 
(1.07, 1.47) 
Normal and higher WHR 1.30 
(1.05, 1.60) 
Overweight and lower WHR 1.13 
(0.98, 1.30) 
Overweight and intermediate WHR 1.09 
(0.96, 1.24) 
Overweight and higher WHR  1.38 
(1.22, 1.57) 
Obese-1 and lower WHR 1.13  
(0.84,1.53) 
Obese-1 and intermediate WHR 1.32  
(1.11, 1.58) 
Obese-1 and higher WHR 1.50  
(1.31, 1.72) 
1 WHR was categorised by population and sex-specific tertiles, lower (men 
<0.91, women < 0.79), intermediate (men 0.91 to <0.96, women 0.79 to <0.85) 
and higher (men ≥0.96, women ≥0.85) 
 
Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years 
Cox proportional hazard models were adjusted for gender, smoking history, 
alcohol intake, and educational attainment. Age was used as the time scale. 
WHR: waist-to-hip ratio. 
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The proposed WHO WHR cut points for abdominal Obesity (World Health 
Organization, 2008) >0.85 for women and >0.90 for men (Table 8.3) was also 
analysed. There was a 22% increased mortality risk (HR 1.22 CI 1.09, 1.37) for 
those within the BMI Overweight range plus higher WHR group and a 42% 
increased mortality risk (HR 1.42 CI 1.26, 1.61) for those within the BMI Obese-
1 range plus higher WHR group relative to those within the BMI Normal range 
plus lower WHR. An analysis using a higher threshold for the males of WHR 
>1.00 was also ran, as with the WHO cut points over 75% of the males were 
classified as centrally Obese. The point estimates were higher for those within 
the BMI Overweight range plus higher WHR and for those within the BMI Obese-
1 range plus higher WHR (Table 8.3). 
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Table 8.3 | Joint association of the BMI categories with binary WHR cut points 
and higher threshold WHR cut points with mortality for ‘healthier agers’ aged 60 
to 69 years (n = 130,473) from the UK Biobank 
BMI range and WHR 
category 
WHO cut points1 
HR (95% CI) 
Higher threshold cut 
points2 
HR (95% CI) 
Normal and low WHR Ref 
 
Ref 
Normal and high WHR 1.25  
(1.07, 1.45) 
1.20  
(0.94, 1.53) 
Overweight and low WHR 1.10  
(0.96, 1.25) 
1.02  
(0.92, 1.12) 
Overweight and high WHR  1.22  
(1.09, 1.37) 
1.40  
(1.23, 1.59) 
Obese-1 and low WHR 1.16  
(0.94, 1.44) 
1.14  
(1.00, 1.29) 
Obese-1 and high WHR 1.42  
(1.26, 1.61) 
1.48  
(1.30, 1.68) 
1 Cut points for waist-to-hip ratio category for women were low WHR ≤0.85 and 
for men were low WHR ≤0.90.  
2 Cut points for waist-to-hip ratio category for women were low WHR ≤0.85 and 
for men were  low WHR ≤1.00.  
 
Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years 
Cox proportional hazard models were adjusted for age, gender, smoking history, 
alcohol intake, and educational attainment. WHR: waist-to-hip ratio 
 
Restricting the analyses to participants who responded that their ethnic 
background was White/British (n = 120,151) only marginally changed the results 
for BMI and WHR for mortality (Table 8.4): unfortunately models for other ethnic 
groups were underpowered.  
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Table 8.4 | Joint associations of the BMI categories and WHR tertiles with 
mortality for ‘healthier agers’ identifying as ‘white’ British aged 60 to 69 years (n 
= 120,151) from the UK Biobank 
BMI range and WHR tertile 1 White British 
HR (95% CI) 
Normal and lower WHR 
 
ref 
Normal and intermediate WHR 1.25 
(1.06, 1.47) 
Normal and higher WHR 1.28 
(1.02, 1.60) 
Overweight and lower WHR 1.10 
(0.95, 1.27) 
Overweight and intermediate WHR 1.08 
(0.94, 1.24) 
Overweight and higher WHR  1.38 
(1.21, 1.57) 
Obese-1 and lower WHR 1.10  
(0.80, 1.50) 
Obese-1 and intermediate WHR 1.28  
(1.07, 1.54) 
Obese-1 and higher WHR 1.52  
(1.33, 1.75) 
1 WHR was categorised by sex-specific tertiles, lower (men <0.91, women < 
0.79), intermediate (men 0.91 to <0.96, women 0.79 to <0.85) and higher (men 
≥0.96, women ≥0.85) 
 
Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years 
Cox proportional hazard models were adjusted for age, gender, smoking history, 
alcohol intake, and educational attainment. WHR: waist-to-hip ratio 
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Restricting the analyses to weight stable participants (n = 93,764) did not 
substantially change the results (Table 8.5).  
 
Table 8.5 | Joint associations of the BMI categories and WHR tertiles with 
mortality for ‘healthier agers’ aged 60 to 69 years who responded that their weight 
was the same as one year previously i.e. weight stable (n = 93,764) using the UK 
Biobank 
BMI range and WHR tertile 1 Weight stable 
HR (95% CI) 
Normal and lower WHR ref 
 
Normal and intermediate WHR 1.24 
(1.04, 1.47) 
Normal and higher WHR 1.39 
(1.10, 1.75) 
Overweight and lower WHR 1.17 
(1.00, 1.37) 
Overweight and intermediate WHR 1.15 
(0.99, 1.33) 
Overweight and higher WHR  1.42 
(1.23, 1.64) 
Obese-1 and lower WHR 0.91  
(0.58, 1.43) 
Obese-1 and intermediate WHR 1.33  
(1.06, 1.66) 
Obese-1 and higher WHR 1.64  
(1.39, 1.92) 
1 WHR was categorised by sex-specific tertiles, lower (men <0.91, women <0.79), 
intermediate (men 0.91 to <0.96, women 0.79 to <0.85) and higher (men ≥0.96, 
women ≥0.85) 
 
Note: ‘Healthier agers’ were non-smokers without recent cancer (except non-
melanoma skin cancer), dementia, heart failure and survived the first 1.9 years 
Cox proportional hazard models were adjusted for age, gender, smoking history, 
alcohol intake, and educational attainment. WHR: waist-to-hip ratio 
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8.6. Discussion 
There is much discussion in the literature about whether or not being Overweight, 
as defined by BMI, is a risk factor for coronary heart disease and all-cause 
mortality in later life. Here I estimated the associations between combined BMI 
and central adiposity measures with mortality and incident coronary heart 
disease, in a large older cohort of healthier agers. Firstly, models including both 
BMI and WHR were substantially more informative compared to models 
accounting for BMI only. For example, those within the BMI Normal range plus 
higher WHR tertile had an increased mortality risk (HR 1.33 CI 1.08, 1.65) 
compared to those within the BMI Normal range plus lower WHR tertile. The 
analyses showed that those within the BMI Overweight range plus higher WHR 
tertile experienced markedly raised risks for all-cause mortality relative to those 
within the BMI Normal range plus lower WHR tertile. There was also an increased 
risk of incident coronary heart disease with increasing WHR tertile for those within 
the BMI Overweight range. For those within the BMI Obese-1 range, mortality 
risks were raised and not paradoxical overall, and increasing tertiles of WHR also 
increased the risk for mortality within the BMI Obese-1 range.  
 
It is clear from this analysis that higher central adiposity for those within the BMI 
Normal range and the BMI Overweight range should be considered as risk factors 
for clinical risk assessment and public health purposes in healthy agers. The 
findings suggest that the reported risk paradox of being overweight in older 
persons (overweight associated with lower mortality) may be due to failure to 
account for central adiposity, a feature that is not captured by BMI. Controlling or 
reducing adiposity to increase the chances of aging well (or successful aging) is 
of relevance to the studied group of healthier agers. The findings presented in 
this chapter therefore do not support the theory that the BMI Overweight risk 
paradox in healthy agers is a real protective physiological effect (Dixon et al., 
2015).  
 
8.6.1. Comparison to previous literature 
The results are difficult to compare with previous work, due to different 
inclusion/exclusion criteria, cut points use for waist-to-hip ratio, inclusion of 
varying older age-ranges, and varying follow-up periods. The results on the 
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association between WHR tertiles and mortality contrast with the non-significant 
associations for the middle and high tertiles reported for mortality for adults aged 
³60 years (n = 1,569) from NHANES III (Batsis, Singh and Lopez-Jimenez, 2014). 
This could be due to their relatively small sample size and their wider age-range, 
which may have weakened the associations. The results on the joint association 
between WHR and BMI categories differ to those by Reis et al., (2009) who 
reported no increased risks for mortality for adults with enlarged WHR tertiles 
across the BMI Normal, Overweight, and Obese ranges for adults aged 65 to 100 
years, again in a relatively small sample size (n = 3,748) from NHANES III  (Reis 
et al., 2009). The findings for the combined associations between WHR and BMI 
categories for coronary heart disease are also difficult to compare with previous 
studies as the analysis presented in this chapter used the recommended 
competing risk model analysis approach, accounting for mortality.  
 
8.6.2. Strengths and limitations  
Strengths of the analyses include the large sample of ‘healthier agers’, and the 
availability of anthropometric measures at baseline. Also, outcomes 
ascertainment was through the national death certificate system and hospital 
records, and is likely to be robust with no loss to follow-up, thus avoiding a 
common bias in aging cohorts (Chatfield, Brayne and Matthews, 2005). 
 
The study inevitably has limitations including the use of a volunteer sample, albeit 
with a wide range of relevant risk exposures (Sudlow et al., 2015). The UK 
Biobank did not aim for population representativeness but due to the wide 
variation in exposures included in the large sample at baseline, it is likely that the 
longitudinal risk estimates are relevant for the wider population (Allen et al., 2012; 
Manolio et al., 2012). The sample was predominately white British (92%), which 
may limit the generalizability to different Caucasian populations. The analysis 
was restricted to a ‘healthier agers’ group and the risk estimates may be inflated 
relative to the overall population, due to there being fewer competing risk factors 
(Stokes and Preston, 2016a), although the exclusions were designed to remove 
confounding and reverse causation. Also, this group of ‘healthier agers’ is the 
main potential target for primary prevention of obesity in later life. 
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Data on recent weight loss or weight change in the previous twelve months were 
based on participant’s self-reports at baseline. It would have been preferable to 
exclude persons with weight loss over a longer time frame and to have had an 
indication on the severity of weight change, but data on these were unavailable. 
Alley et al., (2010) reported that during the last nine years of life there was an 
acceleration of the rate of weight loss for males aged ≥60 years from the 
Baltimore Longitudinal Study of Aging (Alley et al., 2010), so the exclusion of any 
weight loss in the previous year should have accounted for this effect. Stokes and 
Preston (2016) have reported that estimates using baseline BMI may 
underestimate the association between obesity and mortality as BMI fluctuations 
throughout life are not captured; model performance was improved using a 
person’s maximum attained BMI (Stokes and Preston, 2016b). Unfortunately, the 
UK Biobank did not collect data on weight history throughout the life course, so 
the results from the available BMI data may be underestimates of true effect 
sizes. The follow-up period of up to 8.3 years is comparable to other studies but 
longer follow-ups may be more informative. Relatively few of those within the BMI 
Obese-1 range had lower WHR, although many of those within the BMI Normal 
range did have intermediate or higher WHRs.   
 
8.6.3. Future work 
Future work might include a more extensive analysis in a wider age-range and 
with longer follow-up times. With the accumulation of longer follow-up times in 
UK Biobank, well-powered cause-specific mortality estimates should become 
feasible. Overall, much work is needed to develop and test effective interventions 
to limit or reduce excessive adiposity in older groups for whom major gains in 
healthy aging may thereby be attainable.    
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8.7. Conclusions 
In this large sample of 60 to 69 year olds free of smoking and prior weight loss 
(or related disease), risk estimation models for mortality combining BMI and WHR 
were substantially more informative than models with only BMI measures. The 
reported BMI based overweight risk paradox in later life appears to be due in part 
to central adiposity, which is not measured by BMI. ‘Healthier agers’ (i.e. non-
smokers without weight loss) with higher central adiposity within the BMI 
Overweight range have substantial excess mortality and coronary heart disease 
risks. There was no evidence of a risk paradox within the BMI Obese-1 range, 
but instead overall increases in mortality relative to those within the BMI Normal 
range with lower WHR. Overall the findings do not support acceptance of the BMI 
Obese or Overweight risk paradox as a real protective physiological effect in the 
studied older group. 
 
 
 
 
383	
 
Chapter 8 | Supplementary material 
 
Supplementary material Chapter 8 
 
List of tables for supplementary material Chapter 8 
Table S8.1 | Characteristics of the ‘healthier agers’ aged 60 to 69 years (n = 
130,473) from the UK Biobank by BMI category ...................................... 384	
Table S8.2 | Joint association of BMI ranges and WHR tertiles with mortality (n = 
130,473) and incident coronary heart disease (n = 120,358) for participants 
aged 60 to 69 years from the UK Biobank ............................................... 386	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
384	
 
Chapter 8 | Supplementary material 
 
Table S8.1 | Characteristics of the ‘healthier agers’ aged 60 to 69 years (n = 
130,473) from the UK Biobank by BMI category 
Variables BMI  
Normal   
n = 41,369 
BMI  
Overweight 
n = 63,731 
BMI  
Obese-1  
n = 25,373 
Follow-up years, mean (SD) 6.5 (0.9) 6.5 (0.9) 6.5 (0.9) 
Age years, mean (SD) 63.9 (2.8) 64.1 (2.8) 64.1 (2.8) 
Gender    
     Females, n (%) 25,778 (62.3) 29,819  
(46.8) 
12,458  
(49.1) 
BMI (kg/m2) n (%) 23.0  
(1.5) 
27.3  
(1.4) 
32.0 
 (1.4) 
WHR, n (%)    
       WHR lower tertile1 23,885 (57.7) 17,239  
(27.1) 
2,427   
(9.6) 
       WHR intermediate    
       tertile1 
12,172 (29.4) 24,079  
(37.8) 
7,222  
(28.5) 
       WHR higher tertile1 5,312  
(12.8) 
22,413  
(35.2) 
15,724  
(62.0) 
Alcohol intake frequency, 
 n (%) 
   
       Never 3,109   
 (7.5) 
4,455   
 (7.0) 
2,281    
(9.0) 
       Special occasions only 4,157  
(10.1) 
6,335  
  (9.9) 
3,481  
(13.7) 
       One-three times a    
       month 
3,735   
 (9.0) 
5,922   
 (9.3) 
2,736  
(10.8) 
       Once or twice a week 9,491  
(22.9) 
15,502 
 (24.3) 
6,355  
(25.1) 
       Three-four times week 9,861  
(23.8) 
15,595 
 (24.5) 
5,362  
(21.1) 
       Daily or almost daily 11,016 (26.6) 15,922  
(25.0) 
5,158  
(20.3) 
Smoking status, n (%)    
        Never 25,727 (62.2) 34,289  
(53.8) 
12,403  
(48.9) 
        Previous 15,642 (37.8) 29,442  
(46.2) 
12,970  
(51.1) 
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Table S8.1 continued 
Variables BMI 
Normal   
n = 41,369 
BMI 
Overweight 
n = 63,731 
BMI 
Obese-1  
n = 25,373 
Education, n (%)    
  None 8,295 
(20.1) 
16,679 
 (26.2) 
8,183 
(32.3) 
   CSEs 698   
 (1.7) 
1,156    
(1.8) 
499    
(2.0) 
   GCSEs/O-levels 6,212 
(15.0) 
9,019 
 (14.2) 
3,396 
(13.4) 
   A-levels/NVQ/HND/HNC 5,505 
(13.3) 
9,771  
(15.3) 
4,042 
(15.9) 
   Professional Qualification 6,679 
(16.1) 
10,149 
 (15.9) 
4,034 
(15.9) 
   College or University degree 13,980 
(33.8) 
16,957 
 (26.6) 
5,219 
(20.6) 
Diagnosed disease at baseline, 
n (%) 
   
    Coronary Heart Disease 1,886  
(4.6) 
5,207  
(8.2) 
3,022 
(11.9) 
    Type 2 Diabetes 983  
(2.4) 
3,162  
(5.0) 
2,636 
(10.4) 
1 WHR was categorised by population and sex-specific tertiles, lower (men 
<0.91, women < 0.79), intermediate (men 0.91 to <0.96, women 0.79 to <0.85) 
and higher (men ≥0.96, women ≥0.85) 
BMI Normal (BMI 18.5 to <25.0 kg/m2), BMI Overweight (25.0 to <30.0 kg/m2) 
and BMI Obese-1 (30.0 to <35.0 kg/m2). WHR: Waist-to-hip ratio.    
 
 
 
 
 
 
 
 
 
 
 
 
 
386	
 
Chapter 8 | Supplementary material 
 
Table S8.2 | Joint association of BMI ranges and WHR tertiles with mortality (n = 
130,473) and incident coronary heart disease (n = 120,358) for participants aged 
60 to 69 years from the UK Biobank 
BMI category and WHR tertile 1 Mortality 
HR (95% CI) 
Coronary heart disease2 
SHR (95% CI) 
Normal and lower WHR ref ref 
 
Normal and intermediate WHR 1.28 
(1.09, 1.49) 
1.16 
(0.93, 1.44) 
Normal and higher WHR 1.33 
(1.08, 1.65) 
1.27 
(0.95, 1.71) 
Overweight 
 
1.22 
(1.09, 1.36) 
1.49 
(1.29, 1.72) 
Overweight and lower WHR 1.12 
(0.97, 1.30) 
1.29 
(1.07, 1.54) 
Overweight and intermediate WHR 1.10 
(0.97, 1.26) 
1.51 
(1.28, 1.78) 
Overweight and higher WHR  1.41 
(1.25, 1.61) 
1.64 
(1.39, 1.93) 
Obese-1  1.42 
(1.25, 1.61) 
1.86 
(1.59, 2.18) 
Obese-1 and lower WHR 1.11  
(0.82, 1.51) 
2.10  
(1.53, 2.88) 
Obese-1 and intermediate WHR 1.32  
(1.11, 1.57) 
1.46  
(1.16, 1.83) 
Obese-1 and higher WHR 1.51  
(1.32, 1.73) 
2.02  
(1.70, 2.40) 
1 WHR was categorised by population and sex-specific tertiles, lower (men 
<0.91, women <0.79), intermediate (men 0.91 to <0.96, women 0.79 to <0.85) 
and higher (men ≥0.96, women ≥0.85) 
2 Analysis for coronary heart disease excludes prevalent cases at baseline (n = 
10,115).  
Survival models (Competing risk models for CHD) were adjusted for age, 
gender, never or former smoker, alcohol intake, and educational attainment.  
BMI Normal (BMI 18.5 to <25.0 kg/m2), BMI Overweight (25.0 to <30.0 kg/m2) 
and BMI Obese-1 (30.0 to <35.0 kg/m2). SHR: Sub-Hazard Ratio; WHR: waist-
to-hip ratio. 
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9.1. Chapter overview  
In this chapter I will firstly review the aim of this thesis and my contributions to the 
field. The key findings, potential clinical and public health implications, and future 
research directions will then be discussed. This will be followed by a discussion 
on the limitations with the datasets (and the associated analyses) and potential 
measurement errors.  
 
9.2. Summary 
The overall aim of my thesis was to clarify whether older persons with obesity are 
or are not at a greater risk for mortality, coronary heart disease, dementia and 
diabetes. Additionally, I aimed to clarify whether persons within the BMI 
Overweight range had the lowest mortality risk. As highlighted in Chapter 1, the 
prevalence of obesity in the UK has increased since 1975, and this has been 
observed across all age groups, which necessitated an updated assessment of 
the BMI associations with adverse health outcomes in later life. It is well 
established that younger and middle aged adults within the BMI defined Obese 
range are at an increased risk for cardiovascular disease, diabetes, dementia and 
mortality relative to those within the conventional BMI Normal range. In later life, 
the mortality and dementia risks associated with higher BMI values have been 
mixed. These equivocal results may be due to several contributors including: 
 
• Inadequate control for confounders e.g. smoking 
• Inadequate control for health status e.g. reverse causation 
• The BMI referent group 
• The inability of BMI to capture body compositional changes with ageing 
 
I used two complimentary datasets to examine the above potential contributors 
to paradoxical results, the UK CPRD which is representative of the older 
population, and the UK Biobank which is a volunteer prospective cohort. The 
advantage of analysing the CPRD is that I had access to electronic health records 
for registered primary care patients aged ≥60 years which allowed the 
associations between BMI, CHD, and diabetes to be estimated in narrower age 
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groups. Furthermore, I had data relating to mortality due to the external linkages 
for all the studied patients who are known to have died. The advantage of 
analysing the UK Biobank is that I had access to additional measures of adiposity 
and body composition which were concurrently measured. Additionally, in the UK 
Biobank, all lifestyle, socioeconomic, and physical measures were collected on 
the same date. Compared to other volunteer cohort studies only a few volunteers 
have opted to leave the study. Both datasets are large scale and thereby stratified 
analyses could be undertaken whilst maintaining sufficient sample sizes to detect 
associations. Furthermore, both datasets collected BMI measures within the 21st 
century, which allows updated quantification of associations with adverse health 
outcomes.  
 
9.3. New contributions  
 
I have taken this field forward by 
• Conducting a meta-analysis on the mortality risk estimates for adults aged 
≥65 years within the BMI Overweight and BMI Obese-1 ranges for 
analyses with no exclusions, specific exclusions (e.g. smokers only) and 
combined exclusions as well as assessing the choice of the BMI referent 
group. 
• Providing recent mortality estimates for the WHO BMI categories using a 
large electronic health records dataset (CPRD) of English patients across 
progressively older age groups and reporting these for ‘healthier agers’ 
and ‘non-healthier agers’ (i.e. accounting for smokers and conditions 
associated with weight loss). 
o Empirically identifying the major conditions associated with 
substantial weight loss. 
o Clarifying the number of years of follow-up to exclude to minimise 
reverse causation.  
• Re-defining the BMI referent group, using the CPRD, by modelling the 
continuous associations with mortality as well as providing recent 
mortality, incident coronary heart disease, and diabetes risks using this 
revised referent group for progressively older groups of ‘healthier agers’.    
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• Reporting on the pre-diagnosis weight loss in those diagnosed with 
dementia. Reporting on the associations between BMI and dementia for 
the short (0 to <10 years) and long term (10 to <14.9 years). 
• Comparing established measures of body fat distribution and body 
composition to BMI for mortality prediction for ‘healthier agers’ within the 
seventh decade of life from the UK Biobank.  
• Reporting on the associations between combined measures of BMI and 
waist-to-hip ratio with mortality and incident coronary heart disease for 
‘healthier agers’ within the seventh decade of life from the UK Biobank.   
 
9.4. Key findings 
Several key findings have emerged from the data analyses presented in this 
thesis, potentially having implications for clinical and public health. The risks for 
mortality, coronary heart disease, diabetes, and dementia will be discussed.  
Additionally, I will discuss the BMI referent group. The advantages and 
disadvantages of using BMI and measures of central adiposity will then be 
assessed. 
  
Mortality 
In Chapters 3, 4, 5, and 7 I focused on the association between BMI and mortality 
in later life.  Firstly, I will discuss the findings using the conventional WHO BMI 
categories for two separate groups of agers, namely 
• non-smokers free of major weight loss associated diseases  
• smokers plus those with major diseases associated with weight loss.  
	
This will be followed by a summary of the results using revised BMI referent 
groups. Subsequently, the results from using alternative measures of adiposity 
and body composition will be discussed.   
 
 
 
 
 
391	
 
Chapter 9 | Discussion 
Conventional WHO BMI Categories 
 
Non-smokers free of major weight loss associated diseases 
In Chapters 3, 4 and 7 I reported on the mortality risks for the BMI Obese-1 range 
relative to those within the conventional BMI Normal range. Table 9.1 details the 
mortality risks from these chapters. In both Chapters 3 and 4 I found that without 
any exclusions the mortality risks were reduced. Additionally, in Chapter 3 I 
showed that the mortality risks were not significantly different for singular 
exclusions or when smokers plus early deaths were excluded. There were 
increased risks following the exclusion of smokers plus persons with conditions 
associated with weight loss, which achieved the lowest heterogeneity. However, 
there were no studies which provided mortality risks for the conventional WHO 
BMI categories excluding smokers, early deaths plus conditions associated with 
weight loss. Thus, my analysis in Chapter 4 applied these three exclusions, 
which showed increased mortality risks for those aged <75 years and not 
significantly different risks for those aged 75 to 84 years. One of the limitations of 
using the CPRD (Chapter 4) is that BMI records were only available for 62% of 
those eligible. Furthermore, height and weight measurements may be taken more 
frequently for patients with certain health conditions. The UK Biobank was used 
to address these limitations, as most of the volunteers from this cohort study had 
height and weight measurements. The results for this analysis were presented in 
Chapter 7, where I showed that mortality risks for the BMI Obese-1 range were 
in-line with those from the CPRD analysis (Chapter 4) for the two youngest age 
groups, conferring an increased risk. 
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Table 9.1 | Mortality risks for those within the BMI Obese-1 range relative to 
those within the conventional BMI Normal range  
Exclusions Chapter 3 Chapter 4 Chapter 7  
None • Reduced  
     aged ≥65 y  
• Reduced  
     all age groups    
     (≥60 y)  
• NA 
Smokers, 
conditions 
associated with 
weight loss and 
early deaths  
• No studies 
reporting risk 
estimates 
aged ≥65 y 
• Increased  
<75 y 
• Not 
significantly 
different  
75 to 84 y 
• Reduced  
≥85 y  
• Increased  
60 to 69 y 
 
 
In Chapters 3, 4 and 7 I also presented findings for the mortality risks for those 
within the BMI Overweight range relative to those within the conventional BMI 
Normal range. Table 9.2 details the mortality risks for these chapters. Again, 
there were reduced mortality risks reported in both Chapters 3 and 4 when there 
were no exclusions for the BMI Overweight range. Additionally, in Chapter 3 I 
showed the mortality risks were not significantly different for single or with two 
exclusions (smokers plus early deaths or smokers and conditions associated with 
weight loss). There was a lack of studies providing mortality risks for the 
conventional WHO BMI categories excluding smokers, early deaths plus those 
with conditions associated with weight loss. Thus, in Chapter 4 I showed that the 
mortality risks were not significantly different for those aged <70 years, and 
reduced for those aged ≥70 years following the application of these three 
exclusions. Furthermore, the analysis using the UK Biobank in Chapter 7 showed 
the risks for those aged 60 to 69 years for the BMI Overweight range were not 
significantly different to those within the conventional BMI Normal range, albeit 
with wider confidence intervals. 
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Table 9.2 | Mortality risks for those within the BMI Overweight range relative to 
those within the conventional BMI Normal range  
Exclusions Chapter 3 Chapter 4 Chapter 7  
None • Reduced  
aged ≥65 y  
• Reduced  
all age groups 
(≥60 y)  
• NA 
Smokers, 
conditions 
associated with 
weight loss and 
early deaths  
• No studies 
reporting risk 
estimates  
aged ≥65 y 
• Not 
significantly 
different  
<70 y 
• Reduced  
≥70 y  
 
• Not 
significantly 
different 
•  60 to 69 y 
 
In Chapters 4 and 7 I also reported the risks for the BMI Underweight and BMI 
Obese-2 and Obese-3 ranges. The mortality risks for those aged <70 years from 
the CPRD (Chapter 4) and the UK Biobank (Chapter 7) were similar for the BMI 
Underweight range, BMI Obese-2 and BMI Obese-3 ranges, with increased risks. 
In Chapter 4 I also showed that for those aged 70 to <85 years, there were also 
increased risks for the BMI Underweight, BMI Obese-2 and BMI Obese-3 ranges. 
For those aged ≥85 years, there were increased risks for the BMI Underweight 
range only.   
 
Smokers and those with major diseases associated with weight loss  
In my analysis of electronic health records for smokers and those with major 
diseases associated with weight loss, I showed that in all the age-groups relative 
to those within the conventional BMI Normal range:  
• Increased mortality risks for the BMI Underweight range 
• Reduced mortality risks for the BMI Overweight range 
• Reduced mortality risks for the BMI Obese-1 range 
• Reduced mortality risks for the BMI Obese-2 range 
• Mortality risks were not significantly different for the BMI Obese-3 range, 
except for those aged 65 to 69 years with an increased risk 
 
The hazard ratios and 95% confidence intervals did not overlap for the BMI 
Overweight to Obese-2 ranges, i.e. showed larger reduction in risk compared to 
the overall sample (e.g. no exclusions) for those aged <85 years. Improved 
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survival for those within the BMI Obese range has been reported for patients with 
cancer and heart failure, with factors such as the age at presentation, the severity 
of the disease, and the use of BMI being suggested for these paradoxical findings 
(Oreopoulos, et al., 2008; Gonzalez, et al., 2014; Lennon, et al., 2016). Further 
work is required to understand the reduced mortality risks in these patients (see 
section 9.6).     
 
Revised BMI referent groups 
As highlighted in Chapter 1, one of the proposed suggestions contributing to 
paradoxical findings is the referent group. I therefore examined this in Chapters 
3 and 5. In Chapter 3 I showed mortality risks for the BMI Obese-1 range were 
not significantly different when early deaths were excluded or when there were 
no exclusions. There was, however, increased mortality risks when smokers and 
conditions associated with weight loss were excluded or when smokers, 
conditions associated with weight loss plus early deaths were excluded. Table 
9.3 details the mortality risks for these chapters for the BMI Obese-1 range with 
the use of different referent ranges. The results presented in Chapter 5 for non-
smoking ‘healthier agers’ echoed the findings from Chapter 3 for the 
simultaneous exclusions. I did not perform an analysis revising the BMI referent 
range in the UK Biobank as there did not appear to be a substantial increased 
mortality risk for those within the lower end of the conventional BMI Normal range 
when BMI was measured continuously. This could be due to the volunteer 
participants being healthier compared to the patients within the CPRD.           
 
Table 9.3 | Mortality risks for those within the BMI Obese-1 range relative to those 
within a revised referent range  
Exclusions Chapter 3 
(referent ≥20.0 to 
<25.0 kg/m2) 
Chapter 5 
(referent 23.0 to 
<25.0 kg/m2) 
Chapter 5  
(referent 23.0 to 
<27.0 kg/m2) 
Smokers, 
conditions 
associated with 
weight loss and 
early deaths  
• Increased  
aged ≥65 y 
• Increased  
aged <85 y 
• Not 
significantly 
different ≥85 y 
• Increased  
aged <85 y 
• Not 
significantly 
different ≥85 y 
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In Chapters 3 and 5 I also presented results for the BMI Overweight range using 
revised referent groups. In Chapter 3 I showed mortality risks for the BMI 
Overweight range were reduced when there were no exclusions. Mortality risks 
were not significantly different after early deaths were excluded or when there 
were no exclusions. There was, however, increased mortality risks when 
smokers, conditions associated with weight loss plus early deaths were excluded, 
achieving the lowest heterogeneity. In Chapter 5 I showed there were increased 
risks for non-smoking ‘healthier agers’ aged <65 years with a BMI in the range 
27.0 to <30.0 kg/m2 when either the BMI referent group was 23.0 to <25.0 or 23.0 
to <27.0 kg/m2. For those aged 65 to 69 years there was an increased risk when 
the BMI referent range was 23.0 to <27.0 and the risk was not significantly 
different when the BMI range 23.0 to <25.0 was used as the referent group.  The 
mortality risks for those aged 70 to <85 years with a BMI in the range 27.0 to 
<30.0 kg/m2 were not significantly different to either referent group. In Chapter 5 
I additionally reported on the risks for the BMI referent range 25.0 to <27.0 relative 
to those within the BMI range 23.0 to <25.0 kg/m2. The mortality risks were not 
significantly different for those aged <85 years. For those aged ≥85 years the 
mortality risks were reduced.    
  
In Chapter 5 I also showed that the mortality risks for those aged <85 years 
relative to either a BMI in the range 23.0 to <25.0 or 23.0 to <27.0 kg/m2:  
• Increased for the BMI Underweight range 
• Increased for the BMI 18.5 to <23.0 kg/m2 range 
• Increased for the BMI Obese-2 range 
• Increased for the BMI Obese-3 range 
 
For those aged ≥85 years there were increased mortality risks for those within 
the BMI Underweight and BMI range 18.5 to <23.0 kg/m2 when either the BMI 
referent range 23.0 to <25.0 or 23.0 to <27.0 kg/m2 were used. There was a 
reduced risk for those within the BMI range 27.0 to <30.0 kg/m2.  
 
The increased risks found for those within the BMI Underweight and lower BMI 
Normal range across the age-groups could be due to muscle loss with ageing. 
However, the CPRD did not have additional body compositional records.  
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Alternative measures of adiposity and body composition for mortality 
prediction 
The CPRD is limited to height and weight measures, with very few measures of 
alternative measures of adiposity or body composition available. Therefore, I 
used the UK Biobank to compare established measures of body fat distribution 
to BMI for mortality prediction for non-smoking ‘healthier agers’, with the results 
presented in Chapter 7. Measures of central adiposity (waist circumference, 
waist-to-hip ratio, and waist-to-height ratio) were shown to improve mortality 
prediction compared to models containing BMI. Increased levels of central 
adiposity were associated with an increased mortality risk. I found that the 
correlation for these three measures of central adiposity with BMI was weakest 
for the waist-to-hip ratio. Additionally, I showed the lowest concordance was 
found between tertiles of BMI and WHR.  
 
As BMI does not measure the increase in central adiposity with ageing, I therefore 
combined BMI with a measure of central adiposity for mortality and coronary heart 
disease prediction, with these results presented in Chapter 8. The measure of 
central adiposity chosen was the waist-to-hip ratio as it conferred to the best fitting 
model and had the weakest correlation with BMI. Here I aimed to assess whether 
combining these two measures may more accurately identify those at higher risks 
for adverse outcomes. Before combining these two measures I showed that the 
risks for mortality for those within the BMI Overweight range were not significantly 
different to those within the conventional BMI Normal range, whilst those within 
the BMI Obese-1 range had increased risks. Those within the BMI Normal range 
within higher categories of WHR had increased mortality risks. Those within the 
BMI Overweight range were shown to have increased mortality risks using the 
BMI Normal range plus lower WHR as the referent group. The point estimates for 
those within the BMI Overweight range plus higher WHR were much higher to 
the estimates for the BMI Overweight range only. Thus, the results from these 
chapters highlight the importance of measuring central adiposity, especially in 
those considered to have a BMI within the Normal range.  
 
Consistent with previous findings I also showed in Chapter 7 that increased 
skeletal mass index was associated with a reduced mortality risk after accounting 
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for BMI category. However, I did not assess the muscle function or muscle quality 
for this analysis. Thereby without accounting for this loss in muscle mass and 
function, my mortality risks could be an underestimation for adiposity, as BMI is 
a combination of fat mass and fat free mass.   
 
Overall, after accounting for smokers, early deaths, and conditions associated 
with mortality, I have consistently shown from both the CPRD and the UK Biobank 
for adults aged 60 to 69 years, using BMI only that there are: 
• Increased mortality risks for the BMI Underweight range 
• Increased mortality risks for all three classes of Obesity 
 
 
Decline in mortality risks with advancing age 
It is also worth noting that although the BMI mortality risks decline with advancing 
age, this may be due to the chosen risk measure and the accumulation of 
competing risk factors (Chapter 1). Additionally, some persons may have already 
died from obesity and thus persons who have survived may be “resistant” to the 
effect of higher BMI values, which will be accentuated across the progressively 
older age groups.      
 
Coronary heart disease 
In Chapter 5 I showed the risks for coronary heart disease were raised for those 
aged <70 years for BMI values ≥27.0 kg/m2 when either compared to those within 
the referent group 23.0 to <25.0 kg/m2 or 23.0 to <27.0 kg/m2. For those aged 70 
to 74 years, there were increased risks for those with BMI values ≥27.0 kg/m2 
and <40.0 kg/m2, with a non-significant result for those within the BMI Obese-3 
range. For those aged 75 to 84 years, there were increased risks for those with 
BMI values ≥27.0 kg/m2 and <35.0 kg/m2, with non-significant results for those 
within the BMI Obese-2 and BMI Obese-3 ranges. For those aged ≥85 years, 
there were increased risks only for those within the BMI range 27.0 to <30.0 
kg/m2.  
 
As highlighted in the mortality section, one limitation of the CPRD is that BMI 
records were unavailable for 38% of those eligible for analysis. I therefore used 
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the UK Biobank to address this limitation (Chapter 8). I showed there were 
increased risks for CHD for those within the BMI Overweight and Obese-1 ranges 
relative to those within the BMI Normal range in those aged 60 to 69 years. 
Interestingly, the CHD risks for the BMI Obese-1 range were much larger in the 
UK Biobank compared to the CPRD although the referent group was the whole 
of the conventional BMI Normal range (Chapter 8). Similarly, the point estimate 
was higher for the UK Biobank for the BMI Overweight range compared to the 
risks reported for the lower and upper ends of the Overweight range. Additionally, 
in the UK Biobank I showed increased risk of CHD for those who were in the 
Overweight range with increasing central adiposity, i.e. intermediate and higher 
tertiles of waist-to-hip ratio, relative to those who have a BMI Normal plus lower 
waist-to-hip ratio.  
 
Overall, after accounting for smokers, early deaths, and conditions associated 
with mortality, I have consistently shown from both the CPRD and the UK Biobank 
for adults aged 60 to 69 years, using BMI only that there are: 
• Increased risk of incident CHD for the BMI Obese-1 range 
 
 
Diabetes 
In Chapter 5 I showed the risk of incident type 2 diabetes was increased for those 
aged ≥60 years for BMI values ≥25.0 kg/m2 relative to those within the BMI range 
23.0 to <25.0 kg/m2, using data from the CPRD. This is in line with previous 
research. The two youngest groups (60 to 64 years and 65 to 69 years) showed 
no overlap between the confidence intervals for the upper BMI Overweight range 
and the BMI Obese ranges. There were reduced risks for those aged <85 years 
with BMI values <23.0 kg/m2, and risks were not significantly different for those 
aged ≥85 years.  
 
Dementia 
In persons with repeat BMI measures and with incident dementia, weight loss 
was common during the ten years preceding diagnosis, with 67.7% losing weight. 
Reduced risks were shown for those within the BMI Overweight and BMI Obese 
ranges from 0 to <10 years after baseline relative to those within the BMI referent 
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range 22.5 to <25.0 kg/m2. However, when examining the risks from 10 to 14.9 
years there were increased risks for those within the BMI Obese range. The BMI 
Overweight range was not significantly different to the referent range.  
 
 
BMI referent group for later life 
In terms of the conventional BMI Normal range I have shown that there are 
increased mortality and dementia risks for those with BMI values <23.0 kg/m2 
from analysis of the CPRD. This increased mortality risk may be due to 
undiagnosed diseases or from less than optimal body composition. However, in 
the UK Biobank there did not appear to be a substantially increased mortality risk. 
This may be due to the shorter follow up, participants being healthier and able to 
attend the assessment centres. The use of BMI only in later life, however, may 
miss those at a heightened risk due to central adiposity (Chapter 8) or 
sarcopenia.  Thus, more work is required on assessing BMI, additional measures 
of central adiposity, and sarcopenia with a range of health outcomes across 
progressively older age groups for defining the optimum BMI and body 
composition range in later life (see section 9.6).   
 
I showed that there were increased mortality risks only for those within the upper 
end of the BMI Overweight range (BMI 27.0 to <30.0 kg/m2) and aged <65 years 
when only BMI is considered. Mortality risks were similar for those aged 65 to 
<85 years. Mortality risks for the lower end of the BMI Overweight range (25.0 to 
<27.0) were not significantly different to those within the higher end of the BMI 
Normal range (23.0 to <25.0 kg/m2) for those aged <85 years.  For those in the 
upper end of the BMI Overweight range there was also increased risks for 
incident CHD for all ages from the CPRD. I showed increased risks of CHD within 
the UK Biobank for the BMI Overweight range, although in this analysis I did not 
split this range into a lower and upper range. Furthermore, there was increased 
risks for incident diabetes for both the lower and upper end of the BMI Overweight 
range (except for those aged ≥85 years for the lower end) from the analysis of 
the electronic health records. Thus, these findings do not imply that the BMI 
Normal range should be redefined to that of the BMI Overweight range for those 
aged <85 years.    
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Advantages and disadvantages of measuring BMI and central adiposity 
There are many advantages and disadvantages to measuring BMI and measures 
of central adiposity (waist circumference, waist-to-hip, waist-to-height ratio) both 
clinically and for research purposes (Snijder et al., 2006; Duren et al., 2008; Ness-
Abramof and Apovian, 2008; World Health Organization, 2008; National 
Academies of Sciences, Engineering, 2016). Advantages of calculating BMI 
include that minimal to zero training is required to take height and weight 
measures, with these being easy, quick, inexpensive and non-invasive, and 
population trends and comparisons can be made as it is one of the most widely 
used indexes. However, there are several disadvantages to BMI including the 
inability to differentiate fat and fat free mass and to capture fat redistribution. Age, 
ethnicity and fitness can modify the correlation between BMI and fat mass. The 
advantages of the measures of central adiposity include the suitability for 
monitoring population trends and these measures are inexpensive. Measuring 
waist circumference only has the advantage of one measure being required, 
whilst waist-to-hip and waist-to-height allow an adjustment to be made for body 
shape. Disadvantages of obtaining these measures of central adiposity include 
the requirement for bodily contact, training is required, differing protocols as to 
where waist and hip measures should be taken, and the inability to differentiate 
between subcutaneous and visceral adipose tissues (Snijder et al., 2006; Duren 
et al., 2008; Ness-Abramof and Apovian, 2008; World Health Organization, 2008; 
National Academies of Sciences, Engineering, 2016).    
 
 
9.5. Implications of research findings for clinical and public 
health practice 
When I started my PhD, there was extensive literature claiming that being obese 
or overweight was beneficial in old age (Al Snih, et al., 2007; Flicker, et al., 2010; 
van Uffelen, et al., 2010; de Hollander et al 2012 b; Flegal, et al., 2013; Dixon, et 
al., 2015). If this was true, it would require an abandonment of most public health 
efforts to prevent obesity in later life (Cetin and Nasr, 2014; Stevens, et al., 2015). 
Given that 29.9% of females and 32.3% of males aged 65 to 74 years were 
classified as obese and 35.2% of females and 44.2% of males were classified as 
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overweight from the Health Survey for England, this would have major 
implications for public health (Health Survey for England, 2017).    
	
My findings have shown that combining those who are already ill, smokers, and 
relatively ‘healthier agers’ can lead to disparate risk estimates, which should be 
considered when interpreting new research findings. There are several potential 
implications for clinical and public health practice from the research presented in 
this thesis: 
• Supplement BMI with other measures capturing body composition 
• Preventing obesity in later life 
• Increased health risks for the BMI Underweight and the lower end of the 
BMI Normal range 
 
Supplement BMI with other measures capturing body composition 
My thesis has highlighted that BMI does not capture body compositional changes 
with advancing age such as the central redistribution of fat mass which places 
persons at an elevated mortality risk. Persons within the BMI Normal range are 
not spared these body compositional changes. Additionally, BMI does not 
measure the change in fat and fat free mass with ageing. Thus, using BMI only 
will not capture those who are BMI Normal but obese centrally, and those with 
sarcopenia. Encompassing measures of central adiposity and sarcopenia in 
clinical practice could lead to the prevention of a greater proportion of obesity-
related adverse events in later life.  
 
In the UK Biobank analyses I showed that 13.4% of the whole sample were BMI 
Normal but centrally obese (intermediate or higher WHR tertile). Reliance of BMI 
only would therefore misclassify the risk for these persons who are at an elevated 
risk for mortality in later life; the use of BMI and a measure of central adiposity 
should therefore be encouraged for older people. Measures of central adiposity 
are cheaper and require less time than imaging techniques. Interestingly, the 
NICE clinical guidelines on obesity 2014 stated “Think about using waist 
circumference, in addition to BMI, in people with a BMI less than 35 kg/m2” (NICE 
Guidelines, 2014). However, in this guideline, only the health risks for persons 
within the BMI Overweight range and BMI Obese-1 range were documented. My 
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results have shown that there was an increased mortality risk for those within the 
BMI Normal range who were also centrally obese (for non-smokers without major 
conditions associated with weight loss within the seventh decade). At the start of 
my PhD I ran a pilot analysis to assess if and how many waist circumference 
measures were within the CPRD, which showed there was few records. The 
feasibility of clinicians obtaining central adiposity measures needs further 
research (see section 9.6) and incentives to collecting these measures in primary 
care should be explored.  
 
Furthermore, my research highlighted a high proportion of those within the BMI 
Normal range have a low skeletal mass index. In my analysis of the UK Biobank, 
I showed that for ‘healthier agers’ aged 60 to 69 years, 58.8% of those within the 
lowest BMI tertile (BMI ranges 18.56 to 25.91 for males and 18.50 to 24.81 for 
females) were in the lowest tertile of skeletal mass index. The skeletal mass index 
ranges for the lowest tertile for males and females were 5.53-8.65 and 4.18-6.10, 
respectively. These values are below the cut off values for defining sarcopenia 
mass (<8.87 for males and <6.42 for females) (Cruz-Jentoft, et al., 2010). I did 
not evaluate the muscle function or quality in my analyses. This group of 
individuals would therefore be a mix of those with pre-sarcopenia (defined by low 
skeletal mass only) and those with sarcopenia (both low skeletal mass and low 
grip strength). As highlighted previously, those with sarcopenia have increased 
mortality risks. There is, therefore, a need to identify individuals with both pre-
sarcopenia and sarcopenia.  
 
Low physical activity levels have been shown to be associated with an increased 
likelihood of sarcopenia (OR 1.36 95% CI 1.11, 1.67) for adults aged ≥65 years 
(n = 18,363) from the Collaborative Research on Ageing in Europe (Tyrovolas, et 
al., 2016). Similarly, a meta-analysis of 7 cross-sectional and cohort studies 
showed there was a reduced likelihood of sarcopenia for adults who were 
physically active (OR 0.45 95%CI 0.37, 0.55), in 6 of these studies the 
participants were aged >60 years (Steffl, et al., 2017). Naseeb and Volpe recently 
reviewed 20 articles published between January 2010 and April 2015 which had 
examined protein and exercise in relation to sarcopenia. The authors reported 
that physical function, muscle mass and strength can be improved with a 
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combination of resistance training plus either supplementation of amino acids or 
protein, or an increase in dietary protein (Naseeb and Volpe, 2017). Thus, 
practitioners need to be aware of how to measure sarcopenia and the possible 
treatment options.   
 
Preventing BMI defined obesity and central obesity in later life  
My findings showed that there were increased mortality risks and diabetes risks 
for the three categories of obesity, for non-smoking adults without major 
conditions associated with weight loss aged 60 to <85 years, highlighting the 
significant health implications associated with obesity in later life. Thus, there is 
a great need to prevent otherwise healthy persons becoming obese, both overall 
and centrally. This also includes preventing persons within the BMI Normal range 
becoming centrally obese.  
My findings showed that there were increased risks for incident type 2 diabetes 
for those within the BMI Overweight range for those aged ≥60 years. There were 
increased risks for incident coronary heart disease for those within the higher end 
of the BMI Overweight range (27.0 to <30.0 kg/m2). The risks for mortality for 
those within the BMI Overweight range tended to not be significantly different to 
those within the higher end of the BMI Normal range for those aged 60 to <85 
years. This makes the decision of whether persons within the BMI Overweight 
range should lose weight in later life challenging, and more studies are required 
with a broader range of outcomes (see section 9.6). The emphasis, therefore, 
may be on maintaining muscle mass and not gaining weight.   
Public Health England recently published a framework entitled “All our Health” 
which calls for healthcare professionals to prevent, improve and promote health 
and wellbeing at the patient and population level. Included in this framework is 
guidance on adult obesity, which highlights the importance of obesity in later life 
(Public Health England, 2015). My research has also reaffirmed this as a crucial 
age group for obesity prevention. Advice and interventions for weight 
management may focus on increasing physical activity, modification to diets, 
lifestyle modifications, prescribing of drugs, and bariatric surgery (Cetin and Nasr, 
2014). It should also aim to help older people to put into context media claims 
that being overweight in old age is good for them.  
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One of the locations where individuals may receive advice and interventions is at 
the primary care level. Booth et al., (2015) used electronic health records from 
the CPRD to examine accessibility to weight management interventions for 
overweight and obese patients aged 30 to 100 years. The authors used a random 
sample who were registered with a practice between 2005 and 2012 (n = 91,143). 
Access to weight management interventions (advice, referral, or drugs) was 
greater with increasing BMI values. The lowest access to weight management 
was reported for the BMI Overweight range, with 8.6% of the males and 9.7% of 
the females accessing interventions. The highest access to weight management 
was for the BMI Obese-3 range, with 40.0% of the males and 41.9% of females 
accessing interventions. Overweight and Obese patients, therefore, may have 
limited access to weight management interventions, or that advice and 
interventions have not been documented on patients records (Booth, Prevost, 
and Gulliford, 2015). There is a need to update and evaluate the access to weight 
interventions for persons in later life.  
A recent meta-analysis of randomised controlled trials which used a dietary 
intervention for weight loss for obese adults showed a reduced mortality risk (RR 
0.82 95% CI 0.71, 0.95) from 34 studies considered high quality. There was no 
significant difference between those in the treatment arms and control arms for 
new cardiovascular events (Ma, et al., 2017).  Bales and Buhr (2008) reviewed 
16 weight loss randomized controlled trials which had a duration of ≥6 months for 
adults aged ≥60 years with BMI values ≥27.0 kg/m2 and reported that although 
there were adverse effects on bone mineral density and fat free mass, there were 
improvements in physical function, osteoarthritis and type 2 diabetes (Bales and 
Buhr, 2008).  Batsis, et al., (2017) recently reviewed the evidence for obese 
adults aged ≥60 years for behavioural based interventions for weight loss, using 
articles published between January 2005 and October 2015. Six studies met the 
inclusion criteria, and the duration of the studies ranged from 6 to 18 months. The 
minimum weight loss documented was 0.5kg and the maximum 10.7kg, with 
losses greater with interventions focussing on diet. No significant differences in 
weight loss were documented from exercise only interventions. A combination of 
interventions focussed on both diet and exercise led to improvements in physical 
function, self-reported health, bone mineral density, inflammation markers, 
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cognition markers, glucose homeostasis, and with a reduced decline in muscle 
mass. The authors, however, stressed there are a limited number of high quality 
weight loss randomised trials for obesity in later life. Additionally, the outcome of 
these trials should not focus only on weight loss but also include physical function 
and self-reported health. Furthermore, none of the trials were carried out in the 
primary care setting, which is a key area for providing weight loss advice and 
interventions (Batsis, et al., 2017).  
Practitioners may have been reluctant to advise or recommend weight loss 
interventions to adults with obesity in later life due to concerns of accelerated 
losses of bone mineral density and skeletal mass. Additionally, the willingness or 
ability of older adults to make lifestyle changes may hamper weight management 
guidance (Bales and Buhr, 2008; Han, Tajar and Lean, 2011; Decaria, Sharp and 
Petrella, 2012; Batsis, et al., 2017). Interestingly, current NICE guidelines do not 
separate weight management advice by age (NICE Guidelines, 2014). The 
emphasis of weight loss may differ with age, with a primary aim of functional and 
quality of life improvements, although these are applicable for all ages (Han, Tajar 
and Lean, 2011). Guidance regarding weight should be provided on an individual 
basis, which considers both health conditions and the individual’s weight 
trajectory, and ensure dietary restriction does not lead to nutrient deficiencies and 
the conservation of muscle mass (Han, Tajar and Lean, 2011; Decaria, Sharp 
and Petrella, 2012; Batsis, et al., 2017). Continued emphasis should be given to 
preventing obesity in earlier life due to the body compositional changes with 
ageing (Han, Tajar and Lean, 2011).     
 
Health risks for the BMI Underweight and the  lower end of the BMI Normal 
range 
Although this thesis focussed on whether persons who are overweight or 
moderately obese (Obese-1) are or are not at an increased risk for mortality and 
other health outcomes, one of the consistent findings was the increased mortality 
risk for those within the BMI Underweight range both from the analysis of 
electronic health records and from the UK Biobank analysis. From the analysis of 
electronic health records, persons with the BMI lower Normal range (18.5 to 
<23.0 kg/m2) had increased mortality and dementia risks. As highlighted 
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previously, my analysis using the UK Biobank showed that 58.8% of those within 
the lowest BMI tertile (encompassing the lower BMI Normal range) had pre-
sarcopenia or sarcopenia. I did not assess the body composition profile of those 
within the BMI Underweight range, but it is likely that a high proportion of those 
would also have sarcopenia. This may have partly accounted for the high 
mortality rates in the BMI Underweight and lower BMI Normal weight range. 
Patients should firstly be reviewed to rule out any major weight losing conditions. 
Focus should then be on gradually increasing, with dietician support as 
appropriate, the intake of nutrient and calorie dense food, supplements, plus 
exercise (with a resistance training component) for those within the BMI 
Underweight and lower BMI Normal range (Starr and Bales, 2015).  
 
9.6. Future research 
During my PhD, several additional research areas/questions have emerged as I 
have progressed throughout my analyses.   
 
Extension to other populations and ethnic groups 
There is a need to understand the BMI associations with adverse health 
outcomes for individuals from different ethnic backgrounds and other populations. 
Both datasets used in my analyses included patients/participants from the UK 
(England for CPRD) and the ethnic origin of the participants was predominately 
‘white’ British. Populations differ in the prevalence and treatment of 
cardiovascular risk factors. Therefore, there is a need to extend the multiple 
simultaneous approach to assess the associations between recent BMI 
measures and adverse health outcomes to other ethnic groups and countries to 
assess the consistency of these findings.  
 
Extension of CPRD analyses 
 
Weight trajectory and cause specific mortality 
There is a need to understand the BMI associations and weight trajectories with 
cause specific mortality. The health outcomes which I predominately focussed on 
were mortality and dementia due to the mixed research findings with obesity 
407	
 
Chapter 9 | Discussion 
(Chapters 4 to 6). Additionally, I estimated the BMI associations with coronary 
heart disease, and diabetes (Chapter 5). A natural progression from the CPRD 
analyses would be to estimate the BMI associations for cause-specific mortality. 
It would be of great interest to model the variation of weight trajectory with incident 
conditions and cause specific mortality.    
 
Dementia  
My analyses presented in Chapter 6 focussed on the age range 65 to 74 years; 
additional research is required to clarify the association between BMI groups and 
dementia for ‘healthier agers’ above age 74 years. Future work should also 
consider elucidating the associations between other measures of adiposity with 
the risk for incident dementia. This could become possible with the additional 
follow-up data from the UK Biobank. Analyses of specific subtypes of dementia 
(especially vascular versus Alzheimer’s disease) should also be done.  
 
Smokers and those with conditions associated with weight loss 
Further work is needed to clarify whether the apparently protective effects of 
being obese in smokers and those with conditions causing weight loss represents 
a real effect or whether BMI in such groups is a measure of disease severity, with 
less severe disease being associated with less weight loss and higher residual 
adiposity.  
 
Additional outcomes 
Assessing additional outcomes of importance to both clinicians and the 
individuals within the studied age groups need to be identified. For instance, with 
the ageing population, assessing the association between BMI and frailty may 
become of greater importance due to the impact on the quality of life. One could 
use the CPRD to estimate the progression from fit to mild to moderate/severe 
frailty using the electronic frailty index (Song, Mitnitski and Rockwood, 2010). In 
Chapter 7, I used the UK Biobank to compare established measures of body fat 
distribution and components of body composition to BMI for mortality prediction 
with more follow-up data the magnitudes of the associations of these measures 
with alternative health outcomes such as coronary heart disease and diabetes 
would be possible. Currently, the UK Biobank is in the process of linking the 
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volunteers’ data to their primary health care records and this would allow type 2 
diabetes and many other primary care diagnosed conditions to be used as health 
outcomes (e.g. osteoarthritis in the knee).  
 
Qualitative research 
There is a need to identify the feasibility of health care practitioners additionally 
measuring central adiposity. My analysis using the UK Biobank (Chapter 8) 
highlighted the importance of combining BMI and WHR (as a measure of central 
adiposity). Therefore, future research is required to assess what are the barriers 
and enablers to measuring central adiposity in primary care in later life.  
 
Additional measures of adiposity 
My analysis in the UK Biobank showed that the mortality model fit was 
substantially improved compared to the BMI model, hence measures of the 
adipose tissue distribution may improve the mortality model fit further. The UK 
Biobank is currently in the process of collecting imaging data from both DXA and 
MRI scans with an aim of measuring 100,000 UK Biobank volunteers. In my 
analyses using the UK Biobank I showed that measures of central adiposity (waist 
circumference, WHR, and WHtR) were associated with an increased mortality 
risk. The MRI liver scans and abdominal scans would enable associations to be 
estimated for liver fat percentage, subcutaneous and visceral adipose tissue with 
adverse health outcomes on a much larger scale than prior analyses. It would be 
interesting to compare the mortality model fit using the subcutaneous and visceral 
adipose tissue to those using measures of central adiposity, and gender 
differences with fat distribution. There has been a limited amount of research 
using adipose tissue distribution and these analyses have not been restricted to 
‘healthier’ subset or concurrently compared measures (Murphy et al., 2014; 
Koster et al., 2015). Furthermore, the prognostic value of measures capturing 
body compositional changes needs to be assessed across progressively older 
age groups as I was only able to present findings for those within the seventh 
decade of life.  
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Additional statistical methods 
There is potential to improve our understanding of the associations between BMI 
and health outcomes in later life by using different statistical methods. My 
analysis used the CPRD and the UK Biobank with one time point measure only 
for BMI and the confounders (except for documenting weight change). The 
primary aim of my analyses was to use one off measures. However, future studies 
could use time series analyses which would account for changes in baseline 
characteristics and weight. This could be extended to subsets of patients with 
specific changes during follow-up. My analyses from the UK Biobank (and CPRD) 
have been observational designs. The UK Biobank has provided genetic data for 
>150,000 volunteers so far and is in the process of releasing the remaining data 
for the whole cohort. This large scale of genetic data lends itself to Mendelian 
randomization analysis which provides evidence on causal influences. My future 
research will involve analysing genetic risk scores (summation of the number of 
BMI risk alleles) with mortality and health outcomes in later life.   
  
Effect of weight change 
There is still a need to see how weight change affects survival/ healthy survival 
and the development of adverse health conditions in later life using different study 
designs. My analyses showed that for ‘healthier agers’ persons within the BMI 
Obese-1 range had increased risks for CHD, diabetes, and mortality. Future 
research, therefore, needs to clarify what are the health implications of persons 
in later life intentionally changing from a higher weight (BMI) to a lower weight 
e.g. is their risk for CHD reduced. Additional work would, therefore, be required 
on the feasibility and the appropriate intervention to reduce weight. Consideration 
would be required to ensure maintenance of muscle mass and persons do not 
become malnourished.  
 
9.7. Limitations of my meta-analysis  
A key limitation to the meta-analysis in Chapter 3 is that there was large 
heterogeneity for some of the analyses I presented. I realise the level of 
adjustment for confounding within each study will have implications on the pooled 
results. Whilst this was not in the remit of this analysis as my focus was on the 
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inclusion and exclusion criteria, future analyses should consider the study level 
characteristics. For my meta-analysis I extracted mortality risk estimates, where 
possible, from models which have not adjusted for intermediate factors, e.g. 
hypertension. However, mortality risk estimates from four analyses which had 
adjusted for intermediate factors had to be extracted (see Chapter 3). A 
sensitivity analysis was carried out excluding these four analyses where possible. 
Furthermore, my review included English language publications only and 
therefore I may have missed some additional analyses.  
 
9.8. Limitations using the CPRD and presented analyses  
There are several limitations with analysing the data from the CPRD. One of the 
main limitations with the CPRD is that there was no measures of body fat 
distribution or components of body composition. Additionally, only a subset of 
patients had repeat BMI measures to categorise weight loss. There was no 
available data on whether the weight loss was intentional. As noted in Chapter 
2, one of the key limitations with the CPRD is that health records are not primarily 
collected for research purposes (Herrett et al., 2015). The recording of a medical 
event is determined by the general practitioner and data may be collected during 
routine health checks or opportunistically. Lifestyle factors could be documented 
more often in subsets of patients with certain health conditions (Welch and 
Bartlett, 2014; Herrett et al., 2015). Variables are not documented at the same 
baseline date thereby historical records must be used. Additionally, it may be 
assumed that patients without pre-specified Read Codes for the chosen health 
outcomes may be free of the disease or condition of interest (Herrett et al., 2015). 
Patients could be missing data but using complete cases may result in biased 
estimates.  However, this could be due to differences in Read Codes selected by 
health practitioners, the documentation of symptoms and diagnoses in free text, 
and from patients avoiding primary care consultations. The quality and 
completeness of medical records may be altered with new or updates to clinical 
guidelines and financial incentives. A physical activity measure was available for 
55.3% of patients aged 60 to 64 years; 55.6% aged 65 to 69 years; 56.1% of 
patients aged 70 to 74 years; 55.8% of patients aged 75 to 84 years; and 55.9% 
for patients aged ≥85 years and this was based on Read Codes rather than a 
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validated questionnaire. Therefore, my models may not have adequately 
accounted for physical activity. Additionally, in this analysis residual confounding 
may have persisted in the models as the exclusion of conditions most closely 
associated with weight loss did not capture all patients with substantial weight 
loss. Furthermore, there may have been residual confounders; for instance, in 
my dementia analysis there was no measure of educational attainment.          
 
9.9. Limitations using the UK Biobank and presented analyses 
The UK Biobank is a healthy volunteers study and has a relatively short follow-
up period with a maximum of 8.3 years. In a similar manner to the CPRD, there 
is also the issue that some participants may be missing data. Volunteers could 
opt to select the “prefer not to answer” or “do not know” for the touchscreen 
questionnaire (UK Biobank, 2013). To date, there is no data available on primary 
care consultations (although this is planned to be linked in the future). This could 
lead to an underestimation of diagnoses which may be more commonly recorded 
at the primary care level such as diabetes. As highlighted in Chapter 2, the UK 
Biobank participants had lower mortality risks and cancer risks compared to the 
general population. Again, there may have been residual confounding in the 
presented analyses.  
 
9.10. Measurement errors 
Several measurement errors should be considered in light of the presented 
analyses. I used BMI as a surrogate measure of adiposity, however as noted in 
previous chapters, this metric is unable to detect body compositional changes 
with ageing. Batsis et al., (2016) showed that with advancing age the proportion 
of adults correctly classified as BMI Obese declined with age (Batsis et al., 2016). 
This could explain the attenuation of the mortality risks observed across the 
progressively older age groups from the CPRD. As noted earlier, only a subset 
of the CPRD patients and none of the UK Biobank volunteers had repeat BMI 
measures. Using a single BMI measure could result in underestimation of the 
mortality risks. I had no data regarding BMI fluctuations over the life course, the 
age of onset of obesity or the number of years the patients/volunteers were in a 
specific BMI range. Stokes and Preston (2016) showed that the mortality model 
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fit was improved by using a person’s maximum BMI rather than using the BMI 
measure from the survey baseline date (Stokes and Preston, 2016b). However, 
in primary care a general practitioner may only have information on a single BMI 
measure so it is still important to assess the prognostic utility of one BMI measure. 
Furthermore, I was unable to account for changes in risk factor levels across time. 
In both datasets, I excluded persons with recent cancer, dementia and heart 
failure. In the CPRD I excluded the first 3.9 years of follow-up and in the UK 
Biobank I excluded the first 1.9 years (due to a shorter follow-up period and 
healthier volunteers). This length of follow-up period excluded may not have 
captured subclinical diseases (e.g. dementia) with a long latency period. 
Furthermore, there may be residual confounding due to unknown or unmeasured 
risk factors (e.g. diet). As highlighted earlier, a physical activity measure was 
missing for a substantial proportion of patients. 
  
9.11. Conclusion 
Concurrent with the trend of rising obesity is an ageing population. It is well 
established that younger and middle aged adults within the BMI Obese range are 
at an increased risk for mortality relative to those within the conventional BMI 
Normal range. However, mortality risks for older persons within the BMI Obese 
range have been mixed. This presents challenges on interpreting the evidence 
and can impact management and treatment of obesity in later life. My thesis has 
highlighted that multiple factors contribute to the obesity paradox and the need 
to separate out smokers and weight losers. Additionally, there is a need to 
measure central adiposity with BMI. I have shown the heterogeneity of older 
adults can result in disparate risk estimates for the association between BMI and 
health outcomes. My analyses have shown that the obesity paradox can be 
largely accounted for by the pooling of the relatively healthy, smokers, those with 
conditions associated with weight loss plus the chosen BMI referent group. 
‘Healthier agers’ within the BMI Obese-1 range do not have a mortality advantage 
relative to those within the BMI referent range, 23.0-24.9 kg/m2; for those aged 
60 to 84 years there is an increased mortality risk. I also documented no support 
for reduced dementia risks for those within the BMI Obese range. Additionally, I 
found persons within the BMI Obese-1 range have increased risks for incident 
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diabetes and coronary heart disease (up to age 84 years). I provided additional 
evidence, using the UK Biobank, that reliance on BMI measures only may miss 
those at increased risk for health outcomes due to central adiposity; persons 
within the optimum BMI range may not necessarily have ‘ideal’ fat distribution. 
Additionally, my findings do not imply that the BMI Normal range should be 
redefined to that of the BMI Overweight range for adults aged <85 years. My 
results provide no support, in relatively healthy older adults, for the hypothesised 
obesity paradox in later life. There is a great need to prevent persons becoming 
obese in later life and to dispel the claims that obesity in later life provides a 
mortality advantage.      
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